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Abstract 
Cardiovascular disease remains the number 1 cause of death worldwide. Over the past 20 years, 
therapies for treating cardiac disease have come of age and coronary heart disease in particular 
has seen a revolution in new treatments such as statins, stents and beta blockers. These 
therapies have slowed death rates and have shown potential to minimise ischemia induced 
atrophy following myocardial infarction. Crucially however, they are unable to recover lost heart 
function due to cardiomyocyte death, resulting in poor prognosis for patients. Myocardial 
regeneration therapy is a new strategy towards treating cardiac disease that engrafts 
regenerative cells and biomaterials to the myocardium to stimulate repair of tissue and restore 
contractile function. Cardiac regeneration therapy has made a rapid translation from preclinical 
research to clinical trials with the first trial in humans published in 2001. Clinical trials in the 
years since however have produced underwhelming results and there is a general consensus 
that further preclinical optimisation with powerful non-invasive imaging data will be key to the 
future success of regenerative medicine in humans.  
Magnetic resonance imaging is unparalleled in providing non-invasive multiparametric imaging 
of both global and regional cardiac structure and function. MRI provides high spatiotemporal 
resolution and multiple contrast mechanisms revealing information about molecular changes in 
the myocardium. These imaging abilities make MRI a versatile and powerful tool in the 
preclinical optimisation of cardiac regeneration therapies. Over the chapters presented in this 
thesis I have established a set of MR imaging techniques that enable valuable in vivo 
characterisation of cardiac function and structure in for use in studies of regenerative therapy. It 
is hoped that the methods developed over the course of this thesis aid in the uptake of imaging 
applications in studies of regenerative medicine and that the wide range of imaging tools 
demonstrated help to bring regenerative medicine closer to practical clinical therapy.   
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Chapter 1  
Introduction I – Cardiac disease, regenerative 
medicine and tissue engineering 
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1.1 Introduction 
1.1.1 Research aims 
Cardiovascular disease represents the leading cause of death globally. Coronary artery disease 
(CAD) in particular resulted in an estimated 7.4 million deaths in 2012.1 The high oxygen 
requirements of the heart mean that CAD induced ischemia is highly damaging to the 
myocardium resulting in rapid onset of apoptosis and adverse ventricular remodelling.2 The 
ability of the heart to regenerate following injury is extremely limited due to the low populations 
of resident cardiac stem cells and the hostile cellular environment in myocardial ischemia. Over 
the last decade cardiac regeneration therapy has emerged as a potential treatment for 
producing functional repair in cardiac disease. Cell therapy and tissue engineering have 
produced promising preclinical evidence for regenerating the myocardium and has great 
potential for patients. However, clinical trials have shown only modest improvements in heart 
function and a return to preclinical optimisation of therapy is now key to successful clinical 
translation. This thesis aims to develop non-invasive and in-vivo MRI imaging techniques for 
assessing cardiac structure and function and apply them to studies of regenerative medicine in 
preclinical models of myocardial infarction. The aims of this work are summarised as the 
following four objectives, ultimately leading towards the development of a complete MRI 
imaging toolset for assessment of cardiac disease and regeneration: 
1. Establish quantitative MRI techniques for assessing cardiac function and structure in 
preclinical models of cardiac disease 
2. Implement, optimise and develop the current reference standard technique for imaging 
regional heart function with spatial modulation of magnetisation. 
3. Implement, optimise and develop a novel high resolution imaging technique for imaging 
regional heart function using displacement encoding using stimulated echoes 
4. Test the developed imaging toolset in preclinical models of cardiac regeneration 
Development of these goals is seen as key enabling technology to accelerate the development 
and optimisation of myocardial regeneration therapy aiding in the translation from bench to 
bedside.  
 
1.1.2 Structure of thesis 
This thesis is structured into 8 chapters. Each chapter has a specific role within the body of work 
as a whole in describing a project, or series of projects that have a common theme.  
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Chapter 1 provides broad background information about cardiovascular disease worldwide, 
regenerative medicine and tissue engineering. This introduction provides the physiological 
context underpinning the work presented in this thesis.  
Chapter 2 is a second introduction that describes the theory behind the imaging techniques used 
for cardiac imaging in general practice and those that are specific to this work. Magnetic 
resonance imaging (MRI) is discussed in detail as this forms a significant part of this thesis. Other 
imaging modalities that are used less frequently are also introduced including bioluminescence 
imaging (BLI), ultrasound (US) and optical projection tomography (OPT).   
Chapter 3 describes the development of a multiparametric preclinical imaging platform for the 
assessment of cardiac disease. The imaging techniques are applied to a novel model of β 
thalassemia using quantitative assessment of cardiac function, structure and NMR relaxometry. 
These techniques are presented in the context of β thalassemia but the techniques developed 
are applicable to the wider field of cardiac imaging. The methodologies presented here are 
applied in later chapters to studies of cardiac regeneration. 
In chapter 4 the assessment of regional myocardial function is introduced. A large component of 
this work focuses on the development of imaging techniques for assessment regional heart 
function using MRI. In this section the literature is reviewed and a brief study on the effects of 
myocardial infarction on the regional structure of the left ventricle from cine MRI images is 
presented.   
In chapter 5 the first advanced cardiac MR imaging technique is presented. Here, my work in 
developing and implementing a preclinical spatial modulation of magnetisation (SPAMM) 
sequence for tagging the myocardium and enabling the spatiotemporal tracking heart tissue 
through time is presented. This sequence is validated with a motion phantom and processed 
using the harmonic phase technique. 
In chapter 6 another regional assessment technique is developed that offers improved spatial 
and temporal resolution information about myocardial contraction relative to SPAMM. 
Displacement encoding using stimulated echoes (DENSE) is an advanced phase based myocardial 
imaging technique that can be used to quantify myocardial mechanics in fine detail. This chapter 
describes my work on developing, optimising and accelerating this sequence in terms of both 
the acquisition and post processing of data.  
Chapter 7 describes three studies I performed in which preclinical models of myocardial 
regeneration therapy were assessed using advanced imaging techniques. During these pilot 
studies ultrasound, optical projection tomography and bioluminescence imaging are 
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implemented to support the MRI imaging platform that is developed in previous chapters in a 
multimodal approach to imaging.  
Finally, chapter 8 provides a summary of the work presented as well as the findings of this 
thesis, offering a discussion of future developments that would be beneficial to the work. This is 
followed by a discussion of the future directions for myocardial regeneration therapy and the 
role imaging has within its translation to clinical practise.  
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1.2 Cardiac disease and regeneration 
1.2.1 Cardiovascular disease worldwide 
Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, 
they represent the largest cause of deaths worldwide and attribute to a third of all deaths 
globally.3 CVD is a broad term for a range of diseases that affect the heart and blood vessels and 
can be broadly split into the 6 categories described in Table 1.1.  
Table 1.1 Overview of categories of cardiovascular disease including a description and example 
of each major category. 
Category Description Example 
Coronary heart 
disease (CHD) 
Diseases effecting blood vessels supplying the 
myocardium 
Myocardial infarction  
Cerebrovascular 
disease 
Effects blood vessels supplying the brain Stroke 
Peripheral arterial 
disease 
Effects blood vessels in the arms and legs Atherosclerosis 
Rheumatic heart 
disease 
Bacterial infection damaging the heart muscle 
and valves 
Rheumatic fever 
Congenital heart 
disease 
Abnormalities of the heart existing from birth Atrial septal defect 
Venous 
thromboembolism 
Blood clot (thrombus) that forms in veins and 
can occlude vessels 
Deep vein thrombosis 
 
Coronary heart disease (CHD) and cerebrovascular disease are the most severe forms of CVD and 
account for 40 and 25% of CVD deaths respectively.4  Global deaths due to CVD is projected to 
increase year on year to 23.3m by 2030, compared to 16.7m in 2002, an increase of 40% over 28 
years.5,6 Incredibly, by 2030, 40.5% of the population of the USA is predicted to have some form 
of cardiovascular disease by current projections.7  
The huge economic cost of CVD is reflective of its position as the leading contributor to global 
disease burden. Contributions from primary healthcare treatment, prevention and lost 
productivity due to illness are estimated to total €169bn(2008) annually in Europe.4 In the USA 
this estimate is €286bn(2008) of which €70bn can be directly attributed to CHD.7 The wide 
prevalence and high cost of CVD has led to a great amount of investment in research and 
development from basic science through to clinical therapy. In 2015 the national institute of 
health (NIH) received a total of $3.7bn to support research into CVDs.8  
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Myocardial infarction (MI) in particular is a devastating consequence of CHD. Regional ischemia 
in MI causes regions of the heart to form non-contractile scar tissue. These scars result in cardiac 
dysfunction, leading to heart failure and death. This thesis focuses on assessment of targeted 
therapies for treating MI and produces imaging tools for the assessment of disease and therapy.  
 
1.2.2 Anatomy and physiology of the heart 
The cardiovascular system can be separated into two networks, the pulmonary circulation and 
the systemic circulation.9 The function of the heart is to pump blood through these two 
networks. The systemic circulation is supplied by the left side of the heart and provides 
oxygenated blood flow to the body and coronary blood vessels through the aorta. The 
pulmonary circulation is supplied by the right side of the heart and pumps deoxygenated blood 
received from the systemic circulation via the pulmonary artery to the lungs where it becomes 
oxygenated before being passed back into the systemic circulation, this process is illustrated in 
Figure 1.1. Both sides are connected to the body by large veins and arteries known as the great 
vessels. Each side of the mammalian heart consists of two chambers, an atrium and a ventricle 
giving the heart four chambers in total. Each pair of atria and ventricles are isolated from the 
other in normal physiology and so can be thought of as two pumps connected in series via the 
pulmonary and systemic vasculature.  
 
Figure 1.1 Anterior cross section of the heart at diastole and systole. Arrows show direction of 
blood flow in each phase. Red and blue regions indicate components of the systemic and 
pulmonary circulation respectively. SVC: Superior vena cava; RA right atrium; IVC inferior vena 
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cava; RV right ventricle; M myocardium; LV left ventricle; LA left atrium; PA pulmonary artery; AO 
aorta. 
The ventricles serve as the main pumping elements of the heart. They are surrounded by 
muscular myocardium that rhythmically contracts to reduce the volume of the chamber and 
pump the blood. Full relaxation of the ventricular myocardium when the ventricles are at peak 
volume is called end diastole, full contraction when their volume is smallest is called end systole.  
For efficient cardiac function the contraction of the atria, ventricles and valves must be carefully 
timed to produce the least resistance to flow. The contraction of the heart is paced and 
controlled by a network of conductive cells and impeding bundles that propagate an electrical 
impulse (action potential) that causes regular waves of depolarisation in cardiac muscle cells 
(cardiomyocytes) making them contract. This cycle produces electrical signals that can be 
detected by electrodes remote to the heart. The detection of these signals is called an 
electrocardiogram (ECG) that can provide information about the function or instantaneous 
contraction phase of the heart, this signal is illustrated in Figure 1.2. 
 
Figure 1.2 The ECG signal in sinus rhythm is a regular repeating waveform composed of three 
parts. The P wave caused by depolarisation of the atria, the large amplitude QRS complex caused 
by depolarisation of the ventricular myocardium and the T wave produced by ventricular 
repolarisation. The heartrate is normally described by the RR interval. 
The impulse originates in the sinoatrial node, a bundle of specialised cells located in the top wall 
of the right atrium. The regular spontaneous depolarisation of the sinoatrial node acts as the 
hearts pacemaker and initiates each contraction cycle, the normal rhythm of the heart by this 
process is called sinus rhythm. After the sinoatrial node fires the depolarisation wave propagates 
through the atria before slowing in the slowly conducting atrioventricular (AV) node. This 
movement causes the P wave in the ECG signal, during this delay the atria pump blood into the 
ventricles. The depolarisation then propagates quickly down through the septum through the AV 
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bundle and splits into left and right branches, before spreading into the ventricular myocardium 
through the His-Purkinje system. This rapid depolarisation leads to the QRS complex in the ECG 
signal that signals the initiation of ventricular contraction. 
 
 
1.2.3 Coronary vessels and myocardial infarction 
1.2.3.1 Coronary vasculature 
The coronary vasculature is the dense network of blood vessels that supply blood to the 
myocardium. This includes an arterial network that connects to the systemic circulation at the 
base of aorta and a venous network that drains into the right atrium.  
The arterial system stems from the aorta in 2 major coronary arteries, the left main and the right 
coronary artery. The left main splits to form the left anterior descending (LAD) and circumflex 
and the right coronary forms the posterior descending artery. These 5 vessels supply all of the 
oxygenated blood to the myocardium and occlusion or narrowing (stenosis) of these vessels can 
cause significant and rapid damage to the regions of muscle they perfuse. The major coronary 
arteries frequently branch into smaller arteries and capillaries creating a dense vascular network 
that is able to meet the perfusion requirements of the myocardium.   
The heart has one of the highest oxygen requirements in the body (5.6 ml/min/100g at rest and 
increasing up to 10.6 ml/min/100g during exercise).10 Interruption of myocardial perfusion as a 
result of coronary heart disease can have severe and rapid consequences. Coronary occlusion 
has been shown to reduce regional metabolism and impair systolic function within just a few 
heartbeats.11 The hypoxic environment rapidly leads to cell death with regions of the heart 
irreversibly damaged in a process called myocardial infarction. 
 
1.2.3.2 Myocardial infarction 
Myocardial infarction (MI) is the death of myocardial cells that occurs when an artery supplying 
oxygenated blood to the myocardium become narrowed or blocked. The high energy demand of 
the heart requires an uninterrupted supply of oxygen and restriction of blood flow leads to the 
rapid onset of cell death and loss of function. MI is normally a result of coronary occlusion, of 
which the most common cause is coronary atherosclerosis.9 Atherosclerosis is the formation of a 
plaque within the wall of an artery composed of accumulated white blood cells (WBCs), smooth 
muscle and the remnants of dead cells. Plaques with high infiltration of WBCs are unstable and 
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prone to rupture whereupon the inner thrombogenic core is exposed to the bloodstream. The 
resulting thrombus can then occlude the vessel (Figure 1.3) or enter the circulation resulting in 
remote thromboembolism.12 Other causes of MI include aortic stenosis13,14, non-obstructive 
diseases such as coronary artery vasospasms15 and changes in the oxygen supply/demand such 
as anaemia or hypertension.16 
Regional myocardial cell death due to ischemia begins at the subendocardium where energy 
demand is highest and spreads outwards to the subepicardium over a period of hours, this 
process is termed the wavefront phenomenon.17 The region of tissue supplied by the blocked 
vessel is bordered by regions where tissue is perfused by multiple or collateral vessels. This 
region is known as the area at risk (AAR) or border zone and represents tissue that can be 
salvaged if the blocked artery is cleared and tissue reperfused quickly. The proportion of the AAR 
that can be recovered depends on multiple factors including time from infarct to reperfusion, 
ischemic preconditioning and collateral perfusion.18 
Cardiac electrophysiology is altered in infarcted myocardium due to the abnormal conductance 
in infarcted tissue and the accurately timed contraction cycle described in 1.2.2 loses 
coherence.19 In the worst case scenario immediately following infarction the patient can develop 
ventricular fibrillation (VF) where the ventricles cannot contract rhythmically resulting in a 
fluttering motion in which very little or no blood is pumped. The abnormal conductance in 
infarcts is known to predispose patients to future arrhythmia with the surviving AAR thought to 
be the primary arrhythmogenic source.20,21 VF as a result of conduction failure is the most 
common cause of death during the acute phase of MI.22,23  
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Figure 1.3 Myocardial infarction occurs when the blood supply to the heart is restricted. The most 
common cause of myocardial infarct is a ruptured atherosclerotic plaque and resulting 
thrombotic occlusion (inset). The myocardium supplied by the blocked vessel becomes infarcted 
(light grey) but is bordered by salvageable tissue (dark grey). RCA; right coronary artery, PDA; 
posterior coronary artery, LAD; left anterior descending coronary artery, CX; circumflex, LM; left 
main coronary artery. 
Following the ischemic event, the heart begins a remodelling process, in which it undergoes 
changes in size, shape and contractility, in an attempt to adapt to the damaged myocardium. 
The onset and extent of this remodelling process is dependent on the severity of the initial injury 
as well as factors such as haemodynamic load and secondary MI events.24 This remodelling 
process begins within the first few hours of coronary occlusion.25 A major feature of remodelling 
is the formation of a region of non-contractile collagen-rich scar tissue that replaces the ischemic 
tissue. This scar helps prevent myocardial rupture and keeps the structure of the heart intact but 
is not able to contribute to cardiac output. Other major features of cardiac remodelling include 
ventricular dilation, delayed infarct expansion and myocyte hypertrophy.26-28  
Extensive cardiac remodelling eventually leads to chronic heart failure (HF), this occurs when the 
heart loses its ability to adequately pump blood to sustain the body’s needs. HF can be the result 
of severe MI, arrhythmia, disease and hypertension. The transition from adaptive remodelling to 
cope with changes induced by infarction to maladaptive remodelling leading to HF occurs as the 
heart overcompensates for damage.29 In clinical practice the remodelling process following MI is 
typically pharmacologically constrained to limit the extent of remodelling and provide a better 
prognosis for the patient. 
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1.2.3.3 Clinical management of myocardial infarction 
Atherosclerosis and the resulting MI, is a chronic condition and plaques take many years to form 
with patients asymptomatic before plaque rupture with little warning before an ischemic event. 
Early diagnosis is therefore extremely difficult and consequently clinical management tends 
towards damage limitation following MI rather than intervention before the event.  
Pharmacological treatments for MI include the administration of a combination of aspirin, β-
adrenergic blockers and angiotensin-converting-enzyme (ACE) inhibitors.30 These drugs are able 
to manage the major symptoms of MI by antithrombotic, antiarrhythmic and antihypertensive 
properties respectively. Coronary reperfusion therapy can be given either pharmacologically or 
mechanically via percutaneous coronary intervention (PCI) in which a balloon catheter is inflated 
to clear occluded vessels.31,32 Infarct size and functional recovery is strongly dependent on the 
severity of occlusion and time to reperfusion therapy, so in cases where coronary occlusion is 
ongoing, reperfusion therapy will be performed as quickly as possible in centres that possess the 
capability. In the case of major heart failure, the only current clinical treatment is heart 
transplant where donor availability, organ rejection and surgical risk present significant 
complications.  
Although current clinical therapy has provided reductions in infarct size, mortality and adverse 
cardiac remodelling, significant ventricular dysfunction remains in the vast majority of 
patients.33-36 Therefore there is a need for the development of therapies able to stimulate 
growth of new contracting heart tissue or to replace damaged tissue with artificial myocardium 
grown in-vitro in a new regenerative approach to therapy. 
 
1.2.3.4 Animal Models of myocardial infarction 
Accurate animal models of myocardial infarction are important enabler to the study of 
myocardial infarction physiology and the development of effective therapies. Producing an 
animal model of myocardial infarction requires artificially inducing changes to coronary blood 
flow. This has been done using surgical ligation, cauterisation/cryoinjury, balloon occlusion and 
pharmacological methods.37 Balloon occlusion uses a surgically implanted inflatable balloon 
catheter to occlude a coronary artery. This is performed in large animals by inflating the balloon 
following transluminal implantation. The balloon occlusion method has been adapted to small 
animals (rabbit) by using an inflatable balloon catheter that encircles a superficial coronary 
artery.38 This method is reliable and reproducible in the case that the balloon is positioned 
accurately. This procedure requires a high level of surgical expertise and is impractical in small 
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rodent models of disease, especially mice where the major coronary vessels have an average 
diameter of 0.16mm.39 Pharmacologically induced infarction aims to create an ischemic region in 
the myocardium by either increasing the oxygen requirements of the muscle above what the 
coronary circulation is capable of delivering (e.g. Isoproterenol40) or inducing coronary artery 
spasms (e.g. Doxorubicin41). Although these methods offer an easy route to creating myocardial 
ischemia, they offer little control over the location of the infarcted region or degree of damage 
and is limited by to drug toxicity. An electrocoagulation knife or cryoprobe can be used to induce 
cauterisation/cryoinjury respectively in the target coronary artery. This has two effects, local 
tissue damage and cell necrosis due to the thermal injury and myocardial ischemia distal to the 
region of damage. MI caused by this type of injury is easy to produce but has limited 
reproducibility and the damage caused at the site of the injury is not physiologically similar to 
pathological MI.42,43 For this reason surgical ligation of the coronary arteries was chosen to 
produce animal models of MI for research undertaken in this work. Surgical ligation ties off a 
coronary artery using suture ligation. It is the most similar model of MI to pathological MI caused 
by atherosclerosis or coronary thrombosis and causes reliable myocardial infarction. However, 
the procedure can result in infarcts of variable sizes and requires a high degree of surgical skill to 
implement successfully, especially in mouse models due to the small dimensions of the coronary 
arteries.44  
 
1.2.4 Regenerative medicine 
Artificially inducing regeneration in organs and tissues that would not normally have the 
capability is a promising and feasible approach to therapy that has the potential to alleviate 
humans from diseases that have not yet been cured.45 Regeneration occurs in nature, and the 
regrowth of organs and limbs is a characteristic of certain species such as the salamander, 
zebrafish and gecko (Figure 1.4). The regrowth organs in these species originates from a cluster 
of undifferentiated cells called a blastema that accumulates at the site of injury. Most mammals, 
including humans, lack the ability to produce a blastema and so require some other mechanism 
to deliver cells to the regenerating region either through cell signalling to recruit endogenous 
stem cells or through cell transplantation. 
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Figure 1.4 Some species of gecko are able to shed their tails as a defence to regenerate the lost 
appendage. This MRI image of a regenerated gecko tail shows the original tail to the right and 
the regrown tail to the left. This species is unable to fully regenerate the tail and cannot re-shed 
the tail from below the original severance point (red) note lack of vertebra and new fracture 
planes (white) in the regenerated tail. 
The aim of regeneration therapy is to stimulate new growth in tissue, where damaged cells and 
structures are replaced and functionality of the organ restored. Approaches to regeneration 
therapy can take two approaches, 1) stimulating growth or recovery through the activation of 
endogenous regenerative ability or 2) transplanting cells or structures that have been cultured 
in-vitro to replace damaged tissue.46 
 
1.2.4.1 Overview of cardiac cell therapy 
Although the regenerative properties of organs such as skeletal muscle and the liver are well 
known, it was thought until recently that the heart lacks this inherent capability.47 In a 
breakthrough study by Beltrami et al. (2001) it was shown that a subpopulation of 
cardiomyocytes undergo mitosis in response to myocardial infarction.48 A later study by 
Bergmann et al. (2009) used radioactive carbon-14 fallout from cold war era nuclear tests to 
radiometrically determine the age of in-vivo cardiomyocyte populations and provide evidence 
for post-natal cellular renewal in normal physiology.49 This report showed that approximately 1% 
of cardiomyocytes regenerate annually in early adulthood and that this turnover decreases with 
age, in an average human lifespan less than half of all myocytes are regenerated. These 
discoveries challenged the traditional view of the terminally differentiated heart and introduced 
the field of myocardial regeneration and the existence of autologous cardiac stem cells (CSCs). 
This limited regenerative ability suggests that the integration of new cardiomyocytes to the 
heart, although barely perceptible in adults, is possible and consequently that the growth or 
transplantation of new cardiomyocytes is a feasible therapeutic goal.  
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The cell therapy approach to cardiac regeneration typically transplants cells by infusion or 
injection of isolated proregenerative cells in liquid suspension. Cardiac cell therapy offers an 
attractive solution to treating heart failure patients by offering a highly targeted and tailored 
therapy without the risk of donor rejection since cell grafts can be cultured from autologous 
adult stem cells.50 However, the question remains that if the heart possesses a dormant 
regenerative ability as shown by Beltrami et al. (2001) and Bergmann et al. (2009) what factors 
are preventing the total regeneration of large areas of damaged tissue without external 
intervention. One commonly considered obstacle is the hostile cellular environment present in 
many forms of CVD such as infarction where adverse mechanisms such as inflammation and 
ischemia may be preventing the activation of endogenous cardiac stem cells.51 An additional 
barrier to native regeneration is the physical impedance caused by fibrotic and scar tissue 
following injury, this response mechanism is necessary to maintain the structural integrity of the 
heart but poses a barrier to the growth of new cardiomyocytes in the region.52 Finding effective 
and safe ways to circumvent or remove these growth-limiting factors will be vital to the 
development of regenerative medicine. 
  
1.2.4.2 Cell types 
A wide range of stem and progenitor cell types have been proposed for regeneration therapy.53 
The potential of these cells for regeneration comes from their ability to differentiate into a range 
of different mature cells depending on their growth environment. Autologous stem cells can be 
sourced from adipose tissue, blood, bone marrow and heart tissue. Blood derived stem cells 
such as circulating endothelial progenitor cells have undergone clinical trials where they were 
chosen for their angiogenic properties.54 Cells extracted from adipose tissue have been shown to 
differentiate into cardiomyocyte-like cells that exhibit pacemaker activity and beating action.55-57 
Bone marrow is a rich source for regenerative cells including hematopoietic stem cells (HSCs) 
and mesenchymal stem cells (MSCs) and is the most common cell source used in current clinical 
trials.58 Stem cells sourced from cardiac tissue (CSCs) offer an exciting prospective cell type for 
regeneration in the heart.59 Furthering our understanding of CSCs and their role in cell renewal 
in the native myocardium may profoundly change the potential of regenerative medicine in the 
heart over the next decade.60 Due to the small autologous populations of all these cells, they 
must be isolated and amplified in-vitro before transplantation into damaged myocardium.  
The first trials for myocardial regeneration in humans extracted skeletal myoblasts (SM) via 
intramuscular biopsy and cultured populations in-vitro before intramyocardial injection.61 
Skeletal myoblasts are the cell precursors to skeletal myocytes and their similarity to 
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cardiomyocytes makes them a good candidate for cardiac regeneration. Results from a long 
term investigation into the safety and efficacy of myoblast transplantation found that ejection 
fraction was improved in MI patients treated with direct infusion of myoblast as measured by 
echocardiography and Fluorodeoxyglucose (FDG) positron emission tomography (PET). PET 
imaging revealed new regions of glucose uptake in scar tissue suggesting new regions of viable 
tissue.62 However a subsequent and more rigorous study using data from the Myoblast 
Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial has since found that SM 
transplantation can also result in arrhythmogenesis and produces no significant changes in 
global or regional heart function in cell treated patients.63  
There is a growing body of evidence that the beneficial effects of transplanted stem cells to the 
myocardium and other organs is not directly through the integration and proliferation of the 
cells but due to paracrine signalling effects.64 Stem cells are known to secrete cytokines, 
chemokines and growth factors that have been shown to be beneficial in the ischemic 
myocardium.65-67 The paracrine signalling model of cardiac regeneration regards the 
transplanted stem cells as analogous to proregenerative molecule factories secreting bioactive 
molecules to the benefit the surrounding tissue without fully integrating with it. These paracrine 
effects are thought to modulate the physiological response of the body to the infarcted 
myocardium, attenuating the inflammatory response to myocardial infarction, resulting in 
reduced cell death and reduced adverse remodelling.  
This view of stem cell therapy as beneficial only through paracrine effects has led to studies that 
focus on the release of paracrine signalling molecules by delivering cells with little regenerative 
potential such as fibroblasts and macrophages.68 Other studies have genetically altered stem 
cells to overexpress the genes that produce these proregenerative paracrine molecules 
theoretically maximising the effect. For example, Duan et al. (2003) produced a genetically 
modified bone marrow derived mesenchymal stem cell line that overexpressed the hepatocyte 
growth factor(HGF).69 The authors demonstrated improved contraction, denser capillary 
networks, smaller scar size and reduced collagen content in ischemic myocardium treated with 
the cells, attributing these improvements to the high persistence of HGF in the infarcted tissue. 
Another important bioactive molecule in cardiac regeneration is vascular endothelial growth 
factor (VEGF) thought to be key in the development of new vasculature and improving tissue 
perfusion following infarction.70 A study by Ye et al. (2007) transfected skeletal myoblasts with 
the human gene for producing VEGF and transplanted the cells into rats following myocardial 
infarction.71 Based on ultrasound measurements, ejection fraction was improved in animals 
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treated with the VEGF expressing cells. Molecular and histological studies were performed to 
demonstrate improved regional blood flow and blood vessel density in the VEGF group. 
The relative roles of cell differentiation, integration and paracrine effects in the regeneration of 
tissue is an ongoing field of research. The overall consensus of these studies is an acceptance 
that although myocardial regeneration is a feasible goal, optimization of cell type, delivery 
strategy, cell survival and graft integration is still required and is key to producing a successful 
therapy. 
 
1.2.4.3 Delivery routes 
The delivery route chosen for cardiac cell therapy can make a significant difference to the 
therapeutic outcome. An important factor dictating delivery strategy is the invasiveness of the 
procedure, with open chest injections unlikely to gain clinical acceptance unless performed in 
conjunction with necessary invasive surgery. For this reason catheter and infusion based delivery 
routes are preferred.72 
Currently there are 3 common delivery routes that are used in clinical trials, systemic venous 
infusion (SVI), intracoronary infusion (ICI) and intramyocardial injection (IMI). The choice of 
delivery strategy aims to maximise the number of cells retained, efficacy of the treatment and 
minimise complexity and invasiveness of the procedure. SVI is the simplest delivery method and 
does not require anaesthetic or specialised equipment but delivery is indirect and has been shown 
to deposit a high proportion of transplant cells in the lungs and non-target organs such as the liver 
and spleen.73,74 ICI is currently the preferred method for clinical trials, and has the advantage that 
cells are only delivered to perfused tissues in MI, ensuring they settle where oxygen and nutrient 
flow are preserved and there is a favourable environment for cell survival. However, this is a non-
specific delivery technique and cell retention in the heart is low.75 IMI injections can be delivered 
via catheter to the LV where the cells are delivered via the endocardium, this route has shown the 
best retention of cells in the myocardium but a significant number is still deposited to other 
organs. In a study by Hou et al. (2005) radiolabelled blood mononuclear cells were injected by ICI 
and IMI routes and their distributions at 1 hour post engraftment showed that up to 47% of cells 
were located in the lungs and all injection routes showed significant loss of cells from the heart.76 
Low cell retention in the target area following engraftment is a common issue seen throughout 
cell therapy studies.77 Reports suggest that integration of therapeutic cells is a transient process 
with the vast majority of donor cells lost from the heart within hours of delivery.78 This has been 
reported in the case of SM cells, bone marrow cells, cardiac stem cells (CSCs), c-kit+/cardiospheres 
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and embryonic stem cells suggesting that cell choice is unlikely to be the sole cause. Although a 
high cell rejection fraction still has the potential to improve heart function through paracrine 
effects it is only a partial solution for cardiac regeneration. This has necessitated the development 
of a more refined concept of cell therapy in tissue engineering.79 Advanced tissue engineering 
techniques are now at the forefront of regenerative medicine, and an array of technologies under 
development aim to protect and nurture grafted cells and improve the post infarct environment. 
 
1.2.5 Tissue engineering 
Tissue engineering aims to supplement cell therapy for improving outcome in regenerative 
medicine. The aim is to produce functional 3D constructs that are able to stimulate regeneration 
or directly replace damaged tissue. These constructs are produced in-vitro where they can be 
tailored in size, shape and function before engraftment.80 The major difference from standard cell 
therapy and tissue engineered solutions is the movement from liquid suspension of treatment 
cells to the combination of cells with a supporting structure and microenvironment that can be 
tailored to aid cell survival and host integration.  
 
1.2.5.1 Overview of cardiac tissue engineering 
When engineering 3D biomaterials for cardiac regeneration several considerations need to be 
made regarding the mechanical properties and cellular microstructure required to create a 
suitable environment for contractile cells, these requirements are outlined in Figure 1.5. Creating 
artificial force-producing cardiac muscle tissue for engraftment to the damaged myocardium is a 
complex problem and producing a structure that is able to meet all these requirements is a 
significant challenge and will rely on a great deal of cross disciplinary expertise.  
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Figure 1.5 The ideal scaffold for engineered heart tissue would meet all of these requirements. 
Due to complex interactions between the host tissue and the engineered construct this 
represents a major challenge for cardiac tissue engineering.  
Cardiac tissue engineering aims to replicate the native environment of the myocardium, 
requiring a combination of cellular and extracellular structures. More advanced materials may 
also incorporate sources of bioactive molecules, perfusion and oxygen transport.78 The 
extracellular structure is usually referred to as a matrix or scaffold and is seeded with cells in 
culture or bioreactor to create engineered tissue with specific properties. For example, a 
bioreactor in which cells are cultured under mechanical stimulation is able to induce orientation 
in myofibers seeded on a scaffold.81 Cardiac tissue engineering can also be approached without 
cell seeding. In this approach it is hoped that the scaffold will promote in-situ regeneration 
either through mechanical support of the damaged myocardium or through controlled release of 
bioactive molecules or drugs as the scaffold material breaks down.82 Alternatively cells can be 
cultured to form artificial tissue without the use of an artificial scaffold, this approach is 
discussed in depth in Chapter 7. 
 
1.2.5.2 Extracellular biomaterials 
The choice of material with which the engineered extracellular structure is constructed affects 
all stages of development and integration. At the cell culture stage the chosen material must 
allow cell adhesion, promote cell proliferation and allow for cell survival by permitting oxygen 
and nutrient transport. At the engraftment stage the biomaterial must be biocompatible- 
inducing a minimal immune response whilst also being biodegradable and maintaining a 
preregenerative cellular environment.  
In general, there are 2 broad classes of material currently used as a base for creating an artificial 
extracellular matrix (ECM) in engineered heart tissue; natural polymers and synthetic polymers. 
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These ECM materials can be used singularly or they may be combined to create hybrid 
natural/synthetic materials to take advantage of certain characteristics of each. 
Natural polymers currently utilised for cardiac tissue engineering include collagen I, alginate, 
fibrin, Matrigel, glycosaminoglycan’s, gelatin, chitosan and decellularised natural extracellular 
matrix.83-87 Natural polymers are inherently biodegradable in regenerative timescales and 
biocompatible due to their similarities to internal extracellular matrix. Importantly they are also 
highly permissive to enzyme transport and cell signalling making them good candidates for 
promoting regenerative therapy. However, these advantageous biomolecular properties are 
offset by comparatively weak mechanical properties in comparison to synthetic materials. 
Synthetic polymers currently in use include poly(lactic-co-glycolic acid), poly(glycerol sebacate), 
poly(N-isopropylacrylamide), polycaprolactone, polyurethane and polyethylene glycol (PEG).88-92 
Synthetic polymers are much more versatile in terms of mechanical characteristics such as 
stiffness, degradation and microstructure however they are less permissive to chemical 
signalling making them susceptible to immunological rejection. 
There is a strong case for mechanical support being one of the key influences in minimising 
adverse cardiac remodelling. Restoration of the mechanical support lost through tissue apoptosis 
following infarction may be highly beneficial to patients following acute MI. For example, 
ventricular restraint therapy is a surgical treatment for major heart failure in which a supporting 
structure is wrapped around the ventricles to provide passive end-diastolic support reducing the 
severity of ventricular dilation.93 The presence of this support has been shown to reduce end 
systolic and diastolic volumes as well as maintain the shape of the heart in a 300 patient cohort 
from the ACORN trial.94 However, although cardiac morphology was preserved, LV ejection 
fraction showed no significant improvement. This suggests that mechanical support alone is not 
sufficient to regenerate the myocardium and that additional therapeutic agents are needed such 
as integration with cell therapy or incorporation of growth factors. 
 
1.2.5.3 Functionalisation of constructs 
An exciting advantage of implanting a cell loaded biomaterial, as opposed to direct cell injection, 
is that the biomaterial can be more than an inert cell structure for supporting cells. The 
biomaterial can be ‘functionalised’ with a multitude of different properties to make it more 
effective for different applications. Key functionalisation can include incorporating bioactive 
molecules, electromechanical stimulation and imaging contrast agents. 
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The incorporation of bioactive molecules in the structure of biomaterials for regeneration such 
as growth factors and pharmacological agents has been shown to produce therapeutic effects. 
The targeted delivery of VEGF to the infarct border zone for example has been shown by Rosano 
et al. (2012) to significantly improve perfusion and LV function in rats.95 Incorporating growth 
factors such as VEGF within a biomaterial has the advantage that the biomaterial can be tuned 
to a specific degradation profile resulting in the controlled release of the stored growth factors 
over time. This has the potential to significantly improve the uptake of the growth factor within 
the target region and provide long term regional therapy. A study by Silva et al. (2007) injected 
VEGF loaded hydrogels into ischemic hind limbs to demonstrate this concept.96 The authors 
were able to show significantly greater angiogenesis in the treated hind limbs compared to a 
one-time bolus of VEGF. A recent study by Rodness et al. (2016) delivered VEGF to the infarcted 
epicardium in rats via a patch composed of calcium-alginate microspheres with a known 
degradation profile engrafted with a restraining chitosan sheet.97 The authors showed that the 
microspheres with or without VEGF showed improved cardiac function assessed by MRI but that 
the rats treated with VEGF positive microspheres had reduced wall thinning and smaller infarct 
areas at 4 weeks. Regenerative application of microspheres are discussed in more detail in 
chapter 7. 
This delivery approach is not limited to VEGF and can be beneficial in any pharmacological 
therapy for myocardial infarction where spatial and temporal control of drug action can aid 
efficacy. Other studies have been performed with encapsulated superoxide dismutase (SOD) 
encapsulated in polymer microparticles.98,99 SOD scavenges the damaging superoxide radical 
O2·−, following MI it has been shown that there is a significant increase in superoxide levels along 
with a reduced presence of native SOD due to saturation of the clearance system. Regulation of 
SOD levels following MI has therefore been proposed as a potential mechanism for therapy 
following MI.100 However, this approach has led to mixed results and remains an active area of 
research.101,102 
Electromechanical functionalisation of biomaterials has been pioneered by Zimmerman et al. 
with the development of engineered heart tissue (EHT).103 EHT are small loops of 
collagen/Matrigel based scaffold that are cultured with neonatal heart cells while under 
continuous cyclic mechanical stretching. The result is a loop of self-contracting engineered tissue 
that can be transplanted singularly or in a patch onto the epicardium to improve contraction in 
regions of lost function. The first example of EHT was produced by Eschenhagen et al. (1997).104 
The authors developed the EHT as a testbed for cardiac research and proposed it would be 
beneficial to streamlining genetic and pharmacological studies in the heart. The EHT constructs 
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were first transplanted into the infarcted myocardium as a therapy in 2002 by Zimmerman et al. 
who showed that despite the contractile function of the EHT being maintained following 
transplantation there was no significant improvement in left ventricular ejection fraction (LVEF) 
measured using echocardiography. The authors did show however that the EHT was heavily 
vascularised and retained well-ordered muscle structure suggesting that the graft could survive 
and optimisation of the therapy may provide better functional improvements.  
The addition of contrast agents to a biomaterial allows the use of non-invasive imaging 
modalities to observe the location of the engraftment. With an appropriate imaging modality 
the volume and structure of the material can be visualised in situ (see imaging theory 2.1). 
Contrast agents can be bound to the therapeutic cells or molecules within the biomaterial that 
enables tracking the migration of the therapy. This has been used to shown the migration of 
native stem cells to infarcted tissue following an ischemic injury as well as the localisation of 
explanted cells that were labelled with the CxCR4 gene to induce homing to the ischemic 
myocardium.105,106 Contrast agents can also be bound directly to the supporting extracellular 
biomaterial to allow tracking of biomaterial retention that can allow quantification of in vivo 
material degradation. In an example of this Shkand et al. (2016) introduced viscosity sensitive 
fluorescent dyes in an alginate hydrogel. This was used to optically track alginate implants in 
shallow tissue to measure the half-life of hydrogel retention under physiological conditions.107  
The importance of imaging in the assessment of cardiac regeneration therapies is acknowledged 
as key to demonstrating that regenerative medicine is effective and safe. Imaging enables the 
means to optimise therapies and identify which components of tissue engineering or cell 
therapy produce the greatest benefits for the patient and most effective functional repair of the 
myocardium. The regional nature of cardiac disease and the localised therapies described here 
require specialised techniques for tracking regional tissue and assessment of function. Clinically, 
heart function is traditionally quantified using global function measurements such as left 
ventricular ejection fraction (LVEF). There is a requirement for effective imaging tools for 
locating engrafted cells and biomaterials and for quantifying regional heart function. This thesis 
works to develop tools for regional heart assessment with the goal of translating them to the 
assessment of regenerative therapies. Imaging technologies with valuable applications in 
assessment of cardiac disease are introduced in the following chapter. 
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1.3 Summary 
This chapter has introduced the devastating effects of cardiovascular disease worldwide and the 
way in which coronary artery disease and the resulting myocardial infarction leads to heart 
failure and death. The potential benefits of myocardial regeneration therapy are significant and 
the development and optimisation of these techniques offers hope for a better prognosis in 
patients with CVD. Later chapters in this thesis will discuss in detail, specific techniques for 
regenerative therapy and discuss the imaging tools developed for assessing therapeutic 
outcome. The importance of imaging in the assessment of cardiac regeneration therapies is 
acknowledged as key to demonstrating that regenerative medicine is effective and safe as well 
as providing the means to optimise therapies and identify what components of tissue 
engineering and cell therapy produces the maximum benefit for the patient and most effective 
functional repair of the myocardium. 
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Chapter 2  
Introduction II - Imaging background and theory 
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2.1 Introduction 
This chapter describes the principles behind the biomedical imaging modalities used for this 
research. This thesis primarily focuses on developing advanced preclinical MRI techniques and so 
MRI is discussed in detail. Also introduced are optical projection tomography (OPT), Ultrasound 
(US) and bioluminescence imaging (BLI) that are used in a multimodal approach to imaging 
cardiac regeneration in Chapter 7. Since OPT, US and BLI represent comparatively smaller 
components of the project they are briefly summarised. Descriptions of these techniques will 
include short explanations of the origin of the relevant signal, how images are acquired and 
reconstructed and notable applications.  
In vivo imaging is an essential tool for assessing the efficacy of therapy and is utilised in the vast 
majority of studies reporting on regenerative therapies.108 The efficacy of cardiac regeneration 
therapies remains controversial, with the majority of studies reporting little to no improvements 
of standard measures of cardiac health such as left ventricular ejection fraction (LVEF). 
Therefore, there is ongoing discussion concerning whether this regenerative medicine strategy is 
beneficial to patients and worth pursuing.109 With no definitive evidence of major functional 
improvement, cell therapy and tissue engineering will not be preferred to standard techniques 
such as beta blockers and revascularisation therapy that have proven improvements in LVEF. 
Although LVEF has traditionally provided valuable quantification of overall heart function, the 
possible beneficial effects of cell therapy on specific regions of myocardium may not be captured 
using this measurement. Advanced regional assessment techniques such as the MRI techniques 
developed in Chapter 5 and Chapter 6 are therefore required.   
When investigating regeneration, it is valuable to be able to track and monitor cell and 
biomaterial retention following engraftment to the heart. Without this knowledge it is difficult 
to attribute any functional change to the presence of the therapeutic cells or material. Cell 
tracking is typically performed using molecular imaging techniques based on nuclear, fluorescent 
or bioluminescent emissions. Tracking biomaterials can be performed in the same way, the 
objective being the introduction of imaging contrast to the transplanted material that makes it 
valuable using a non-invasive in-vivo imaging modality. The work described in this thesis takes a 
multi-modal imaging approach, allowing each imaging modality to be used for a specific 
optimised purpose.  
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2.2 Cardiac imaging overview 
By far the most common imaging modality used for cardiac imaging is ultrasound 
echocardiography. This is mainly due to the convenience offered by an ultrasound examination 
thanks to the imaging device being portable and widely available. However, the improved tissue 
contrast and spatial resolution of MRI has led to it being the gold standard imaging modality for 
assessing heart function where available.110 In preclinical imaging studies it has been shown that 
cine-MRI is more sensitive to functional change that standard 2D echocardiography.111 However, 
the high temporal resolution and real time imaging of ultrasound has made it the ideal tool for 
image guided procedures. This has found frequent use in myocardial regeneration therapy as an 
aid to cell and biomaterial injections. For cell tracking, nuclear imaging systems such as PET and 
SPECT are regarded as the gold standard for tracking cells in vivo. However, the cost and 
complexity introduced by adding nuclear imaging to a study makes it unappealing for many 
studies. Alternative and more convenient cell tracking systems such as bioluminescence imaging 
are available that are also able to offer another layer of information by imaging only viable cells. 
This study makes use of magnetic resonance imaging in Chapter 3, 4, 5, 6 and 7 for its ability to 
offer high quality and versatile assessment of cardiac structure and function, ultrasound is used 
for image guided delivery of treatment material to the heart and BLI is used of cell tracking since 
it is the most suited modality for tracking both the spatial distribution of cells and their viability.  
The following sections will discuss in more detail the inner workings of each of these chosen 
imaging modalities describing the mechanisms by which they produce image contrast and how 
they form an image. The therapeutic biomaterial imaging studies described in Chapter 7 make 
use of the imaging techniques described in this section.  
 
2.3 Magnetic Resonance Imaging 
A large fraction of this thesis is focused on developing and using MRI acquisition techniques. It is 
therefore helpful for the reader to have a basic understanding of fundamental MRI principles. 
Since MRI has been described extensively in previous works this section will aim to briefly 
describe the major concepts. For a full description of physical principles and MRI theory readers 
are directed to Haacke et al. (1999).112 This section will begin with an explanation of nuclear 
magnetic resonance and its origin this is followed by a description of the essential components 
of an MRI system and how radiofrequency (RF) energy can be used to manipulate nuclear spins. 
Next, the concept of image formation from these RF signals will be described and the gradient 
echo and spin echo imaging pulse sequences described. Finally, the necessary modifications to 
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adapt MRI to cardiac imaging are introduced including frequently used pulse sequences for 
measuring global heart function with cine MRI, T1 mapping, MRI contrast agents and late 
gadolinium enhancement imaging for mapping myocardial viability. 
 
2.3.1 Nuclear magnetic resonance 
Nuclear magnetic resonance (NMR) refers to the phenomenon of specific atomic nuclei 
absorbing and reemitting radiation of specific frequencies when experiencing an external 
magnetic field. NMR refers to ‘nuclear’ as the process occurs within atomic nuclei, it requires the 
application of a series of ‘magnetic’ fields and these fields must oscillate at the specific 
precession frequency of the nucleus in ‘resonance’.  
Protons and neutrons are fermions and possess a half integer spin value. Spin is an intrinsic 
property within the quantum mechanical description of matter and is a quantised form of 
angular momentum. For the purposes of this description spin can be thought of as a particle 
spinning about its own axis. Any nuclei with an odd number of protons/neutrons will have 
nonzero spin and possess a magnetic moment along the direction of their spin. Stern and 
Gerlach showed in 1922 that spin was quantised by passing a beam of silver ions through a 
magnetic field gradient. They found that each silver ion in the beam was deflected into one of 
two discrete paths corresponding the spin ‘up’ or spin ‘down’ state of the nuclei. This 
quantisation of states is a fundamental principle of MRI. Following our previous description of a 
spinning magnetic moment, a proton, such as those constituting the nuclei of hydrogen atoms in 
physiological water and fat molecules can be described using classical physics as a spinning bar 
magnet that can point up or down. Manipulation of these magnetic moments using external 
magnetic fields is utilised in MRI to produce an image. The term spin, proton and nuclei are used 
interchangeably within this work and all terms refer to any particle with spin and a magnetic 
moment that produces MRI signal. 
Figure 2.1 illustrates the spin up/down states of a proton within an external magnetic field 𝐵0. 
When there is no external field i.e. 𝐵0 = 0, the two spin states are equally populated and 
possess equivalent energy. When the spin population is placed within an external magnetic field 
(𝐵0 > 0) the spin state in which the magnetic moment is aligned to the magnetic field has a 
lower energy than the anti-aligned state. Therefore, it is energetically favourable for spins to 
align with the magnetic field resulting in a small excess of spins aligning with the field. The 
reason that only a small excess, rather than all spins align with the field is due to the thermal 
motion of particles forcing local interaction that equalises the two states. The small excess is 
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therefore temperature dependent and follows the Boltzmann distribution. At physiological 
temperatures this results in a small net magnetisation vector aligned with the 𝐵0 field.  
 
 
Figure 2.1 Ordering of spin states in a magnetic field. (A) When the external field (𝐵0) is zero the 
population of spins in each state is approximately equal As 𝐵0 increases the state aligned with 
the magnetic field has a lower associated energy (+1/2) resulting in a small excess of spins 
(green) taking this state (B). This splitting of states allows spins to absorb energy ∆𝐸 in 
resonance. 
The spin excess ∆𝑁 is equal to the number of additional of spins occupying the aligned state 
(↑) relative to the anti-aligned (↓) state, described by the Boltzmann distribution, Equation 2.1. 
 ∆𝑁 = 𝑁(↑) − 𝑁(↓) =
1
2
𝑁 (𝑒
ℏ𝜔
𝑘𝑇 ) =
1
2
𝑁 (𝑒
∆𝐸
𝑘𝑇) Equation 2.1 
Where N is the number of spins, ℏ is the reduced Planck constant, 𝜔 is the Larmor frequency 
(see below), k is Boltzmann’s constant and T is temperature. The spins are able to absorb energy 
equal to the energy gap between these two states. The relative proportions of these two states 
becomes higher at increasing field strengths. A higher main 𝐵0 field therefore produces a larger 
magnetic moment as more spins align with the field, producing a correspondingly higher signal 
due to increased interaction with detection coils (see 2.3.3). 
The external field exerts a torque or turning force on the spinning magnetic moment of the 
protons within the field. This torque causes them to precess about the axis to which they align. 
The angular frequency of this precession (Larmor frequency) was described by Joseph Larmor in 
the early 1900s by Equation 2.2. 
 𝜔 = −𝛾𝐵0 Equation 2.2 
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Where 𝐵0 is the main magnetic field strength, 𝛾 is the gyromagnetic ratio – a constant 
determined by the nuclei being imaged and 𝜔 is the precessional Larmor frequency. Hydrogen is 
the most abundant element in the body and as such is the main target for MRI imaging providing 
the highest signal. Hydrogen precesses at a frequency of 42.6 MHz/T, in a modern clinical system 
(𝐵0 = 3𝑇) this results in resonant absorption occurring at 127.8MHz in a preclinical 9.4T system 
such as that used throughout this work resonance occurs at 400.4MHz. These frequencies fall 
within the radio frequency (RF) spectrum. RF energy can be used to perturb the physical state 
described above and produce image data, this process will be described below following a brief 
introduction to the key components in an MR imaging system.  
 
2.3.2 The components of an MRI system 
This section will describe the hardware required for MRI imaging, how these systems are used to 
create an image will be described in the following section (2.3.3). The basic components of an 
MRI system can be split into 3 subsystems, these are the magnet, equipment and control 
systems. Figure 2.2 illustrates how these components are connected. The magnet is the system 
that performs the imaging and produces the various magnetic fields and RF energy 
transmission/detections to/from the body being imaged. The magnet system is stored within a 
room where walls often have magnetic, acoustic and RF shielding to minimise external sources 
of interference. The magnet is housed adjacent to an equipment room that stores the electrical 
amplifiers required to produce the rapid gradient and RF switching with timing provided by the 
MRI console. This room also houses the cooling equipment that maintains the temperature of 
the gradients to maintain electrical performance. From Equation 2.1 we can see that the 
population of spins in the aligned state increases with field strength 𝐵0, more spins in this state 
produces a larger net magnetisation vector that can induce higher signals within detecting 
electronics. Modern MRI systems will have main field strengths in excess of 1.5T. Creating this 
high field requires many loops of wire carrying a high current. The heating induced by resistance 
in these wires at these high currents means that the main field electromagnet is constructed 
with superconducting wires with a critical temperature of around 4K requiring cryogen cooling. 
The equipment room stores the cryogen compressor that circulates liquid helium within the 
magnet to maintain the critical temperature of the superconducting wire. The final room is the 
control room where the MRI system operator controls the magnet using a computer running 
specialised software produced by the magnet manufacturer as well as physiological monitoring 
systems. 
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Figure 2.2 Complete MRI system. The system is spread over 3 rooms- the magnet room, the 
equipment room and the control room. Image credit Agilent 9.4T manual. 
For the following sections it is necessary to look in more detail at the magnet system, specifically 
magnetic gradients used for image formation (2.3.4) and RF coils for signal excitation and 
detection (2.3.3). 
The gradients are additional resistive electromagnets built within the main magnet body that are 
used to modulate the main field creating spatial dependence in precession frequency. Three 
gradient systems are used to modulate the field in the x, y and z directions respectively. These 
gradient systems may also be referred to as the phase encoding, frequency encoding and slice 
select gradients depending on the orientation of the imaging plane. The approximate 
configuration of these coils is shown in Figure 2.3. The z gradient by convention induces 
magnetic fields that superimpose with the main field in the axis of the scanner these coils are 
produced in a circular Maxwell coil configuration. The x and y gradients induce fields that 
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superimpose on the main field in the x and y directions perpendicular to the main field. The x 
and y directions are typically arranged in a Golay coil configuration. 
 
Figure 2.3 MRI gradient systems. The z gradient modulates the field in the direction of the main 
field. The x and y gradients modulate the field in the perpendicular directions. Vector plot below 
each gradient shows the resulting magnetic field when each gradient is turned on. Note that the 
x and y gradient act only on the z components of 𝐵0. 
RF coils are the components that transmit and detect RF frequency energy for manipulating the 
spins within the system. In the most basic sense the RF coils are loops of conducting wire that 
produce an additional magnetic field denoted 𝐵1 that is discussed further below. The majority of 
RF coils used for this work operate as both RF transmitter and receivers, however it is sometimes 
preferable to use a larger volume transmit coil with a separate detection coil close to the organ 
being imaged. The voltage induced in the coil by the precession of the magnetisation has a 
distance dependence and placing the receive coil as close to the organ as possible allows for 
higher signal detection. 
 
2.3.3 Excitation, relaxation and detection 
In the above sections the manipulation of the net magnetisation vector has been described as 
fundamental to the imaging process in MRI, this section will elaborate on that and describe how 
𝑀0 can undergo excitation and relaxation to produce measurable signals.  
The excitation process is induced by the application of a 𝐵1 field produced by current in the RF 
coil as described above. The 𝐵1 field is a rotating magnetic field applied perpendicular to the 
main 𝐵0 field. The frequency of the rotation is matched to the Larmor frequency meaning that 
spins within the 𝐵1 field absorb the RF energy transmitted by the coil. As they absorb RF energy 
the spins rotate to align with the 𝐵1 field offsetting the net magnetisation vector 𝑀0. These 
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rotating 𝐵1 magnetic fields are switched on briefly in what is termed an RF pulse. The duration 
and magnitude of the RF pulse determines the angle to which 𝑀0 is tipped relative to the main 
𝐵0 field. 
The excitation process is illustrated in Figure 2.4. The net magnetisation 𝑀0 initially points along 
the main field typically defined as the z axis. The application of the perpendicular 𝐵1 field 
oscillating at the Larmor frequency induces a reorientation of 𝑀0 so that it lies in the transverse 
plane. When the RF pulse is switched off and 𝐵1 returns to zero, 𝑀0 is in an unstable state and 
attempts to return to equilibrium along the z-axis. In the lab (stationary) reference frame this 
relaxation process occurs as a dense spiralling precession about 𝐵0 where 𝑀0 spins at the 
Larmor frequency while undergoing both longitudinal (along z) recovery and transverse (xy 
plane) relaxation. If we view the process from a reference frame rotating at the Larmor 
frequency, then the process is greatly simplified and 𝑀0 returns to equilibrium along a linear 
path where both longitudinal and transverse relaxation occur exponentially.  
 
Figure 2.4 Relaxation of 𝑀0 in the lab and rotating frames of reference. The red vector shows the 
NMV and the blue lines show the trajectory of the tip of the NMV. This illustrates the relaxation 
in the transverse (xy plane) and longitudinal (z) recovery of the magnetic vector. The lab view is 
the stationary reference frame and shows the rapid precession of the NVM, the rotating frame is 
an aid to visualising the spin relaxation in a reference frame rotating at the Larmor frequency.  
64 
 
The longitudinal and transverse recovery times are governed by the local magnetic environment 
that can be altered by the presence of molecules indicating disease or dysfunction. The 
longitudinal recovery is due to the exchange of energy with surrounding nuclei, atoms and 
molecules through physical collisions or electromagnetic interaction. These interactions create 
small fluctuations in the local magnetic field and these fluctuations occur at a frequency called 
the tumbling rate, related to properties of the molecule. When the tumbling rate of molecule is 
close to the Larmor frequency, the energy exchange is more efficient resulting in faster 
longitudinal recovery. The energy input to the system through the 𝐵1 field is dissipated to the 
surrounding molecules as heat and equilibrium returns. This longitudinal relaxation process 
occurs exponentially and is governed by Equation 2.3.  
 
𝑀𝑧 = 𝑀0 (1 − 𝑒
−𝑡
𝑇1) 
Equation 2.3 
Where 𝑀𝑧 is the component of magnetisation along the longitudinal axis, 𝑀0 is the unperturbed 
net magnetisation vector, 𝑡 is the time since recovery began and T1 is the relaxation constant 
that determines the rate of recovery. For this reason, longitudinal recovery is often termed T1 
relaxation and T1 mapping is a valuable quantitative technique in MRI where this constant is 
measured for regions of tissue.  
The mechanism by which the transverse component of magnetisation is lost following excitation 
is termed spin-spin relaxation and is due to the interaction between neighbouring nuclei. 
Transverse relaxation occurs much more rapidly than longitudinal recovery. The transverse 
component of magnetisation is dependent on adjacent nuclei precessing with a coherent phase. 
Immediately following an RF pulse the spins can be considered to be precessing in phase with 
each other. Due to the variation in the magnetic field strength at microscopic and nanoscopic 
scales these spins experience slightly different magnetic fields and so begin to precess at slightly 
different frequencies. Differences in precision frequency lead to magnetic interaction between 
neighbouring nuclei inducing further dephasing until the transverse component of 
magnetisation has a net value of zero. Transverse relaxation follows an exponential decay curve 
described by Equation 2.4. 
 𝑀𝑥𝑦 = 𝑀0𝑒
−𝑡
𝑇2 
Equation 2.4 
Where 𝑀𝑥𝑦 is the transverse component of the net magnetisation vector and 𝑇2 is the 
transverse relaxation decay constant. As was the case with T1 relaxation transverse relaxation 
through this spin-spin interaction is named for this relaxation constant and called T2 relaxation. 
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In any real experiment transverse relaxation occurs at a faster rate than would be predicted by 
inter-spin nuclear interactions. The cause of this faster decay is the inhomogeneities in the main 
magnetic field 𝐵0. These inhomogeneities arise from many different imperfections in the system 
including hardware limitations, poor shimming, high magnetic susceptibility boundaries at tissue 
interfaces and magnetic particles. This accelerated T2 decay is called T2* decay and follows the 
same relaxation equation given in Equation 2.4. Importantly T2* relaxation can be recovered 
using a spin echo acquisition (see 2.3.5). This recovery is possible because the T2* relaxation is 
not random but dependent on position within the field and is therefore not a true relaxation 
process.  
Following application of 𝐵1 and perturbation of the magnetisation vector the coils switch to 
receive mode, where the precession of 𝑀0 can be detected as an induced voltage within the 
receiving coil that may be the same one used to transmit the 𝐵1 field. This voltage is induced by 
the interaction of a rotating magnetic field with a conductor. Typical MRI systems detect this 
voltage in quadrature. This means that two coils are used making the system sensitive to the 
voltage induced in two orthogonal directions. The detected signal from these orthogonal 
receivers can be represented as a vector in complex space where the signal from one channel is 
termed real and the other is termed imaginary and multiplied by the complex number 𝑖. This 
process is illustrated in Figure 2.5. 
 
Figure 2.5 Quadrature detection of the NMR signal. Two coils sensitive to the magnetisation in 
orthogonal planes measure the same precessing magnetisation vector 𝑀 meaning that it can be 
described with both a magnitude (M) and a phase (𝜑). 
The voltages induced in each coil are able to describe the same precessing magnetisation (M) 
but with a π phase shift between them. This means the system can describe the magnetisation 
vector with both a magnitude and direction. The designation of which coil is imaginary or real is 
arbitrary since both coils measure the same real signal. The introduction of the imaginary 
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component is purely to allow for the description of the vector in complex space. The magnitude 
and direction of the quadrature detection are used to create images based on the MRI signal size 
in a ‘magnitude’ reconstruction or the angle of rotation in a ‘phase’ image. The values of 
magnitude and phase are calculated by Equation 2.5 and Equation 2.6 respectively. where 𝑉𝐴 
and 𝑉𝐵 are the signals measured by each quadrature coil. 
 M = √VA
2 + VB
2 Equation 2.5 
 φ = tan−1 (
VB
VA
⁄ ). Equation 2.6 
 
These voltages are received by the MRI console where it is digitised before undergoing Fourier 
reconstruction. The processes by which these quadrature voltages induced by a precessing spin 
is translated to an image through spatial encoding is described in the next section. 
 
2.3.4 Image formation and reconstruction 
Using NMR for imaging can be traced back to the original experiments of Lauterbur and 
Mansfield (1973), who demonstrated that the application of spatially varying magnetic fields or 
gradient produced a spatially dependent precession frequency that could be used to create 
tomographic imaging planes.113,114 
The 3 gradient sets described above in the introduction to MRI hardware are essential in 
creating this spatial selectivity in NMR that allows us to form images. The three gradients 
combine in a linear fashion with each other and the main magnetic field 𝐵0 to produce magnetic 
gradients that can be orientated in any direction. The three orthogonal directions created by 
these gradients are termed the slice select, phase encode and frequency encode gradients. Each 
of these gradients is used to spatially localise the NMR signal within 3D space by altering the 
Larmor frequency with modulation of the magnetic field experienced by spins as a function of 
distance along that gradient. The full spatial encoding process will be described in 3 steps 
relating to the order in which the steps are played out during a typical MRI acquisition. The first 
step is slice selection, the second is phase encoding and finally frequency encoding. These three 
steps and how they encode position in 3D space is illustrated in Figure 2.6. 
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Figure 2.6 Full spatial encoding in 3D space requires the application of 3 orthogonal magnetic 
gradients defined as the slice select (1-Gss), phase encode (2-Gpe) and frequency encode (3-Gro) 
gradients. These are used to induce changes in the precession frequency or phase of spins with 
spatial dependence. The three orthogonal gradients can be reoriented to any direction to image 
different slice orientations. The acquired signal from this encoding is a superposition of all 
frequencies along one line of phase encoding and so requires separation by Fourier transform. 
The first gradient to be applied is the slice select gradient (Gss), this is switched on during the 
application of the RF pulse and localises the excitation to a 2D plane with thickness ∆z. The 
frequency of the coincident RF pulse will have a bandwidth ∆f and this range of frequencies will 
centre on the Larmor frequency in a slice of tissue with thickness ∆z. Where ∆z depends on 
excitation bandwidth and the steepness of the slice select gradient. 
The second applied gradient is the phase encoding gradient which while applied causes spins 
that have been excited by the RF + slice select gradient (i.e. in the imaging plane) to precess at 
different frequencies along that direction. Where the phase encode gradient is lower than the 
𝐵0 field the spins will precess slower and where it is higher they will precess faster. Once the 
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phase encode gradient is switched off, the spins return to precessing at the same frequency but 
have acquired a phase shift related to their position along the phase encode gradient. 
The final spatial encoding gradient to be applied is the frequency encoding gradient which is 
applied for longer than the other two and coincides with the readout of the RF coil, hence this 
gradient is often called the readout gradient (Gro). The application of the readout gradient has a 
similar effect on the spins as the phase encode gradient, making the spins precess faster at high 
gradient and slower and low gradient strengths. The RF coils detect the precession frequencies 
of spins during the application of this gradient resulting in the detection of a composite signal 
containing many different frequencies corresponding to all points along the readout gradient 
direction. The process is repeated for a series of different phase encoding gradients that allow 
the readout gradient to read out one line of phase encoded data per repetition. This is repeated 
until the whole FOV has been sampled.  
Since the data acquired is in the frequency domain, the data is filled into a mathematic k-space 
matrix. Simply put, k-space is to frequency information what an image is to spatial information 
and a Fourier transform is the mathematical process that can transform one to the other. Where 
in image space we observe x and y, in k-space we sample the spatial frequencies kx and ky. Each 
point in k-space represents how much of a specific spatial frequency is contained within the 
acquired image. In general, high spatial frequencies contain image resolution and edges, while 
low spatial frequencies contain the image contrast. The data acquired by digitising the detected 
signal during the readout/ frequency encoding gradient fills one line of k-space since it is a 
superposition of all the frequencies across the receiver bandwidth. In a standard Cartesian 
acquisition, the phase encoding gradient is stepped linearly across k-space so that one line of k-
space is filled per repetition (also called a phase encoding step) resulting in a full k-space matrix 
that contains all the spatial frequencies required to reconstruct the tomographic slice being 
imaged.  
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Figure 2.7 In a Cartesian acquisition k-space is filled in line by line requiring a separate phase 
encoding gradient for each line of k-space. Here only the central phase encoding steps are shown 
for clarity. Once k-space is filled an inverse fast Fourier transform can be applied to complex data 
to produce a complex image that can then be transformed to magnitude or phase contrast. 
Each pixel in the acquired k-space matrix is of the complex form 𝑉𝐴 + 𝑖𝑉𝐵. Performing a 2D fast 
Fourier transform on this data produces another complex image in image space from which 
magnitude and phase images can be calculated as described in Equation 2.5 and Equation 2.6. 
 
2.3.5 Gradient echo and spin echo 
Specific compositions of RF pulses and gradients are called pulse sequences. The most common 
types of pulse sequence are the gradient echo and the spin echo which are the basic imaging 
modules often combined with other RF pulses and gradients to produce more specific contrast 
or encoding properties. It is therefore helpful to have an understanding of how the gradient 
echo and spin echo form images. A pulse sequence diagram represents each gradient and coil as 
a line with time in the horizontal axis. The basic pulse sequence diagrams for each sequence are 
shown in Figure 2.8 and Figure 2.9. The choice of gradient echo or spin echo readout depends on 
the application of the pulse sequence. Gradient echo pulse sequences tend to be much faster at 
acquiring data but spin echoes tend to have better SNR due to the refocussing pulse removing 
the T2* relaxation effect.  
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Figure 2.8 Gradient echo MRI acquisition pulse sequence. In this diagram the net magnetisation 
is displayed a red vector while the individual spins are represented in blue. (1) An RF pulse of flip 
angle α tips the magnetisation into the transverse plane where the spins are dephased by the 
gradients occurring at (2) reducing the magnitude of the net magnetisation. The spins are then 
brought back into coherence by the readout gradient at (3) before reaching complete coherence 
at (4) and then dephasing in the other direction at (5).  
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Figure 2.9 Spin echo MRI acquisition pulse sequence. In this diagram the net magnetisation is 
displayed a red vector while the individual spins are represented in blue. The magnetisation is 
tipped into the transverse plane by a large 90° RF pulse (A) before the spins are dephased by the 
phase encoding gradients at (B). Another RF pulse of 180° called a refocussing pulse flips the 
magnetisation around (C) so the spins are now rephrasing (D). An echo forms when the spins are 
totally rephased at (E) before losing coherence again after (F). 
These basic pulse sequences are able to produce non-invasive in vivo images of the body. In 
most organs these sequences are suitable but for cardiac imaging a number of additional 
complications unique to the heart must be taken into consideration. The following sections will 
discuss MRI specifically in the context of practical cardiac imaging.  
 
2.3.6 Local hardware 
The MRI system used throughout this work was a 9.4T main field imaging system (Agilent 
technologies, Santa Clara, CA, USA). The system was equipped with 400mT/m gradients with a 
gradient bore diameter of 120mm, a geometrically smaller gradient set insert was available with 
a maximum ramp of 1000mT/m and a diameter of 60mm. These gradient configurations were 
used for rat and mouse imaging respectively. The basic components of the magnet setup are 
described in Figure 2.10. 
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Figure 2.10 Varian system used for all MRI experiments. A- heated water lines; B- main magnet 
and cryogen storage; C- anaesthetic delivery and scavenger; D- fibre optic cables for 
physiological monitoring; E- small gradient inserts; F- larger gradients; G- shim coils; H- scanner 
bed. 
RF transmission and detection was performed with a variety of MRI specific RF coils (RAPID 
Biomedical, Rimpar, Germany). All in vivo mouse imaging and ex vivo MRI used volume 
resonator quadrature RF coils with diameters between 26 – 39mm depending on the size of the 
imaging subject. Rat imaging was performed with a 72mm volume transmission coil with a 4-
channel phased array surface coil for detection. Electrical resonance of the RF coil was tuned and 
matched for optimal signal detection at the NMR frequency of water using an external Probe 
Tuning Device 505NV+ (Morris Instruments Inc, Ottawa, Canada). The imaging system was 
controlled using the Varian VNMRJ software v 3.1 (Agilent, Santa Clara, CA, USA). This program 
performed imaging, shimming and calibration protocols as well as basic reconstruction. All 
custom sequences were written and optimised for implementation in the VNMRJ 3.1 
environment.  
Animals were anaesthetised in an infusion chamber under a mixture of isoflurane and oxygen 
before being transferred to one of the beds shown in Figure 2.11. The size of each is tailored to 
be suited to mouse or rat imaging but both incorporate rectal temperature probes and heated 
water lines to maintain thermostatis, a respiration balloon to record respirations, a gadolinium 
infusion line, 3 subcutaneous electrodes for recording the ECG signal and a nose cone to deliver 
anaesthetic while the animal is in the scanner. 
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Mice were positioned supine in the mouse bed with the ECG electrodes implanted in the 
Einthoven’s Triangle configuration- positive and negative terminals placed on the anterior 
shoulders and a ground lead in the flank. The respiration balloon was taped across the abdomen 
and was decompressed during respiration as the chest moves upwards. For rat imaging the rat 
was placed prone on top of the RF surface array with ECG leads placed across the posterior 
shoulders and the respiration balloon taped across the flank.  
The ECG, respiration and temperature probes were connected to a physiological monitoring 
system (SA Instruments, Stony Brook, NY). This monitoring system was integrated with the MRI 
console to allow for precise respiration and ECG image acquisition gating.  
 
Figure 2.11 Cardiac MRI mouse (A) and rat (B) imaging configurations. A- anaesthetic nose cone; 
B- heated water lines; C- respiration balloon; D- rectal temperature probe; E- gadolinium infusion 
line; F- 3 lead ECG electrodes. Note that ECG leads and infusions lines are also present in the rat 
configuration but not shown.  
 
2.3.7 Image acquisition gating 
The heart is effected by two sources of motion effecting cardiac imaging. The first source is 
cardiac motion in the contraction and relaxation of the atria and ventricles as well as blood flow. 
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The second is respiratory motion that applies large displacements to the heart during inspiration 
and expiration. Images can be severely affected by artefacts if these sources of motion are not 
accounted for and corrected. For this reason the physiological monitoring equipment described 
in section 2.3.6 is used to synchronise the MRI acquisition to physiological motion in a process 
called gating. 
In preclinical MRI where animals are typically anaesthetised during imaging the respiration and 
cardiac motion becomes periodic and predictable and so can be corrected using prospective 
gating techniques. The ECG trace recorded using the physiological monitoring equipment is 
evaluated where the start of each cardiac cycle is identified using a dynamic differential of the 
ECG signal identifying the sharp high amplitude characteristic peak of the R-wave. This event is 
converted to a transistor-transistor logic (TTL) pulse that can be interpreted by the MRI 
acquisition console as an ECG trigger. The same feature tracking system is used for identifying 
the start of inspiration and the end of expiration for respiratory gating.  
For cardiac imaging it is necessary to freeze the motion of the heart during acquisition to 
prevent artefacts. This is typically done by segmenting the k-space acquisition with respect to 
the detected ECG triggers. This technique is described in detail as part of the description of cine 
MRI acquisition described below. Respiratory motion is accounted for by recording the 
respiration events through the balloon probe (see Figure 2.11A.C). This signal is converted to TTL 
pulses at the start and end of each respiration signalling the phases of respiration in which the 
heart is stationary. This gating process is illustrated in Figure 2.12. The analogue respiration 
signal and digitised signal are illustrated in blue and the ECG and digitised signal are shown in 
red. The respiratory motion is stationary when the RESP-GATE signal is 1. The heart is stationary 
at any identical point in the RR interval, and the digitised signal is used as a temporal reference 
to synchronise the scanner to keep acquisitions timed to the contraction cycle. Stationary phases 
of the heart are illustrated by the coloured blocks where blocks of the same colour illustrate 
coherent stationary phases between heartbeats.  
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Figure 2.12 Description of image acquisition gating for cardiac MRI. The respiration trace and the 
ECG trace are converted to digital 0/1 signals. The heart is stationary and at end diastole when 
both gates are equal to 1 (blue blocks) equivalent to a logical AND operation. Applying a 
constant offset from the ECG trigger the heart can be viewed as stationary at different cardiac 
phases cyan, green, orange and red blocks show alternative stationary heart phases.  
 
2.3.1 Cardiac imaging planes 
The structure of the heart is not suited to imaging in the standard body axis image planes (axial, 
sagittal and coronal) due to its double oblique orientation. Tomographic images are therefore 
conventionally reoriented and acquired in the cardiac imaging planes, these are shown overlaid 
on an illustrated human heart in Figure 2.13. Typically three orthogonal planes (e.g. Figure 
2.13.1-3-5) are used for orientation within the image space, once these planes are defined then 
imaging can begin. This reorientation process requires careful slice planning and several pilot 
scans at the start of any cardiac imaging procedure making imaging the heart more complex 
than many other organs. Images acquired in the cardiac axes however provide the best view of 
contractile motion and the simplest delineation of internal structures.   
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Figure 2.13 Illustration describing the cardiac imaging planes. Long axis images (1,2,3) are 
typically used for orientation of the short axis planes (4,5,6) although are also useful in providing 
the most complete single slice views of the heart. Cardiac MRI for structural and functional 
assessment typically uses a stack of cardiac short axis images covering the whole LV. Figure from 
Lang et al. (2006)115 
Representative images of the wild type mouse heart in these planes are shown in Figure 2.14A at 
end systole and diastole to illustrate their appearance in MRI. The most commonly used axis for 
describing the heart is the short axis view and this will be used as convention for presenting 
results in this thesis. The 4 chamber long axis view provides a view of a large number of cardiac 
structures as illustrated in Figure 2.14B. The short axis is preferred since the LA view is severely 
affected by partial volume effects (see Figure 2.14A- 2ch LA at end-systole) when the contracting 
myocardium passes through the image plane making functional quantification difficult.  
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Figure 2.14 (A) Representative images showing the appearance of the cardiac axes in bright-
blood MR images. LA- long axis; SA- short axis; ED- end diastole; ES- end systole. (B) detailed view 
of the 4 chamber long axis view of the heart at end diastole. LSA- left subclavian artery; LA- left 
atrium; MV- mitral valve; LV- left ventricle; LCC- left common carotid artery; BA- brachiocephalic 
artery; AO- aorta; RA- right atrium; RV- right ventricle.  
 
2.3.2 Cine MRI 
Cardiac cine imaging is the workhorse of cardiac MRI and is used to provide quantification of 
global cardiac function and visual assessment of cardiac motion. Cine imaging acquires a time 
series of static images of the heart that when displayed sequentially visualises the beating heart. 
Cine imaging relies on accurate gating for physiological motion as described above (2.3.6). Due 
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to the rapid heart rate of small animals used in preclinical imaging each segment of k-space must 
be acquired in <10ms requiring a fast gradient echo (GRE) acquisition sequence. Note that Figure 
2.12 shows 5 stationary phases of the heart but the RR interval can be split arbitrarily into any 
number of stationary phases. Hardware limitations determine the maximum number of frames 
in a cine sequence. A typical mouse heart rate of around 550ms will allow for 20-25 frames with 
a TR=5ms. The basic principles of the cine acquisition scheme and the GRE pulse sequence are 
described in Figure 2.15.  
 
Figure 2.15 Cine MRI acquisition sequence. A GRE readout acquires one line of k-space per time 
frame sequentially for each ECG trigger. This repeats until each 2D k-space matrix is filled. A FFT 
applied to the data translates the frequency and phase information in k-space to image space. 
The raw data the cine sequence acquires fills a stack of 2D k-space arrays where each 2D array is 
a stationary phase in the cardiac cycle. To describe the cine acquisition each line of k-space will 
be assigned 𝑘𝑛,𝑡 describing the 𝑛𝑡ℎ line of k-space in the image in the cardiac cycle 𝑡. Note that 
𝑛 and 𝑡 are defined by the user as the image acquisition parameters for acquisition matrix size 
and number of cine frames respectively, A cine data stack will have dimensions 𝑛 × 𝑛 × 𝑡. The 
sequence starts after the detection of an ECG trigger initiating the acquisition of the first line of 
k-space for every frame in the cardiac cycle 𝑘1,2, 𝑘1,3, 𝑘1,4  … 𝑘1,𝑡. At the detection of the next 
ECG trigger the acquisition repeats for the second line of k-space 𝑘2,1, 𝑘2,2, 𝑘2,3  … 𝑘2,𝑡. This 
process repeats until 𝑘𝑛,1, 𝑘𝑛,2, 𝑘𝑛,3  … 𝑘𝑛,𝑡 and each 2D k-space array is fully acquired for each 
point in time. During this acquisition respiratory motion continues, when the respiration gate 
switches to 0 the scanner continues to transmit the pulse sequence as normal but does not 
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acquire data. This means data is acquired only in the stationary phases of respiration but the 
magnetisation history is not perturbed helping maintain the steady state.  
Cine sequences are typically acquired with low flip angles <30° which produces bright blood 
contrast aiding in the segmentation of the blood pool from the myocardium. In cases where it is 
necessary to identify the epicardial boundaries (e.g. wall thickening Chapter 4 a lower flip angle 
is used, at 9.4T good epicardial contrast is seen with a flip angle of around 5-10°. Typical cine 
acquisitions for assessing global cardiac function for the work undertaken for this thesis had 
resolution = 0.2×0.2×1mm; TR = 5ms; TE = 1.1ms; flip angle = 15°.  
Visually cine images can provide qualitative assessment of myocardial mechanics and 
morphology but for research purposes it is necessary to quantify these images. This 
quantification requires segmenting cine images to identify the myocardial boundaries. An 
example of a processed cine image is shown in Figure 2.16. Cine images were processed by 
segmenting the endocardial boundaries at systole and diastole for each 2D image in the cine 
stack. Segmentation was performed using a semi-automatic method implemented in the freely 
available software Segment v2.0 R5294 (http://segment.heiberg.se/). 
 
Figure 2.16 Cine image analysis in Segment, numbers indicate slice order from 1 (apex) to 8 
(base). By identifying the epicardial (green) and endocardial (red) boundaries at systole and 
diastole information about the blood volume and myocardial shape can be calculated. 
Once the endocardial and epicardial boundaries are segmented then a number of useful and 
quantitative cardiac metrics can be calculated, these are summarised in Table 2.1. The most 
commonly used value is left ventricular ejection fraction- the fraction of blood ejected from the 
LV during each cardiac contraction. This is a widely accepted value for global heart function and 
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is lowered is disease as the heart pumps less efficiently. End diastolic volume is another useful 
measure that gives information about the dilation of the LV following adverse post-infarct 
remodelling. 
Table 2.1 Summary of quantitative values calculated from epicardial/endocardial segmentation. 
Where V is the volume of one voxel calculated from image acquisition matrix size and FOV, and 
𝑁𝑟𝑒𝑔𝑖𝑜𝑛
𝑝ℎ𝑎𝑠𝑒
 is the number of pixels in a segmented region at a specific phase of the cardiac cycle and 
bpm is the heart rate. 
Value Principle Equation 
End systolic 
volume (ESV) 
Volume of the heart at end systole [μl] 𝐸𝑆𝑉 = 𝑉 × 𝑁𝑏𝑙𝑜𝑜𝑑 𝑝𝑜𝑜𝑙
𝑠𝑦𝑠𝑡𝑜𝑙𝑒
 
End diastole 
volume (EDV) 
Volume of the heart at end diastole [μl] 𝐸𝑆𝑉 = 𝑉 × 𝑁𝑏𝑙𝑜𝑜𝑑 𝑝𝑜𝑜𝑙
𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑒  
Stroke volume (SV) 
Volume of blood ejected with each 
contraction [μl] 
𝑆𝑉 = 𝐸𝐷𝑉 − 𝐸𝑆𝑉 
Ejection fraction 
(EF) 
Fraction of blood ejected with each 
contraction [%] 
𝐸𝐹 =
𝑆𝑉
𝐸𝐷𝑉
× 100 
Cardiac output 
(CO)  
Volume of blood pumped per unit time 
[μl /min] 
𝐶𝑂 = 𝑆𝑉 × 𝑏𝑝𝑚 
Left ventricular 
mass (LVM) 
Mass of left ventricle [μg] 
𝐿𝑉𝑀 = 
𝑉 × 𝑁𝑚𝑦𝑜𝑐𝑎𝑟𝑑𝑖𝑢𝑚 × 1.05 
 
 
2.3.3 Cardiac T1 mapping 
T1 mapping is used for quantitative assessment of T1 relaxation and is performed by fitting the 
T1 decay constant to every pixel time course in an image sampling the magnitude of the T1 
signal. Inversion recovery is the most common imaging technique for measuring T1 relaxation. 
The standard cardiac inversion recovery sequence is shown below in Figure 2.17. Inversion 
recovery refers to the process of applying a complete global 180° inversion RF pulse that flips 
every spin within the imaging volume by 180°. Following inversion, the longitudinal T1 
magnetisation begins to recover to the equilibrium following a T1 relaxation curve as described 
in Magnetic Resonance Imaging. Sampling at positions along this relaxation curve then allow for 
fitting of the T1 constant. 
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Following the first instance of respiration and ECG gate equal to 1, the 180° RF pulse flips all 
spins. The recovery of the T1 relaxation is then imaged at each RR interval. In the figure we show 
up to 3 ECG triggers acquiring at 3 different inversion times (TI – the time since the inversion 
pulse). In cardiac MRI the TI must always be integer multiple of the RR interval. The sequence 
shown is repeated for every phase encoding line to produce an image sequence showing the 
recovery of the T1 signal. Since the MRI scanner measures all signals as positive the recovery 
curve is constrained to lie above the x-axis resulting in an image sequence that starts bright, 
goes dark and then recovers to bright again. Following each sequence of samples an inversion 
recovery delay time is given to allow full magnetisation recovery before the next inversion. 
This type of acquisition where the T1 relaxation curve is repeatedly sampled over the course of a 
single inversion-recovery cycle was developed by Look and Locker and carries their name (Look-
Locker sequence). Each sample on the T1 relaxation curve requires an excitation and gradient 
readout that removes energy from the system and perturbs the relaxation. The result of this is 
that the magnetisation will recover to a saturated state. The Look-Locker sequence therefore 
typically uses a sequence of low flip angle gradient echo readouts to minimise perturbation to 
the T1 recovery curve. The more frequently the recovery curve is sampled the greater the 
saturation of the recovery and 𝑀𝑧 → 𝑀𝑧𝑐𝑜𝑠(𝛼) as more samples are acquired. This saturated 
recovery can be accounted for when fitting the T1 recovery curve by applying the look locker 
correction factor as derived by Deichmann et al. (1992).116 In brief the saturated Look Locker 
recovery can be fitted with the three parameter partial solution given by Equation 2.7. The fitted 
values of 𝑀0, 𝛽 and 𝑇1
∗ can then be used to recover the true decay signal assuming linear 
spacing between echoes (i.e. consistent heart rate) using Equation 2.8. 
 𝑀𝑧(𝑡) = 𝑀0 (1 − 𝛽𝑒
−
𝑡
𝑇1∗) Equation 2.7 
 𝑇1 = 𝑇1∗(𝛽 − 1) Equation 2.8 
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Figure 2.17 Basic cardiac inversion recovery imaging sequence. Following the detection of an ECG 
trigger the sequence applies a 180° inversion pulse and then samples the T1 recovery curve using 
a small flip angle (α) GRE readout at each subsequent ECG trigger to the specified number of 
inversion times. The sequence repeats for each phase encoding step. The saturation effect of the 
look-locker readout on the T1 recovery curve is shown in red.  
The Look Locker acquisition scheme described above acquires a single line of k-space per RR 
interval. To fill a typical acquisition matrix for mouse imaging of 128 lines this requires 
128×(IRD+NTI×RR) seconds, where NTI is the number of inversion times sampled, IRD is the 
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inversion recovery delay time and RR is the RR interval. Typical values for these parameters 
result in an acquisition time around 20 minutes depending on heart rate. This long acquisition 
time can make T1 impractical for inclusion in preclinical studies that perform a wide range of 
other imaging techniques, especially in the case of ECVF mapping (section 7.3) where two T1 
maps are required. To reduce the scan time of T1 mapping a segmented k-space acquisition 
protocol was implemented for some work in this thesis. The segmented k-space approach was 
developed by Dr Adrienne Campbell-Washburn and has been extensively validated against the 
standard Look-Locker acquisition.117 This approach acquires 4 lines of k-space per RR interval, 
thereby sampling the whole of k-space within a quarter of the time. Each of these 4 samples 
have individual excitation pulses and encoding gradients and so must be performed in quick 
succession to avoid motion artefacts. The T1 mapping performed for the preclinical thalassemia 
imaging project (Chapter 3) used the single line per RR interval scheme while every other 
chapter used the accelerated segmented k-space approach. 
Both of the standard and segmented k-space Look-Locker techniques for investigating T1 
relaxation are incompatible with respiration gating. This results in acquisitions over respirations 
resulting in corrupted images (Figure 2.18). The effect of this motion on T1 decay model fitting is 
dependent on the respiration frequency and heart rate. When the respiration rate is low (40 -50 
/minute) the model fitting is robust to outliers as seen in Figure 2.18A. High respiration rates 
(50+ /minute) where a large fraction of images are corrupted can lead to inaccurate fitting 
shown by the different T1 relaxation curves in Figure 2.18B. To compensate for this a respiration 
image removal algorithm was implemented for all T1 data sets. Corrupted frames were 
automatically removed retrospectively using the phase encoded noise-based image rejection 
(PENIR) scheme.118 PENIR exploits the presence of extra-corporeal ghosting artefacts in the 
phase encode direction induced by respiratory motion to identify acquisitions occurring during 
respiration without requiring a log of acquisition and respiration. When the mean noise signal in 
the extra-corporeal space exceeds a dynamic threshold determined by the noise mean + 
standard deviation then an image is said to be corrupted. The threshold was updated every 10 
inversion times (TI’s) to account for T1 signal recovery.  
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Figure 2.18 These images show the effect of motion corrupted frames (yellow) on T1 relaxation 
fits. Red lines show the fitted T1 including corrupted frames and blue lines are fitted with these 
frames excluded. Low respiration rates (A) have little effect on T1 fitting but at high respiration 
rates (B) the effect can become significant. 
 
2.3.4 Contrast agents 
Endogenous MRI contrast depends on three properties of tissue- T1, T2 and spin density. 
Differences in these properties alter the response of tissue to a pulse sequence resulting in 
varying signal magnitude with contrast depending on the pulse sequence applied. Contrast 
agents are exogenous molecules that alter the T1 and/or T2 of the tissue around them, providing 
sensitive and specific markers for their distribution. The spatial localisation of contrast agents 
85 
 
makes them valuable tools for tracking material such as regeneration cells or biomaterials as 
well as useful diagnostic agents for assessing pathology in which their distribution is altered.  
Paramagnetic MRI contrast agents such as gadolinium shorten T1 relaxation in the surrounding 
tissue causing comparatively faster relaxation to equilibrium and therefore a brighter signal. 
When the contrast enhanced region is brighter than surrounding tissue this is known as positive 
contrast. Alternatively, superparamagnetic iron contrast agents have a T2/T2* shortening effect 
that creates regions of hypointensity in T2 weighted imaging. These regions of lower signal have 
negative contrast. A wide variety of MRI contrast agents based on gadolinium and iron oxide 
have been approved for use by the FDA and European Union.119 The work undertaken in this 
thesis does not make us of exogenous iron contrast agents, although the T2/T2* shortening 
effect of iron is described in more detail in the context of pathological iron overload in Chapter 
3. 
Gadolinium based contrast agents universally contain the paramagnetic ion of the lanthanide 
metal gadolinium (Gd3+). This ion has almost identical ionic radius to calcium meaning that it 
competes with calcium in all biological processes in which calcium is active.120 The trivalent ion 
binds with higher affinity than biological Ca2+ and the replacement of calcium within these 
processes alters the kinetics of that biological process. This property makes Gd3+ as a free ion 
extremely toxic. For this reason, Gd administered as a contrast agent is always chelated with 
organic ligands such as diethylenetriaminepentaacetic acid (Gd-DTPA).  
The T1 shortening effect of Gd based contrast agents such as Gd-DTPA arises from the seven 
electrons in the valence shell of gadolinium bestowing these molecules with a high magnetic 
moment. This high magnetic moment shortens T1 in the surrounding tissue by increasing the 
dipole-dipole relaxation interaction (2.3.3). This leads to an efficient exchange of energy 
between bound protons in tissue and nearby Gd ions shortening both the T1 and T2 relaxation 
constants. This prominently effects T1 at clinically approved concentrations of Gd-DTPA 
(between 0.1-0.3mmol/kg body weight) making Gd-DTPA primarily a T1 contrast agent.121 Gd 
based contrast molecules are nonspecific agents that are too large to enter the intracellular 
space giving them a biodistribution occupying the vascular and extracellular space and cannot 
cross the blood-brain barrier in normal physiology. 
Gadolinium based contrast agents are used throughout this work as an aid to enhancing the LV 
blood pool, for mapping ECV and identifying viable tissue through late gadolinium enhancement.  
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2.3.5 Late Gadolinium Enhancement 
Late gadolinium enhancement (LGE) is a common cardiac MRI protocol that is used for assessing 
the extent of myocardial scarring following myocardial infarction. LGE is based on the inversion 
recovery MRI sequence as described for T1 mapping in 2.3.3. The shape of the Inversion 
recovery curve allows the signal from a tissue of a specific T1 to be nulled if imaged at the TI 
where the relaxation curve crosses zero.  Selective nulling of tissues can allow easy delineation 
of nearby regions with different T1 by making them appear comparatively brighter.  
Following injection of a Gd contrast agent the contrast distributes throughout the extracellular 
space. In healthy tissue this distribution is even throughout tissues. In infarcted tissue the 
increased extracellular volume fraction due to necrosis and fibrosis causes these regions to 
accumulate a higher fraction of Gd compared to surrounding healthy tissue. This increased 
concentration gives the non-viable infarcted tissue a shorter T1 relative to viable tissue. LGE uses 
this selective distribution of gadolinium contrast within the extracellular space to quantify 
infarcted tissue and identify salvageable myocardium by the relative enhancement versus 
healthy tissue. 
For a typical preclinical LGE imaging protocol an intraperitoneal bolus of Gd-DTPA is injected and 
15-20 minutes given for circulation. During this time, it is sometimes useful to perform a cine 
imaging protocol to take advantage of the brighter blood pool resulting from the circulating Gd-
DTPA. Following this initial waiting period, a T1 scout will be acquired. The T1 scout is a 
shortened version of the Look-Locker sequence described in 2.3.3 that acquires a low resolution 
(96×96) sequence of images only over 6-8 heartbeats in a single mid-papillary level slice. The 
goal of this acquisition illustrated in Figure 2.19 is to identify the number of RR intervals at which 
the healthy myocardium signal is most effectively nulled providing the best contrast with the 
hyperenhanced infarcted tissue.  
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Figure 2.19 TI scout for LGE. The purpose of this acquisition is as a primer for the full LGE image 
acquisition. The aim is to identify the TI at which the differing T1 of viable and infarcted 
myocardium provide the greatest contrast. Typically, this is when the viable myocardium is 
nulled. In this example the myocardial null point is closest to TI (3) or 3 RR intervals after the 
inversion pulse. Yellow arrow indicates infarction. 
The TI scout acquisition is required due to the variability between animals and acquisitions. 
Small differences in heart rate, weight and dosage mean that the null point of the myocardium 
will occur at a different time after inversion and identifying the closest RR interval to the null 
point must always be determined empirically. Following the low resolution scout a multislice, 
high resolution (192×192) image is acquired at the appropriate inversion time. An example full 
resolution image stack in an infarcted mosue is shown in Figure 2.20. 
 
Figure 2.20 Example full acquisition for LGE. The high resolution and multislice acquisition allows 
for accurate quantification of the infarcted tissue as a fraction of the whole LV myocardium. In 
this example the infarct can be seen in the anterior wall in slices 3,4, 5 and 6.  
Quantifying the volume of scarred myocardium was performed by the semi-automated 
Expectation maximisation, Weighted, A priori information (EWA) method proposed by Engblom 
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et al. (2016) and implemented in Segment v2.0 R5270.122 In this method the user defines the 
endocardial and epicardial boundaries and the midventricular septum. This information is used 
to restrict the identified infarction to areas of hyperintensity within the myocardium and to 
utilise a priori information about vessel anatomy. The algorithm is given a culprit artery as a 
priori information allowing for exclusion of artifactual hyperintensity. Step 6 weights the size of 
each pixel based on its intensity. This allows for compensation of partial volume effects where 
the weight of each pixel is a representation of the fraction of dead cells contained within a voxel. 
A processed example is shown in Figure 2.21 for the full acquisition data shown in Figure 2.20 
with the LAD defined as the culprit artery. Knowledge of the culprit artery helps constrain 
infarction identification to physiologically accurate regions. 
 
Figure 2.21 LGE image with infarct quantification performed by the EWA method. Yellow 
boundaries show infarcted pixels. The algorithm has successfully picked up regions of 
hyperenhancement as seen in Figure 2.20 and has used a priori information to restrict artifactual 
identification of infarct. 
 
2.4 Optical Projection Tomography 
Optical projection tomography (OPT) is a fluorescent tomographic imaging technique that is 
used in Chapter 7 to locate the distribution of a transplanted cell sheet. OPT is introduced here 
in the imaging theory section so that its imaging mechanism and uses can be described more 
fully.  The advantage of imaging fluorescent samples with OPT over more traditional methods 
such as fluorescence microscopy is that it offers a wider large field of view that can image whole 
organs with the 3D distribution of fluorescence. OPT is a non-destructive technique making it 
applicable to imaging the in situ distribution of fluorescent molecules such as those bound to 
cells. This wide field of view does however come at a cost of spatial resolution. OPT is not able to 
resolve single cells but is a valuable tool for imaging the distribution of transplanted cells over a 
wide area.   
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2.4.1 Origin of OPT signal 
Optical projection tomography is a 3D ex vivo optical imaging technique using light emissions or 
transmission for transparent samples of approximately 1-20mm. In transmission mode, the 
system works in a fashion analogous to x-ray computed CT, where the attenuation of x rays as 
they pass through a sample generate image contrast. In this case, light in the optical band is 
attenuated through the sample and the variable attenuation coefficient of the tissue for that 
wavelength provides tissue contrast. In transmission mode then the contrast originates only 
from tissue features and can provide high resolution structural information with resolutions of 
approximately 100um. An alternative contrast mechanism for OPT is from optical fluorescence. 
In fluorescence mode an excitation and or emission filter is introduced to isolate specific spectral 
contents of the optical signal. This allows OPT to produce contrast from light emissions from 
fluorescent molecules. In fluorescence mode the OPT system behaves less like X-ray CT and 
more like a single photon emission computed tomography (SPECT) system where a distribution 
of fluorescent particles provide contrast within a volume. The origin of these molecules can be 
endogenous or exogenous. Fluorescence from endogenous tissues result in a wide range of 
wavelengths from the natural fluorescence of tissue in a process called autofluorescence. 
Alternatively, a targeted exogenous molecular probe can be introduced to the tissue before or 
after excision to produce more specific emissions. These molecular probes can be manufactured 
to bind to specific proteins to produce a fluorescent signal originating only at the site of a 
specific tissue or molecule of interest. Multiple probes can be used in fluorescence imaging with 
appropriate excitation/emission filters. Introducing these molecular probes makes OPT unique in 
being a sensitive and specific modality for imaging gene expression or cellular distributions over 
the scale of a whole organ. 
Optical light is strongly absorbed and scattered in biological tissue limiting visible light 
penetration to approximately 100µm.123 Due to the relatively large samples imaged using OPT 
this necessitates the addition of a chemical clearing process to allow transmission of excitation 
light into tissue as well as emission light out of tissue. Clearing refers to the process of making a 
sample transparent to optical light. The goal of this optical clearing process is to alter the 
refractive index of tissue to match its surroundings. The process of optical clearing was 
pioneered by Tuchin et al. who proposed diffusing a clearing agent with a high refractive index 
into tissue to reduce the degree of internal scattering.124,125 Biological tissue is composed of a 
mixture of components with high e.g. collagen, cell membranes and low e.g. interstitial fluid, 
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cytoplasm refractive index. This combination of refractive indices causes penetrating light to 
frequently change path, scatter and lose coherence. By diffusing the high refractive index 
clearing agent into the extracellular space the refractive indices become matched and are more 
permissive to optical transmission.  
 
2.4.2 Image acquisition and reconstruction 
A schematic of the basic imaging components for an OPT system is shown in Figure 2.22. As 
opposed to CT or SPECT systems the imaging components remain fixed and the sample is 
rotated to provide angular projections. The system operates in a ‘step and shoot’ mode where 
the sample rotates by a fixed angular increment, stops then undergoes illumination and imaging 
before rotating again. A series of lenses focus the emission and excitation light to create a focal 
plane within the sample. Filters within the OPT system can be switched to tailor each acquisition 
to the molecular probes under investigation. An appropriate narrow bandwidth excitation filter 
with peak transmission in the absorption wavelength of the probe produces the maximal 
excitation while minimising the autofluorescent background signal. The excitation filter can 
further isolate the signal from the probe by removing remaining autofluorescent signal. 
Following excitation/emission focussing /filtering the image is formed on a CCD camera resulting 
in a sequence of images showing the angular projections of the sample. An example OPT 
acquisition using transmission and fluorescence mode is shown in Figure 2.23. 
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Figure 2.22 OPT imaging system schematic. An ultraviolet light source illuminates a sample after 
focussing and filtering the light to specify the optical excitation bandwidth. The light then passes 
through the rotating sample before the signal is filtered to isolate the optical emission bandwidth 
and focussed onto a CCD camera.  
To create a tomographic volume from the imaged projections the data is restructured to form a 
sinogram. A sinogram is created by extracting each line of 1D image data orthogonal to the axis 
of rotation and create an array where one axis is the 1D image data and the second axis is 
rotation angle. A sinogram can be transformed into tomographic image space using the radon 
transform with filtered back projection to create a 2D tomographic slice for each line of image 
data.126 
 
Figure 2.23 Example of OPT projections. Here two scaffoldless single cell thick fibroblast sheets 
(discussed further in 7.2) are imaged suspended in agarose. The sheet at the top is composed of 
cells labelled with the membrane stain DiL that has a fluorescent peak at 565nm. In the 
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transmission image both sheets show light attenuation. In fluorescence mode with a Texas red 
filter (peak transmission 560nm) only the labelled cells are visible. A composite image is then 
shown with the fluorescence in the red channel. This figure is extracted from section 7.2 
 
2.4.3 Local hardware 
Prior to OPT imaging samples required optical clearing to allow optical transmission for 
illumination and detection. The optical clearing process began by excising hearts by perfusion 
fixation. The hearts were then immersed in 70% ethanol in PBS for 2 days before switching to 
100% ethanol and allowed to diffuse over 7 days, changing the ethanol every 2 days. This 
removed all water from the tissue, this step is necessary since the clearing solution is 
hydrophobic, dehydration is required to allow the solution to penetrate the tissue. Following 
dehydration, the sample is moved to a solution of benzyl alcohol and benzyl benzoate in a 1:2 
ratio referred to as BABB or Murray’s clear. The sample is left immersed in the clearing solution 
for 10 days, changing the solution every 2 days. Following clearing ,samples were imaged using 
the Bioptonics 3001 OPT system shown in Figure 2.24 (Bioptonics, Edinburgh, UK). The sample is 
attached to the rotating imaging stage using superglue adhesive in a region of tissue that was 
not to be imaged. The sample is then lowered into the imaging chamber and the optical system 
focused to achieve the best resolution in the structures of interest. The sample is then raised 
and a background light field acquisition performed and corrected for. The sample is then 
lowered back into the chamber and the exposure time set for each fluorescence filter. The 
sample is rotated by 0.45° over a full 360° resulting in the acquisition of 800 angular images.  
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Figure 2.24 Bioptonics 3001 optical projection tomography imaging system. A- control system; B- 
light-sealing door; C- rotating imaging stage; D- Light source and diffuser; E- sample chamber; F- 
optical focusing and filtering chamber.  
 
2.4.4 Applications 
The wealth of existing fluorescent optical imaging probes manufactured for use in standard 
microscopy techniques are applicable to OPT imaging with the correct filtering and detection 
systems. This makes OPT uniquely valuable in imaging the whole organ distribution of these 
established probes in 3D. Although the resolution of the system is inferior to standard 2D 
fluorescent microscopy techniques, the capability to image larger samples without sectioning 
makes it useful in imaging larger 3D structures such as in situ engineered tissue. One field in 
which the availability of fluorescent probes has made OPT a useful tool is gene expression. 
Molecular probes that exhibit fluorescence as a marker for the spatial distribution of gene 
expression can be imaged with OPT. An advantage OPT has over standard microscopy 
techniques here is the ability to rapidly image whole samples making high throughput studies 
using multiple markers of gene expression viable. For example Sharpe et al. used multiple 
probes to investigate the 3D developing shape of embryonic mouse organs.127 The authors 
imaged mouse embryos at multiple time points following labelling with two antibodies targeted 
to the HNF3β protein and neurofilaments with individual fluorochromes assigned to each. The 
resulting 3D volume allowed high resolution tracking of the development of nerve tracts and 
HNF3β expressing tissues such as the oesophagus, stomach and lungs. OPT has also found use in 
cardiac imaging. For example, recent work by Zhao et al. (2015) has shown that following 
myocardial infarction and consequential myocardial remodelling the autofluorescence in 
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infarcted tissue measured by OPT is brighter than remote regions.128 The regions of OPT 
hyperintensity correlated with non-viable tissue identified by LGE MRI in vivo. Making it a useful 
alternative to measuring infarct volume in studies of myocardial infarction where expensive MRI 
systems are not available. Finally, and most relevant to studies of tissue engineering and cardiac 
regeneration therapy OPT is able to image high resolution distributions of fluorescently labelled 
cells or structures. Transplantation of labelled therapeutic cells can then be checked for 
retention in the organ as well as the redistribution of cells at the transplant site following 
transplantation. In a related example, Wilkie et al. (2003) used OPT imaging to track progenitor 
cells migrating across the mouse embryo. Knowledge of the intrasample migration of cells will 
be a useful feature of improving cell retention in cardiac regeneration therapy.  
 
2.5 Ultrasound 
In the work presented in this thesis, ultrasound is used to deliver regenerative therapies to the 
heart in two of the studies presented in Chapter 7. US is well suited to deliver intracardiac 
injections due its unique ability to image the beating heart in real time with sufficient resolution 
to locate the myocardial boundaries. It is worth noting that US is commonly used for assessment 
of cardiac function and is well suited to this purpose. However, preclinical cardiac MRI is able to 
provide superior images describing heart function in 3D as opposed to the 2D interpolated 
methods found in preclinical US systems.129 For this reason in this work, MRI was always used for 
quantifying heart function and US was used for image guided procedures.  
 
2.5.1 Origin of US signal 
Ultrasound (US) refers to acoustic pressure waves above the audible range of humans (>20Mhz). 
The use of ultrasound as a medical device began with Karl Theo Dussik in 1941 who measured 
the ventricles of the human brain using transmission of US. He was followed closely by Wolfe 
Dieter Keidel in the late 1940s who attempted to measure the volume variations of the heart 
also using transmission of US. Neither technique was considered effective or quantitative due to 
limitations of transmission US.130 The first to observe US reflections from the myocardium was 
Inge Edler and Carl Hertz in 1953 who borrowed an ultrasonic Reflectoscope normally used to 
investigate ships hulls for cracks.131 From this first observation Edler and Hertz developed the 
field of echocardiography.132 Today clinical US is typically generated in the 1-20MHz range 
depending on the depth of the tissue being examined. Lower frequencies are able to penetrate 
the body further but suffer reduced spatial resolution compared to weakly penetrating high 
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frequencies. Ultrasound is generated by a piezoelectric crystal transducer placed at the surface 
of the body under investigation, this emits and detects ultrasonic pressure waves that pass into 
and out of the body. The passage of US through the body is scattered and reflected by internal 
acoustic boundaries that occur at interfaces between tissues or tissue structures. This scattering 
property known as acoustic impedance is analogous to refractive index and causes reflections 
and deflections of acoustic waves as is the case of refractive index with optics. An ultrasound 
image is formed from information on echo amplitude, echo time and frequency.  
 
2.5.2 Image acquisition and reconstruction 
Modern US commonly operates in 2 modes. M-mode US uses a series of 1D US pulses to rapidly 
measure the relative separation of tissue interfaces. M-mode has been found to be useful in 
measuring myocardial contraction and can be used to assess myocardial function along the axis 
of the US beam with very high temporal resolution. Alternatively, B-mode ultrasound forms an 
image by sampling multiple m-mode lines in a cross section of the body. These multiple samples 
are produced either using a linear array of transducers and/or sweeping the US beam back and 
forth using a phased array of transducers. Knowledge of the time of emission and detection 
allow the depth of tissue interface to be determined while the echo magnitude determines the 
brightness of the displayed echo to provide contrast at tissue boundaries with a mismatch in 
acoustic impedance. Figure 2.25 illustrates this process, where the red line depicts a single 1D m-
mode acquisition line. An echo is reflected every time the 1D beam passes through an acoustic 
boundary. The echoes shown in Figure 2.25 are formed as the beam is reflected at the front and 
back boundaries of object 1 and object 2. The amplitude of the echo is determined by the 
proportion of reflected energy depending on acoustic impedance 𝑍 where a higher difference in 
𝑍 resulting a larger echo in the figure 𝑍2 > 𝑍1 > 𝑍𝑏𝑜𝑑𝑦. To extend this illustration to b-mode 
imaging consider multiple lines emitting from the transducer following the black outlines of the 
focussed beam. The circumference of object 1 and 2 would become visible by the change in echo 
time and echo separation 2D.  
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Figure 2.25 Principles of US imaging. The ultrasound transducer produces a beam that passes 
through the body and is reflected at every acoustic impedance (Z) boundary it passes through. 
These echoes are detected at the transducer and the amplitude and detection time can be used 
to infer the location and acoustic properties of the structure that caused the reflection.  
Example echocardiography data from a mouse is shown in Figure 2.26. The LV endocardium is 
identified by blue circles. By identifying the endocardial boundaries global LV function 
parameters such as ejection fraction, stroke volume and systolic and diastolic volumes can be 
calculated - often incorporating geometric models of the LV. Also visible in this example data is 
the characteristic speckle texture present in ultrasound images. Tracking this acoustic speckle 
can allow quantification of regional myocardial function, this is discussed in further detail in 
Chapters 4, 5 and 6. 
 
Figure 2.26 Example US acquisition. This image shows the long axis view of the heart at end-
diastole (left) and end-systole (right). The LV endocardial boundary is indicated by the green 
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circles. By identifying the endocardial boundaries global LV function parameters such as ejection 
fraction can be extracted often incorporating geometric models of the LV. 
 
2.5.3 Local hardware 
The ultrasound system used for imaging and guided procedures was a Visualsonics Vevo 2100 
system (Visualsonics, Toronto, CAN). The system was adapted for the mouse and rat 
experiments by equipping a 55MHz transducer for mouse and 24MHz for rat imaging. The setup 
for US imaging is shown in Figure 2.27. Animals were anaesthetised using a mixture of isoflurane 
and oxygen. Hair is a major scatterer of ultrasound on transmission and detection so the bulk of 
fur covering the imaging window was removed using a shaver and finer hairs removed using hair 
removal cream (Veet, Reckitt Benckiser, Slough, UK). The animal was then transferred to the 
imaging stage and acoustic coupling gel was applied to the shaved region. Surface electrodes at 
all 4 paws were used to monitor the ECG trace and a rectal thermometer and heat lamp used to 
maintain temperature.  
 
Figure 2.27 Visualsonics Vevo 2100 ultrasound preclinical imaging system. A- display and control 
system; B- Anaesthetic vaporiser and delivery; C- transducer; D- imaging stage; E-heating lamp; 
F- guided injection stage. 
 
98 
 
2.5.4 Applications 
Ultrasound has found a wide range of diagnostic and therapeutic uses. Perhaps the most well-
known application of medical US is in obstetrics for assessing foetal health. This has become 
widely used a tool to evaluate growth, malformations and identify multiple gestations.133 
Echocardiography is another common use of medical ultrasound and has become one of the 
most valuable tools for the diagnosis and assessment of clinical heart disease. Thanks to its low 
material costs, high temporal resolution and wide availability echocardiography is frequently 
preferred to cardiac MRI despite its lower spatial resolution, contrast and the more limited 
range of diagnostic information it is able to provide. Cardiac US can provide information about 
the geometry of the heart, functional pumping information and identify damaged regions of 
tissue through measures such as wall thinning. Common measurements made in clinical cardiac 
US are measures of ejection fraction, diastolic function and cardiac output measurements. The 
acoustic scattering properties of red blood cells make it possible to image the frequency shift 
associated with scattering from flowing blood (Doppler effect). Doppler ultrasound has 
revolutionised the diagnosis of valvular heart disease. Abnormal flow defects such as valvular 
regurgitation and turbulent/jet flow in stenosis can be quantified using Doppler ultrasound. US 
has also been used for interventional procedures, such as using the cavitation effect of high 
amplitude US to break apart kidney stones.134 The high temporal resolution and real time 
reconstruction of US imaging makes it ideally suited to image guided procedures. For example, 
ultrasound guided injections use the high acoustic impedance mismatch between the needle 
and surround tissue make the needle easily differentiable from surrounding tissue. This makes it 
possible to inject or aspirate fluids with a high degree of accuracy from within the body.135 
Adapting clinical ultrasound systems for preclinical use has been hindered by the rapid murine 
heart rate that requires a very high frame rate for accurate US quantification and the small size 
of mice with the associated imaging requirements- less penetration, higher resolution- higher 
frequencies meaning that hardware could not be directly translated from human systems. 
However, over the last 10 years dedicated preclinical US systems have become available opening 
up preclinical research to the benefits of high throughput accurate in vivo imaging.136,137 
 
2.6 Bioluminescence Imaging 
Cell tracking is an important aspect of cell based therapies as it allows a change in organ function 
to be attributed clearly to the presence of therapeutic cells in that organ. Although cell tracking 
is possible using MRI by transfection of iron oxide nanoparticles this technique is non 
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quantitative and provides no information about cell viability. Direct labelling of cell with 
radionuclide tracers allow nuclear imaging techniques SPECT/PET to provide high resolution and 
quantitative cell tracking but also offer no information on cell viability. Cell tracking was 
therefore performed using bioluminescence imaging since this offers a semi-quantitative 
information on cell population and crucially is able to track cell viability. Bioluminescence is used 
in the cell retention studies presented in Chapter 7. 
 
2.6.1 Origin of BLI signal 
Bioluminescence is the emission of light from a living organism. This phenomenon occurs in a 
wide variety of marine species and a smaller number of land dwelling plants, fungi and insects. 
The chemical reaction that results in the bioluminescence emission occurs between a Luciferin 
molecule and a luciferase enzyme. The reaction is markedly similar in most species. In every case 
a luciferin and luciferase reaction is observed although in some species this reaction is assisted 
by other reactive cofactors such as metal ions or adenosine triphosphate (ATP).138 Luciferin and 
Luciferase are generic terms for a wide range of biologically occurring light emitting compounds 
where different bioluminescent species have different forms of Luciferin and Luciferase. The 
most commonly used variants for biomedical imaging originates from the North American firefly, 
photinus pyralis. The peak emission of firefly luciferase is around 560nm; this relatively long 
wavelength is better at penetrating tissue making it suitable for in vivo imaging. For BLI to be a 
practical imaging modality the bioluminescent property must be translated into traditional 
research species such as mice. This is done by creating transgenic mice or cell lines with the 
firefly DNA fragment encoding the production of luciferase typically through the use of a viral 
vector. The luciferin enzyme required to provide the bioluminescent emission (D-luciferin) must 
be injected prior to imaging since there is currently no technique to produce this in situ. Since 
the bioluminescence reaction requires ATP to produce an emission, BLI has found use as an in 
vivo tool for tracking the distribution of viable cells. 
 
2.6.2 Image acquisition and reconstruction 
Following the injection of the firefly luminescence substrate D-Luciferin the mouse is 
anaesthetised and placed within the BLI system. The system is contained within a light tight 
container with an ultrasensitive CCD imaging system above the mouse (Figure 2.28). The CCD 
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system operates as a photon counter and can determine properties such as light flux, radiance 
and emission count.  
 
 
Figure 2.28 BLI acquisition schematic. The reaction of the firefly luciferase substrate contained 
within cells of interest with the D-luciferin bolus results in the emission of a photon that can be 
focused and detected by a sensitive cooled CCD array. Since the bioluminescence reaction 
requires ATP only metabolising cells are detected. 
As was the case with OPT biological tissue presents a challenging optical environment with high 
degrees of scattering and absorption. Unlike fluorescent imaging, for BLI there is no need to get 
light into the sample as the photoreaction occurs internally. The emitted photon is scattered at 
structures such as cell membranes and is absorbed by pigmented macromolecules depending on 
the wavelength of emission.139 The depth of emission is importnat and superficial tissues provide 
higher signal than internal organs. The high degree of scattering from internal structures means 
that light may be scattered many times before passing out of the body. This results in a highly 
diffuse light emission that is the primary contributor to the poor resolution of BLI systems. 
Example BLI acquisition data from intracardiac injections of bioluminescent macrophages are 
shown in Figure 2.29. 
101 
 
 
Figure 2.29 Example BLI image data. Here 3 mice underwent Intracardiac injection of 
bioluminescent luciferase transduced macrophage cells. The BLI overlay shows that the majority 
of cells remain localised to the heart. Units are radiance [photons/s/cm2/sr]. 
 
2.6.3 Local hardware 
Imaging was performed with a Biospace PhotonImager (Biospace lab, Nesles-la-Vallée, Fr), this 
system is depicted and labelled in Figure 2.30. Animals were injected with an intraperitoneal 
infusion of D-luciferin potassium salt solution at a dose of 150mg/kg.140 The animals were then 
placed on the heated bed and the system would acquire an illuminated reference image. The 
illumination would then turn off and the bioluminescence signal acquired for some time. The 
number of photons emitted from an area could be converted to units of photon radiance- count 
per square metre per steradian per second [m-2 sr-1 s-1]. This unit of measure removed 
dependence on exposure time. The system was capable of fluorescence imaging and was 
equipped with illumination devices for this purpose although this was not used for this project 
due to the low penetration of this light for in vivo studies.  
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Figure 2.30 Biospace PhotonImager BLI imaging system. The basic system consists of a light proof 
box with an ultra-sensitive cooled CCD positioned above the imaging stage for detecting 
bioluminescent emissions. A- cooled CCD; B- anaesthetic delivery; C- fluorescence illumination; D- 
light-sealing door; E- heated imaging stage; F- secondary illumination. 
 
2.6.4 Applications 
The requirements for the bioluminescence reaction, Luciferin, luciferase, ATP and oxygen make 
it highly applicable to investigation of viable cells or cell environments conductive to 
proliferation. BLI is also applicable to in vitro applications for validating processes such as cell 
proliferation in real time.141  
Xiong et al. (2005) used BLI imaging to provide real time quantification of the efficacy of novel 
antibiotics in a rat model of endocarditis; a bacterial infection of the endocardium. The authors 
transduced the Staphylococcus aureus bacteria that causes the infection to produce firefly 
luciferase. The proliferation of the infection and the antibiotic efficacy of their agents could then 
be monitored serially in vivo. The decline in BLI signal following the antibiotic treatment could be 
quantified along with the infection relapse upon removal of treatment. BLI has also been used 
for tracking precursor cells with a  view to regenerating the damaged liver by Di Rocco et al. 
(2012).142 The authors produced hepatic precursor cells transuded with lentiviral vectors 
expressing firefly luciferase. This allowed them to transplant cells and track their viability and 
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retention over time. Zhao et al (2008) used BLI to investigate the kinetics and efficacy of a 
vascular disrupting agent (VDA) for chemotherapy.143 The authors imaged luciferase expressing 
cancer cells before and after the application of a VDA. Prior to the therapy the cancerous cells 
produced a reproducible and bright BLI signal in the tumour region. Following the application of 
the VDA therapy the tumours showed a 50-90% decrease in radiance. This is caused in part by 
the reduced perfusion of the d-luciferase substrate and partly by the ischemia cutting off the 
tumours blood supply. BLI in cardiac regeneration therapy and tissue engineering is a valuable 
tool for tracking transplanted cells to ensure retention and survival within the target region or 
the engrafted biomaterial.  
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2.7 Summary 
This chapter has introduced the imaging techniques that will be used throughout this thesis. The 
bulk of this thesis is focused on developing MRI imaging techniques for quantifying cardiac 
function and structure. Other relevant techniques were also described, introducing the added 
value of multi modal imaging studies and the combination of unique information from different 
imaging systems. In the next chapter a multi-parametric MR imaging platform is established that 
is widely applicable to the assessment of cardiac disease. This next section will draw on the 
physical principles outlined in this chapter. Later chapters 5 and 6 in which advanced imaging 
techniques are developed for assessing regional cardiac function also draws from the imaging 
theory introduced here. The OPT, US and BLI imaging are used only in the final results chapter 
(chapter 7) where they are used in several studies for cell/material tracking and guided injection.   
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Chapter 3 MRI biomarkers for the early 
assessment of iron overload in a humanized 
mouse model of β-thalassemia  
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3.1 Introduction 
MRI is frequently used clinically to diagnose and monitor disease and as a research tool to 
investigate experimental animal models. In order to develop and validate advanced in-vivo MRI 
imaging techniques for tissue engineering I undertook a quantitative study to investigate MRI 
detectable changes in cardiac function and tissue composition in a clinically relevant mouse 
model of cardiac disease. The multiparametric imaging tools developed in this chapter are 
applicable to the wider field of cardiac imaging and are able to provide quantitative information 
on cardiac health. This study was performed in collaboration with Professor John Porter 
(University College London) and Professor Anna David (University College London). We were 
asked to develop imaging tools that would be able to quantify the presence of cardiac 
dysfunction and tissue iron deposition in a novel animal model of beta thalassemia, a disease 
with cardiac implications that frequently leads to heart failure. 
The role of this chapter in the thesis as a whole is to present the established cardiac MRI imaging 
techniques used to evaluate cardiovascular disease. The techniques presented are applied here 
to a mouse model of thalassemia but the methods are broadly applicable to any study requiring 
evaluation of the cardiovascular structure or function. This chapter then serves as an 
introduction to existing techniques to provide context before the technological developments 
presented in Chapters 5 and 6, these technologies, along with the established techniques 
presented in this chapter are then used in combination in studies of cardiac regeneration in 
Chapter 7. 
Parts of this chapter are contained in the paper: MRI biomarkers for the early assessment of iron 
overload in a humanized mouse model of β-thalassemia. (2016) Laurence H. Jackson, Evangelia 
Vlachodimitropoulou, Panicos Shangaris, Thomas A. Roberts, Thomas M. Ryan, Adrienne E. 
Campbell-Washburn, Anna L. David, John Porter, Mark F. Lythgoe and Daniel J. Stuckey. (under 
review)  
Work contained in this chapter was presented at the British Chapter ISMRM annual meeting 
2015 where it won runner up for the British chapter prize for in-vivo imaging with potential 
utility in medicine. 
β-thalassemia (βT) is a genetic blood disorder that can result in profound and life threatening 
anaemia. Current clinical management of βT is a lifelong dependence on regular blood 
transfusions, a consequence of which is systemic iron overload that leads to acute heart failure. 
Recent developments in gene and chelation therapy give hope of better prognosis for patients, 
but successful translation to clinical practice is hindered by the lack of thorough preclinical 
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testing using representative animal models and clinically relevant quantitative biomarkers. Stem 
cell transplantation has also been demonstrated as a therapy for beta thalassemia, 
demonstrating the versatile applications of regenerative cell transplant in disorders outside of 
ischemic heart disease.144,145 The aim of this work was to produce a quantitative, non-invasive 
and in vivo preclinical MRI platform for the assessment of βT in a clinically relevant humanized 
mouse model to accelerate the development of these therapies.  
 
3.1.1 β-thalassemia and iron overload 
β-thalassemia is a genetic disorder resulting in the production of ineffective red blood cells (RBC) 
that are unable to sufficiently transport metabolic oxygen resulting in life threatening 
anaemia.146 βT affects the production of haemoglobin (Hb) in the body. Hb is the main molecular 
component of RBCs making up 96% of the cell’s dry weight and are the main transporters for 
oxygen in the body.147  Hb is composed of 4 subunits, each subunit consisting of a globular amino 
acid bound to a haem group. The haem group is an iron containing protein that can bind to a 
single oxygen molecule, the 4 subunits of Hb then allow for each Hb molecule to transport 4 
oxygen molecules. The use of Hb results in a seventy-fold increase in the ability of blood to 
transport oxygen compared to if the circulation relied on dissolved oxygen in other blood liquids, 
making it essential for functioning human metabolism.148 The variants of the protein chain 
components of Hb and their relative proportions with age are outlined in  Figure 3.1. 
 
Figure 3.1 The relative proportions of the globin chain components of Hb over time. Following birth 
there is a transition at 6 weeks from HbF (α2γ2) to HbA (α2β2). Note also the change in production 
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organ, from the liver and spleen during foetal development to the bone marrow in adults. Figure 
adapted from 149 
In human physiology Hb undergoes a characteristic structural change during the transition from 
foetal to adult development. In the foetal stage of development, the body survives on foetal 
haemoglobin (HbF) composed of 2 α chains and 2 γ globin chains. After birth there is a transition 
at approximately 6 weeks of age to adult haemoglobin (HbA) consisting of 2 α chains and 2 β 
chains. In adults there is also residual production of HbF and HbA2 (2 α chains and 2 δ chains), 
together making up approximately 3% of the total Hb fraction.150 
βT causes severely reduced or absent synthesis of the beta globin chain of HbA. The resulting 
α/β-globin chain imbalance leads to the production of ineffective RBCs. At birth βT patients 
survive on HbF and do not present symptoms until completing the transition to adult 
haemoglobin HbA at around 6 weeks of age. Survival into adulthood is then dependent on 
regular blood transfusions.151,152 A consequence of these repeated blood transfusions is the 
accumulation of iron due to the systematic infusion of RBCs.146 
Iron overload is the pathophysiological accumulation of iron in body tissue and can have 
deleterious effects on the heart and other organs. The mechanism by which transfusional iron 
overload occurs is outlined in Figure 3.2. RBCs from native and transfused blood load the 
macrophage system with non-transferrin bound iron (NTBI). In normal physiology most of this 
NTBI is bound to the iron stabilising protein transferrin that transports the iron for metabolism 
or to the liver for storage. The liver has a high tolerance to iron and is able to remove NTBI and 
transferrin from the circulation and store the deposits safely. In thalassemia the unbound 
transferrin in circulation is greatly reduced resulting in a high proportion of circulating NTBI. This 
iron is then free to accumulate in extra-hepatic tissues where it can produce toxic hydroxyl 
radicals via the Fenton reaction as well as inhibit cardiomyocyte coupling.153 
Iron overload occurs initially in the macrophage system of the spleen, liver and bone marrow but 
subsequently spreads to hepatocytes and ultimately to the heart and endocrine systems. Iron 
overload in βT is compounded by increased iron absorption due to hepcidin suppression 
associated with ineffective erythropoiesis.154 If left untreated, iron accumulation leads to tissue 
iron overload and heart failure as a result of cardiac siderosis. This remains the leading cause of 
death in transfusion dependent patients.155,156   
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Figure 3.2 Mechanisms of iron overload. In normal physiology transferrin is used to transport 
NTBI for metabolism to the liver for storage. In thalassemia due to high NTBI levels from broken 
down native and transfused RBCs the transferrin system becomes saturated leaving a high 
proportion of NTBI in circulation. 
An additional consequence of βT is splenomegaly (enlargement of the spleen). The role of the 
spleen is to filter blood by breaking down senescent and defective RBCs. Haemoglobin is broken 
down into its constituent globular amino acids and haem groups. In normal physiology these 
constituent parts are then reused in the formation of new RBCs. In βT the typically small 
misshapen RBCs can become stuck in the spleen without breaking down completely resulting in 
the haem portion of Hb not being removed leading to splenic iron overload and organ 
enlargement.157,158  Another mechanism of splenomegaly in βT is extramedullary erythropoiesis; 
this happens when organs other than the bone marrow begin to produce RBCs in response to 
low Hb levels. Splenomegaly leads to the spleen becoming overactive (hypersplenism), an 
irreversible change that requires partial or complete splenectomy.  
Thalassemia affects approximately 1 in every 2200 births, the disease has a regional variation 
with those in southeast Asia particularly affected. Since the widespread introduction of iron 
chelation therapy in the 1970s survival rates have improved dramatically, patients can now be 
expected to live into their 40-50’s. However myocardial iron removal is slow with existing 
chelation regimens and the development of more effective therapies and curative approaches to 
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βT has been limited by the paucity of relevant animal models in which testing of new treatments 
can be investigated.159-161 
 
3.1.2 Experimental models of thalassemia 
Mouse models of thalassemia have great potential for therapeutic research and there have been 
many efforts to create a clinically representative model of disease. The first method to be used 
to create a mouse model of βT was through deletion of the mouse β-globin gene. Yang et al. 
(1995) used a “plug and socket” targeting technique to delete the β-globin locus from the mouse 
DNA.162 Mice homozygous for this deletion lack the ability to produce Hb and die in-utero due to 
switching from embryonic to adult haemoglobin at around 7-8 days prior to birth. Although this 
makes these mice unsuited to studying serially they have found use in studies using in-utero 
gene therapy.163 Mice heterozygous for the β-globin deletion survive into adulthood but present 
characteristic traits of thalassemia such as splenomegaly, iron overload, and abnormal RBC 
indices making them useful for studying the pathophysiology of thalassemia. In a separate study 
in the same year Ciavatta et al. (1995) also produced a β-globin deletion model that expressed 
similar traits. In this case the authors bred the deletion mice with a transgenic model that 
expressed high levels of Hb and found that anaemia was alleviated in the offspring.164 This study 
was one of the first to take a genetic approach to therapy in thalassemia. These mice however 
are not clinically accurate since they are created through deletion of the β-globin gene rather 
than possessing the mutated gene seen in human thalassemia. The differences in phenotype 
between deleted and mutated genes in transgenic models is complex and has implications for 
creating accurate models of human disease. For example, disruption of the β-globin gene in a 
mouse model created by Shehee et al. (1992) resulted in perinatal death but deletion of the 
same gene resulted in a 60% survival into adulthood with only mild anaemia.165 
More recent models of β-thalassemia have spliced the human β-globin locus expressing the 
thalassemia mutation into the mouse genome.166,167 These ‘humanised’ mouse models with 
knock-in genes have become feasible models of disease since the availability of intact functional 
human genes from the Human Genome Project as well as efficient methods of gene 
transplantation.166 However, models such as those discussed above do not express the 
characteristic transition from HbF to HbA seen in humans since mice have no equivalent of 
human HbF. Recent work by Huo et al. has developed a more clinically accurate mouse model of 
βT that closely mimics the temporal onset of anaemia seen in humans with βT as well as the 
pathophysiological RBC indices and splenomegaly.168 This model was created by replacing the 
111 
 
mouse β-globin gene with a human HbF to HbA switching cassette (γHPFHδβ0), the mouse survives 
by synthesising human HbF at birth but shows typical symptoms of βT following the HbF to HbA 
transition including splenomegaly and anaemia. Heterozygous knockin mice (γHPFHδβ0/γβA) 
persistently express HbF from the HPFH (hereditary persistence of foetal haemoglobin) allele 
and so exhibit mild anaemia despite significant changes in red blood cell (RBC) indices. 
Homozygous knockin mice (γHPFHδβ0/γHPFHδβ0) suffer from severe anaemia and are transfusion 
dependent following haemoglobin switching and mimic the subsequent onset of iron overload in 
human βT.  
 
3.1.3 MRI in thalassemia 
MRI for quantification of iron content in tissue was first conceptualised in the 1980s by Stark et 
al. (1983) who observed hypointensity of the MRI signal in the livers of patients with 
thalassemia.169 Liver biopsy was the gold-standard method for somatic iron stores and the 
development of MRI was fuelled by the need for a non-invasive alternative. MRI has two primary 
advantages over other imaging or invasive diagnostic techniques; accurate quantification of 
cardiac structure and function and importantly, direct sensitivity to the concentration of iron 
stores within tissues. However, it was not until the early 2000s that MRI developed to the point 
where it could become clinical practice initially as a measure of chelation response but 
eventually for diagnosis of iron overload in asymptomatic transfusional patients.170,171 Anderson 
et al. (2001) produced the seminal paper establishing MRI in thalassemia, describing how 
myocardial T2* could be related to left ventricular ejection fraction (LVEF). In a study of 104 
thalassemia patients it was found that those with a myocardial T2* of >20ms presented normal 
cardiac function while those <20ms saw a decrease in LVEF proportional to T2*. Additionally it 
was observed that some patients exhibiting short T2* relaxation and detectable iron content 
had normal LVEF suggesting that MRI could be used to detect cardiac iron overload before the 
onset of symptoms.172 In the 15 years since Anderson’s paper the use of magnetic resonance 
imaging (MRI) to assess the extent of iron loading in organs has revolutionized the diagnosis, 
management and treatment of βT patients.173-176  
The sensitivity of MRI to iron arises from perturbations to the local magnetic field in the 
presence of iron and results in faster transverse relaxation in direct proportion to iron 
concentration.177,178 However, not all forms of iron are MR visible. The most disruptive and toxic 
form of iron is cellular labile iron which is not visible by MRI in physiological concentrations. The 
primary source of iron based MRI contrast is the storage protein ferritin and its breakdown 
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product haemosiderin. Ferritin and haemosiderin are relatively safe forms of iron but they exist 
in a dynamic equilibrium with the toxic labile iron making the detection of one a clinically useful 
marker for the indirect quantification of the other.179 The primary clinical method for 
quantification of tissue iron is gradient echo T2* mapping and a T2* of <10ms is seen as sign to 
begin aggressive chelation therapy. In addition to tissue iron sensitivity, MRI is able to perform 
structural and functional measurements during the same imaging protocol. In βT patients 
relevant additional imaging is cine-MRI to quantify cardiac function and structural imaging to 
quantify spleen size.157,158 
There was initially some controversy surrounding the relationship between cardiac T2* and liver 
iron as well as variability in LVEF with decreasing cardiac T2* in patients with β-thalassemia. The 
first point of contention arose following another study by Anderson et al. (2004) in which it was 
shown that there is a significant difference between the rates of iron clearance in the liver, 
serum ferritin and the heart.180 The authors found that under chelation therapy patient’s liver 
iron and serum ferritin reached clinical end points where therapy could be stopped before the 
cardiac iron loading had returned to acceptable levels. This finding contradicted established 
treatment protocols for patients with iron overload where liver iron or serum ferritin were seen 
as indirect markers for total body iron. The reason for this difference is the different iron 
uptake/clearance mechanisms in the heart and liver, as described in 3.1.1 the liver acts as the 
body’s primary iron storage and readily acquires excess transferrin and NTBI whereas the heart 
is much more vulnerable to rapid uptake of NTBI as the transferrin system become saturated. 
The clearance of cardiac iron is a two-step process, initially chelators are able to remove the 
toxic labile iron but removal of the stored ferritin and haemosiderin is dependent on the natural 
degradation of these molecules. This relates to the second point of controversy in that it is these 
storage proteins that create the detectable iron signal, so patients with severe cardiac iron 
loading detected by T2* MRI may be totally asymptomatic due to low labile iron but elevated 
haemosiderin stores. The gradual breakdown of these iron stores does however lead to eventual 
labile iron free to cause oxidative damage to heart tissue, high iron in the heart is therefore seen 
as a high risk precursor to iron related cardiomyopathy. Although MRI has gradually become the 
standard for clinical care and major clinical trials relating to iron chelation it has seen little use as 
a tool for preclinical animal research.181 Preclinical MRI in models of thalassemia will be valuable 
in the assessment of therapy and may offer insight into the controversial relationship between 
cardiac T2* and liver iron in thalassemia. 
This study applied clinically established MRI assessment methods to the novel γHPFHδβ0 knockin 
mouse model of βT in disease and in the presence of iron overload for the first time. Tissue 
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magnetic resonance relaxation rates (T1/T2/T2*), spleen volumetrics and cardiac function were 
quantified and provide a proof of principle for the use of preclinical MRI assessment in small 
animal models of thalassemia as an enabler to in-vivo and non-invasive serial investigation for 
the development of new therapies.  
 
3.2 Methods 
3.2.1 Animal model 
All animal studies were approved by the University College London Biological Services Ethical 
Review Committee and licensed under the UK Home Office regulations and the Guidance for the 
Operation of Animals (Scientific Procedures) Act 1986 (Home Office, London, United Kingdom). 
The transgenic mouse models of βT were prepared by Evangelia Vlachodimitropoulou 
(University College London). Three groups of animals were studied, a humanised control group, 
a thalassemia control group and a thalassemia iron loaded group. The process by which these 
animal groups were created and prepared is outlined in Figure 3.3.  
 
Figure 3.3 Outline for preparation of animal groups. Injections began at 4 months of ages and 
mice received daily injections of either PBS or 100mg iron dextran for a period of 4 weeks. 
Imaging was then performed at 5 months of age. 
Heterozygous knockin γHPFHδβ0/γβA thalassemia mice (n=6) received intraperitoneal injections of 
iron dextran solution (10mg in 100μL 5 days/week for 4 weeks) to simulate iron loading resulting 
from repeated blood transfusions. Control and thalassemia mice received injections of PBS with 
the same regimen. All injections began at 4 Months of age. 
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3.2.2 In vivo MRI 
Imaging was performed at 5 months of age using a 9.4T MRI system (Agilent Technologies, Santa 
Clara, USA) equipped with 1000mT/m gradient inserts and a 39mm volume resonator RF coil 
(RAPID Biomedical, Rimpar, Germany). A small animal physiological monitoring system (SA 
Instruments, Stony Brook, NY) was using to record the ECG trace, respiration rate and internal 
temperature. Animals were anesthetised under a mixture of isoflurane and oxygen with 
physiological measurements used to maintain depth of anaesthesia.  
 
3.2.3 Spleen volume 
Spleen volume data were acquired in control and non-loaded thalassemia mice using a 
respiration gated multislice gradient echo axial sequence (GRE) with resolution = 
156×156×500um, flip angle = 20°, TE = 3.2ms. In iron loaded mice due to ultra-short T2/T2* 
decay in the spleen a GEMS protocol was impractical (see Figure 3.4), in this case a respiration 
gated T1-weighted spin-echo multislice sequence was used (SEMS) with in-plane resolution = 
234μm, slice thickness = 1mm, TE = 2.5ms, TR = 600ms. In both cases the number of slices was 
adapted to cover the whole spleen volume. Image data was reconstructed offline and spleen 
tissue was identified by drawing contours on individual 2D slices and propagating through plane 
to measure organ volume. The ratio of spleen volume to total animal mass was used as a 
quantitative and animal-independent value for spleen size. 
 
Figure 3.4 Example of the issues encountered when imaging in iron loaded mice. In the control 
group (A) the spleen is clearly visible (green contour), due to the high iron content in iron loaded 
mice (B) gradient echo (GRE) sequences are unsuitable, for this reason in iron loaded mice a T1 
weighted fast spin echo (FSE) sequence was used to quantify spleen volume (C).  
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3.2.4 Relaxometry imaging 
To fully characterise the magnetic properties of tissue, imaging sequences were designed to 
measure T1, T2 and T2*. When acquiring data for relaxometry in the heart consideration must 
be made to acquire images at the same cardiac phase at each echo time. This results in some 
limitations as to echo spacing and acquisition protocols. The following section describes how T1, 
T2 and T2* data sets were acquired in the heart. 
 
3.2.4.1 T2 relaxation imaging 
For measuring T2 this study used a double gated multi-slice spin echo T2-mapping acquisition 
scheme designed by Dr. Adrienne Campbell-Washburn (University College London). This 
acquisition scheme is based on a spin echo imaging sequence and is detailed in Figure 3.5. Image 
acquisition starts when the respiration gate switches to open (i.e. not during inspiration or 
exhalation) and an ECG pulse is received. The first ECG pulse triggers the acquisition of a single 
line of k-space and each subsequent ECG pulse in the same respiration cycle acquires the same 
line in adjacent slices. Any ECG pulses received when the respiration gate closes are ignored. 
This cycle repeats and each successive respiration acquires the next phase encoding line. 
Therefore, the respiration rate determines the number of slices that can be acquired and the 
total acquisition time. Typical murine respiration and heart rates allowed for 5-8 slices. To 
sample the T2 decay curve separate image volumes were acquired with different TE’s. An 
excitation delay was included following each ECG trigger equal to 30ms minus the current TE. 
This was included to ensure that the acquisition echo always occurred at the same point in the 
cardiac cycle (QRS + 30ms). 
In this study T2 data was acquired at 8 echo times ranging from 2.7 – 20ms these values were 
chosen to sufficiently sample the T2 decay curve for accurate fitting. TR was the respiration 
interval, image resolution was 0.3×0.3×1.5mm, 7 slices were acquired in total with 1mm 
thickness, where 6 slices passed through the heart and liver and one offset slice through the 
spleen. 
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Figure 3.5 MRI sequence used for acquiring multislice T2 mapping data. In this example 5 slices 
are acquired for each respiration cycle. Each respiration triggers the acquisition of 5 lines of k-
space, 1 for each ECG pulse in successive slices (red ECG) at a fixed TE interval. The imaging 
protocol used a standard 90-180 spin echo acquisition.  
 
3.2.4.2 T2* relaxation imaging 
T2* decay was imaged using a double gated multi-echo gradient echo sequence. Each ECG pulse 
detected outside of a respiration triggered the acquisition of one phase encoding line in each of 
15 sequential images with a temporal resolution of 0.92ms.  
T2* relaxation was measured using 15 echo times in the range of 0.9 – 14.9ms, image resolution 
was 0.23×0.23×1.5mm. Two single slice acquisitions were performed with one slice placed in the 
same orientation as the T1 look locker and second acquisition orientated to pass through the 
largest part of the spleen based on the earlier volumetric scan. 
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3.2.4.3 T1 Inversion recovery 
T1 image data were acquired using an extended version of the inversion recovery (IR) scout 
described in section 2.3.5. The IR scout sequence was extended to sample the T1 decay at each 
ECG trigger and continue over respirations. Resulting in respiration corruption as described in 
2.3.3. Initially acquisitions were inspected by eye and the respiration corruption in some cases 
deemed to be effecting the accuracy of T1 fitting. The PENIR respiration corruption removal 
scheme was therefore implemented to minimise this effect. To measure T1 relaxation a cardiac 
gated look locker sequence was used with a minimum TE of 2.8ms followed by 30 echo times 
separated by the RR interval.182 The slice was orientated so as to cover the mid-papillary level 
short axis of the heart and a portion of liver allowing for both tissues to be quantified during a 
single scan with an in-plane resolution of 0.3×0.3×1mm and a slice thickness of 1.5mm. 
 
3.2.5 Relaxation model fitting 
Regions of interest (ROIs) were drawn manually using ITK-SNAP183 in each image slice to segment 
organs and remove contributions from surrounding tissue or blood vessels, representative ROIs 
are shown in Figure 3.6.  The relaxation of the mean pixel value in each ROI was used to fit a 
curve so a single value could be assigned to each organ. The heart was split into 4 regions that 
could be used individually or combined to get a single value for the whole heart. 
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Figure 3.6 Representative ROIs drawn to fit relaxation. The heart was split into 4 regions which 
could be combined for an overall measure for heart tissue. Liver regions were drawn to minimise 
the contribution from major hepatic blood vessels.  
T2 signal decay was modelled from the image series using Eq. 3.1, where 𝑇𝐸 is echo time. T2* 
decay was also modelled using Eq. 3.1 with T2* substituted for T2.   
 𝑆(𝑇𝐸) = 𝑆0𝑒
−𝑇𝐸
𝑇2⁄ + 𝐶 Eq. 3.1 
The T1 acquisition described in section 3.2.4.3 resulted in an image sequence where T1 image 
intensity could be modelled by Eq. 3.2.  
 𝑆(𝑇𝐼) =  𝑆0 (1 − 𝐵𝑒
−𝑇𝐼 𝑇1∗⁄ ) + 𝐶 Eq. 3.2 
   
Where 𝑆0 initial signal intensity, TI is the time following the look locker inversion pulse, 𝐵 is a 
fitted parameter to account for imperfect inversion, 𝐶 is a fitted offset to account for image 
noise and 𝑇1∗ is the apparent T1 under the influence of look locker saturation, this is corrected 
by the look locker correction factor (Eq. 3.3). 
 𝑇1 = (𝐵 − 1) 𝑇1∗ Eq. 3.3 
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Pixel values from the segmented tissue regions were taken and models fitted to mean ROI values 
at each echo time. Model fitting was performed in Matlab (2014b, The Mathworks, Inc., Natick, 
USA) using a minimisation function based on the Nelder-Mead Simplex method.184 Results are 
presented as mean value ± standard error and significance values were calculated by one way 
analysis of variance corrected for multiple comparisons (Holm-Sidak).  
 
3.2.6 Cardiac function 
Cardiac function was assessed with a spoiled gradient echo cine MRI sequence with a temporal 
resolution of 5.2ms, an in plane spatial resolution of 0.17×0.17×1mm. The left ventricular blood 
pool was segmented at systole and diastole using Segment v1.8 R0462185 and the corresponding 
volumes used to calculate left ventricular ejection fraction (EF), stroke volume (SV) and end 
systolic/diastolic volumes (ESV/EDV).186 
 
3.2.7 Iron quantification and histology  
Ex-vivo iron assay and staining were performed by Evangelia Vlachodimitropoulou and Panicos 
Shangaris (University College London). Animals were sacrificed after imaging and samples of 
heart, spleen and liver fixed in 4% PFA for analysis. Non-haem tissue iron concentration was 
measured using the iron assay described by Bothwell et al. and iron deposits were observed 
histologically by Perls’ stain.187.  
 
3.2.8 Statistical tests 
All results are presented as mean value ± standard error. All data were tested for normality using 
the Kolmogorov-Smirnov test and significance values were calculated by one-way analysis of 
variance corrected for multiple comparisons using the Holm-Šídák method. In all cases a p-value 
of less than 0.05 was considered significant.  
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3.3 Results 
3.3.1 T2/T2* relaxation 
Example data sets and fitted relaxation curves are shown in Figure 3.7. Both acquisitions 
provided data suitable for fitting the relaxation curves although additional samples at late times 
(>25ms) may have improved T2 curve fitting in controls due to incomplete relaxation in the 
current sampling scheme. Note also the difficulty in measuring T2* in the heart (Figure 3.7B). 
Due to inhomogeneity caused by the lungs and blood flow there is a major discrepancy between 
T2* on the anterior and posterior sides of the heart best seen by the visibly brighter anterior 
wall. Of the 4 ROIs drawn in the heart the septum is the least effected by inhomogeneities and 
so this region was used for heart T2*, this is the solution used in clinical measurements of T2*. 
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Figure 3.7 Representative T2 (A) and T2* (B) data from control group. To demonstrate the 
relaxation signal from which T2 and T2* are calculated this example takes a circular region of 
interest in the liver and plots the signal decay (C) with fitted T2 and T2* curves. 
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Measurements of cardiac, hepatic and splenic T2 and T2* are shown in Figure 3.8A and Figure 
3.8B respectively, along with representative images from each group at identical echo times. 
 
Figure 3.8 Results of T2 (A) and T2* (B) measurements. RepresentativeT2* images at TE=1.8ms. 
(*p<0.05, **p<0.01, ***p<0.001) 
Myocardial T2 was shortened in iron-loaded thalassemia mice (3.3±0.3ms) versus humanized 
controls (18.0±0.8ms) and thalassemia controls (17.2±2.1ms). Similarly, myocardial T2* in iron 
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overload (0.7±0.2ms) was shortened relative to humanized controls (11.5±4.3ms) and 
thalassemia controls (10.1±5.2ms). These data show that T2 and T2* measures are sensitive to 
iron loading in this animal model. It can be inferred from this that the additional gastrointestinal 
iron uptake in the γHPFHδβ0 knockin is not severe enough in itself to produce a detectable change 
in cardiac T2 or T2* at 5 months of age.  
Hepatic T2 was shortened in both the control thalassemia (9.4±2.9ms) and iron-loaded 
thalassemia mice (1.3±0.3ms) relative to humanized controls (13.2±01.0ms). Similarly, hepatic 
T2* was shortened in the control thalassemia (4.7±1.5ms) and iron-loaded thalassemia mice 
(0.6±0.2ms) models relative to humanized controls (7.6±1.9ms). This shortening of T2 and T2* in 
both the thalassemia groups can be related to the role of the liver as the primary reserve for 
body iron stored as ferritin. In the thalassemia control group increased dietary iron uptake could 
explain this shortening while in the iron-loaded thalassemia group we see this effect 
exaggerated by the additional iron intake. 
The role of the spleen in breaking down senescent erythrocytes makes it hyperactive in 
thalassemia where a large population of erythrocytes are defective. Iron deposition is a by-
product of the metabolism of the haemoglobin in the spleen. The shortened T2 and T2* in both 
thalassemia groups reflects this process. Splenic T2 was shortened in control thalassemia mice 
(3.9±0.8ms) and iron-loaded thalassemia (1.7±0.9ms) compared with humanized controls 
(6.2±0.8ms).  Splenic T2* was shortened in iron overload mice (0.8±0.1ms) and control 
thalassemia (0.6±0.5ms) relative to humanized controls (1.5±0.3ms).  
It is known that iron accumulation occurs initially in the macrophage system of the spleen, liver 
and bone marrow but subsequently in hepatocytes and ultimately in the heart and endocrine 
systems. These MRI measurements show that at 5 months of age the liver and spleen in the 
knockin mice are showing signs of iron loading but the process has not yet begun to accumulate 
iron in the heart suggesting that is a relatively early stage of disease  
 
3.3.2 T1 relaxation 
T1 values were significantly shorter in the presence of iron loading (Figure 3.9).Cardiac T1 was 
shorter in iron-loaded mice (620±125ms) relative to control thalassemia mice (1041±261ms) and 
humanized control animals (928±115ms). This was also the case for hepatic T1, with iron loaded 
thalassemia animals having shorter T1 (456±85ms) than control thalassemia (1014±255ms) and 
humanized control animals (929±117ms). These data show that T1 is sensitive to the presence of 
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iron loading however, T1 changes in the presence of iron require direct interaction with ferric 
molecules, the sensitivity is therefore lower than T2/T2*. T1 measurements could be most 
useful at particularly high iron concentrations where T2/T2* can be too short to accurately 
quantify.  
 
Figure 3.9 (A) Example of control group inversion recovery T1 look locker image sequence. 
Although far less sensitive to the presence of iron than transverse relaxation, T1 in heart and liver 
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was significantly shortened in iron-loaded thalassemia mice (B).  Representative images for 
groups at TI=200ms (*p<0.05, ***p<0.001) 
 
3.3.3 Spleen volume 
A severe increase in spleen size was observed in the presence of the γHPFHδβ0 gene. Figure 3.10 
shows a comparison of the axial spleen images and highlights the enlarged spleens in iron loaded 
and control thalassemia mice.  Spleen volume normalized to body mass was significantly 
increased in control thalassemia (9.5±1.2mm3/g) and iron loaded thalassemia mice 
(9.1±1.3mm3/g) relative to humanized control mice (4.0±0.4mm3/g), however there was no 
significant change in volume between iron loaded and control thalassemia mice suggesting that 
hypersplenism in this animal model is a consequence of γHPFHδβ0 knockin and is not directly 
altered by the degree of iron deposition.  
 
Figure 3.10 Spleen volume was dramatically increased in the thalassemia groups. The top row of 
images shows axial MRI images of the spleen (S), below are the corresponding volume renders of 
the segmentation used to quantify volume. The figure plots the organ volume to animal mass 
ratio for each group. VMR = volume spleen/ animal mass ratio. 
 
3.3.4 Cardiac function 
Quantitative values describing left ventricular function are shown in Figure 3.11. Left ventricular 
end diastolic, end systolic and stroke volumes (SV) were preserved between groups. Cardiac 
output (CO), measured as the product of stroke volume and heart rate was not significantly 
altered in control thalassemia mice (14.1±2.1ml/min) relative to humanized controls 
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(15.6±1.1ml/min) and iron-loaded mice (12.4±1.5ml/min) indicating that at 5 months of age that 
the two heterozygous knockin groups have not developed the pathological high output state 
characteristic of anaemia. Left ventricular EF was also unchanged in iron-loaded mice (70±2%) 
relative to control thalassemia mice (57±4%) and humanized control animals (65±2%).  
 
Figure 3.11 Heart function measured by cine MRI was not significantly changed in all groups. It 
can be concluded that relaxometry changes precede the onset of cardiac dysfunction and can 
offer an early biomarker for iron induced heart failure.  
 
3.3.5 Histology 
Histological sections of spleen, heart and liver are shown in Figure 3.12A. Iron deposits are 
visible as blue regions in the liver and spleen thalassemia control group and there is no 
accumulation of iron in cardiomyocytes. This iron distribution is consistent with early stage iron 
overload where the iron has not spread beyond the macrophage system of the liver and spleen. 
In the iron loaded thalassemia group there are large iron deposits in the liver and spleen but 
most importantly iron is also visible in the myocardium.  Iron concentration determined by the 
Bothwell non-heme assay for each organ and group is shown in Figure 3.12B. Control 
thalassemia hearts did not show significantly higher iron content than humanized controls but 
iron loaded thalassemia animals showed large myocardial iron depositions.  Hepatic iron content 
was higher than humanized controls in control thalassemia and iron-loaded animals while 
splenic iron showed an increasing trend but the results did not reach statistical significance. 
These results match the T2/T2* relaxometry measurements.  
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Figure 3.12 Perls stain for iron (A) show iron deposits in the spleen, liver and heart. However, only 
after iron-loading do the thalassemia mice exhibit iron accumulation within cardiomyocytes. 
Results of the Bothwell iron assay (B) show that T2 and T2* measurements are good markers for 
iron content, significance relative to humanized controls (*p<0.05, ***p<0.001).  
 
3.3.6 Iron calibration 
The cardiac T2* and iron dry weight measurements can be used to create a calibration curve to 
estimate iron content of dry tissue. This relationship can be modelled as Eq. 3.4.188 
 [𝐹𝑒]𝑑𝑟𝑦 = (1 𝑇2
∗⁄ − 1 𝑇20
∗⁄ ) 𝐾𝑑𝑟𝑦⁄  Eq. 3.4 
   
Where T2* is the measured T2* value, T20* is the T2* of the heart in the absence of iron loading 
and Kdry is a proportionality constant for dry tissue. Here the average T2* of humanized controls 
is taken as T20* and fitted Kdry to the measured T2* and dry iron concentrations. The resulting 
calibration curve fits measured values moderately well (Figure 3.13) and shows a sharp increase 
in estimated tissue iron at T2* < 2ms. The process can be repeated for T2 measurements by 
substituting T2 for T2*. In this case we find that iron concentration increases sharply at T2 < 
5ms. 
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Figure 3.13 Iron calibration curves overlaid with ejection fraction (red – right y-axis). The lack of 
any relationship between heart iron content and ejection fraction may be explained by the early 
imaging time point. 
If the ejection fraction is overlaid on the right axis (Figure 3.13 Red ) we could expect to see a 
decrease in ejection fraction as cardiac T2* get shorter as shown by wood et al.(2005).188 In this 
data we do not see this trend. The most likely reason for this is that the imaging time point is too 
early to observe the onset of reduced ejection fraction. This is consistent with the pattern of iron 
accumulation in non-loaded thalassemia mice, where iron accumulates in the liver and spleen 
before affecting the heart. The Bothwell iron assay used to measure iron content does not 
differentiate between the forms of physiological iron. The cardiac iron in the iron loaded mice 
may therefore be stored in a safe form that does not immediately affect cardiac function such as 
ferritin.  
 
3.4 Discussion 
In humans T2* measurement by MRI is the primary technique for identifying pathological iron 
overload in βT and has revolutionized the early diagnosis of disease prompting a leap in life 
expectancy as MRI becomes more readily available.146 A myocardial T2* of <10ms is the 
recognized primary predictor of heart failure in humans. In this study, we find a similar rapid 
increase in estimated cardiac iron content at <2ms. The T2 and T2* calibration curves fitted in 
Figure 3.13 are representative of calibration curves seen in humans. This is a promising sign that 
the animal model is clinically representative and that serial measurements of tissue iron by MRI 
can establish trends in tissue iron loading during the onset and following the treatment of βT, 
enabling more clinically useful interpretation of efficacy of such treatments.  
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The small organ size of rodents necessitates the use of high field MR imaging systems to obtain 
adequate temporal and spatial resolution, but this brings its own challenges, with relaxation 
times shortened and field inhomogeneity accentuated. T2* is currently the clinical standard for 
assessment of iron overload and has been universally adopted, however T2* is influenced by a 
number of factors independent of tissue iron concentration. The dense capillary networks within 
the myocardium have a significant impact on cardiac T2* relaxation due to their geometry and 
susceptibility which can be altered in disease, additionally in βT blood of varying degrees of 
oxygenation depending on severity of disease can drastically alter T2* relaxation rates. Variation 
in B0 shimming and long range susceptibility effects from the lungs can also influence 
measurements. As an alternative, T2 relaxation is less affected by these variations but has a 
lower sensitivity to iron. Here we found that T2 and T2*provide the same information with 
regards to iron concentration in the heart, liver and spleen. It is therefore feasible to use T2 as a 
more accurate quantitative measure of tissue iron when high sensitivity to iron is not required. 
T2 has also been shown to be a useful and reproducible measure of tissue iron in humans, 
however T2* remains the gold standard due to the substantial number of validation studies 
performed to establish this technique.189,190 
The true relationship between myocardial iron and T2/T2* relaxation has previously proven 
difficult to determine; although the shortening effect of iron is recognized it must be determined 
that iron is the dominant factor in faster transverse relaxation in βT as opposed to the abnormal 
haemodynamics. Iron concentration in this study was found to match T2 and T2* values for each 
organ. The control thalassemia and iron-loaded thalassemia groups have the same γHPFHδβ0/γβA 
knockin gene and present the same variable blood oxygenation and myocardial capillary 
networks of βT. The iron-loaded animals demonstrated a shortening of T2 and T2* regardless of 
this similarity providing evidence that the dominant T2/T2* shortening factor in βT is iron 
accumulation.  
Pronounced splenomegaly was observed in the γHPFHδβ0 knockin mice irrespective of the 
presence of iron overload in the organ. Hypersplenism shortens the lifetime of transfused RBCs 
creating a requirement for more frequent transfusions and compounding the consequential iron 
overload, therefore successful treatment of βT will require slowing or reversing the effects of 
hypersplenism. These results show that MRI can quantify the change in spleen volume caused by 
the knockin thalassemia gene making it a useful tool for assessing therapy. 
In anaemic states the heart compensates for a lack of blood oxygen capacity by increasing 
cardiac output to maintain tissue oxygenation, typically through increasing end diastolic 
volume.191 Results here however do not show a significant increase of these cardiac metrics in 
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γHPFHδβ0 knockin mice relative to humanized γβA/γβA controls. One likely explanation for this is 
the mild anaemia and persistent HbF known to be expressed in the heterozygous γHPFHδβ0 
knockin mice, this would preserve the ability of the blood to transport oxygen, meaning that 
compensatory increases in cardiac output are not required. Although cardiac dysfunction is not 
observed, an increase in iron content through assay and relaxometry measurements is seen in 
iron loaded and thalassemia mice and is known to predispose a patient to cardiac dysfunction in 
the future.192 The onset of cardiac dysfunction in the presence of iron overload is well 
established and the data presented here suggests that relaxometry measurements and 
increased spleen volume precede the onset of cardiac dysfunction and can be used as early 
markers for the progression of disease and is the same in the clinical setting.146  
Current research into therapies for βT typically focuses on either gene therapy, iron chelation 
agents or inducing post-natal production of HbF. Gene therapy approaches aim to modify 
harvested autologous haemopoietic stem cells in-vitro, repairing the dysfunctional β-globin 
genes before transplanting them back to the patient.193 Gene therapy has been shown to be 
effective in mice for various forms of β-thalassemia.194-196 These studies required animals to be 
culled at each time point to assess severity of disease, the in-vivo nature of MRI imaging means 
it would be a valuable addition to these studies providing a means to characterizing the time 
course of treatment. 
Iron chelation therapy is a necessary accompaniment to regular blood transfusions in clinical 
treatment. Currently there are three FDA approved iron chelators: Deferoxamine, Deferiprone 
and Deferasirox. Each drug has its relative adverse effects and challenges making the 
development of new chelating agents is an active field of research.197 There are promising agents 
such as FBS0701 that has many advantageous properties relative to current chelators and is 
currently undergoing phase II clinical trials in which MRI assessment of iron concentration and 
cardiac function are primary endpoints.198 FBS0701 has undergone preclinical assessment of 
toxicity and safety but these studies did not utilize MRI techniques which would have provided 
translatable information for clinical trials.199,200 Future preclinical studies into the safety of new 
agents will greatly benefit from integrating the MRI assessments that we present here, allowing 
parallel investigation of toxicity and iron chelation efficacy serially in vivo. 
This study has been limited by the single measurement at 5 months. Cardiac factors in βT such as 
dysfunction and iron accumulation without iron loading may have provided interesting results if 
the study had imaged at multiple later time points. The next stage in continuation of this project 
would be to incorporate a therapeutic element to the study. This could be any of the approaches 
discussed above. This work has shown that MRI analysis of these animals is able to quantify 
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changes in severity of disease in terms of spleen volume or iron accumulation in tissue. 
Assessment of chelation agents in particular would benefit from the ability of MRI to image at 
multiple time points to track the accumulation and removal of iron along with the consequential 
cardiac dysfunction.  
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3.5 Conclusion 
The data presented here demonstrates that MRI can be used to characterize the γHPFHδβ0 knockin 
mouse model of βT. Both spleen volumetrics and relaxometry distinguished between humanized 
controls, control thalassemia knockin mice and iron-loaded thalassemia mice with a marked 
increase in spleen volume and shortening of relaxation times in βT mice. The increasing iron 
content in the thalassemia animals quantified by chemical iron assay and visualized by Perls’ 
stain (Figure 3.12) confirms the inverse relationship between increasing iron load and decreased 
T2 and T2*relaxation time in tissue.  
In conclusion we have presented the first study to use quantitative MRI to assess tissue iron, 
spleen volume and cardiac function in the γHPFHδβ0 knockin mouse model of βT. Measurements 
of T2/T2* show great potential as a sensitive biomarker for preclinical monitoring of iron 
accumulation, while measurements of spleen volume and heart function are able to provide 
additional biomarkers to assess disease progression. Using MRI to quantify βT in experimental 
animal models will have application in the development of new therapies and is directly 
translatable to clinical practice. 
The multiparametric imaging platform developed here in the context of preclinical beta 
thalassemia has applications in the quantification of cardiac disease and regeneration therapy. 
Relaxometry changes are often the hallmarks of underlying pathology, in this case a reduced T2* 
represents increased iron content, similar links exist between T2 and oedema or T1 and contrast 
agent concentration. Measurements such as these offer valuable quantitative measurements of 
underlying physiology. 
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Chapter 4 Introduction to regional function and 
regional structure from cine images 
 
  
134 
 
4.1 Part 1 - Introduction to regional function 
Many cardiac diseases, myocardial infarction (MI) included, are regional in nature. Localised 
damage and regional dysfunction are characteristic symptoms of MI. It is necessary therefore to 
quantify cardiac disease using regional function measurements. Only with this information can 
cardiac mechanics be accurately described. This chapter provides an introduction to regional 
function measurements using MRI. The development of techniques for assessing regional 
function in the heart using MRI is the main component of the imaging platform being developed 
within this thesis. Chapter 5 and chapter 6 will describe my work in developing advanced 
preclinical tissue tracking methods and the present chapter serves as an intro to these chapters. 
This chapter is presented in two parts. The first provides an overview of regional function and 
ways it can be measured. In this section the limitations of quantifying heart function using only 
global functional measures are described, the quantitative values used to describe regional 
function are defined and an overview given of the various imaging modalities that are able to 
quantify regional heart mechanics. 
The second part of this chapter describes my work in implementing regional function 
assessment in cine MRI images to demonstrate and quantify the regional nature of myocardial 
infarction. This is performed through morphology based measurements of wall thickening and 
fractional shortening with radial sampling of the LV endocardial and epicardial borders.  
 
4.1.1 Limitations of global function 
The cardiac system is immensely complex and when healthy, operates in a finely tuned state of 
optimal efficiency. The normal function of the heart depends not only on the mechanical 
contraction of the myocardium but on the entirety of the cardiac system through feedback 
mechanisms that regulate cardiac performance. 
A large interconnected network of variables is required to describe cardiac function. 
Abnormalities in heart rate, blood pressure, renal function, myocardial function and vascular 
compliance can all impact a healthy and properly functioning heart. Despite this, the vast 
majority of research and clinical investigations rely on a single measure, namely left ventricular 
ejection fraction (LVEF) for an overall measure of cardiac health.201 LVEF is the fraction of blood 
ejected between end diastole and end systole. This value is given as a percentage and typically 
ranges from 51-80% in healthy humans when measured using MRI.202 In mice this range is 60-
70%.203,204 Using only a single value to measure global cardiac function has limitations, LVEF is 
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used as a pseudo-average, combining all mechanisms contributing to heart physiology that can 
mask irregularities in contraction that do not directly alter LVEF. This has led to two categories of 
heart failure (HF) known as heart failure with preserved ejection fraction also known as diastolic 
heart failure (DHF) and heart failure with reduced ejection fraction also known as systolic heart 
failure (SHF).9 In DHF the myocardium contracts and maintains an ejection fraction within the 
normal range but does not relax normally resulting in impaired ventricular filling. In SHF the 
opposite is true and the myocardium does not contract causing a reduction in ejection fraction. 
SHF is a common outcome in MII with 40% of MI patients developing systolic dysfunction 
detectable by reduced LVEF.205 LVEF has proven to be limited in its ability to predict HF, in a 
study by Curtis et al. (2003) LVEF was found to be a good predictor of HF in patients with LVEF 
<45% but an LVEF >45% although still below the typical range was not related to the occurrence 
of HF.206 This suggests that LVEF lacks the specificity to identify those at risk from HF in 
borderline cases. Gottdiener et al. (2002) showed that mortality was greater in elderly patients 
with preserved LVEF than those with reduced LVEF.207 This result is significant in that it shows 
LVEF cannot be used exclusively as a predictor of cardiac health and cannot independently 
determine prognosis.  
MI is a regional pathology where the infarcted region develops contractile dysfunction due to 
adverse remodelling, as described in 1.2.3.2. However, regional changes in contraction are not 
limited to the infarct area. Remote tissue can be affected by the propagation of systolic wall 
stress and loading from the non-contractile infarct tissue.208 This remote dysfunction has been 
shown to significantly contribute to the reduction of global LVEF.209 The homogeneous 
appearance of the myocardium in MRI however makes standard imaging tools unsuited to 
regional investigation. The complex motion of the heart includes through plane and rotational 
motion meaning that any imaging technique based solely on epicardial and endocardial 
boundaries will exclude this intramural motion. Imaging tools sensitive to regional motion are 
therefore desirable for their ability to provide additional information in combination with LVEF 
to comprehensively describe myocardial mechanics in myocardial infarction. 
 
4.1.2 Quantifying myocardial mechanics 
There are a number of ways of quantifying the movement of the heart in a way that provides 
information about the health or function of that region of tissue. This can be based on tissue 
morphology, velocity or displacement. 
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Tissue morphology provides the most basic measurements of myocardial mechanics. These 
measurements are based on the physical dimensions of the myocardium and include values such 
as fractional shortening or wall thickening that are based on delineation of the epicardial and 
endocardial boundaries. Tissue velocity measurements can be performed using ultrasound or 
phase contrast MRI but tissue velocity is a poor measure of function since it describes only 
moving tissue not mechanical deformations and so can be corrupted by the tethering effect. The 
tethering effect is observed when non-contractile tissue such as infarct scar is dragged by 
surrounding viable tissue. Velocity measurements are unable to differentiate between motion 
caused by viable tissue contraction or this tethering effect making its use in ischemic disease 
limited. 
The most complete metric for myocardial motion is mechanical displacement that can be used 
to quantify myocardial strain through the strain tensor 𝑬 (Equation 4.1). The strain tensor is an 
𝑁 × 𝑁 matrix that contains information about an 𝑁 dimensional deformation for a finite 
element of tissue.  
 𝑬 =  
1
2
(𝑭𝑇𝑭 − 𝑰) Equation 4.1 
Where 𝑇 represents the transpose operator, 𝑭 is the deformation gradient tensor and 𝑰 
represents the identity matrix. Figure 4.1 depicts the deformation of a square element and how 
this deformation can be used to define the deformation gradient tensor 𝑭. The deformation is 
described by 3 material points (a, b, d) and their positions following deformation (a’, b’, d’). It is 
therefore possible to define the strain tensor in 4 different ways for a material point surrounded 
on all sides corresponding to the displacement vectors above, below, left and right of the point 
a. It is common to average the strain tensor for all available configurations of 𝑭 and use this 
mean tensor to calculate 𝑬 for that point.  
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Figure 4.1 Definition of the 2D deformation gradient tensor F, for a square element of uniform 
material that is used to calculate the strain tensor as described by Equation 4.1.  
The strain tensor contains all the information about how an element of tissue has deformed. 
Decomposing the tensor into its eigenvalues and eigenvectors provides the principal strains for 
that element. For the 2D case this corresponds to two components, the first principle 
component describes the largest deformation by magnitude and gives its direction while the 
second describes the second principle strain. These can be visualised as the major and minor 
axes of an ellipse. When investigating cardiac mechanics, images are typically acquired in the 
short axis where the strain tensor is given reference to the LV centre and projected on the 
circumferential and radial directions, these strains are illustrated in Figure 4.2. This gives a 
quantification of circumferential strain (𝐸𝑅𝑅) and radial strain (𝐸𝐶𝐶), and in the case of a 3D 
tensor this definition can be expanded to provide through plane or longitudinal strain(𝐸𝐿𝐿). 
These strain components are more physiologically relevant to the heart since the contraction of 
the heart in the short axis can broadly be considered as circularly symmetric in healthy function.  
 
138 
 
 
Figure 4.2 Myocardial wall motion can be described through mechanical strain. The 3 
components of the strain tensor can be projected onto the cylindrical axis of the LV to give 3 
principle strains; radial, circumferential and longitudinal to describe the deformation of the 
myocardium. 
 
4.1.3 Techniques for measuring regional function 
The first measurements of regional heart function were performed using ultrasound or planar X-
ray imaging following the implantation of an invasive marker to provide contrast.210,211 The 
uniform x-ray attenuation of myocardium in x-ray imaging means that measuring regional 
displacement once required the implantation of trackable radiopaque markers. One of the first 
such studies by Rankin et al. (1976) surgically attached multiple ultrasound transducers to the 
epicardium to investigate changes in geometry during contraction.212 Brower at al. (1978) 
implanted a string of platinum shapes onto the epicardium and tracked their displacement with 
planar x-ray imaging.210 A later study by Villarreal et al. (1988) developed this technique to 
measure 2-dimensional strain (see 4.1.2) in the myocardium based on the relative deformation 
of a triangular array of surgically implanted ultrasound crystals.211 These techniques were crude 
and presented a number of issues regarding safety and accuracy. Invasive methods raise 
concerns about the damage caused by implantation of markers into the myocardium, the effect 
of markers on myocardial contraction, the risk of performing repeated measurements and the 
limited number of tracking points available. Modern methods are able to measure regional heart 
function non-invasively using advanced ultrasound or MRI.  
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Regional assessment by ultrasound can be performed either through tissue Doppler imaging or 
speckle tracking. Tissue Doppler imaging (TDI) measures the frequency shift of the ultrasound 
signal due to moving tissue to calculate the velocity of the tissue relative to the transducer. TDI, 
although fast and simple to perform, is limited in that it can only measure the velocity vector in 
parallel to the ultrasound beam, this limitation is particularly problematic in the heart due to 
complex torsion mechanics.213 Additionally TDI is limited by the ‘tethering effect’ limiting its use 
in assessment of myocardial infarction. The alternative ultrasound technique is speckle tracking 
echocardiography (STE). STE is a software based method that tracks the acoustic speckle texture 
present in the myocardium in b-mode imaging. The speckle pattern in the myocardium is 
randomly created by reflections, refractions and scattering of the ultrasound beam. Any region 
of heart tissue will have a unique speckle pattern that is mostly maintained throughout the 
contraction cycle. The regional pattern produced by a cluster of speckles in tissue is called a 
kernel, this kernel is tracked between successive b-mode frames by a feature recognition 
algorithm. This information can be used to measure myocardial strain, strain rate or tissue 
velocity. STE is not susceptible to the tethering effect since it directly measures myocardial 
displacements of tissues rather than their velocities, this allows accurate strain calculations 
based on deformation of tissue. Another advantage of STE is its ability to measure deformations 
in non-parallel directions, however the resolution of ultrasound tends to be much higher in the 
axial direction due limitation in beam width resulting in more accurate strain information in the 
direction parallel to the beam.  
MRI methods have superior signal-to-noise ratio (SNR) and contrast relative to ultrasound as 
well as comparable spatial resolution. There are a large number of approaches used to measure 
regional function with MRI (see Ibrahim et al. (2011) for a comprehensive review 214). There are 
three main approaches, the simplest method is to use standard cine-MRI data and analyse 
regional wall thickening or feature movement during contraction, secondly the position or 
displacement of the myocardium can be encoded within the MRI signal in a process known as 
‘tagging’ or tissue velocity can be measured using phase contrast techniques. Assessing regional 
function based on velocity measurements in MRI suffers from the same tethering effect 
discussed above in the case of TDI, for this reason only cine based and MRI tissue tagging 
methods will be discussed here.  
Tissue tagging for assessing regional function began in the late 1980’s with the development of 
magnetisation saturation methods by Zerhouni et al. (1988).215 The authors used selective 
radiofrequency saturation of the MRI signal to create planes of hypointensity that were a 
magnetisation property of the tissue. These tagged planes appear as lines in the orthogonal 
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imaging plane and could be seen to deform during systole providing the first non-invasive means 
of directly measuring myocardial contraction. The lifetime of these saturated ‘tagged’ planes 
depends on the degree of saturation and the T1 relaxation of the tissue, resulting in tag fading 
over the cardiac cycle. In the time since this first study there have been two periods of 
development for tagging techniques. The first period developed basic tagging methods based on 
magnetisation saturation and provided a deforming pattern of linear, gridded or radial tag lines 
in MRI magnitude images that were conductive to visual assessment of function but proved 
difficult to quantify. This included tagging sequences such as spatial modulation of 
magnetisation (SPAMM) (discussed in detail in chapter 5), complementary SPAMM (CSPAMM) 
and delay alternating with nutations for tailored excitation (DANTE). The second period of 
tagging development came about with advanced tagging methods based on image phase and 
manipulation of image k-space. These advanced tagging methods allowed for faster and more 
accurate quantification of cardiac motion relative to the basic pattern tracking techniques. These 
second period techniques are the most commonly used methods today and include harmonic 
phase (HARP), displacement encoding using stimulated echoes (DENSE) and strain encoding 
(SENC) MRI. My developments of SPAMM/HARP and DENSE will be discussed in detail as part of 
this chapter in chapter 5 and 6 respectively. 
 
4.1.4 Regional function with MRI in disease 
The first instance of someone using assessment of regional function by MRI to show 
heterogeneity between contracting myocardial region was performed by Clark et al. (1991).216 
The authors used gridded SPAMM tagging to calculate regional circumferential shortening (FS) 
from the end systolic tag line separation. This study found that apical segments of the LV have a 
higher FS than basal segments suggesting more forceful contraction towards the apex. The study 
also investigated intra-slice contraction and showed that the FS was highest in the endocardium. 
This describes an upwards twisting motion from apex to base with a large endocardial 
contraction component pumping the blood. Fractional shortening is a tool for extracting regional 
function from standard cine images. This study showed the utility of tagged MRI for quantifying 
myocardial mechanics and demonstrated that SPAMM was sensitive to regional heterogeneity. 
The results were confirmed in a later study by Azhari et al (1993), who introduced 3D strain 
analysis to tagged images (section 4.1.2) to show that the principle component of strain was 
aligned with the myofiber angle at the epicardium but was misaligned at the endocardium 
suggesting a reorientation of endocardial fibres during systole.217 More recently Bogaert et al. 
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(2001) confirmed these results using higher resolution images aiding in transmural 
observations.218 These studies among others219-223 form a wide body of work aiming to fully 
characterise the regional function profile of the human heart in normal physiology. The result is 
a better understanding of the complex 3D contraction of the heart and an acceptance that the 
heart cannot be treated as a symmetrically contracting cylinder. These works have helped 
establish what can be considered normal heterogeneity between different regions aiding the 
diagnosis of regional dysfunction. 
A wide variety of cardiomyopathies have been investigated using regional function assessment 
by MRI. Including, but not limited to dilated/hypertrophic cardiomyopathy, valvular and 
congenital heart disease and ischemic heart disease. The following section will present a brief 
review of some key papers and notable results for these categories of cardiac disease.  
The first regional assessment of hypertrophic cardiomyopathy (HCM) was performed by Maier et 
al. (1992).224 Maier observed moderately reduced myocardial torsion in patients with HCM that 
occurred in all segments. A later study by Mishiro et al. (1999) showed that HCM patients have 
intraventricular dyssynchrony. Using SPAMM tagging the authors showed that the strain rate of 
regions was not coherent. This is likely due to the underlying pathology of HCM, where 
cardiomyocyte disarray and fibrosis in hypertrophied regions causing reduced contraction or 
delayed electrical propagation. Dilated cardiomyopathy (DCM) is a common result of adverse 
cardiac remodelling following infarction and is therefore a valid target for therapy in cardiac 
regenerative medicine. The first study to examine the effect of DCM with a regional approach 
using MRI was performed by MacGowan et al. (1997). The authors showed that in normal 
physiology the epicardial principle strain component aligned with the cardiomyofibres but in the 
endocardium it was perpendicular suggesting wall thickening is the dominant contraction 
mechanism in the endocardium. The authors also showed that this transmural contraction 
pattern is unaltered in DCM despite significantly reduced fibre shortening. This suggests that in 
ischemic DCM the fibre structure is partially preserved and may present a viable regenerative 
target.  
In an interesting study of the effect of valve disease on regional function Sandstede et al. (2002) 
used MRI SPAMM tagging to assess the effect of chronic pressure overload due to aortic stenosis 
and the associated regional benefits following surgical valve replacement.225 The results showed 
that prior to surgery patients exhibited an LV wringing motion where basal and apical regions 
twist in opposite directions during systole. Following surgical valve replacement there was a 
recovery of LV torsion to normal physiology 1 year after surgery. This study showed the benefits 
of a regional assessment in following up surgical intervention and also provides evidence of the 
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myocardium producing a reversible adaptation to its contraction mechanism to pressure loads. 
This is a promising example for myocardial recovery showing that the heart may have the ability 
to reverse certain remodelling processes.  
MRI tagging was used in a study by Donofrio et al. (1999) to establish the abnormal ventricular 
systolic function following full cardiac transplantation in paediatric patients.226 The authors 
showed that compared to healthy controls transplanted hearts showed normal regional strain 
but abnormal twist. Including regions of akinetic tissue and abnormalities in regional contraction 
even in cases where the transplant was not rejected by the patient. This study will have 
relevance to ensuring the successful transplantation of engineered heart tissue. The introduction 
of abnormal function following transplant in the absence of rejection suggests that if tissue 
engineering will become clinical practice it will require longitudinal studies into the effect of the 
graft on regional function. MRI is the ideal tool for this sort of longitudinal validation due to its 
non-invasive and use of non-ionising radiation making repeated investigations practical.  
The regeneration of tissue following myocardial infarction is a major goal for cardiac 
regenerative medicine and studies involving MI represent a large fraction of this work. The 
assessment of the myocardial mechanics following MI has been an active area of research since 
the development of the first open chest video based regional assessment techniques.227 
Myocardial remodelling following MI produces a number of changes to the function of the heart 
in both the directly affected ischemic area and neighbouring and remote tissue as the whole 
heart adapts to the changes in contraction forces. A 1995 study by Lima et al. used SPAMM 
tagging to investigate the effect of MI on myocardial strain mechanics.228 The authors were the 
first to use MRI tagging to show that strain is severely reduced in non-reperfused sheep hearts 
as early as 1 week after coronary ligation. The orientation of these principle strain components 
was also affected following MI with contraction showing an overall reduction in contraction. An 
important study the next year by Kramer et al. (1996) showed that dysfunction following MI was 
not restricted to the infarcted tissue.209 SPAMM tagging was performed in patients with single 
vessel (LAD) disease who had undergone reperfusion therapy but maintained a low ejection 
fraction. Analysis showed that these patients showed 15% less contraction at the apex due to 
the infarcted tissue, but also 10% and 3% lower in the mid papillary and base levels respectively. 
The base level should be relatively unaffected by LAD occlusion. The authors suggest factors 
such as tethering or altered mechanical loads and coronary vasculature have significant effects 
not isolated to the infarcted tissue. A later MRI tagging study by Marcus et al. however showed 
that contraction strain in remote tissue was increased as a compensation mechanism for 
reduced apical contraction. The authors suggest this is a result of the Frank-Starling mechanism. 
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This mechanism states that when a larger volume of blood enters the LV the LV myocardium 
stretches, this in turn causes a more forceful contraction as the LV returns to its systolic shape. 
Early after MI the end diastolic volume increases to maintain cardiac output, this increased 
volume stretches non-infarcted myocardium and produces the hypercontraction seen in remote 
tissue. More recently, advanced tissue tagging techniques such as HARP and DENSE have been 
applied to investigate mechanics in MI.229 A novel study by Ashikaga et al. (2005) correlated 
electrometrical properties of the infarcted myocardium. The authors performed 
electrophysiological mapping of the heart using epicardial electrodes immediately before and 
after MRI imaging using LGE, cine and high resolution 3D DENSE. The authors showed that the 
infarct region exhibited delayed conduction of the action potential. In the border zone of the 
infarct however, despite normal conduction properties the authors showed abnormal strain 
properties extending far beyond the infarct zone. This study shows that border zone dysfunction 
is not caused by abnormal electrical properties but by mechanical interaction with the infarct 
zone. This study is an example of how multiparametric MRI imaging is able to provide many 
layers of complementary data. The LGE imaging was used to isolate the infarct and border zones 
while regional function showed the differences in strain between them and cine imaging 
quantified global cardiac function. This multiparametric approach is a valuable tool for complete 
investigation of cardiac function and MRI as an imaging modality is well suited to this 
methodology.  
 
4.1.5 Regional function with MRI in regenerative medicine 
Measurements of region myocardial mechanics are particularly relevant in tissue engineering 
since successful integration of a therapeutic graft to a particular region will require close 
mechanical matching with healthy tissue and must be proven not to negatively influence 
contraction in border and remote regions. 
Regional motion assessment has been part of a relatively small number of clinical and preclinical 
tissue regeneration studies. Rickers et al. (2004) established methods for real time MRI guided 
injections to graft cells, gadolinium contrast and blue dye into the myocardium.230 The use of 
HARP assessment of regional function gave evidence of better contraction in cell treated groups 
at 4 months post-engraftment in large animals. In a subset of the Prospective Randomized Study 
of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial 
(2014), chronic ischemic cardiomyopathy patients receiving injections of autologous MSCs were 
assessed using tagged MRI images. The study was able to demonstrate that in myocardial 
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segments that received cell transplants there was a significant increase in wall thickness and 
contractility relative to segments that did not receive cell transplants after 18 months.231 
Another study by MacArthur et al. (2014) showed using tagged MRI, that a larger region of 
infarct border tissue underwent functional recovery following MI in sheep after injections of 
stromal cell-derived factor 1α.232 Tissue tagging for regional function was investigated in a subset 
of the autologous stem cell transplantation in acute myocardial infarction clinical trial 
(ASTAMI).233 This study aimed to improve left ventricular (LV) function and reduce scar size by 
transplantation of mononuclear bone marrow cells (mBMC).  However, regional myocardial 
strain was not significantly altered following the intracoronary injection of mBMCs. Tissue 
tagging applied to this study allowed more detailed analysis of myocardial contraction and 
verified the negative result.  
 
4.2 Part 1 – Summary 
Here I have highlighted articles of interest from a large body of work involving regional 
assessment. The role of regional function measurements has been largely limited to a research 
role due to the long scan times and/or complex processing techniques that are necessary for 
measuring regional function and has seen limited clinical implementation. The value of regional 
function as a research tool is clear in the detailed functional information it provides over 
measures such as ejection fraction. Accurate assessment of regional function is essential for 
investigating regenerative therapies that aim to repair specific regions of tissue. This is especially 
important when combined with MRI cell and biomaterial tracking so that changes in the regional 
function of myocardium can be directly related to the site of engraftment. A large component of 
this work (chapters 4,5 and 6) describes my work in developing MRI tools for assessing regional 
function in small animal models of myocardial regeneration therapy. An advantage of using MRI 
for this purpose is the inherent translational potential of MRI methods. All of these methods are 
compatible with human studies of myocardial regeneration and it is hoped that this work will 
contribute the use of regional function measurements in clinical cardiac MRI.  
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4.3 Part 2 - Regional function from cine MRI 
For part 2 of this introduction to regional function in the heart I present tools I developed for 
assessing radial cardiac structure from previously acquired cine MRI data in myocardial 
infarction. This demonstrates the basic principles of regional function and how it is altered in 
cardiac disease.  
One of the most basic methods of measuring regional heart function is to extract regional 
morphological information from the standard cine images on which volumes such as LVEF are 
calculated. The advantage of this approach in MRI is that regional analysis can be performed 
without requiring additional specialised acquisitions. Two basic methods for collecting regional 
information from images of the hearts are fractional shortening and wall thickening, these 
measurements are based on the LV centre and epicardial/endocardial borders depicted in Figure 
4.3.  
 
Figure 4.3 Schematic illustrating wall thickening and fractional shortening. Using the centre of 
the LV as a reference point for line projections are measured at the points they cross the 
epicardial (red) and endocardial (blue) borders this process is repeated for all radial projections. 
Fractional shortening (FS) is an alternative measurement that is sometimes used in the 
quantification of m-mode ultrasound images. FS is based on the fractional change in ventricular 
diameter between diastole and systole computed from the radial distance between the centre 
of the LV to the endocardium Equation 4.2 describes how to calculate FS as a percentage from 
the LV end diastole diameter (EDD) and the LV end systolic diameter (ESD).  
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𝐹𝑆[ % ] =  
𝐸𝐷𝐷 − 𝐸𝑆𝐷
𝐸𝐷𝐷
× 100 
 
Equation 4.2 
Myocardial wall thickening (WTHK) is a similar measure to FS and can also be measured using m-
mode ultrasound but investigates the radial thickening of the myocardium based on the 
epicardial and endocardial boundaries with the centre of the LV as a reference point.234 WTHK is 
calculated using Equation 4.3 where TES is wall thickness at end systole and TED is wall thickness 
and end diastole. 
 
 
𝑊𝑇𝐻𝐾[ % ] =  
𝑇𝐸𝑆 − 𝑇𝐸𝐷
𝑇𝐸𝐷
× 100 
 
Equation 4.3 
Assessment of FS and WTHK measurements by m-mode ultrasound is a 1D measurement 
requiring a new beam path for every region of tissue. Additionally, there is uncertainty in the 
region of tissue being measured due to difficult positioning of the transducer as well as 
restrictions on which regions of tissue can be measured due to the requirements for an acoustic 
window. In MRI a complete 3D stack of images can be segmented to provide a regional map of 
fractional shortening or wall thickening without limitations on transducer placement. 
 
4.4 Methods and development 
4.4.1 Animal preparation and imaging 
The FS and WTHK processing methods were developed on image data acquired by Dr Thomas 
Roberts (University College London) as part of an unrelated study investigating the utility of 
retrospectively gated cine MRI in myocardial infarction. In this study standard prospectively 
gated cine images were also acquired and it was this data that was used here. 
Two groups of mice were studied, a wild type control group (N=8) and a myocardial infarction 
group (N=8). Myocardial infarction was induced surgically using the methods described in 
1.2.3.4. Image acquisition included the standard cine-MRI sequence with the following 
parameters: TR = 5ms, TE = 1.21ms, FA = 15°, resolution = 0.2×0.2×1mm. In addition, LGE 
imaging was performed in the MI group to assess infarct severity with the following parameters: 
TR = 3.1ms, TE = 1.21ms, FA = 90°, TI =4× RR interval, resolution = 0.2×0.2×1mm.  
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4.4.2 Image processing 
Following image acquisition the cine images were segmented in Segment v1.8 R0462.185 The LV 
endocardial borders were identified using a semi-automatic method at end systole and end 
diastole with the corresponding volumes used to calculate left ventricular ejection fraction (EF). 
Due to the labour intensive process of segmenting the epicardium this was only performed in 
one mid-apical slice where infarction forms following LAD occlusion.  
The myocardial boundaries extracted from Segment were then then used as an input to custom 
Matlab software to extract the FS and WTHK information. The major processing stages in this 
Matlab code are depicted in Figure 4.4.  
 
Figure 4.4 Cine regional function analysis pipeline. The centre of the LV was found in each slice 
automatically using a distance transform (A) and the RV anterior corner was chosen manually 
(B). This created a consistent reference system (C) for drawing and measuring LV ‘spokes’ from 
which the epicardial and endocardial boundaries and their radial separations could be 
established (D, E). 
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A consistent cardiac region reference system is needed to compare between animals, this is 
based on the centre of the LV and the anterior RV corner. Locating the centre of the LV in MI can 
be difficult due to the non-linear wall thicknesses due to tissue atrophy so a system was created 
to located the centre of the LV automatically to reduce operator bias. Figure 4.4A outlines this 
process. Two images were created from a 2D short axis LV mask, a filled image where the 
ventricular cavity was also masked and a distance transform (DT). A distance transform changes 
every pixel value to reflect the distance of that pixel from the nearest boundary to create a 
distance field. The product of the DT and filled images showed only the DT for the LV cavity, co-
ordinates of the maximum value in this image then corresponds to the pixel furthest from the LV 
wall which was taken to be the LV centre. The anterior RV corner was identified manually using a 
crosshair tool. The radial distance from the LV centre to the epicardial and endocardial borders 
was measured in a clockwise direction using 180 line spokes where the intersection of each 
spoke with the myocardial borders was recorded and used to calculate FS and WTHK for that 
radial segment of heart tissue. The number of spokes is an arbitrary measure, 180 spokes was 
chosen as a good compromise between speed and accuracy, excessive spoke counts can become 
slow to process without significant improvement in information. 
 
4.5 Results 
Fractional shortening (Figure 4.5A,C,E) in naïve mice was largest in anterolateral, inferolateral 
and inferior segments. This corresponds to the free wall of the heart. The free wall defines the 
posterior and lateral region of LV myocardium that are not in contact with the interventricular 
septum or the apex. In infarcted mice there is a reduction in FS for free wall regions but when 
compared to naïve mice there was no significant change in anterior or septal regions. This is 
consistent with infarct by LAD occlusion. The regions myocardium supplied by the LAD include 
the tissue regions where we see a reduction in FS while remote tissue regions such as the 
septum and anterior wall are comparatively unaffected.   
Wall thickening (Figure 4.5B,D,F) showed uniform contraction in all regions of myocardium in 
naïve mice at around 40-45%. Following MI all regions show a reduction in WTHK. This is 
opposed to FS where remote tissue retained normal function, in this case the anterior and septal 
regions also showed a reduction in WTHK, although the infarcted tissue showed the largest 
reduction in WTHK. 
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Figure 4.5 Changes in fractional shortening and wall thickening in myocardial infarction. Both FS 
and WTHK were significantly reduced relative to wild type animals (A and B) in all regions 
following myocardial infarction (C and D). This reduction is greatest in the anterolateral to 
inferior regions of myocardium which correspond to where an infarct is expected to form 
following LAD occlusion. Polar plots displayed as mean ±SEM. 
To validate the regional impairment seen with FS and WTHK. The infarct location was confirmed 
by matching regions of reduced FS and WTHK with regions of hyperenhancement in the LGE 
images. A representative LGE image from an infarcted mouse is shown in Figure 4.6. The 
Hyperenhancement in the anterolateral – inferior slices are clearly visible in the inset slice. This 
provides evidence that FS and WTHK are able to detect regions of impaired function and that 
these regions correlate to regions of hyperenhancement in LGE images.  
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Figure 4.6 Representative LGE image from MI group. (A) Going from apical slices (1) to basal (8). 
Regions of the heart are defined in (B) (B.a) Anterior, (B.b) anteroseptal, (B.c) inferoseptal, (B.d) 
inferior, (B.e) inferolateral, (B.f) anterolateral. The infarct (hyperintensity) can be seen to develop 
on the mid apical inferolateral wall validating the FS and WTHK results in the infarct model (C 
and D).  
 
4.6 Discussion 
As a measure of regional function FS and WTHK are able to detect functional impairment in 
regions of tissue corresponding to increased ECV as measured by LGE imaging. This impairment 
manifests itself as reduced wall thickening and a reduced ventricular shortening in infarcted 
tissue.  
The key advantage of using FS or WTHK measures of regional function is that they require no 
additional image acquisitions as is the case with more advanced techniques such as SPAMM and 
DENSE. The measurements obtained are morphological changes during contraction that can be 
easily interpreted as healthy or impaired. The measurements also have the advantage of being 
widely reported in cardiac ultrasound literature making them accessible to the wider cardiac 
field outside of advanced imaging techniques.  
The values reported here are for the end-systolic frame only however it could be useful to 
analyse the WTHK and FS over the duration of contraction. This could provide temporal 
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information about systolic or diastolic impairment that may be beneficial. The process of 
accurately segmenting the epicardial borders over the contraction cycle is labour intensive and 
time constraints meant that this could not be performed in this instance.  For the same reason 
the data presented uses just a single 2D slice passing through the infarct zone, segmenting 
additional slices could be useful in investigating how the remote tissue is effected to 
compensate for reduced function in the infarcted tissue.  
The high dependence of these techniques on accurate delineation of the myocardial borders 
makes it susceptible to inter user variability in cases where these borders cannot be 
automatically segmented as is often the case with preclinical MRI. This will also be affected by 
the inclusion or exclusion of the papillary muscles in the borders. The effect of the papillary 
muscles should be beneficial due to their contribution to cardiac mechanics, but if they may 
introduce rapid artificial changes in FS and WTHK when they cross different radial spokes. 
Further investigation will be required to determine whether their inclusion is beneficial to 
analysis. Another disadvantage of these methods is the linear nature of the measurement. FS 
and WTHK are based on a total of three points all placed along a single radial line. The location 
of the points at the epi and endocardial borders takes no account of the through plane motion, 
torsion or twist of the myocardium during contraction. This results in a limited view of heart 
contraction excluding several degree of freedom for cardiac motion. Another consequence of 
these sparse radial measurements is a lack of sensitivity to transmural dysfunction. Using this 
method, a single measurement for WTHK or FS is assigned to each spoke, however the tissue the 
spoke passes through may exhibit different degrees of dysfunction dependent on disease and 
severity. Additionally, the magnitude of myocardial contraction has transmural dependence in 
healthy tissue where subendocardial tissue shows greater deformation than subepicardial tissue.  
These disadvantages do however come from a processing technique that operates on standard 
acquisition data, essentially FS and WTHK are able to provide regional function information 
without additional acquisition time costs. The processing methods although relatively slow and 
labour intensive can be applied to studies where regional function was not initially planned 
giving them some utility in reinterpretation of old data if required. In tissue regeneration studies 
however accurate, transmural data of myocardial function is required. It is not clear whether FS 
and WTHK can by themselves provide enough information on the regional effect of transplanted 
cells or material in the heart. Additionally, work by Bogaert et al. (2001) has previously shown 
that simple regional function measures such as wall thickening and fractional shortening are not 
directly related to the local contribution to ejection fraction.218 For these reasons, two advanced 
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regional analysis methods; SPAMM/HARP and DENSE based on dedicated acquisition schemes 
were developed and are discussed in chapters 5 and 6 respectively. 
 
4.7 Conclusion 
The first part of this chapter introduced the field of regional assessment for cardiac MRI has 
been introduced with key papers and concepts introduced. In the second part, post processing 
techniques were developed to apply some of these concepts to provide retrospective regional 
analysis to cine images. Fractional shortening was found to be greatly reduced in regions of 
myocardial infarction while remote tissue maintained similar values to naïve animals. Wall 
thickening was shown to be reduced in all regions of the heart including infarcted and remote 
tissue. Regional accuracy was confirmed by late gadolinium enhancement for scar identification. 
The radial and 1 dimensional measurements provided by WTHK and FS do not fully describe the 
complex contraction of the heart and offer no information about transmural function, 
mechanical twist or strain during systole. Fully quantitative and descriptive information about 
cardiac function require the development of specialised MRI acquisition strategies. The following 
chapters describe my work in developing two advanced preclinical imaging sequences for 
complete regional analysis.  
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Chapter 5 Development of Spatial Modulation of 
MAgnetisation (SPAMM) and HARmonic Phase 
(HARP) MRI 
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5.1 Introduction and theory 
5.1.1 Study overview 
This chapter describes my work in developing, implementing and validating a preclinical spatial 
modulation of magnetisation (SPAMM) tagging sequence with harmonic phase (HARP) 
processing. SPAMM and HARP are currently the clinical standard tools for assessment of regional 
myocardial function. The objectives of this chapter are outlined in the following points.  
1. Implement a preclinical SPAMM sequence 
2. Create advanced motion phantom for validating sequence 
3. Optimise acquisition parameters for preclinical imaging 
4. Validate optimised sequence using motion phantom 
First an introduction is given describing the concepts underpinning the development of the 
motion phantom, SPAMM sequence and HARP algorithm. Next a series of experiments are 
performed to implement and optimise the sequence before finally it is validated using the 
designed motion phantom and demonstrated in vivo. The result is an optimised SPAMM 
sequence and HARP processing method for quantifying regional myocardial strain in the mouse 
or rat heart following engraftment of regenerative cells or material. 
The workflow for the methods and development of this chapter is shown in Figure 5.1. The 
methods and results are divided into 3 parts relating to the field of work undertaken. The first 
part covers the motion phantom development (red components Figure 5.1), the second 
describes the sequence implementation and optimisation (blue components Figure 5.1) and the 
final section describes the HARP implementation and the validation of the sequence for 
measuring displacement (green components Figure 5.1). 
 
Figure 5.1 SPAMM sequence development and validation workflow. The aim of this study was to 
implement, optimise and validate a cine SPAMM sequence for assessing cardiac contraction. 
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5.1.2 Requirements for cardiac motion phantom 
To assess the accuracy of MRI techniques for measuring regional displacement a ground truth is 
required for comparison. For this purpose, a controllable rotation phantom was designed and 
manufactured to provide a known displacement with which to compare measurements from 
MRI. The basic specifications I propose for the design of this phantom are listed in Table 5.1.  
Table 5.1 Proposed basic requirements for an MRI compatible cardiac motion phantom 
Requirement Description 
MRI compatible No metal components or electronics near scanner 
Periodic motion Reproducible back and forth motion 
Stable and easy to position As similar to scanner set up for mouse as possible 
Variable displacement Provide a range of motion magnitudes 
The primary concern when designing any phantom is MRI compatibility. Metal parts present 
hazards to the user and can cause damage to the scanner while electronic components have the 
potential to produce image artefacts through RF interference and spark conduction. 
Reproducible, periodic and controllable motion is necessary to simulate the movement of the 
heart. Cardiac phantoms have previously been produced based on continuous rotation, and 
although this motion is simpler to produce and more reproducible, they do not properly mimic 
heart motion.235 It is important for the phantom to be stable when in motion to prevent 
uncontrolled displacements or vibrations, these can cause not only inaccuracies when validating 
displacement but also motion artefacts due to non-periodic oscillations. A range of 
displacements is useful to define the range over which the imaging technique is valid. Variable 
displacements are simple to achieve in a rotating phantom since displacement is a function of a 
points separation from the axis of rotation.  
 
5.1.3 Spatial modulation of magnetisation (SPAMM) 
A year after Zerhouni et al. (1989) developed the first MRI tagging sequence using spatially 
selective RF pulses, Axel and Dougherty (1989) introduced a more efficient tagging sequence 
that is still in use today.236 Spatial modulation of magnetisation (SPAMM) is able to apply a 
regular tag pattern across the whole field of view fast enough to be unaffected by the start of 
systole. The next sections discuss the theory of SPAMM and the harmonic phase (HARP) tag 
analysis technique developed by Osman et al. (1999) that made regional analysis by SPAMM a 
practical clinical tool.237 Since SPAMM’s applications to cardiac disease have been discussed in 
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Chapter 4  this section will focus on the technical developments of the sequence, post 
processing and analysis.  
SPAMM is an alternative to the magnetisation saturation technique presented by Zerhouni et al., 
which takes advantage of magnetisation wrapping to apply a regular 1D sinusoidal tagging 
pattern in the direction of an applied tagging gradient. The pulse sequence and acquisition 
scheme that produces this modulation is shown in Figure 5.2A. The SPAMM sequence can be 
separated into two modules; the tagging module and an imaging modules. Imaging is typically 
performed using a gradient echo or balanced steady state free precession cine sequence that 
samples the transverse magnetisation uniformly over the cardiac cycle.  
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Figure 5.2. Principles of SPAMM tagging. On detection of an ECG trigger (A) a short tagging 
module encodes a cosine modulation to the magnetisation in a chosen direction before being 
imaged by a standard cine readout. The magnetisation is modulated in the wrapping gradient 
direction as described in the text (B). The magnetisation modulation (C) creates a series of 
parallel planes of saturated signal (D) that appear as tag lines in the orthogonal imaging plane. 
Tagging begins with the detection of an R-wave signalling the start of systole. This triggers an RF 
pulse with flip angle α tipping the magnetisation into the transverse plane. This is followed by 
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the application of a gradient known as the modulation gradient that gives the spins along the 
direction of the gradient a phase shift as a function of the strength of the gradient experienced 
i.e. position along the tagging gradient direction. Since this phase shift can only take values in 
the range ±π there is a periodic magnetisation wrapping effect over the FOV. A second RF pulse 
then tips the magnetisation back into the longitudinal plane and a large crusher gradient 
removes residual transverse magnetisation. This preserves the modulation pattern by taking it 
from the transverse magnetisation plane where relaxation occurs rapidly and storing it in the 
longer T1 recovery. It can then be sampled by the imaging component over the duration of the 
cardiac cycle using an excitation RF pulse to partially tip it back into the transverse plane. Each 
stage of this process is depicted in Figure 5.2B-C. The non-selective RF pulses used to create the 
modulation means that this magnetisation pattern is applied throughout the entire imaging 
volume in a 1D pattern creating planes of magnetisation saturation. The tagging plane is 
orientated to be orthogonal to the imaging plane creating the tag lines. Figure 5.2D illustrates 
this concept, the red sphere representing the imaged object. A 1D in-vivo example of the 
SPAMM tagging pattern is shown in Figure 5.3. Often a 2D grid tagging pattern is used to 
visualise the tag deformation this can be achieved by combination of 2 separately acquired 1D 
tag patterns or alternatively two SPAMM tagging modules can be applied consecutively during 
acquisition, with the wrapping gradient in orthogonal directions. 
 
Figure 5.3 The appearance of the SPAMM tagging sequence is a periodic cosine pattern applied 
at end diastole that deforms as the heart contracts.ES end-systole; ED end-diastole. 
The properties of the tagging pattern are controlled by altering the RF flip angle α and the 
tagging gradient area. The frequency of the tagging modulation is controlled by altering the 
tagging gradient strength and duration and follows the relationship described by Equation 5.1. 
 
𝐾𝑒 =  𝛾𝐻 ∫ 𝐺𝑒𝑛𝑐(𝑡) 𝑑𝑡 
Equation 5.1 
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Where 𝐺𝑒𝑛𝑐 is the gradient strength,  𝑡 is the duration of the gradient, 𝛾𝐻 is the gyromagnetic 
ratio for hydrogen and 𝐾𝑒 is the tagging pattern encoding frequency. This tagging frequency can 
be used to describe the magnetisation across the image immediately following tagging and prior 
to any deformation according to Equation 5.2. 
 𝑀𝑧(𝑥) =  𝑀cos (𝐾𝑒 𝑥) Equation 5.2 
Where 𝑀𝑧 is the longitudinal magnetisation, 𝑀 is the magnetisation prior to RF excitation and 𝑥 
is the position in the tagging direction. The tagging modulation is stored in the T1 decay of tissue 
so it is retained throughout the contraction cycle, however unavoidable T1 relaxation results in a 
degree of tag fading towards the end of the cardiac cycle. This T1 relaxation factor can be 
incorporated into the function describing the image modulation (Equation 5.2) by including a T1 
decay term. 
 
𝑀𝑧(𝑥, 𝑡) = (𝑀 cos(𝐾𝑒 𝑥) −  𝑀0)𝑒
−
𝑡
𝑇1 + 𝑀0 
Equation 5.3 
Where 𝑡 is the time over which T1 decay has occurred, 𝑇1 is the T1 constant of the tissue and 
𝑀0 is the equilibrium magnetisation of the tissue. The result of this is a sinusoidal tagging 
pattern that loses amplitude as T1 relaxation occurs creating a time dependent tagging contrast. 
This tag fading process described by Equation 5.3 can be simulated in Matlab to illustrate this 
process. Figure 5.4 shows the T1 relaxation induced tag fading of synthetic data where input 
parameters were chosen to be representative of the mouse myocardium. 
 
Figure 5.4 SPAMM tag fading of synthetic tag data. Function inputs were chosen to match mouse 
myocardium. Tag fading occurs at a rate equal to the T1 of tissue (simulated with T1 = 1200ms), 
although in in vivo data tag fading occurs more rapidly due to hardware limitations and tissue 
inhomogeneity.  
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In this simulated example the synthetic tags are persistent throughout the duration of the 
cardiac cycle (approximately 110ms). In vivo data however suffers from imperfect tag 
application, T1 variations, intravoxel dephasing and lost magnetisation through imaging readout. 
These imperfections accelerate tag fading and can making end diastolic function difficult to 
image accurately. Tag fading is an important consideration when quantifying tagged images 
since all displacement information is determined from the tag lines. As the tagging modulation 
fades the information about the displacement becomes noisier and is more prone to errors. 
A second important tagging variable is the frequency of the modulation pattern. Optimal tag 
frequency is a compromise between image SNR and spatial tagging information. A high tag 
frequency may provide detailed spatial deformation information but comes at a cost of rapid tag 
fading and low signal due to intravoxel dephasing and saturated tissue respectively. Lower tag 
frequencies are less susceptible to intravoxel effects due to a slower rate of change of the signal 
modulation over adjacent voxels but sparse tags provide less information on local deformations. 
 
5.1.4 Harmonic Phase (HARP) analysis 
The conversion of tagged MRI data into a relevant quantifiable value describing myocardial 
mechanics, such as those introduced in 4.1.2 is a complex problem that has been approached 
from many angles since the development of SPAMM. Active contours, optical flow, sinusoid 
analysis and finite element modelling are some examples of tag analysis approaches that have 
been implemented.214,223,238-241 These tag analysis methods almost universally operate on 2D grid 
tagged images. The fundamental requirement of these tag analysis algorithms is to find every 
tag intersection point consistently and accurately for all images covering the cardiac cycle. These 
can then be connected to form a deforming quadrilateral element that describes the 
deformation of that piece of myocardium. One major issue with this kind of analysis is that since 
all deformations are based on tag intersection the resolution of the deformation information is 
limited by tag spacing. Increasing tag frequency to improve strain resolution causes an SNR 
penalty as described above. There have been several attempts to work around this limitation 
using interpolation or biomechanical modelling systems. For example, Young and Axel (1992) 
fitted a 3D deformable model of LV geometry to the tag intersections.242 Alternatively, Kumar 
and Goldof (1994) used a thin plate spline model with active contours in the imaging plane to 
interpolate the space between intersection points.243 These methods are computationally 
intense and highly susceptible to inaccurate tag identification, often requiring manual 
intervention making them time consuming and unsuitable for clinical timeframes.  
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Harmonic phase (HARP) analysis for SPAMM images was proposed by Osman et al. (1999) as a 
way to improve accuracy in tag analysis and reduce processing time.244 HARP analysis is based on 
filtering of the harmonic stimulated echoes produced by the SPAMM tagging pattern in k-space. 
These peaks occur at positive and negative integer multiples of 𝐾𝑒 from the central peak (T1 
echo) of k-space and are known as the displacement encoded stimulated echo in the positive 
gradient direction and the complex conjugate/anti echo in the negative direction. Each of these 
peaks contains information about the motion encoded in the tagging dimension due to them 
containing spatial frequencies associated with the periodic tag lines. The appearance of these k-
space peaks in image space and k-space is shown in Figure 5.5 along with a profile showing the 
separation of these peaks. 
 
Figure 5.5 Appearance of SPAMM tagged MRI images in k-space. The displacement encoded 
echo and anti-echo arise from the periodic SPAMM tag lines and are offset from the T1 echo at 
the centre of k-space by integer multiples of the encoding frequency ±Ke. 
These spectral peaks arise from the evolution of magnetisation described by Equation 5.3 
following RF excitation. These displacement-encoded echoes, once isolated from the T1 echo 
and anti-echo, can be reconstructed using an iFFT to create a complex image where phase is 
linearly related to the position along the encoded dimension. The stimulated echo containing 
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the tagging frequencies must be filtered to isolate it from the T1 and anti-echo since these 
introduce additional signal contributions unrelated to displacement. HARP images are defined as 
the phase reconstruction images following isolation of the displacement encoded peak. Where 
the constraint on image phase to lie between ±π creates a densely wrapped phase image that 
describes pixel wise heart motion. Figure 5.6 illustrates this process for creating HARP images 
which contain motion encoding in the horizontal and vertical directions. 
 
Figure 5.6 Generation of harmonic phase images. Two SPAMM acquisitions are required to 
describe 2D motion of the heart (red circle), one each for horizontal and vertical motion 
encoding. A harmonic spectral peak is isolated and undergoes an inverse Fourier transform to 
create HARP magnitude and phase images that contain motion information. Here only the phase 
images are shown since the magnitude images are typically discarded. 
In simple terms these HARP images have a phase value for each pixel that is locally unique. 
Tracking a single phase value through consecutive image frames is done by finding the most 
similar value in the local region of tissue throughout an image sequence. In this way the path 
followed by that element of tissue can be traced through time and related to neighbouring 
traces to quantify myocardial function. 
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The following sections describe the work I have undertaken to establish SPAMM imaging with 
HARP processing for assessing regional function in mouse models of cardiac regeneration. 
 
5.2 Methods 
5.2.1 Methods: Motion phantom development 
The development of the motion phantom was performed in two parts. The first was the design 
and manufacture of the physical phantom and its control system. The second part is the 
implementation of the same phantom simulated in Matlab that provides the ground truth for 
validation. First I will describe the development of the physical phantom and second I will 
describe the development of the simulation. 
The motion phantom was designed in the Inventor computer aided design (CAD) environment 
(Autodesk, San Rafael, CA, U.S.A). The final CAD model design is shown in Figure 5.7. Parts were 
designed to be compatible with 3D printing fabrication methods allowing for fine control of 
dimensions and shapes during manufacture. The design features a chamber containing 3 cavities 
for MRI visible material of different sizes and offsets from the axis of rotation. The chamber is 
attached to an axial rod that extends out of the scanner bore to an external servo that provides 
a controllable torque. The phantom was designed to be placed in the standard mouse cradle 
used for in-vivo imaging with two stabilising structures either side of the agarose chamber to 
minimise the effect of flex in the rod and provide stability to the structure during operation. 
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Figure 5.7. Design for motion phantom. (A) rod connected to servo (B) stationary supports (C) 
agarose chamber (D) chamber cap. A cross section of the agarose chamber shows 3 independent 
cavities for agarose ranging in size and distance from the rotation axis. 
The control system for the phantom was an Arduino Uno board based on the ATmega328P 
microcontroller. A simple C++ program was written to produce a repetitive and controllable 
motion that could simulate the heart. The outline for this program is depicted in Figure 5.8. The 
controller initiates rotating the phantom to zero degrees of rotation a position which defined as 
‘diastole’. Next a transistor-transistor logic (TTL) pulse was output into the scanner gating system 
which was interpreted as an R-wave marking the start of contraction. The phantom then rotated 
in +2° increments to 10° (‘systole’) with a tuneable delay between each increment to modify 
rotation speed. Rotation was performed using a TowerPro MG995 controllable digital 
servomechanism (servo). Once the rotation reached +10° a delay was added to simulate end 
systole before the motion reversed until back at position zero. The controller emits another TTL 
pulse and the program looped indefinitely.  
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Figure 5.8 Arduino program. The motion starts by sending a TTL pulse into the MRI gating system 
to simulate an R wave, the servo motor then turns to 10° in 2° intervals with a tuneable delay to 
alter the simulated heart rate. This process then reverses until back in the original position and 
loops until the system is turned off.  
Due to hardware limitations the highest frequency for reproducible motion was around 2.4Hz 
(142bpm). This was principally due to the poor performance of the servo motor. Although the 
servo specifications state a 3ms/° rotational velocity, when the load from the phantom is 
included this rate is severely reduced.  
To test the phantom, the chambers were filled with 1% agarose doped with Gd-DTPA at 
concentrations of 23.6 and 58.5μmol/kg to match heart and liver tissue T1 respectively.245  Since 
chamber 1 exhibited the widest range of motion it was chosen to contain agarose that was T1 
matched to myocardium where we are most interested in measuring displacement. Chambers 2 
and 3 were filled with liver T1 matched agarose. The phantom was imaged using 1000mT/m 
gradients and fitted inside a 39mm diameter volume resonator RF coil. A standard single slice 
cine sequence was performed with acquisition parameters TR=15ms; TE = 1.1ms, FA=15°; 
resolution=0.2×0.2×1mm. These values are typical of a mouse cine scan with an extended TR to 
account for the slower motion of the phantom while maintaining relative frame rates. 
The second part of the motion phantom development revolved around building an accurate 
simulation of the phantom in Matlab. This simulation was used as a ground truth for comparing 
measured displacement with simulated displacement.  
A synthetic model of the phantom was written in Matlab which could simulate the true 
displacement of the agarose in the chambers. The model inputs were image acquisition 
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parameters and information from the phantom control program, this includes the image 
acquisition matrix size, FOV, TR, cine frames, phantom rotation, motion delays and systole 
delays. The aim of including these input parameters was to make the simulation as versatile as 
possible to make it adaptable in the case of variable acquisitions. The model created a 2D grid 
mesh that is set to the resolution of the acquisition, it then defines the three chambers based on 
the CAD design files and the offset defining the centre of rotation. The three chambers are 
converted to a point cloud where each point defines a unique element of agarose, the 
dimensions of each element can be scaled by changing the resolution of the 2D mesh.  The 
Euclidean distance separating a point in each cine frame from its position in frame 1 is then 
calculated and assigned this displacement. The point cloud is then converted back to an image 
matrix using a cubic grid interpolation method. This switching between scattered points and an 
image matrix allows the displacement of each pixel to take on a continuous range of values that 
is more representative of acquired image data. This is as opposed to defining rotation and 
displacement by rotating synthetic pixels where displacement can only occur in discrete intervals 
corresponding to the dimensions of the matrix the data is synthesised on. 
In the physical phantom, the initial position included an offset in rotation and translation due to 
variation in how the phantom was set up on the day of scanning. To correct for this and enable 
direct comparison with the simulated phantom data, a registration step was included when 
synthesising images. The first frame of the synthesised data undergoes a rigid deformation to co-
register with the first frame of the acquired data. This transformation was then applied to all 
subsequent image frames. This process aligns the images and by applying the same 
transformation to all image ensures that inaccuracies in the image acquisition are not masked by 
the registration step. 
 
5.2.2 Methods: SPAMM implementation and optimisation 
The vendor software on the MRI system used in this thesis does not include a SPAMM tagging 
sequence, opting instead to include a variation of the DANTE tagging method. The DANTE 
method is similar in principle to the original inefficient tagging sequence proposed by Zerhouni 
et al.215 and was used in two studies later in this thesis due to the absence of a SPAMM 
implementation at the time (sections 7.2 and 7.3)  
It was therefore necessary to create an efficient SPAMM tagging sequence, this was done by 
modifying the cine MRI sequence code to incorporate a SPAMM tagging module. This tagging 
module consists of two RF pulses separated by a modulation gradient which are followed by a 
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large crusher gradient in the slice select direction. The SPAMM pulse sequence is displayed in 
Figure 5.9. Hard shaped RF pulses were used for the tagging module high power and short 
duration, as this pulse shape excites a wide bandwidth of frequencies non-selectively and allows 
for rapid tagging to minimise tag distortion caused by movement during application. 
 
Figure 5.9 VNMRJ pulse sequence display for SPAMM tagging cine MRI. This is the practical 
implementation of the pulse sequence described in Figure 5.2. Numbers describe pulse sequence 
feature timing (white s; yellow ms; blue μs). 
The SPAMM sequence was tested on the motion phantom to evaluate sensitivity to motion. The 
SPAMM sequence was performed with acquisition parameters TR=15ms; TE = 1.1ms, FA=15°; 
resolution=0.2×0.2×1mm. The tagging module was applied with an encoding strength of 𝐾𝑒 =
1.1cycles/mm created by a gradient of strength 5G/cm and a duration of 500us. 
The process of optimising this sequence focussed on two properties of the tagging pattern- tag 
fading over the cardiac cycle and tag distortion following application. Optimising these two 
properties was performed by varying receiver bandwidth and tagging gradient strength in 
acquisitions of the motion phantom. These optimisations aimed to improve the contrast, 
duration and linearity of the tag lines to enable accurate quantification of displacement 
throughout the cardiac cycle.   
Tag fading due to T1 relaxation reduces tag contrast in later cine frames limiting the information 
on diastolic function. Tag fading is determined by complex interactions between intravoxel 
dephasing, gradient readout and tagging frequency. High resolution acquisitions are less 
susceptible to intravoxel effects and high tag frequency but result in long acquisitions with low 
SNR. To characterise tag fading as a function of tagging frequency, a number of SPAMM tagging 
images were acquired where the duration of the wrapping gradient was kept the same but 
different gradient strengths were used to vary the tagging pattern frequency. This resulted in a 
series of identical acquisitions of the motion phantom, varying the frequency of the tagging 
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modulation applied as described by Equation 5.4. Four gradient strengths in total were 
examined at 3, 5, 7 and 9G/cm. To quantify the degree of tag fading, the mean signal intensity of 
the first and last images in the cine acquisition were measured in all chambers of the phantom 
using Equation 5.5. Where 𝑆𝑛 represent the mean signal intensity of the line profile in frame 𝑛. 
 
𝑇𝑎𝑔 𝑓𝑎𝑑𝑖𝑛𝑔 [ % ] =  
𝑆𝑙𝑎𝑠𝑡̅̅ ̅̅ ̅̅ −  𝑆𝑓𝑖𝑟𝑠𝑡̅̅ ̅̅ ̅̅ ̅
𝑆𝑙𝑎𝑠𝑡̅̅ ̅̅ ̅̅
× 100 
Equation 5.5 
The second target of optimisation was the distortion of tag lines. Following an empirical 
observation, a shorter acquisition bandwidth was thought to reduce this distortion. The 
reasoning behind this was that a shorter receiver bandwidth and corresponding shorter read out 
gradient would sample less noise frequencies resulting in lower noise power and a less 
corrupted signal. Additionally, the faster readout would include less motion in the case that the 
phantom was moving during acquisition. To test this hypothesis acquisitions were performed 
while varying the spectral bandwidth of the acquisition from 50, 100, 150 and 200KHz. Other 
acquisition parameters remained fixed between scans with TR=15ms; TE = 1.1ms, FA=15°; 
resolution=0.2×0.2×1mm, 𝐾𝑒 = 1.1cycles/mm created by a gradient of strength 5G/cm and a 
duration of 500us. Results were then analysed for distortion by drawing taking a profile across 
each acquisition. Image SNR was characterised as a function of bandwidth. 
Tag distortion was also investigated as a function of tagging frequency. In this case the 
acquisitions used previously as part of the optimisation for tag fading were reanalysed. Tag 
distortion was therefore investigated at tagging strengths of 3, 5, 7 and 9G/cm. 
 
5.2.3 Methods: SPAMM validation 
The validation of the SPAMM sequence was performed by comparing the measured 
displacement from the SPAMM sequence- analysed with HARP- to the displacements produced 
by the phantom simulation describing the true motion. 
The implementation of HARP used for this project was the HARP Matlab toolbox Version 2.1 
(2013) developed by Image Analysis and Communications Lab (IACL), Johns Hopkins 
University.237,246,247 The semi-automatic workflow for HARP processing using this software is 
outlined in Figure 5.10. The user chooses image data for each encoding direction and manually 
defines a bandpass filter to isolate the displacement encoded echo. The image is then passed 
through the user-defined filter removing all other frequency information. This filtered k-space 
undergoes an iFFT to reconstruct the HARP phase and magnitude images. The HARP phase 
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images for each direction are then passed to the point tracking algorithm where the most likely 
position of each point in successive frames is calculated based on distance travelled and 
surrounding pixels. For any element of heart tissue with a HARP phase value only one point in a 
later frame is the correct match. If the image sequence has an appropriately high temporal 
resolution relative to the heart rate and a suitable tagging frequency, then the most likely 
position in a later time frame for a point will be the closest point with a matching HARP value. 
The result of the motion tracking is a 4D numerical matrix with a size equal to 𝑓𝑟𝑎𝑚𝑒𝑠 ×
𝑃𝐸 𝑑𝑖𝑚𝑒𝑛𝑠𝑖𝑜𝑛 × 𝑅𝑂 𝑑𝑖𝑚𝑒𝑛𝑠𝑖𝑜𝑛 × 2 containing the x and y co-ordinates of each point through 
the image sequence. This matrix can be exported from the HARP software into the Matlab 
workspace for further custom analysis.  
 
Figure 5.10 HARP software workflow. Each SPAMM encoding direction undergoes HARP 
processing as described in Figure 5.6. An Each point in the HARP phase images is then tracked 
through every image frame describing the motion of that point. 
Although each tissue point has a unique phase value within its local area, due to phase wrapping 
the adjacent lines contain the same values meaning a large displacement can cause a tracked 
point to jump across adjacent phase wraps. The potential then is for this error to propagate as 
the mistracked point is tracked through time. This tracking error was investigated as a function 
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of displacement and encoding strength for validating the SPAMM acquisition over the range of 
motion expected in the mouse and rat heart.  
SPAMM images were acquired at tagging frequencies produced by gradients of 3, 5, 7 and 
9G/cm. Displacement of acquired data was calculated in the same way as with the synthesised 
data, defining the displacement as the Euclidean distance between a point at any time with its 
position in the first frame. The motion of the phantom was reproduced synthetically using the 
simulation described above (5.2.1) to provide the ground truth. This allowed subtraction of the 
two displacement maps to produce difference images that show the accuracy of the 
implemented SPAMM and HARP techniques for tracking motion.   
 
5.2.4 Methods: in vivo implementation 
Finally, the SPAMM sequence was tested in-vivo using the optimised acquisition protocol. 
SPAMM imaging was performed in a naïve wild type mouse with image acquisition parameters; 
TR = 5ms, TE = 1.5ms, 192×192 acquisition, with a tagging frequency of 𝐾𝑒 =  1.4 cycles/mm 
corresponding to a wrapping gradient strength of 7G/cm with a duration of 0.5ms while a 
normal mouse heart rate ≈550bpm allowed for 20 cine frames and 10 averages within a 5 
minute/direction scan.  
 
5.3 Results 
5.3.1 Results: Motion phantom development 
Figure 5.11 shows the acquired cine acquisition frames of the motion phantom with the original 
position of the phantom in green. End systole occurs from frames 8-11 corresponding to 120-
165ms after the start of systole. There is some degree of motion artefact in the phase encoding 
direction. These motion artefacts although visible do not seriously degrade image quality. 
Alternatively, these mismatches in position can be likened to the variability of the heart rate 
over the duration of an acquisition. The artefacts are most likely caused by the quantised nature 
of the servo motion. The servo incorporates an internal feedback system to ensure it reaches the 
position instructed by the microcontroller, a motor is turned on and off in an attempt to reach 
and maintain the position of the mechanism. This is the reason for including a motion delay to 
give the servo time to reach the desired position. Each increment of rotation therefore includes 
a period of motion and a stationary period in between reaching position and waiting for the next 
instruction. The motion artefacts in the cine image is due to acquisition occurring partially in 
171 
 
both of these periods depending on sequence timing. It is extremely difficult to match the 
sequence timing and the servo position since the servo feedback system operates independently 
and depends heavily on the mechanical load and position of the phantom.  
 
Figure 5.11 Cine MRI of motion phantom. Axis of rotation is approximately in the centre of the 
image with 10° of CW rotation followed by 10° CCW. Green circles represent the position of the 
three chambers in the first frame.  
The same acquisition protocol presented in Figure 5.11 was simulated using the synthetic 
phantom in Matlab. This simulation is shown in Figure 5.12. The displacement of each point in 
the simulated data is scaled by colour for visualisation. The simulated data is comparable to the 
acquired cine data. The displacement is seen to be proportional to the distance from the centre 
of rotation as would be expected. The simulated motion described by the simulation shows a 
well matched motion path to the cine sequence from the physical phantom above.  
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Figure 5.12 Simulation of motion phantom showing pixel-wise displacement based on image 
acquisition and phantom properties. Each frame shows a scatter plot with a dot representing 
each unique element of agarose along with a faded image of the phantom in frame 1 for 
reference. the colour of each point is scaled by the magnitude of its displacement from frame 1. 
The range of displacements produced by the physical and simulated phantom are shown in 
Figure 5.13. At end systole chamber 1 is displaced by 0.64mm at the edge closest to the rotation 
axis and 3.67mm at the furthest edge. This covers the expected range of displacements for the 
contracting LV of the mouse (0 – 1.2mm) and rat (0 – 2.4 mm)39 illustrated by the blue and green 
contours respectively in Figure 5.13. 
 
Figure 5.13 Simulated phantom displacement map at the maximum rotation overlaid with 
expected magnitude of motion in normal physiology for mouse and rat left ventricles during 
systole.  
This phantom design is a good model of cardiac displacement but it is a simplification of the 
complex contraction of the myocardium. In the living heart the physical shape of the heart 
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changes during contraction, becoming shorter and thicker at systole due to the flattening of 
myocardial laminae. The contraction of the opposing helical myocardial fibres also induces a 
torsion force where the epicardium and endocardium contract in opposing helical directions, 
this induces a torsion (twisting) force as well as shearing forces during systole that this phantom 
cannot simulate. These complex motions are extremely difficult to reproduce without complex 
and elaborate phantom design. However, these motions play an important role in the definitions 
of wall thickening and fractional shortening making this phantom unsuitable for testing the cine 
regional morphology analysis presented in Chapter 4.  
For the purpose of validating MRI measures of cardiac displacement however, these forces are 
not necessary, if displacement can be accurately measured using this phantom then the complex 
deformations in vivo can be inferred from that basic information. The following results sections 
describe how this motion phantom was used further for the optimisation of the SPAMM 
acquisition. 
 
5.3.2 Results: SPAMM implementation and optimisation 
5.3.2.1 SPAMM sequence implementation 
An example SPAMM image sequence from the motion phantom is shown in Figure 5.14. 
Acquisition parameters were identical to the standard  encoded cine sequence shown in Figure 
5.11 and the original agarose chamber positions are again shown as green circles to help 
visualise displacement.  
The acquired SPAMM images appear identical to the original cine acquisition (Figure 5.11) but 
with the sinusoidal modulation of signal in the vertical direction. At later frames of the imaging 
cycle, the modulation pattern fades according to T1 decay as described by Equation 5.3. 
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Figure 5.14 Example of acquired SPAMM tagging cine images. The motion phantom is shown 
using the same motion parameters as the cine sequence shown in Figure 5.11. Green circles 
represent the initial chamber position. 
Figure 5.14 shows the first implementation of the SPAMM sequence I produced. The parameters 
for encoding the modulation pattern were chosen empirically. The result is that the applied tag 
lines exhibit some degree of unoptimised tag fading and distortion not related to deformation of 
the phantom. The following section describes how I optimised the acquisition and encoding 
parameters for imaging regional function in mice with improvements in tag fading and 
distortion.  
  
5.3.2.2 SPAMM optimisation: Tag fading 
The results of the acquisitions varying encoding strength to investigate the relationship between 
tag fading and tag frequency are shown in Figure 5.15. The variation in the tag patterns can be 
clearly visualised as tag lines get thinner and more tightly packed with increasing gradient 
strength, although tag fading appears to be accentuated at higher tag frequencies. 
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Figure 5.15 Increasing the tagging gradient strength increases tagging frequency. Encoding 
values shown here are G=3, 5, 7 and 9 G/cm in phase encode (PE) and readout (RO) orientations. 
Bottom row shows the intensity profile (yellow line, top left) for each encoding strength in the 
first and last image frames to illustrate the effects of tag fading with increased tag frequency. 
Tag fading over the complete imaging cycle and its relationship to encoding strength is plotted in 
Figure 5.16. The relationship between tag fading and encoding strength is visible although there 
is initially increased fading at 3G/cm. When the RF flip angle (α) used to excite the tagging 
pattern is high, the magnetisation pattern can pass the zero line and take a negative value in the 
troughs. Since the scanner measures the absolute value of magnetisation this results in the small 
positive secondary peaks at the bottom of the troughs best seen in Figure 5.15 for 3G/cm. When 
these secondary peaks are wide enough relative to the spatial resolution of an image they can 
contribute to the mean signal and produce an artificial increase in tag fading. This relative 
increase in fading at at 3G/cm is likely a result of a partial sampling of the tagging pattern in this 
way. As tag frequency increases relative to the image resolution these small peaks are lost 
through partial volume effects.  
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Figure 5.16 The relationship between the extent of tag fading between the first and last cine 
frames and SPAMM encoding gradient strength. Note the artificially increased fading at 3G/cm 
due to partial volume effects.  
 
5.3.2.3 SPAMM optimisation: Tag distortion 
Tag distortion was observed in the initial pilot scans for the SPAMM sequence. This distortion is 
not due to deformation since the phantom only exhibits rotational motion. This section 
describes the results of my efforts to minimise this distortion. Figure 5.17A shows the first frame 
of acquisitions at 5G/cm encoding with 50, 100, 150 and 200KHz receiver bandwidths. Visually 
tag lines appear sharper at lower bandwidths but when that is quantified by drawing a profile 
across a tag line (red line in Figure 5.17A insets) and plotting the pixel values (Figure 5.17B) the 
acquisitions show very similar curves in the tag line. There is a small reduction in tag distortion at 
50KHz shown by the low signal at around position 10 (arrow) in Figure 5.17B. This improvement 
does not account for the larger visible distortions and so receiver bandwidth could be excluded 
as the primary cause of tag distortion in these images. Subsequent imaging tested distortion in 
terms of tag frequency.  
SNR improvements with receiver bandwidth were quantified using the same data. Results are 
shown in Figure 5.17C. SNR improves rapidly from 200 to 100KHz with a smaller improvement at 
50KHz. Following this result, the bandwidth was fixed to 50KHz for all future acquisitions. 
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Figure 5.17 Effects of acquisition bandwidth on tag distortion and image SNR. (A) shows the first 
images at a number of different acquisition bandwidths. To quantify tag distortion a profile was 
plotted for each bandwidth (see A. insets) but showed no real change other than the inclusion of 
a secondary peak (arrow). Higher SNR (C) was related to lower acquisition bandwidth.  
Since the presence of tag line distortion was only observed at low tagging frequencies it suggests 
that there may be some influence of tag separation on this artefact. To investigate this, we can 
observe the separation of the displacement encoded echoes in k-space. Figure 5.18 shows the 
central portion of k-space in the tagging direction for each gradient strength.  
At low encoding strengths the displacement encoded echoes (B/B’) appear close to the central 
T1 echo (A). This figure shows additional echoes at harmonic frequencies (C/C’). The appearance 
of these echoes in k-space are related to the secondary peaks we see in image space. Where 
B/B’ represent the main tagging pattern, C/C’ are created from the secondary peaks and 
contribute to the primary modulation pattern by superimposing a pattern with the same phase 
and double the frequency of the intended modulation. The superposition of the stimulated 
echoes with the T1 echo without sufficient spatial resolution to resolve them independently is 
likely the cause of the tag distortion seen in image space. As the gradient strength is increased 
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these peaks move further away from the central echo allowing the information in each echo to 
be resolved at this acquisition resolution.  
 
Figure 5.18 Magnitude k-space profiles for the variable tagging frequency acquisitions shown in 
Figure 5.15. The tagging information is encoded in peaks offset from the centre of k-space by a 
distance specified by encoding strength. Low frequency tag lines near the centre of k-space 
become distorted due to superposition of displacement encoded echoes with the central T1 peak. 
 
5.3.3 Results: SPAMM Validation 
Displacement maps for the measured and simulated motion phantom are shown in Figure 5.19B. 
Here the top row shows the simulated displacement map (ground truth), the second row shows 
the measured displacement and the third row shows the subtraction of these two maps. In 
these difference images a low value (dark) shows good agreement with the synthetic data while 
a high value (bright) shows poorly tracked regions with a high mismatch. The first frame of each 
image sequence is uniform.  
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Figure 5.19 Quantifying displacement from HARP output data. The acquired displacement data 
can be compared to the synthetic data generated from knowledge of the phantom motion to 
create a difference image showing the error in measurement. 
The example data shown in Figure 5.19 shows displacement errors when measuring the large 
motion at the edge of chamber 1. This is most easily seen in the difference images in Figure 5.19 
as the bright region furthest from the centre of rotation. The onset of this error is rapid as 
tracking errors propagate and occurs at displacements >2.5mm. This example data was acquired 
using a gradient encoding strength of 7G/cm and it is likely that the tagging frequency is too high 
to measure large displacements. A high tagging frequency produces a dense pattern of phase 
wrapping in HARP phase images, if the displacement between image frames is large relative to 
the tagging frequency then a tracked point in these phase images may skip into an adjacent 
wrapped line.  
The displacement maps from the data shown in Figure 5.18 for end systole are shown in Figure 
5.20A. As encoding strength increases the threshold at which measurement errors occur can be 
seen to move radially inwards towards the centre of rotation beginning at 7G/cm. To investigate 
this in more detail a profile was plotted from the centre of rotation across chamber 1 for each 
encoding strength and the synthetic data (coloured lines in Figure 5.20A). The displacement 
values along these profiles are plotted against the synthetic data (black lines) in Figure 5.20B. 
These graphs are a clear illustration of the rapid deterioration of tracking accuracy above certain 
displacements. At 3-5G/cm the tracking is accurate across the range of displacements present in 
the phantom motion, however for encoding strengths of ≥7G/cm there is a threshold of 
displacement above which accuracy is severely impaired. This threshold is lower at 9G/cm 
relative to 7G/cm showing a dependence on tagging frequency.  
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Figure 5.20 Displacement errors with encoding strength. (A) displacement images at phantom 
systole an overlay showing the line profile used to plot the displacement errors (B). Dashed lines 
show the total range of motion in the phantom, dotted lines show the expected displacement 
range for the mouse LV. Taking the mean error over these ranges allow the accuracy of each 
encoding strength to be quantified (C-D). 
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Figure 5.20C-D shows the mean difference between measured and synthesised displacements 
across the profiles to give a single value quantifying the quality of the displacement 
measurements for each encoding strength. If the complete range of displacements across 
chamber 1 are considered (dashed lines Figure 5.20B) then tagging with an encoding strength of 
5G/cm produces the most accurate map of displacement with encoding at ≥7G/cm producing 
significantly less accurate results. However, the range of displacements produced by this 
phantom far exceed the expected motion of the mouse heart (see Figure 5.13). If we consider 
only the measurements over the expected range of displacements for the contracting mouse 
heart (dotted lines Figure 5.20B) then 7G/cm becomes significantly more accurate (P=0.036; one 
way ANOVA) than the other gradient strengths. This increased accuracy at small displacements 
at higher encoding strengths is the inverse effect of the cause of inaccuracies at high 
displacements. Higher tagging frequencies provide a higher concentration of phase wraps in 
HARP images, at small displacements this can provide higher resolution displacement 
information.  
 
5.3.4 In vivo implementation 
Figure 5.21 shows the in vivo implementation from the final optimised SPAMM tagging protocol. 
Tag distortion was minimal in these images thanks to a relative high encoding strength of 
7G/cm. This produced a tagging frequency of 𝐾𝑒 = 1.4cycles/mm that resulting in tag fading of 
approximately 33% as determined above. This value was slightly less in vivo however due to the 
more rapid heart rate of the mouse compared to the phantom motion. 
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Figure 5.21 In-vivo SPAMM tagging test showing the first, end-systolic and last cine images for 
tagging in the readout and phase encoding direction. Also shown is the product of the RO and PE 
images to produce an artificial 2D tagging grid pattern. 
 
5.4 Discussion 
This chapter described the implementation and optimisation of a SPAMM cardiac cine sequence 
with HARP processing using a custom motion phantom. An in-vivo assessment of this technique 
is included in chapter 7 as part of a comparison of SPAMM and DENSE for regional function 
assessment in myocardial infarction following regenerative therapy. 
Development of the motion phantom was important for validation of the tagging technique. A 
reproducible and programmable motion allowed the measurements of displacements by HARP 
to be compared to true displacement (Figure 5.20) determined by simulations. The contraction 
cycle of the mouse heart in vivo occurs around 550Hz and due to mechanical limitations of the 
motor controlling motion, this rapid motion could not be reproduced. The 2.4Hz that could be 
reproducibly achieved using available hardware is significantly slower. Although the speed of 
motion was limited, the displacement of the phantom was within the expected range for both 
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mouse and rat hearts ensuring the phantom work was a useful exercise for validation and 
optimising tagging properties for maximising sensitivity and image quality to this range of 
motion. The duration of acquisitions was, however, significantly longer using the motion 
phantom than in vivo imaging since each cine dataset has duration proportional to the 
contraction cycle duration (RR interval). 
The result of the phantom optimisation was a tagging module consisting of two 90° RF pulses 
separated by a tagging gradient with a duration of 0.5ms and strength of 7G/cm. Inputting these 
values into Equation 5.1 returns an encoding strength of 𝐾𝑒 = 1.49 cycles/mm.  
Optimisation of SPAMM cine imaging for minimising tag fading over a contraction cycle showed 
that higher tagging frequencies suffer greater contrast loss compared to lower frequencies. Tag 
fading of 30 – 36% was observed for the phantom over a single contraction cycle lasting 410ms 
which is 4x longer than the mouse heart cycle. For in vivo imaging the shorter contraction cycle 
should result in less tag fading. However, despite matching the T1 of the agarose phantom to 
cardiac tissue, the relatively uniform magnetic homogeneity of the agarose makes it a non-ideal 
model of heart tissue. The SPAMM tagging module stores the magnetisation pattern in the T1 
decay where tag fading is dependent only on the T1 of tissue as described by Equation 5.3. 
During cine acquisition however this magnetisation is restored to the transverse plane for 
gradient readout allowing T2/T2* decay to attenuate the magnetisation pattern. The effect of 
magnetic field inhomogeneity in the heart due to factors such as the lung/tissue boundary, 
motion and flow is therefore likely to cause more rapid tag fading in vivo compared to in the 
phantom. 
Overall there was good agreement of displacement measured by HARP with true phantom 
motion over the range of displacements that could be accurately measured for each encoding 
strength (Figure 5.20D). Over the entire range of displacements performed by the phantom an 
encoding gradient of 5G/cm (𝐾𝑒 = 1.06cycles/mm ) performed best, however, when considering 
only the expected range of displacements for the mouse heart, an encoding strength of 7G/cm 
was found to be more accurate.  
An interesting idea for continuation of this work would be to produce a T1 map from SPAMM 
tagged images. T1 mapping and tagging are two time consuming sequences that are typically 
considered too long for practical use in clinical MRI. The ability to extract two useful parameters 
from a single acquisition may aid in the uptake of regional function assessment in the clinic. 
Since the tag fading (see Figure 5.15 and Figure 5.16) occurs due to the recovery of the 
longitudinal magnetisation it has dependence on T1 as described by Equation 5.3. However, with 
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tagging there are stripes in the image that do not fade since they are already fully relaxed, these 
are the dark bands in the tagged image. To sample T1 relaxation in these lines, a complementary 
SPAMM acquisition with a 90° phase offset in the modulation pattern would be required. The 
acquisitions can be combined for an efficient CSPAMM acquisition to reduce tag fading 
(complementary acquisition are discussed further in Chapter 6). To account for the motion of an 
element of tissue the motion path of a pixel can be traced using HARP to correct for cardiac 
motion during T1 relaxation. This T1 mapping concept is an exciting idea with great potential for 
research and clinical imaging and remains an objective for further work.  
SPAMM and HARP are effective for measuring regional function in the heart but MRI sequences 
based on tagging such as this are inherently limited in the spatial resolution of the displacements 
they can resolve. This limited resolution can become a problem in studies of biomaterials where 
high resolution information is required. The resolution of SPAMM and HARP based techniques 
are limited by the tagging frequency and the k-space HARP filter. These two factors are 
interconnected since a higher tagging frequency will allow a wider k-space filter that will pass 
high frequency displacement components. Regional information is also limited by fact that the 
myocardial signal is intentionally suppressed to produce the saturated tag pattern. Although 
these resolution limits are not significant when investigating broad regional function- for 
example, a comparison of contraction in the anterior/septal regions- it can be a limiting factor 
when investigating transmural function. In cardiac tissue engineering for regenerative therapy 
the engraftment location of the biomaterial may have a significant effect on its efficacy and 
compatibility with the existing myocardium. SPAMM and HARP are limited in their ability to 
identify the transmural strain and an alternative technique with improved spatial resolution is 
required to quantify intramyocardial function in response to a therapeutic material. For this 
reason, the Displacement encoding using stimulated echoes (DENSE) sequence was developed in 
parallel with SPAMM and HARP.  
 
5.5 Summary 
This chapter described the internal development, optimisation and validation of a cine Spatial 
Modulation of Magnetisation (SPAMM) tagging sequence with Harmonic Phase (HARP) 
processing. A motion phantom was designed, manufactured and simulated in Matlab. This was 
used to optimise the SNR and tag fading of the sequence and validate the SPAMM sequence and 
HARP processing over the range of mouse and rat myocardial displacements. The result is an 
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optimised SPAMM sequence and processing system that is able to accurately track regional 
myocardial displacement.  
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Chapter 6 Development of Displacement 
ENcoding using Stimulated Echoes (DENSE) 
MRI 
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6.1 Introduction and theory 
6.1.1 Study overview 
This chapter describes the development of a displacement encoding using stimulated echoes 
(DENSE) MRI sequence for preclinical assessment of regional function. DENSE is a phase based 
imaging technique that can provide higher resolution displacement information than SPAMM or 
HARP, which may provide useful biomarkers for the efficacy and safety of cardiac regeneration 
therapies in transmural myocardium, such as intramyocardial injections. This chapter introduces 
the theory underlying DENSE and describes the experimental optimisation of a DENSE sequence, 
including cine DENSE imaging, phase correction, artefact suppression and fitting trajectories for 
improved strain analysis. The aims of this chapter can be summarised in 4 objectives. 
1. Develop and optimise preclinical cine DENSE sequence 
2. Apply novel method for background field removal for accelerating acquisition 
3. Investigate approaches to removing artefacts echoes and determine which method is 
optimal for preclinical imaging. 
4. Implement motion trajectory fitting and strain calculations for displacement analysis 
The workflow to meet these aims is shown in Figure 6.1 and describes the outline of how the 
work is presented in this chapter. The chapter can be roughly split into 4 parts where each 
aims to develop or optimise a specific component of the DENSE acquisition and post 
processing pipeline. Part 1 aims to implement the DENSE sequence- first as a single phase 
sequence as originally described by Aletras et al.248 before expanding it with a cine imaging 
capability. Part 2 aims to test a new method for phase correction in DENSE data using 
projection onto dipole fields. Part 3 investigates advanced methods for isolating the 
displacement encoded echo without k-space filtering. Finally, part 4 aims to calculate strain 
from the displacement field images as well as assess an optional processing step where 
myocardial trajectories are fitted to displacement data to produce more physiologically 
accurate motion.  
 
189 
 
 
Figure 6.1 Study design for the work described in this chapter with the aim of producing a 
regional strain map from DENSE data. Each stage of this development process is separated 
by a box and a colour with the lines describing the processing steps necessary to produce the 
strain map. 0 
 
6.1.2 DENSE sequence 
DENSE MRI developed in parallel with HARP and the two techniques share many similarities and 
can be described as two approaches to phase based regional displacement tracking249. Both are 
imaging techniques for assessing regional myocardial displacement mapping based on spatial 
modulation of the MRI signal and are able to produce displacement maps of cardiac tissue. They 
differ in that DENSE has been developed as a stimulated echo acquisition scheme that aims to 
isolate the displacement encoded echo at the centre of k-space while HARP and SPAMM are 
based on filtering acquired data to perform analysis. 
DENSE was introduced in 1999 by Aletras et al.248 The original DENSE sequence was not cine-
capable and imaged the displacement of the heart tissue at end systole only. This original DENSE 
pulse sequence is shown in Figure 6.2A. The sequence consists of 3 stages modulation, mixing 
and demodulation which combine to encode and decode the MRI signal with information about 
cardiac motion. 
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Figure 6.2 DENSE acquisition scheme (A) the pulse sequence acquires with ECG and respiration 
gating. The modulation stage is applied at end diastole and the echo is formed at end systole. 
The appearance of DENSE in k-space (B) is identical to SPAMM at the modulation stage (B1), the 
second demodulation gradient however shifts the final acquisition so that the displacement 
encoded echo forms at the centre of k-space (B2).   
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The modulation stage is applied immediately following detection of an R-wave trigger and is 
identical to a SPAMM tagging module. The magnetisation is modulated in the same way as with 
SPAMM (see chapter 5). This modulation produces a tagged k-space image as seen in Figure 
6.2B2 with a T1 relaxation echo and a displacement encoded echo and anti-echo. Following the 
modulation period, the tissue acquires a phase value that is sinusoidally modulated by its 
position along the encoding direction. This is followed by the mixing period during which motion 
occurs while the magnetisation is stored in the longitudinal direction. The duration of the mixing 
period is designated 𝑇𝑀. When imaging a single cardiac phase this value is typically set to the 
finish at end systole to capture the largest component of motion. The demodulation phase is a 
combined motion decoding and the image acquisition sequence. Following the selective RF 
excitation that tips the stored magnetisation into the transverse plane for imaging, a 
demodulation gradient is applied with the same gradient area as the SPAMM wrapping gradient. 
The effect of this demodulation gradient is to rewind phase in tissue in which no motion has 
occurred over the mixing time since it experiences an identical encoding and decoding gradient. 
In tissue that has moved during the mixing time the tissue accumulates a phase change that is 
proportional to the magnitude of displacement along the encoding gradient direction. To 
describe this mathematically a spin that has moved by a distance ∆𝑥 between the application of 
the encoding and decoding gradients will accumulate a phase ϕ described by Equation 6.1. 
 𝜑 = ∆𝑥 [𝛾𝐻 ∫ 𝐺𝑒𝑛𝑐(𝑡) 𝑑𝑡] Equation 6.1 
In k-space the demodulating gradient translates the displacement encoded echo to the centre of 
k-space (see Figure 6.2B.1). Depending on the tagging frequency controlled by the encoding 
gradient area it is possible to shift the T1 echo and complex conjugate outside of the acquisition 
window. The goal of shifting k-space in this fashion is to produce an acquisition in which the 
displacement echo is sampled without corruption from the other echoes. By centring the 
displacement echo at the k-space origin and removing extraneous echoes DENSE is able to 
produce high spatial resolution maps of displacement since there is no need to filter the 
encoded echo and discard corrupted k-space as is the case with SPAMM.  
DENSE requires 3 acquisitions to describe 2D motion in the heart. One acquisition to image x-
axis displacement one for y-axis displacement and a third identical acquisition with a different 
encoding strength to remove sources of background phase. The background phase image 
provides a reference for the encoded images. By subtracting the reference image from the 
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directionally encoded images the result is a phase image showing only the phase change induced 
by motion occurring the mixing time.  
Image processing in DENSE is straightforward in comparison to HARP since tracking individual 
points through time is not necessary to measure displacement because pixel phase values are 
directly related to their displacement in DENSE. Depending on the value of 𝐾𝑒 however it can be 
necessary to perform phase unwrapping if the displacement of the tissue meets the phase wrap 
condition (Equation 6.2). 
 ∆𝑥 ≥  1 𝐾⁄ 𝑒
  Equation 6.2 
This condition describes the case where if the displacement ∆𝑥 is large enough or the encoding 
strength high enough for a tissue region to accumulate a phase change > 2𝜋 then phase 
wrapping will occur and require correction. In HARP the phase wrapping provides image features 
which aid the tracking of tissue motion however in DENSE this wrapping introduces severe errors 
in displacement due to sudden changes in phase values. The result of DENSE imaging are maps 
of the displacement of heart tissue for each encoded direction such as those shown in Figure 
6.3. Plotting the values of these maps as x and y-components of a vector produces a 2D 
displacement field map. From this displacement field the strain tensor can be calculated based 
on the deformation of a uniform square grid by the measured displacement. 
 
Figure 6.3 Example DENSE data encoded in 2 directions to produce a typical displacement field 
visualised using a small vector in each pixel defined by the x and y displacements. 
 
6.1.3 DENSE artefact echoes 
To enable extraction of useful uncorrupted displacement information from these DENSE 
acquisitions it is necessary to filter out or suppress the T1 relaxation echo and the complex 
conjugate of the displacement encoded echo. The simplest method for removing these 
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unwanted echoes is using a bandpass filter centred on the displacement encoded echo and 
zeroing all frequencies outside this band. However, this has the effect of removing high 
frequency spatial information removing fine detail in images and limiting the resolution of 
displacement maps. It is therefore desirable to supress these echoes rather remove those 
frequencies completely.  
Before describing the different methods for supressing these echoes it is first necessary to 
describe how the artifactual echoes are generated during DENSE acquisition. The DENSE 
sequence begins with the detection of an R-wave and the application of a SPAMM tagging 
module that modulates the signal by a cosine function and stores it in the longitudinal 
magnetisation 𝑀𝑧 as described in Equation 5.2. The modulation stored 𝑀𝑧 then undergoes T1 
relaxation according to Equation 5.3. 𝑀𝑧 is sampled after a time 𝑡 by the application of an RF 
excitation pulse with flip angle α that tips 𝑀𝑧 into the transverse (𝑥𝑦) plane. Including this 
excitation and rearranging Equation 5.3 with the exponential form of cosine results in a function 
with 3 terms, one for each of the  3 echoes in DENSE acquisitions (Equation 6.3).250  
 
𝑀𝑥𝑦(𝑥, 𝑡) =  
𝑀
2
𝑠𝑖𝑛(𝛼) 𝑒
−𝑡
𝑇1⁄ 𝑒𝑖𝑘𝑒𝑥 +
𝑀
2
𝑠𝑖𝑛(𝛼) 𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒𝑥
+ 𝑀0 𝑠𝑖𝑛(𝛼) (1 − 𝑒
−𝑡
𝑇1⁄ ) 
Equation 6.3 
The final component of each term containing the 𝑥 value describes the position of the signal 
peak in k-space for encoding in the 𝑥 direction. The first term has phase 𝐾𝑒𝑥, the second term 
has phase −𝐾𝑒𝑥 and the third has 0 phase. These correspond to the displacement encoded 
echo, the complex conjugate echo and the T1 relaxation echo respectively. This describes the 
magnetisation state following the SPAMM module prior to the application of a DENSE 
unencoding gradient and is equivalent to the magnetisation in a SPAMM acquisition. The T1 
echo is therefore at the k-space origin with the displacement encoded echoes at ±𝐾𝑒 . If a DENSE 
demodulation gradient equal to the encoding gradient is applied immediately following RF 
excitation and before readout with a tissue displacement ∆𝑥 between them the magnetisation 
takes the form described by Equation 6.4. 
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𝑀𝑥𝑦(𝑥, 𝑡) =  
𝑀
2
𝑠𝑖𝑛(𝛼) 𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥
+
𝑀
2
𝑠𝑖𝑛(𝛼) 𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖2𝑘𝑒𝑥
+ 𝑀0 𝑠𝑖𝑛(𝛼) (1 − 𝑒
−𝑡
𝑇1⁄ ) 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖𝑘𝑒𝑥 
Equation 6.4 
It can be seen that the terms describing the position of the signal peaks in the 𝑥 direction are 
shifted by the second gradient. The first term describing the displacement encoded echo now 
has no 𝑥 component positioning it at the k-space origin. The second term describing the complex 
conjugate echo has shifted to −2𝐾𝑒𝑥 and the T1 echo now appears at −𝐾𝑒𝑥.  
A simple method to isolate the acquisition to the displacement encoded echo without filtering is 
to increase encoding strength 𝐾𝑒 until the artefact echoes are outside acquisition window, i.e. 
increase 𝐾𝑒 to the point where 𝐾𝑒 is higher than the range of sampled frequencies and all 
echoes are generated outside of the FOV or sample lower frequencies only. Removing echoes 
through this method is a compromise and results in either a loss of spatial resolution as less 
frequencies are sampled or a decrease in SNR due to intravoxel dephasing when 𝐾𝑒 is large.  
Three advanced methods for removing these artefact echoes are investigated in this chapter 
based on complementary acquisitions (cDENSE and CANSEL) and through plane dephasing. The 
Theory underpinning these echo suppression techniques will be described below. 
 
6.1.3.1 Complementary acquisitions 
There are two complementary acquisition schemes that have been applied to DENSE, the first is 
complementary DENSE (cDENSE) and the second is cosine and sine modulation to eliminate 
(CANSEL) artefact generating echoes. Complementary acquisitions were first proposed in the 
context of SPAMM tagging with complementary SPAMM (CSPAMM). A standard SPAMM tagging 
pulse as used in Chapter 5 and for all implementations of DENSE so far uses two 90° RF pulses 
for tipping the magnetisation vector. This results in a cosine modulated magnetisation as 
described by Equation 5.2. A complementary image is an identical acquisition where the second 
RF pulse is given a phase offset to shift the modulation pattern by nπ/2. Figure 6.4 illustrates the 
effect of changing the second RF pulse phase has on the resulting magnetisation pattern. The 
phase of the second RF pulse (RF2) changes the transverse orientation of the net magnetisation 
vector to produce a phase offset in the pattern of modulation across the tagging direction (in 
this example the x direction).  
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Figure 6.4 Effect of changing the phase of the second RF pulse on precessing spins for CANSEL 
and cDENSE. Changing the position of the magnetisation vector in the transverse 𝑥𝑦 plane 
creates π/2 phase shifts in the resulting SPAMM pattern. 
In cDENSE the complementary image is acquired with the second RF pulse given a π phase offset 
resulting in a negative cosine modulation pattern. Subtraction of these images in k-space 
supresses the T1 relaxation echo leaving only the displacement encoded echo and the complex 
conjugate echo. The result of this is reduced tag fading due to the removal of the a large T1 
relaxation component in the MRI signal, this subtraction process is described graphically in 
Figure 6.5. 
 
 
Figure 6.5 Illustration describing the effect of the complementary subtraction method on cosine 
modulated magnetisation in the x direction. The result is the removal of the ‘DC’ T1 offset decay 
term, reducing tag fading and providing more displacement information at later stages of the 
cardiac cycle. 
Mathematically this subtraction process can be described as follows. If we rearrange Equation 
6.4 to separate the common 𝑠𝑖𝑛(𝛼) terms we have Equation 6.5 and Equation 6.6 describing the 
first DENSE image and the complementary image respectively. 
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𝑀𝑥𝑦
𝑐𝑜𝑠(𝑥, 𝑡) =  [
𝑀
2
𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥 +
𝑀
2
𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖2𝑘𝑒𝑥
+ 𝑀0 (1 − 𝑒
−𝑡
𝑇1⁄ ) 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖𝑘𝑒𝑥] 𝑠𝑖𝑛(𝛼) 
Equation 6.5 
 
𝑀𝑥𝑦
−𝑐𝑜𝑠(𝑥, 𝑡) =  [−
𝑀
2
𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥
−
𝑀
2
𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖2𝑘𝑒𝑥
+ 𝑀0 (1 − 𝑒
−𝑡
𝑇1⁄ ) 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖𝑘𝑒𝑥] 𝑠𝑖𝑛(𝛼) 
Equation 6.6 
Subtraction of Equation 6.6 from Equation 6.5 results in the complementary image with the T1 
echo at −𝐾𝑒 offset from the k-space origin subtracted and an image that can be described by 
Equation 6.7. 
 
𝑀𝑥𝑦
𝑠𝑢𝑏𝑐𝑜𝑠(𝑥, 𝑡) =  [𝑀𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥
+ 𝑀𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖2𝑘𝑒𝑥] 𝑠𝑖𝑛(𝛼) 
Equation 6.7 
Here we have isolated the displacement encoded echo and the complex conjugate echo. If 𝐾𝑒 is 
set such that 2𝐾𝑒 is greater than the range of sampled frequencies the second term inside the 
brackets is removed since the complex conjugate echo is outside of the acquisition window. The 
subtraction image then contains the desired uncorrupted displacement information. An 
additional advantage of this technique is that the addition of two datasets with independent 
noise terms yields an image with an SNR improvement of approximately 40%.214  
The cDENSE technique is able to accurately supress the T1 echo so long as heart rate remains 
consistent and the two complementary images contain the same information. If 𝐾𝑒 is not set 
high enough to isolate the displacement encoded echo then the complex conjugate echo can 
remain and corrupt motion information.  
The CANSEL technique was developed to remove all artifactual echoes from DENSE images 
including the complex conjugate echo and can be thought of as an extension to cDENSE. CANSEL 
is another complementary acquisition scheme but relies on 4 acquisitions with positive and 
negative sine and cosine modulation patterns. In cDENSE there are two complementary 
acquisitions with cosine and –cosine modulation. In DENSE the second RF pulse of the SPAMM 
module is given a phase offset of 0, 𝜋/2, 𝜋, 2𝜋/3 relative to the first RF pulse producing 
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complementary cosine, sine, -cosine and –sine modulation respectively. The subtraction process 
to create the cDENSE image described by Equation 6.7 is repeated for the sine and –sine images. 
The sine and –sine images are identical to the functions described by Equation 6.5 and Equation 
6.6 but including a 𝜋 phase shift that is accounted for by multiplying these functions by the 
complex number 𝑖 (Equation 6.8 - Equation 6.10). 
 
𝑀𝑥𝑦
𝑠𝑖𝑛(𝑥, 𝑡) =  𝑖 [
𝑀
2
𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥 −
𝑀
2
𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖2𝑘𝑒𝑥
+ 𝑀0 (1 − 𝑒
−𝑡
𝑇1⁄ ) 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖𝑘𝑒𝑥] 𝑠𝑖𝑛(𝛼) 
Equation 6.8 
 
𝑀𝑥𝑦
−𝑠𝑖𝑛(𝑥, 𝑡) = 𝑖 [−
𝑀
2
𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥
+
𝑀
2
𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖2𝑘𝑒𝑥
+ 𝑀0 (1 − 𝑒
−𝑡
𝑇1⁄ ) 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖𝑘𝑒𝑥] 𝑠𝑖𝑛(𝛼) 
Equation 6.9 
 
𝑀𝑥𝑦
𝑠𝑢𝑏𝑠𝑖𝑛(𝑥, 𝑡) = 𝑖 [𝑀𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥
− 𝑀𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖2𝑘𝑒𝑥] 𝑠𝑖𝑛(𝛼) 
Equation 6.10 
Finally to remove the complex conjugate echo from the image the sine and cosine subtractions 
are subtracted from each with the phase offset in the sine acquisition corrected by multiplying 
by a factor of 𝑖 according to Equation 6.11. The result of this subtraction is an isolated 
displacement encoded signal centred at the k-space origin described by Equation 6.12. Note that 
the displacement signal term is 4× greater than a single modulation image.  
 𝑀𝑥𝑦
𝐶𝐴𝑁𝑆𝐿(𝑥, 𝑡) =  𝑀𝑥𝑦
𝑠𝑢𝑏𝑐𝑜𝑠(𝑥, 𝑡) − 𝑖 𝑀𝑥𝑦
𝑠𝑢𝑏𝑠𝑖𝑛(𝑥, 𝑡) Equation 6.11 
 𝑀𝑥𝑦
𝐶𝐴𝑁𝑆𝐸𝐿(𝑥, 𝑡) =  [2𝑀𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥] 𝑠𝑖𝑛(𝛼) Equation 6.12 
The primary advantage of using these complementary acquisitions is that it allows images to be 
acquired with lower encoding frequencies. When relying on k-space filtering as described 
previously to separate the displacement encoded echo there is a significant loss of spatial 
resolution due to the removal of high spatial frequencies. Using the cDENSE acquisition allows 
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the k-space filter to be placed at a greater radius from the displacement echo since the T1 echo 
is removed. In cDENSE the filter removes only the complex conjugate echoes in cases where the 
choice of encoding strength causes these echoes to lie within the acquisition window. In CANSEL 
there is no need to perform k-space filtering since all artifactual echoes are suppressed before 
reconstruction. Figure 6.6 illustrates this process at a low encoding frequency, 𝐾𝑒 = 0.5 
cycles/mm. In this example the acquisitions are from a stationary agarose phantom, the 
reduction in resolution due to k-space filtering is clearly visible in image space. Lower encoding 
strength are associated with improved SNR and greater sensitivity to large displacements.  
 
Figure 6.6 Illustrating spatial resolution improvements with complementary acquisitions at low 
encoding frequencies (𝐾𝑒 = 0.5  cycles/mm). The detrimental effect of k-space filtering on spatial 
resolution is visible in uncorrected and cDENSE images. Since CANSEL requires no filtering it offers 
the highest resolution displacement images at these encoding frequencies. 
 
6.1.3.2 Through plane dephasing 
TPD was developed by Zhong et al. (2006) and aimed to produce an echo suppression technique 
without dependence on time or displacement encoding frequency or requiring additional 
acquisitions.251 TPD applies additional encoding gradients in the through plane direction in 
concurrence with the in plane encoding gradients. The primary mechanism of echo suppression 
in this case is the selective dephasing of echoes not centred at the k-space origin.  
The application of TPD gradients with an encoding frequency of 𝐾𝑑 in addition to the normal 
DENSE sequence parameters described above results in a magnetisation pattern described by a 
version of Equation 5.2 modified to include the through plane gradient term 𝐾𝑑 and through 
plane position 𝑧 as described Equation 6.13. 
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 𝑀𝑧(𝑥, 𝑧) =  𝑀cos (𝐾𝑒𝑥 + 𝐾𝑑𝑧) Equation 6.13 
This equation evolves following the completion of the tagging module and excitation pulse in the 
same way as Equation 6.4 but with the added 𝐾𝑑𝑧 term. After including the imaging excitation 
term with flip angle α and converting to the Euler exponential form of cosine the transverse 
magnetisation can be described in a fashion very similar in form to Equation 6.4 but accounting 
for possible displacements in the encoding direction ∆x and the through plane direction ∆z. This 
modification is described by Equation 6.14. 
 
𝑀𝑥𝑦(𝑥, 𝑧, 𝑡) =  
𝑀
2
𝑠𝑖𝑛(𝛼) 𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖(𝑘𝑒∆𝑥) 𝑒−𝑖(𝑘𝑑∆𝑧) 
+
𝑀
2
𝑠𝑖𝑛(𝛼) 𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖2𝑘𝑒𝑥𝑒−𝑖𝑘𝑑∆𝑧𝑒−𝑖2𝑘𝑑𝑧
+ 𝑀0 𝑠𝑖𝑛(𝛼) (1 − 𝑒
−𝑡
𝑇1⁄ ) 𝑒−𝑖𝑘𝑒∆𝑥𝑒−𝑖𝑘𝑒𝑥𝑒−𝑖𝑘𝑑∆𝑧𝑒−𝑖𝑘𝑑𝑧 
Equation 6.14 
Which can be simplified to the form described by Equation 6.15 by combining the in plane and 
through plane terms. 
 
𝑀𝑥𝑦(𝑥, 𝑧, 𝑡) =  
𝑀
2
𝑠𝑖𝑛(𝛼) 𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖(𝑘𝑒∆𝑥) 𝑒−𝑖(𝑘𝑑∆𝑧) 
+
𝑀
2
𝑠𝑖𝑛(𝛼) 𝑒
−𝑡
𝑇1⁄ 𝑒−𝑖𝑘𝑒(2𝑥+∆𝑥)𝑒−𝑖𝑘𝑑(2𝑧+∆𝑧)
+ 𝑀0 𝑠𝑖𝑛(𝛼) (1 − 𝑒
−𝑡
𝑇1⁄ ) 𝑒−𝑖𝑘𝑒(𝑥+∆𝑥)𝑒−𝑖𝑘𝑑(𝑧+∆𝑧) 
Equation 6.15 
With the TPD gradients applied the artefact echoes (second and third terms of Equation 6.15) 
still occur at −2𝑘𝑒𝑥 and −𝑘𝑒𝑥 but also undergo a through plane dephasing of  −2𝑘𝑑𝑧 and −𝑘𝑑𝑧 
repectively. This is in contrast to the location of the displacement encoded echo described by 
the first term of Equation 6.15 that contains no z component and therefore no through plane 
dephasing only a phase shift of ∆z. This through plane effect is analogous to introducing a 
through plane tilt to the magnetisation in the displacement encoding direction. This has the 
effect of pushing the T1 and complex conjugate echoes out of the acquisition plane attenuating 
their signal in the image plane. This process can be described using spin phase diagrams such as 
in Figure 6.7. In these figures diagonal lines represent transverse magnetisation and horizontal 
lines represent longitudinal magnetisation. The horizontal axis defines time and the vertical axis 
represents the phase. In Figure 6.7, RF1 and RF2 refer to the RF pulses of the tagging modules 
and RF3 refers to the RF excitation prior to imaging. Each line is this figure is a ‘spin phase 
pathway’ that represents the phase evolution of a given component of the total magnetisation. 
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So In the case of DENSE imaging (e.g. Equation 6.15) the magnetisation splits into 3 
subpopulations following 3 distinct pathways. Each subpopulation branches from the initial 
magnetisation as it is acted on by RF pulses and branching of the magnetisation only occurs at 
the application of an RF pulse. The original of this branching arises from considering every 
possible evolution of the magnetisation following the RF pulse. A complete and detailed 
description of spin phase pathways is given by Haacke et al. (1999).112 For this purpose it is 
necessary only to understand that each line represents a subpopulation of the total 
magnetisation and its position along the vertical axis determines the phase of the 
subpopulation.  
 
Figure 6.7 Spin diagram description of TPD. Through plane dephasing depicted by the shading in 
the right inset defines the degree to which an echo cannot be refocused for readout in-plane. 
Echoes that are further offset in the through plane direction therefore produce smaller echoes in 
the in plane direction. Figure modified from Zhong et al.251 
Figure 6.7 describes the evolution of 3 spin subpopulations in the DENSE sequence for both the 
in plane and through plane magnetisation. Note that these are simplified diagrams that show 
the ideal case, i.e. no magnetisation decay, no longitudinal magnetisation following FR3 and no 
B0 or B1 inhomogeneity. If we first look at the in-plane magnetisation (kx), at the application of 
the readout gradients (labelled ‘Echo’) the spins refocus to form the 3 echoes described 
previously. The sampled portion the k-space is enclosed by the red lines in Figure 6.7 meaning 
that the image acquired for these spins contains information from all 3 echoes. If we apply the 
TPD gradients the spins also follow the through plane spin phase diagram. In this case we have 
echoes forming in the through plane direction (Kz). In this direction we get through plane 
dephasing of spins, the magnitude of this dephasing effect is depicted by the degree of shading 
in the spin phase diagram. Echoes experience a degree of dephasing proportional to their 
position along Kz determined by slice thickness and 𝐾𝑑. This dephasing effect prevents the 
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complete refocusing of spins in the transverse plane to form detectable echoes. If we observe 
the displacement encoded echo centred at 0 in Kx it experiences no through plane dephasing 
due to its position of 0 in Kz. However the T1 echo occurring at −𝐾𝑒𝑥 in the in plane direction 
experiences incomplete refocusing due to the dephasing of −𝐾𝑑𝑧 in the through plane direction 
with the complex conjugate echo experiencing a higher degree of dephasing. The result then is 
an image where the echoes that have a through plane component are dephased and 
suppressed, since the displacement echo has no through plane component it retains its signal. 
TPD is therefore a useful technique for selectively suppressing the artefact echoes in DENSE.   
 
6.1.4 DENSE developments 
Since the original DENSE implementation by Aletras et al. in 1999 the sequence has been under 
continuous development with several key improvements made including cine, 3D and multislice 
capabilities. The technique was adapted to a cine sequence by Kim et al. (2004)250 who 
implemented a complementary acquisition strategy which was the first instance of a time 
independent suppression of the T1 echo making cine DENSE practical. The authors deployed a 
2D echo planar imaging (EPI) DENSE sequence in humans that applied a single modulation 
module after the detection of an R wave followed by a demodulation gradient combined with 
segment EPI readout where the demodulation gradient was reapplied at each cardiac phase. 
This produced high spatial resolution and uncorrupted displacement information for multiple 
cardiac phases covering contraction and relaxation. The primary advantages of a cine sequence 
as opposed to a single phase sequence is the ability to observe dyssynchrony between 
contracting segments and greater sensitivity to time dependent components of cardiac 
dysfunction. The next major development of DENSE was the introduction of 3D displacement 
mapping. The first example of 3D DENSE was published by Gilson et al. (2005).252 The authors 
produced a sequence that implemented a multislice cine gradient echo readout with 
displacement encoding gradients applied in the x, y and z directions where the T1 and anti-echo 
were suppressed using the CANSEL technique. CANSEL will be discussed in detail in 6.3.3.1. This 
sequence achieved multi slice imaging by sacrificing the cine component and imaging only at end 
systole. Following the application of DENSE modulation, a single phase encode line was read out 
at end systole for 3 successive slices for the next 3 successive ECG triggers. This long readout is 
possible due to the rapid heart rate of the mouse (RR ≈120ms) and the persistence of the 
modulation pattern when it is stored in the longitudinal magnetisation where it depends 
primarily on T1 of tissue (T1 ≈1200ms). There is an SNR penalty the longer the magnetisation has 
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been stored, however, with later slices having reduced signal. To extend the DENSE encoding to 
3 dimensions an additional acquisition was required with the modulation gradients applied in 
the z direction. Since the through plane displacement in the cardiac short axis is larger than in 
plane, the encoding strength was smaller to provide better sensitivity to large displacements. 
The primary disadvantage of 3D DENSE is the requirement for additional acquisitions to encode 
in the longitudinal direction.  
Aside from improvements to the acquisition sequence there have been developments in the 
field of DENSE image processing that aim to streamline processing or interpolate additional 
cardiac information. These include point trajectory fitting, myocardial modelling and automated 
LV segmentation methods. Spottiswoode et al. (2006) proposed a novel spatiotemporal 
unwrapping algorithm to remove phase wrapping at high encoding frequencies in a consistent 
fashion throughout the cardiac cycle.235 In addition to the DENSE phase unwrapping algorithm, 
Spottiswoode et al. (2007) implemented a temporal fitting method to improve tissue trajectory 
estimates. By fitting trajectories to tissue regions it is possible to calculate strain to any temporal 
resolution without being limited by the image acquisition. Trajectories were fitted to the 
displacement data using fifth order Fourier basis functions. The result was accurate tissue 
displacement tracking that improved strain mapping and was able to identify infarcted regions 
of myocardium even in images severely affected by noise. Computational modelling of the LV is 
a powerful technique for expanding multislice DENSE data into a true 3D model of cardiac 
deformation. The goal of this expansion is to produce a whole heart view of cardiac mechanical 
dysfunction. Lui et al. (2009) created a patient specific finite element model of the heart that 
could interpolate DENSE data to provide a continuous 3D strain information.253 The modelling 
provided a more complete view of cardiac contraction where each dataset is fitted to a model 
based on LV epi and endocardial borders making it robust to changes in heart structure, such as 
following infarction. However, the method is computationally intensive and mathematically 
complex beyond the scope of this study. Accurate LV segmentation is important in DENSE 
images to exclude displacement errors arising from including extra-myocardial pixels such as 
those in the lung that contain a large noise component. Performing this segmentation manually 
can be time consuming. An interesting approach by Spottiswoode et al. (2009) took a motion 
guided approach to semi-automated segmentation based on their trajectory fitting method 
described above.254  Their approach projects the epicardial and endocardial borders defined in a 
single frame through time based on the trajectory information. This approach has the benefit of 
being limited by physiological information, robust to low contrast between blood and 
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myocardium in early frames and is independent of LV shape making it applicable to atrophied 
infarct tissue in both SA and LA views. 
 
6.2 Methods 
6.2.1 Methods: DENSE sequence development 
6.2.1.1 Single-phase DENSE 
This section corresponds to stage 1 of the workflow described in Figure 6.1. The aim of this 
section is to describe the implementation and development of single phase and cine-capable 
DENSE sequences. 
The first implementation of DENSE I created was based on a cardiac gated 2D gradient echo 
imaging sequence. In normal use this sequence is used to acquire fast static images of the heart. 
The sequence was modified to include the additional RF and gradient components necessary for 
displacement encoding. A variable delay was added so that the time between application of the 
first and second displacement encoding gradients (TM) could be varied. For in-vivo scans this 
delay is tuned so that the second displacement encoding gradient is applied at end systole.  
This sequence was tested on a phantom containing 1% agarose where T1 was matched to heart 
tissue by gadolinium doping. Three acquisitions were performed where the displacement 
encoding gradients were applied in the readout (RO), phase encode (PE) directions and one 
where the gradient amplitude was set to zero (reference image). The images were acquired 
using a 35mm volume resonator RF coil, with acquisition parameters; matrix size of 128×128, 
FOV = 25.6×25.6mm, TE = 2.5ms, TR = 500ms, 3 averages, a DENSE delay of 50ms and 𝐾𝑒=0.5 
cycles/mm. The total duration of the tagging module was 3ms. 
The resulting images were corrupted by the T1 and complex conjugate stimulated echoes, in this 
case the displacement encoded peak is isolated through a bandpass filter centred at the origin of 
k-space and was tuned to exclude all other echoes. These filtered images were then 
reconstructed using the iFFT to create magnitude and wrapped phase images. Phase unwrapping 
was performed using the graph cuts method with magnitude weighting. Subtracting the 
unwrapped phase of the reference images from the unwrapped phase of the RO and PE encoded 
images yielded maps of the phase accumulated by displacement between the two encoding 
gradients. 
204 
 
Displacement magnitude maps were produced using the quadrature sum of the X and Y 
displacements according to Equation 6.16. Where D is displacement and ∆x and ∆y are the X and 
Y displacements respectively.  
 𝐷 = √ (∆𝑥2+∆𝑦2)  Equation 6.16 
 
The same single phase DENSE sequence was then tested in-vivo in a wild type mouse heart. The 
images were acquired using a 35mm volume resonator RF coil, with acquisition parameters; 
matrix size of 128×128, FOV = 25.6×25.6mm, TE= 2.5ms, TR = RR interval (approx. 110ms), 3 
averages, a DENSE delay of 50ms and 𝐾𝑒=1.3 cycles/mm. 
 
6.2.1.2 Cine DENSE 
In the same way that single phase DENSE was developed by modifying a single phase cardiac 
imaging sequence, cine DENSE was created by modifying a cardiac cine sequence. The cine 
sequence is based on a rapid low flip angle gradient echo readout. To incorporate the DENSE 
sequence, the SPAMM module was included immediately after the R-wave trigger and a 
displacement unencoding gradient was included after every slice selective excitation readout 
pulse.  
The cine DENSE sequence was first tested on a stationary agarose phantom with T1 matched to 
heart tissue. Since the properties of a cine sequence must be tuned to the RR interval of the ECG 
signal an ECG simulator (SA Instruments, Stony Brook, NY, USA) was used to trigger the 
acquisition. The signal generator was programmed to produce a regular ECG signal at a 
frequency of 550bpm and included respiratory artefacts at approximately 40bpm to simulate 
normal physiology of a mouse under anaesthetic. The total duration of the tagging module was 
3ms following the R-wave trigger. The images were acquired using a 35mm volume resonator RF 
coil, with acquisition parameters; matrix size of 128×128, FOV = 25.6×25.6mm, TE= 2.5ms, TR = 
5ms, flip angle = 15°, 8 averages and 𝐾𝑒=1.7 cycles/mm. The scan was repeated 3 times with 
encoding in the RO and PE directions and with the displacement encoding gradients set to 𝐾𝑒=0 
cycles/mm. Displacement images were filtered to remove all frequencies > 𝐾𝑒/2, . 
 
6.2.2 Methods: Phase correction  
This section corresponds to stage 2 of the workflow described in Figure 6.1. The aim of the 
techniques discussed below is to remove the background field sources that produce phase 
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measurements that are unrelated to cardiac displacement. This allows the isolation of motion 
due to contraction producing a more accurate displacement field map. 
To solve this field removal problem and remove the offset in the in-vivo cine DENSE protocol a 
processing technique was adapted from the field of quantitative susceptibility mapping MRI 
(QSM). QSM is a quantitative parametric imaging technique that aims to map the magnetic 
susceptibility of tissue revealing details about underlying pathology. Magnetic susceptibility is a 
fundamental property of a material and can become altered in disease providing a novel 
contrast mechanism and biomarker for MRI. The main obstacle to overcome in QSM is the 
isolation of the small local magnetic field sources that arise from the susceptibility of tissue from 
the much larger background field sources. Contributions to the background field arise from a 
number of sources such as high susceptibility boundaries and imperfect shimming. This is 
analogous to the problem faced with DENSE where the aim is to isolate the small phase changes 
due to tissue motion from background sources. 
Any gradient echo MRI image of a region of tissue is a convolution of the background field and 
local field contributions. Although QSM was theorised early on in the history of MRI by Young et 
al. (1987) it has only been in the last decade that the mathematical tools have come of age, 
making QSM a feasible tool for MRI research.255,256 These QSM tools include mathematical 
methods for separating field sources and solving the ill posed inverse problem required to 
quantify magnetic susceptibility from the resulting field map. Projection onto dipole fields (PDF) 
is a tool used in QSM to remove background field contributions and isolate the local sources.257 
PDF was developed based on the observation that the field projected from any magnetic dipole 
outside of a region of interest is orthogonal to the magnetic dipole inside the region of interest. 
The total field inside the ROI can then be projected onto the background field sources outside 
the ROI using the projection theorem in Hilbert space. This projection can then be used to 
deconvolve the field inside the ROI and decompose it into two fields, one for dipoles originating 
within the ROI and one from outside due to background sources. For DENSE background field 
removal, the PDF function was applied to both the encoding directions separately. This is a valid 
operation since the field contribution induced by motion is independent of the background field 
and depends only on distance tissue has travelled between the encoding gradients applied 
during acquisition. The PDF function is a complex mathematical solution and so an established 
Matlab implementation developed by the authors of the original PDF paper was used.257,258 
The PDF background field removal technique was tested first in a stationary agarose phantom 
and then on in vivo DENSE data acquired in a wild type mouse heart. The images were acquired 
using a 35mm volume resonator RF coil, with acquisition parameters; matrix size of 128×128, 
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FOV = 25.6×25.6mm, TE= 1.5ms, TR = 5ms, cine frames = 19, flip angle = 15°, 15 averages and 
𝐾𝑒=1.7 cycles/mm. The scan was repeated twice with encoding in the RO and PE directions and 
displacement images were filtered to remove all frequencies > 𝐾𝑒/2.  
 
6.2.3 Methods: Artefact echo suppression 
This section corresponds to stage 3 of the workflow described in Figure 6.1. The aim of the work 
discussed below is to remove the unwanted T1 and complex conjugate echoes from the 
acquisition either through the addition of complementary acquisitions or the application of a 
through plane dephasing gradient. The theory behind these techniques was discussed in detail in 
sections 6.2.3.1 and 6.2.3.2 respectively. 
 
6.2.3.1 Complementary acquisitions: cDENSE and CANSEL 
The DENSE sequence was modified so that the second RF pulse in the tagging module could be 
assigned a variable phase. This allowed the generation of all the phase modulation patterns 
described in Figure 6.4. 
In vivo pilot data were acquired using a 35mm volume resonator RF coil, with acquisition 
parameters; matrix size of 128×128, FOV = 25.6×25.6mm, TE= 2.6ms, TR = 10ms, flip angle = 20°, 
8 averages and 𝐾𝑒=1.4 cycles/mm. The scan was repeated 4 times with sine, cosine-sine and –
cosine modulation patterns. This allowed reconstruction of the data with either cDENSE or 
CANSEL echo removal. Since the aim here was to assess echo removal not displacement 
information the acquisition was performed with encoding in the RO direction only. In the case of 
the processed cDENSE acquisition, k-space was filtered to remove all frequencies > 𝐾𝑒/2. Each 
scan took approximately 9minutes depending on heart rate and respiration. Data were then 
reconstructed in Matlab using the cDENSE or CANSEL subtraction methods described above.  
 
6.2.3.2 Through plane dephasing 
Testing of the TPD technique was performed on a stationary agarose phantom consisting of 4 
tubes of 1% agarose with gadolinium doping to achieve a range of T1 values consistent with 
physiological values, these were quantified using the inversion recovery look locker method and 
model fitting described in Chapter 3. The aim of the agarose phantom imaging was to determine 
the relationship between 𝐾𝑑  and the effectiveness of echo suppression. Cine DENSE imaging was 
performed with TPD gradients of duration 0.8ms and varying gradient strengths to achieve 𝐾𝑑 
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values between 0 and 2.04 cycles/mm. In plane encoding 𝐾𝑒 was set to a relatively low encoding 
strength of 𝐾𝑒 = 1.02 cycles/mm to ensure acquisition of the complex conjugate echo. These 
data were acquired using a 35mm volume resonator RF coil, with acquisition parameters; matrix 
size of 128×128, FOV = 25.6×25.6mm, TE= 1.8ms, TR = 10ms, flip angle = 20°, 5 averages and a 
slice thickness of 1mm. Images were then reconstructed in Matlab and the centre of the k-space 
peaks located manually. A circular region of interest was drawn around the T1 and displacement 
encoded peaks including all frequencies within 𝐾𝑒/4 of the peak centroid. The values within this 
range were used to quantify the total energy contained in the peak as a percentage of total 
image energy where energy was evaluated by summing the square of the absolute values of the 
k-space data as described by Zhong et al. (2006). Peak energy was calculated for each cine frame 
in the cine DENSE sequence allowing visualisation of T1 recovery term and resulting loss of 
displacement encoding as a function of time from the encoding gradient.   
Cine DENSE imaging was performed with TPD gradients of duration 0.8ms and varying gradient 
strengths to achieve 𝐾𝑑 values between 0 and 1.36 cycles/mm. In plane encoding 𝐾𝑒 was set to a 
higher encoding strength  than used for the phantom study at more conventional encoding 
frequencies for mouse heart DENSE of 𝐾𝑒 = 1.36 cycles/mm. These data were acquired using a 
35mm volume resonator RF coil, with acquisition parameters; matrix size of 128×128, FOV = 
25.6×25.6mm, TE= 1.8ms, TR = 10ms, flip angle = 20°, 8 averages and a slice thickness of 1mm. 
Data was reconstructed and the relative energy of each peak computed as described above for 
the phantom. 
 
6.2.3.1 Comparison of echo removal techniques 
The cDENSE, CANSEL and TPD methods all aim to remove the T1 and complex conjugate artefact 
echoes while retaining the displacement encoded stimulated echo at the k-space origin. To 
compare the capability of each technique and the spatial resolution preserved by each, a wild 
type mouse was imaged with DENSE encoding in a single direction and the displacement map 
produced by each echo removal technique compared. Comparison was performed by empirical 
inspection of the resolution in each displacement map, along with the SNR available in each 
method.  
Cine DENSE imaging was performed with in plane encoding 𝐾𝑒 = 1.36 cycles/mm. These data 
were acquired using a 35mm volume resonator RF coil, with acquisition parameters; matrix size 
of 128×128, FOV = 25.6×25.6mm, TE= 1.8ms, TR = 10ms, flip angle = 20°, 8 averages and a slice 
thickness of 1mm with 12 cine frames. Data was acquired with cos, sine,-cosine and –sine 
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modulation patterns as well as one TPD dataset with cosine modulation and 𝐾𝑒 =
1.02cycles/mm. 
These acquisitions allow 4 different echo suppression techniques to be tested. The first is a 
standard cosine modulated DENSE dataset filtered with a circular bandpass filter with a radius of 
𝐾𝑒/2. The second is a cSPAMM dataset, this requires a combination of cosine and –cosine 
acquisitions to supress the T1 echo meaning the centre of the bandpass filter can be extended to 
3𝐾𝑒/2 to remove only the complex conjugate echo. The third combines all complementary 
datasets to remove both echoes and requires no filter. The fourth dataset using the TPD 
acquisition to suppress the echoes and also requires no filtering.  
 
6.2.4 Methods: Trajectories and strain 
6.2.4.1 Myocardial trajectories 
DENSE displacement maps describe the phase accumulated by a pixel due to its displacement 
between the application of two displacement encoding gradients. This means that every point 
refers back to the position of that pixel at diastole. The trajectory of a myocardial element 
through time follows a path defined by the cardiac function of that region. DENSE data is subject 
to noise and tracing the trajectory can result in discontinuous and non-physiological path of 
motion. The periodic contraction of the heart is naturally suited to fitting with a periodic Fourier 
function.  Creating these trajectories starts by converting the cine displacement maps to a 
motion path originating at the centre of each pixel within the myocardium at the beginning of 
diastole. The value of each pixel in the sequential x and y displacement maps can be used to 
describe the raw 2D trajectory. Equation 6.17 describes the Fourier basis function used to 
describe the periodic trajectory of a single myocardial element.  
 𝑓𝑥,𝑦(𝑡) =
1
2
𝑎0 + ∑(𝑎𝐾 cos(nωt) + 𝑏𝐾 sin(nωt))
𝐾
𝑛=1
 Equation 6.17 
Where 𝑓𝑥,𝑦 is the motion path of the tissue in either the 𝑥 or 𝑦 direction fitted using least 
squares minimisation, 𝑎𝐾 and 𝑏𝐾 are the fitted coefficients of the Kth order Fourier series and 
𝜔 = 2𝜋 𝑇⁄  where 𝑇 is the cardiac period or RR interval. Fitting was performed using a nonlinear 
least squares optimisation function. Fitting the Fourier coefficients of the x displacement 
followed by the y displacement independently relative to time produces a time dependent 2D 
trajectory of the cardiac motion.  
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6.2.4.2 Strain calculation 
A custom strain calculating function was implemented in Matlab based on the displacement 
images. This function was also made applicable to the HARP data by converting the point 
tracking result of HARP to displacement maps. This enabled data from HARP and DENSE could be 
readily processed using the same functions. 
Strain was calculated by calculating the differential of the x and y displacement maps in the x 
and y direction to produce the 4 components of the displacement gradient tensor 𝑭. This tensor 
was then converted to the strain tensor 𝑬 by Equation 4.1. The resulting 2D tensor contained 
two components in x and y, however a more physiological coordinate system for cardiac strain is 
cylindrical with circumferential and radial components. The tensors were therefore converted to 
their projections onto the cylindrical axis to allow calculation of circumferential (Ecc) and radial 
(Err) strain components.259 This was done by rotating the strain matrix by the angle made to the 
centroid of the LV (𝜃) to produce the transformed strain tensor ?̇? as described in Equation 6.18. 
In this coordinate system negative values of strain represent contraction while positive values 
indicate stretching. 
 ?̇? = 𝑸𝑬𝑸𝑻 
 
𝑸 =  [
𝑐𝑜𝑠𝜃 𝑠𝑖𝑛𝜃
−𝑠𝑖𝑛𝜃 𝑐𝑜𝑠𝜃
] 
Equation 6.18 
 
 
6.3 Results 
6.3.1 Results: DENSE sequence development 
6.3.1.1 Single phase DENSE 
The result of the single phase DENSE sequence applied to a stationary phantom is shown in 
Figure 6.8. The ideal displacement images for this phantom would show zero motion in the 
agarose and artifactual displacement in the surrounding space. In a stationary phantom we see 
minimal displacement within the phantom and relatively large artifactual displacements in the 
surrounding space. The colourmap in the displacement images is the magnitude of motion 
calculated by adding the displacement vectors in quadrature. The displacement measurements 
in Figure 6.8 are reasonable for a stationary phantom, with an average displacement  within the 
agarose of  0.33±0.31mm (mean ± standard deviation). There is also a clear ring of artifactual 
displacement around the perimeter of the agarose phantom, this is due to the low spatial 
resolution of the filtered acquisition. Although the uncertainty in measurements its fairly high 
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the displacement is low making this example adequate but requires optimisation. The main issue 
with this acquisition and processing scheme is the k-space filtering. The majority of spatial 
information is thrown away when using the bandpass filter method, more sophisticated 
methods of removing the artefact echoes and preserving spatial information are investigated in 
section 6.3.3. 
 
Figure 6.8 Single phase DENSE of stationary agarose phantom. Magnitude images (top row) 
show the banding artefacts resulting from the T1 and complex conjugate echoes, these are 
present in k-space (second row) as stimulated echoes offset from the k-space origin. Isolating the 
central displacement encoded peak with bandpass filter results in wrapped phase maps (third 
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row) these can be unwrapped and background phase removed with the reference acquisition to 
produce maps of 2D displacement (bottom row).  
The results of the in-vivo acquisition are presented in Figure 6.9. The higher encoding strength 
relative to the stationary phantom acquisition pushed the artefact echoes further towards the 
edge of k-space meaning that the displacement encoded echo could be isolated using a larger 
filter, therefore excluding less spatial frequencies and preserving more spatial information than 
in the case of the stationary phantom. This higher resolution information can be seen when 
comparing the phase maps of the stationary phantom acquisition and the in vivo acquisition.  
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Figure 6.9 In-vivo single phase DENSE. As above the image is filtered to isolate the displacement 
encoded echo, in this case the filter can include more frequencies since the high encoding 
strength offsets the artefact echoes. Phase unwrapping provides displacement magnitude and 
direction maps (bottom row). White contours indicate LV myocardium. 
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The displacement fields in Figure 6.9 show consistent and small displacements in tissue such as 
the liver, fat and muscle regions while regions of noisy or corrupted signal such as the 
pulmonary cavity, blood pool and extra corporeal space show highly variable displacements. If 
we apply a mask to the displacement maps to isolate only the displacement of the LV 
myocardium we find that the average displacement to systole in the LV is 1.31±0.68mm. This is 
consistent with previous myocardial displacement studies demonstrating the accuracy of this 
sequence.39 However, although the average displacement is within the physiological range, the 
ability of DENSE to image regional displacement reveals that there is uncertainty in specific 
regions of myocardium. The vector plots in Figure 6.10 show the masked myocardial 
displacements to illustrate this point.  
 
Figure 6.10 Heart displacement only (90° rotation CCW from Figure 6.9). Some regions of heart 
tissue show physiologically accurate displacements (right inset) while others appear effected by 
phase errors (left inset). The reasons for this variability are due to background field contributions 
that have not been accurately removed in the phase subtraction step. 
The region shown in Figure 6.10(Left inset) is the inferior wall of the LV bordering the pulmonary 
cavity. The magnetic field homogeneity is lowest in this region due to the high magnetic 
susceptibility boundary with the cavity. The result of this is decreased DENSE signal intensity due 
to intravoxel dephasing, as was the case with SPAMM tagging, at higher encoding frequencies 
this dephasing becomes more. This is a recognised issue associated with all stimulated echo 
acquisitions in the heart.260 This region of low signal causes displacement errors due to the 
ineffective removal of background field contributions to image phase during the phase 
subtraction step. Steps taken in future acquisitions to minimise this dephasing effect were more 
homogenous shimming gradients and the use of lower encoding frequencies of around 
𝐾𝑒=1.1cycles/mm for in vivo imaging, this value was chosen based on previous mouse DENSE 
literature as a good compromise between displacement sensitivity in the range of motion for the 
mouse heart and reduced intravoxel dephasing. 
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Single phase DENSE was a useful starting point to establish the processing pipeline and identify 
initial implementation issues with the in-vivo DENSE sequence however cine DENSE offers far 
more useful information about the dynamic motion of the heart and developing this was the 
next logical step for improvement of the DENSE implementation. 
 
6.3.1.2 Cine DENSE 
The result of the cine DENSE sequence in a stationary phantom is shown in Figure 6.11. The data 
in Figure 6.11A were filtered using the illustrated bandpass filter with an identical filter applied 
to every frame in the cine sequence resulting in displacement maps for each direction (Figure 
6.11B). This sequence would be expected to measure zero displacement throughout the imaging 
sequence, however, these displacement maps suffer from a significant offset. The mean x and y 
displacements within the stationary agarose are -21.5±1.7mm and -14±1.6mm respectively. This 
offset is caused during the phase subtraction step since the unwrapped phase in the reference 
image is much higher than in the directionally encoded images resulting in a large offset after 
phase subtraction. The most likely cause of this is the automated graph cuts phase unwrapping 
algorithm. The graph cuts technique is weighted by image magnitude meaning the phase of 
pixels with a high signal content strongly effect the assigned phase in nearby darker pixels. In the 
agarose phantom a uniform signal is expected throughout, however image magnitude was not 
always uniform, as seen in the example image of the reference scan in Figure 6.11A. The cause 
of this non-uniformity is complex and due to a number of factors. A major contribution to signal 
inhomogeneity is from insufficient B0 shimming before the acquisition. This would also explain 
the distorted tag lines observed in the encoded images. The filtering necessary to isolate the 
displacement encoded peak must be applied in the reference image as well as the displacement 
encoded images to maintain consistent spatial information between images. This has the effect 
of removing a large fraction of the acquired signal in the reference image. The sensitivity of this 
field removal method to accurate shimming and acquisition properties makes it impractical for 
in vivo cardiac cine DENSE, where shimming is limited by persistent flow, susceptibility 
boundaries and cardiac and respiratory motion. These phase removal errors led to the 
development of a novel phase removal method based on the PDF method.  
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Figure 6.11 Example cine DENSE images acquired with a stationary agarose phantom.(A) cine 
DENSE image data was produced to be similar in appearance to the stationary single phase 
DENSE images. The k-space filter removing frequencies >Ke/2 was propagated through the time 
dimension to remove artefact echoes in all frames. Displacement maps for the RO and PE 
directions (B) are produced by phase unwrapping and reference phase subtraction of the DENSE 
data, shown here are cine frames 1,6,12 and 18. 
 
6.3.2 Results: Projection onto dipole fields phase correction 
The results of the PDF field removal algorithm applied to the data shown in Figure 6.11 as well as 
the original field removal method for comparison are shown below in Figure 6.12.  
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Figure 6.12 PDF is an effective method for removing background field contributions from DENSE 
data without the need for a reference scan (second row). The PDF method is significantly closer 
to the zero motion expected for the stationary phantom than the previously used phase 
subtraction method (first row). Numbers indicate cine frame index. 
The mean 2D displacement magnitude in the phantom when field removal was performed by 
the subtraction method was 26.0±2.1mm while the PDF method performed much better with a 
mean displacement of 0.12±0.04mm, much closer to the true value of zero. The PDF subtraction 
images show some image artefacts, there is a speckled texture to the displacement and some 
small regions of high displacement near the top, bottom, left and right edges of the agarose. The 
lack of high frequency image information due to the DENSE filtering process is likely to 
contribute to both of these artefacts. The high displacement regions near the boundary of the 
agarose could also be affected by the inaccuracy of the PDF technique near ROI boundaries. 
Near the boundaries of the ROI the field originating from inside the ROI and outside the ROI 
have a significant correlation making them more difficult to deconvolve since they do not satisfy 
the PDF assumption that the fields are orthogonal.261 To counter this effect for in vivo data the 
ROI for PDF was made to cover the entire corporeal body including  lungs and blood pool. 
Although this removes the ability of PDF to remove field contributions from high susceptibility 
boundaries it prevents the generation of boundary errors since the heart is well inside the ROI. 
A secondary advantage of the PDF field removal method is that it makes the acquisition of a 
reference image redundant. Since the PDF function operates only on the directionally encoded 
images there is no need to acquire a separate reference scan reducing acquisition time equal to 
the time required to acquire one volume. Since the assumption of PDF is that all external field 
contributions arise from outside the region of interest this method corrects only for phase 
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changes due to B0 inhomogeneity. This means that field perturbations due to high susceptibility 
boundaries such as between the myocardium and lungs are not corrected. 
The application of PDF phase correction to in vivo cine DENSE data in the wild type mouse heart 
is shown in Figure 6.13. The results show physiologically realistic concentric twisting 
displacement around the circumference of the LV over the duration of the cardiac cycle. 
 
Figure 6.13 in vivo cine DENSE testing using the PDF field removal technique. Displacement maps 
from unwrapped and PDF corrected phase are shown in the top two rows. The heart, lungs and 
blood pool are clearly visible by their variation through time. Numbers indicate cine frame index . 
The displacement can be seen to increase in magnitude to systole and return to baseline during 
diastole. This cycle is plotted in Figure 6.14A. The displacement is smallest at the anterior and 
septal walls and largest at the lateral and posterior regions of myocardium consistent with other 
studies of regional myocardial function.218 This can most easily be seen in maps of the maximum 
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displacement that in normal physiology occurs at end systole (Figure 6.14B) and the variance of 
displacement over the cardiac cycle (Figure 6.14C). Figure 6.14C shows bright regions where 
there is a high degree of motion while dark regions show little motion. In this map the heart and 
lungs show high variance due to cardiac motion and artifactual signal respectively while the 
stationary body shows low variance as expected.  
 
Figure 6.14 plot of mean myocardial displacement ±SD over the cardiac cycle. Showing 
contraction and relaxation either side of end systole (dashed line). Also shown are the 
displacement map for end systole and the variance of the displacement over the cardiac cycle. 
A key advantage of DENSE imaging over tagging methods such as HARP is its higher spatial 
resolution. In HARP the displacement encoded echo is isolated by use of a bandpass filter 
removing much of the high frequency spatial information. All DENSE developments up to this 
point have used the same filtering method to remove the T1 and complex conjugate echoes. 
This type of filtering severely limits spatial resolution and negates the primary advantage of 
using DENSE. The following section investigates the development and implementation of 
advanced techniques for removing artefact echoes while retaining higher frequencies and spatial 
information. 
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6.3.3 Results: Artefact echo suppression 
6.3.3.1  Complementary acquisitions: cDENSE and CANSEL 
The in vivo example of the two complementary DENSE acquisition schemes are shown in Figure 
6.15. It can be seen that both cDENSE and CANSEL are able to achieve this goal in-vivo despite 
complications such as heart rate variability (541±31 bpm over acquisition duration). 
 
Figure 6.15 CANSEL and cDENSE in vivo example. Representative images of systole for all 4 
modulations required to create a CANSEL dataset. To achieve removal of the T1 echo only the 
positive and negative cosine modulations are required. To remove the residual complex 
conjugate echo at the edge of k-space either a bandpass filter (white circle) or additional sine 
modulations are required.  
Note that despite the almost identical appearance of the different modulations in k-space there 
is a significant difference in the data. The similarities arise from the complications of displaying 
complex data, here we follow convention and display k-space data as the magnitude of the 
complex number describing that point.  
The primary trade-off between these two complementary schemes is between time and removal 
of the complex conjugate echo. cDENSE is faster to acquire but requires higher encoding 
strengths to remove the complex conjugate without implementing a filter. CANSEL acquisition 
times may be prohibitively long, acquisitions using the parameters described here took 
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approximately 9 minutes per volume. To describe 2D motion 2 volumes are required with 
orthogonal encoding, introducing the multiplicative factors of 2x acquisition time for cDENSE 
and 4x acquisition time for CANSEL can lead to acquisition times of 36 minutes and 72 minutes 
respectively. Long scan durations such as these are ill suited to studies of cardiac regeneration 
therapy or other preclinical imaging projects that are typically multiparametric in nature. 
Preclinical studies often aim to quantitatively image as many relevant features as possible, 
requiring multiple acquisitions for each. Combined with a requirement for high study 
populations to ensure statistical robustness it is difficult to justify a 72-minute imaging 
sequence. These are factors that have led to the development of through plane dephasing (TPD) 
as a technique to accelerate complete DENSE dataset acquisitions. 
A full quantitative comparison of cDENSE and CANSEL as well as the through plane dephasing 
technique is performed in section 6.3.3.3 following the description of the development of TPD. 
 
6.3.3.2 Through-plane dephasing 
The results of this investigation into the influences of 𝐾𝑑 on TPD  DENSE imaging are shown in 
Figure 6.16. Results are displayed in both a graphical form on the left and quantitated on the 
right. At 𝐾𝑑 = 0 we see no change in the tagging pattern and no suppression of artifactual 
echoes. This can be seen in k-space by the large T1 and complex conjugate echoes that can be 
seen to increase in proportional magnitude to the displacement echo over the RR interval 
duration. 
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Figure 6.16 TPD testing in a multiple T1 phantom. Values describe the degree of through plane 
dephasing 𝐾𝑑. As 𝐾𝑑 is increased the artefact echoes that are offset from the centre of k-space 
are suppressed proportionally resulting in the removal of the banding pattern in the DENSE 
images. The proportion of total image energy contained in the displacement echo becomes more 
consistent with 𝐾𝑑, however the increased 𝐾𝑑 can be related to a decrease in total image energy 
reducing the available signal. All images are displayed using the same windowing. 
 As 𝐾𝑑 is increased there is a visible reduction in the appearance of the tagging planes in images 
space. In k-space this is shown by the reduced magnitude of the artefact peaks. Additionally the 
relative amplitude of the displacement encoded peak vs the artefact echoes is seen to be more 
consistent as 𝐾𝑑 increases. At 𝐾𝑑 = 2.04 we see no significant artefact echoes and no visible 
tagging planes. However, there is a noticeable reduction in total acquired image energy as 𝐾𝑑 
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increases. This suggests that there is an SNR trade off with stronger artefact suppression. The 
plots on the right of Figure 6.16 show the variation of echo energy with time. The recovery of 
the T1 echo with 𝐾𝑑 = 0 follows a multi exponential where each term is of the form described 
by Equation 2.3, and a term exists for each value of T1 in the acquisition. The 4 chambers in this 
case then make the recovery of the T1 echo a quad-exponential recovery. Once 𝐾𝑑 > 0 this 
relationship is no longer true due to the through plane dephasing terms. The displacement echo 
as a fraction of total image energy can be seen to decay in cases where 𝐾𝑑 does not sufficiently 
supress the artefact echoes i.e. where 𝐾𝑑 < 1.02. These figures are a good example of why 
these echoes need to be suppressed. Since only the displacement encoded echo contains 
information about tissue displacement it is important for this information to be isolated. The 
displacement encoded echo with 𝐾𝑑 = 0 shows that at its peak the displacement echo only 
accounts for 38% of total image energy. Meaning the other 62% is artifactual information.  
Although a useful examination of the effects of 𝐾𝑑  on DENSE images these data are not fully 
relatable to the in-vivo case due to the absence of motion and physiological effects. The effect of 
𝐾𝑑 on echo suppression was next tested in vivo by imaging healthy mouse heart. Results are 
shown in Figure 6.17. 
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Figure 6.17 TPD in vivo testing in the wild type mouse heart. Values describe the degree of 
through plane dephasing 𝐾𝑑. SNR is an order of magnitude lower in vivo relative to the phantom. 
Increasing 𝐾𝑑 however shows a consistent relationship with the suppression of the T1 echo. All 
images are displayed using the same windowing. 
The echo suppression in vivo is similar to the phantom case. With the echoes sufficiently 
supressed from approximately  𝐾𝑑 = 1 cycles/mm. The recovery of the T1 echo follows a 
complex exponential recovery relative to the phantom example due to the wide range of T1 
values present in the in-vivo case. The displacement echo appears to be far more susceptible to 
signal decay for the in vivo case relative to the phantom tests potentially limiting the accuracy of 
DENSE later in the cardiac cycle.  
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The most significant change when implementing TPD DENSE to in vivo is the marked decrease in 
SNR at higher values of 𝐾𝑑. This is partially due to the presence of a higher TPD gradient 
although the primary cause of SNR at higher values of 𝐾𝑑 is the removal of the T1 echo. The 
DENSE technique is limited to relatively low SNR due to the isolation of a single stimulated echo 
that contains all image information. The majority of image energy tends to be contained within 
the T1 echo, by suppressing this there is a significant SNR penalty. The additional SNR penalty of 
introducing the TPD gradient is assessed below (6.3.3.3) as part of a comparison of echo removal 
techniques. Figure 6.18 shows the SNR in TPD images as a function 𝐾𝑑 for both the phantom and 
in vivo case. SNR in the phantom was largely unaffected by 𝐾𝑑 following a short period of 
decreasing SNR at low encoding strengths and the SNR plateaued after around 𝐾𝑑 = 0.5 
cycles/mm. For the in vivo case the SNR is approximately an order of magnitude lower and over 
the range of 𝐾𝑑 tested the SNR continued to decline with increased 𝐾𝑑. This suggests that the 
ideal value of 𝐾𝑑 for TPD DENSE in vivo is the smallest value that can sufficiently suppress the 
artefact echoes. In this case that was found to be around 𝐾𝑑 = 1.3 cycles/mm. 
 
Figure 6.18 SNR vs 𝐾𝑑 for the phantom the SNR penalty for increased 𝐾𝑑 plateaus at around 
𝐾𝑑 = 0.5. Over the range tested in vivo the SNR continued to decrease in the liver and 
myocardium. The ideal value of 𝐾𝑑 therefore is the lowest that is able to suppress the artefact 
echoes. 
The key advantage of TPD relative to the other echo removal techniques is that it only requires a 
single acquisition for each direction removing the requirement for additional complementary 
acquisitions. It is worth noting however that the complementary acquisition methods cDENSE 
and CANSEL care compatible with the TPD method. Although the TPD gradients induce a phase 
shift in the magnetisation pattern, so long as the TPD gradients are consistent the phase shift 
represents a relative offset and does not limit the application of complementary subtraction 
methods. This suggests that there may be an optimised echo removal technique that utilises 
complementary acquisitions to remove the majority of the artefact echo signal and a smaller 
TPD component with a low value of  𝐾𝑑 to remove the residual information induced by 
variations in animal physiology and hardware non uniformities. This may offer accurate artefact 
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echo removal while reserving displacement encoding and SNR. This remains an objective for 
future work. 
 
6.3.3.3 Comparison of echo removal techniques for DENSE 
Representative images for each dataset with the heart at end systole are shown in Figure 6.19. It 
can be seen that the techniques that implement a k-space filter suffer from reduced spatial 
resolution in the image domain resulting in smooth and blocky images. Since CANSEL and TPD do 
not require a filter they maintain the spatial resolution of the acquisition.  
 
Figure 6.19 Comparison of DENSE echo removal techniques. Top row shows the k-space images 
following each respective processing method all with the same windowing. Bottom row shows 
the respective displacement maps (y direction) all with the same windowing. 
All acquisitions in Figure 6.19 are displayed with the same windowing, this allows visualisation of 
the increase in displacement echo signal with echo combination. Recall that cDENSE offers a 
two-fold increase in displacement echo signal (Equation 6.7) and CANSEL improves the signal by 
4x (Equation 6.12). The SNR for each technique plotted against time to show the decay of the 
displacement encoded echo is shown in Figure 6.20. SNR was calculated from the absolute 
values in image domain. It can be seen that as expected the CANSEL technique offers the best 
SNR, although this is only marginally better than the cDENSE method that is twice as fast. The 
filtering method also provides good SNR but the necessary loss of resolution from the filtering in 
this method makes it mostly unsuitable to identifying changes in myocardial function. The TPD 
method requires only one acquisition per direction but has the lowest SNR of all techniques. Due 
in partially to the dephasing of the signal but the single acquisition nature of this method puts it 
as a disadvantage relative to the complementary acquisitions that take multiple images.  
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Figure 6.20 Comparison of SNR available with each  echo removal technique. CANSEL offers the 
best SNR but requires 4 acquisitions/direction. cDENSE is close behind but requires only 2, k-space 
filtering is unsuitable due to its low resolution and phase errors and TPD has the lowest SNR but 
maintains resolution and requires only one acquisition/direction. 
Looking at this information the techniques that provides the best DENSE information is CANSEL, 
however the long acquisition time makes it impractical. The effect of SNR on the ability of these 
images to detect changes in heart function is difficult to quantify since DENSE relies on 
unwrapped phase data. So long as the noise is not sufficient to effect the effectiveness of the 
unwrapping algorithm it is unlikely to have a noticeable effect on the displacement maps. Table 
6.1 summarises the key points for all 4 techniques. 
Table 6.1 Summary of DENSE artefact echo removal techniques 
Technique Mechanism Advantages Disadvantages 
k-space 
Filtering 
Bandpass filter 
isolates 
displacement 
echo 
 Simple and fast 
 No extra acquisitions 
 Removes all high 
frequencies 
 Lowers resolution 
 Prone to errors 
cDENSE 
Subtraction of 
positive and 
negative sines 
 Removes T1 echo 
 Does not require 
filtering until +2𝐾𝑒 
 Requires consistent 
heart rate 
 Requires 2 acquisitions 
per direction 
 Does not remove 
complex conjugate 
CANSEL 
Subtraction of 
positive and 
negative sines 
and cosines 
 Removes all artefact 
echoes 
 No filtering required 
 Requires 4 acquisitions 
per direction 
 Requires consistent 
heart rate 
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TPD 
Supress 
artifactual 
echoes in-plane 
 Removes all artefact 
echoes 
 No filtering required 
 No extra acquisitions 
 Low SNR 
 No through plane DENSE 
 
The low resolution of the k-space filtering technique makes it unsuitable for use in studies 
investigating regional heart function in detail. In tissue engineering it is important to maintain 
the high resolution of MRI acquisition data of identify subtle changes in regional function. 
CANSEL is also unsuited to multiparametric imaging due to its long scan time, it is difficult to 
incorporate it in large studies involving multiple acquisitions. cDENSE and TPD are both suitable 
however. cDENSE has a slightly limited resolution due to the filter removing the complex 
conjugate echo although this has a minimal effect on displacement maps. The 2 acquisitions per 
direction is not excessively long and allows for accurate suppression of the T1 echo while 
maintaining a high SNR. TPD is the fastest imaging technique and its low SNR has a limited effect 
on displacement maps.  
 
6.3.4 Results: Myocardial trajectories and strain 
This section corresponds to stage 4 of the workflow described in Figure 6.1. The aim of the 
techniques discussed below is to calculate the mechanical strain of tissue based on the 
displacement fields produced by DENSE. An additional post processing step whereby myocardial 
trajectories are calculated is described with the goal of improving temporal strain resolution and 
producing more physiological motion. 
Extracting useful and quantifiable values from DENSE images is vital to making the data useful 
for identifying cardiac dysfunction or recovery. Previous examples in this chapter have used the 
myocardial displacement as a quantitative value and although this is useful for visualisation and 
establishing the sequence it is not necessarily related to cardiac function due to factors such as 
the tethering effect. For this reason, a processing step was included to calculate the myocardial 
strain tensor from displacement information.  
Examples of fitted LV trajectories are shown in Figure 6.21. Figure 6.21A shows the paths traced 
by these trajectories where each yellow path corresponds to a single pixel, the overall path 
follows what is expected of the heart tissue with a twisting and contracting component. The 
benefits of these smoothed trajectories can be seen in Figure 6.21B where the yellow fitted 
trajectories are overlaid on the red raw trajectories. The raw trajectories follow jagged paths due 
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to image noise and phase errors, by utilising a fitting algorithm the motion can be smoothed and 
any non-physiological roughness in the motion suppressed. Figure 6.21C and D show the vector 
field plots for a frame in mid-systole for the raw and fitted trajectories respectively. 
 
 
Figure 6.21 (A) fitted trajectories traced in yellow with epicardial and endocardial borders in 
white. (B) inset showing overlay of raw (red) and fitted (yellow) trajectories. (C) Inset of raw 
trajectories with mid-systole vector displacement. (D) Inset with fitted trajectories and mi-systole 
vector displacement map.  
Strain values can be calculated from fitted trajectories in the same way as the raw displacement 
information. Strain fitted to trajectories was found to be smoother and closer to what was 
expected from previous studies of regional function.235 Figure 6.22 shows a comparison of raw 
and fitted strain curves for a naïve mouse in 3 regions. The rough motion of the raw motion 
229 
 
curve over the cardiac cycle causes a jagged strain curve following strain calculations. This strain 
is not physiological and it is useful to apply the trajectories calculation to remove these rapid 
transient displacement errors.  
 
Figure 6.22 Comparison of strain curves in the septal, anterolateral and inferior regions of LV. 
The fitted trajectories (red) show much smoother strain response compared to the raw motion 
paths (blue). The fitted trajectories are likely to be more accurate since the strain calculations 
based on fitted trajectories are less susceptible to phase errors during contraction. 
 
6.4 Discussion 
As a measure of regional myocardial function DENSE offers a high resolution alternative to 
SPAMM and HARP processing. This increased resolution however comes at a cost of scan time, 
processing time and image noise. A direct comparison between SPAMM and DENSE for 
investigating regional function will be included as part of a later study on the efficacy of 
regenerative alginate microspheres in myocardial infarction (7.3).  
In this chapter, I develop and optimise a DENSE protocol for preclinical imaging. The result is a 
cine DENSE sequence that can image displacement over the whole cardiac cycle and a novel PDF 
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method for removing background field contribution, making this accelerated approach highly 
attractive for preclinical imaging. An appropriate encoding strength for mouse heart imaging 
determined heuristically was 𝑘𝑒 =1.7 cycles/mm. Through plane dephasing was chosen as the 
best technique to remove the T1 and complex conjugate artefact echoes due to its shortened 
acquisition time. The associated SNR penalty with TPD does not appear significant at a through 
plane encoding of 𝑘𝑑 = 1.3cycles/mm.  
This is the first application of PDF to DENSE field removal and in this case it has proven to be 
significantly more reliable than subtraction methods to isolate phase changes due to 
displacement from background sources. Future work would be to further validate this method 
and find the optimal masking method to minimise the effects of flow and susceptibility 
boundaries on displacement images without causing excessive boundary artefacts.  
A limitation of this sequence is that it currently only supports 2D displacement in a single slice. 
This is suitable for locating regions of higher or lower contraction in disease models with 
regional pathology but is not suited to assessing the whole heart. Whole heart assessment will 
be a valuable tool in assessing the effects of a biomaterial or cell therapy in remote tissue. The 
long scan time of the DENSE sequence makes it unsuited to performing in multiple slices in its 
current form and particularly in any study where many scans are performed for a 
multiparametric outcome. Although accelerating the technique with TPD and PDF goes some 
way to making this a practical goal the scan time for the finalised protocol was still around 
25minutes for a single slice encoded in two directions. Clinical DENSE imaging has been 
extended to a multislice sequence by Gilson et al. (2005) who used a single modulation phase to 
read out a phase encode step in 3 short axis slices in each RR interval.252 The result is a multislice 
acquisition that sacrifices the cine capability of the sequence. In some cases, the peak strain at 
systole may be sufficient to describe cardiac function and in these cases this single phase 
multislice may be useful.  
This sequence measures 2D strain by applying the DENSE encoding gradients in the x and y 
directions sequentially. Each direction requires the acquisition of a single image volume. It is 
possible to extend the acquisition and acquire an additional image volume where encoding is 
applied in the through plane z-direction. This allows a single slice acquisition to completely 
describe 3D motion for all tissue within that slice. This results in a circumferential, radial and 
longitudinal strain measurement through a 3×3 strain tensor 
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6.5 Conclusion 
In this chapter I have implemented and optimised a DENSE sequence for mapping myocardial 
strain. The sequence is capable of cine imaging of myocardial displacement with a novel phase 
correction method that can measure displacement in 2 in-plane dimensions. This sequence will 
be utilised in a later study on the engraftment of regenerative biomaterials. Future work would 
aim to extend this sequence to 3D whole heart coverage to produce complete strain maps of the 
LV.  
In chapters 5 and chapter 6 I have described my development of two advanced preclinical 
imaging techniques for assessing regional heart function in mouse models of cardiac disease. 
These sequences provide pixel wise maps of 2D myocardial motion that can be converted to full 
mechanical descriptions of cardiac contraction using measures such as displacement, twist and 
strain. These sequences add to the MRI imaging toolbox that I have developed over this work for 
the assessment of regeneration therapies. In chapter 7 I demonstrate the application of these 
sequences to 3 studies of regenerative biomaterials in myocardial infarction. 
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Chapter 7  
Applications of imaging in cardiac regeneration 
therapy 
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7.1 Introduction 
Over the course of this thesis I have been performing imaging studies into the efficacy and safety 
of biomaterial regeneration therapy in parallel with the method developments that have been 
the focus of previous chapters. This chapter describes three key proof-of-concept studies I 
performed and demonstrates the evolving protocol that I have developed for assessing 
preclinical myocardial regeneration therapy. Three separate imaging studies are presented in 
chronological order: 
1. Global and regional cardiac function measurements in scaffoldless cell transplants 
2. MRI visible hydrogel with mechanical matching for reduced dysfunction in engraftment 
region 
3. MRI measurements of extracellular, global and regional function changes following 
alginate microspheres engrafted to the infarcted myocardium   
Each study has its own short introduction, methods, results and discussion sections, as well as 
the key results from that study that led to the development of the subsequent study. 
 
7.1.1 Global and regional cardiac function 
measurements in scaffoldless cell transplants 
 
7.1.2 Introduction 
As discussed in 1.2.5 tissue engineered approaches to cardiac regeneration have many 
advantages over the more common approach of direct injection of cells in liquid suspension. 
Following myocardial infarction, regions of heart tissue exhibit changes such as inflammation 
and hypoxia that make them hostile to cell growth. Transplanting regenerative cells for 
regeneration into this region results in a high proportion of therapeutic cells undergoing rapid 
apoptosis following engraftment due to this hostile environment.262 Promoting the survival of 
transplanted cells following engraftment is a key field of research for improving cell retention 
and efficacy in cardiac regeneration therapy.78 One avenue of research for improving therapeutic 
cell survival is transplanting cells in scaffoldless cell sheets or monolayers.263 These are single cell 
thick patches that are grown in-vitro and can be layered to create a viable 3D construct. The 
individual layers can be of the same cell type or contain a mixture of cell types. It is also possible 
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to layer different cell types together. Layered cell types provides a means to tune the properties 
of the construct and allow additional control over the mechanisms by which the layers interact. 
This targeted approach allows more direct control of the tissue formation process, allowing 
therapy to be tuned to the morphological and cellular architecture of the treatment region 
allowing for more effective therapy.264 The growth of cellular monolayers became possible 
following the work of Okano et al. in 1995, developing a process for coating standard 
polystyrene cell culture dishes with a temperature sensitive Poly(N-isopropylacrylamide) 
(PIPAAm) film.265 This film exhibits hydrophobic surface properties at incubation temperature 
(37°C) but transitions to a hydrophilic state at around 32°C. Cells will adhere to a hydrophobic 
surface during culture but not to a hydrated hydrophilic surface.40 This allows whole cell sheets 
to be lifted from the culture dish intact. Photographs of the lifting process for a cell sheet 
composed of neonatal rat fibroblasts is shown in Figure 7.1. This lifting process is what makes 
monolayers an appealing cell delivery strategy. During cell culture neighbouring cells form a 
complex intercellular microenvironment, comprising cell-cell signalling molecules, surface 
proteins and accumulated growth factors. Standard practice for extracting cells from culture 
takes an enzymatic approach such as trypsinization that destroy these intercellular contacts and 
isolate the cells in suspension. Lifting cultured cell sheets allows the sheet to be transplanted 
with this microenvironment intact, providing a local beneficial cellular environment that 
enhances cell survival after engraftment.266 Cell sheets also overcome several complications 
associated with other tissue engineering therapies which utilise a biodegradable scaffold as a 
temporary support and artificial environment for the cells, such as biocompatibility of the ECM 
and controlled degradation of the scaffold.267  
 
Figure 7.1  The PIPAAm coating on the culture dish is hydrophobic at incubation temperature 
(37°C) and the cells will actively adhere to the surface. As the temperature is decreased the 
coating becomes hydrophilic and the cells change shape to detach themselves from the surface 
while PBS solution is attracted into the space beneath them. 
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Cellular monolayers have been cultured in vitro using cardiomyocytes by Shimizu et al (2002).268 
The authors produced multiple monolayers cultured from neonatal rat cardiomyocytes and 
layered 4 sheets together to create viable 3D engineered cardiac tissue. These constructs were 
observed to mechanically pulse spontaneously demonstrating a contraction mechanism that 
could potentially be used to restore lost function following MI. The authors then transplanted 
these cell sheets into subcutaneous tissue of nude rats. Three weeks after engraftment surface 
ECG electrodes detected electrical pulsatility originating from the graft and macroscopic beating 
motion could be observed. Histological analysis then showed that the cell sheets had developed 
into subcutaneous tissue similar to myocardium. This demonstrated the potential for the 
regeneration of both cardiac tissue structure and electrical activity from transplantations of 
these monolayers.  
Subsequent in vivo studies have engrafted these contractile constructs to the infarcted heart in 
rodent and porcine models of infarction and have produced promising results. Sekine et al. 
(2008) transplanted sheets consisting of neonatal cardiomyocytes and endothelial cells in a 6:1 
ratio to the infarcted rat heart.269  The authors demonstrated a significant improvement in 
capillary density  in the infarcted tissue along with increased presence of growth factors VEGF, 
HGF and basic fibroblast growth factor (bFGF). In another rat study, Narita et al. (2013) 
demonstrated that skeletal myoblast (SM) cell sheets reduce the impact of arrhythmias in 
infarcted hearts relative to direct injection of SMs suspended in saline.270 They propose that this 
is due to the increased control over transplanted cellular architecture, specifically, preventing 
the formation of cell clusters which can disrupt electrical conduction. The cellular monolayers 
have also been validated as a therapy in large animals. A study by Miyagawa et al. (2010) 
cultured autologous skeletal cells into monolayers and engrafted them to the epicardium in a 
porcine model of MI.271 The authors used echocardiography to show that cardiac function was 
significantly improved following therapy, with increased ejection fractions, fractional shortening 
and preserved LV architecture. 
In this first study I aimed to familiarise myself with the basic imaging techniques for the 
quantification of infarct size as well as global and regional heart function in rat hearts following 
neonatal rat fibroblast monolayers as a therapy for myocardial infarction.  
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7.1.3 Methods 
7.1.3.1 Cell sheet preparation 
Cell sheets were cultured by Dr Vassilis Georgiadis (University College London).78  300,000 
neonatal rat cardiac fibroblasts were seeded into temperature sensitive dishes and cultured for 
14 days in DMEM with 10% FBS at 37˚C in 5% CO2. Fibroblasts were chosen for the culture of the 
cell sheets for their availability and known paracrine effects.272 The cell culture was labelled with 
the fluorescent membrane stain DiL (molecular probes) 549/565nm excitation/emission to 
enable fluorescent imaging at the study end. Example OPT images showing labelled and 
unlabelled cell sheets suspended in 1% agarose are shown in Figure 7.2. 
 
Figure 7.2 Example OPT images showing cell sheets in agarose suspension. Transmission images 
show attenuation of light through monolayers, TXR filter isolates fluorescent emissions at 
560/20nm from the DiL membrane stain. Combining these images in a composite allows 
visualisation of fluorescent cells. 
On the day of engraftment, the temperature of the dishes was reduced to 30˚C to induce the 
thermal change in culture surface affinity. The cells were left to lift form the dish for 1 hour to 
ensure complete separation of the sheet from the culture surface. Sheets were transferred to a 
standard 12 well plate in culture medium and stored at 37˚C to await engraftment. Cell sheets 
were engrafted to the myocardium within 5 hours of lifting.  
 
7.1.3.2 Animal preparation 
Coronary ligation surgery and cell sheet engraftment was performed by Valerie Taylor 
(University College London). Adult Wistar rats were anaesthetised in an induction chamber using 
3% isoflurane in oxygen before intubation so that respiration could be artificially maintained by 
an external ventilator with a stroke volume of 500μL at a rate of 40 breaths per minute and 2% 
isoflurane in oxygen. The rat was placed on a heated operating surface with body temperature 
maintained at 37±0.5°C. The heart was accessed through the fourth intercostal space where an 
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incision was made through the skin and pericardium to expose the anterior wall of the LV. The 
LAD was identified and a suture placed underneath the vessel at the point of ligation before 
being tied off around a piece of sterile tubing placed above the vessel. During this 40-minute 
occlusion period, 3 individual cell sheets were removed from suspension in PBS and layered 
directly over the epicardium at the anticipated anteroapical infarct region. Sheets were adhered 
to the epicardium by the preserved cell surface proteins, an inherent advantage of this cell lifting 
technique. Following the desired ligation time, the tubing was removed and the suture severed 
to reperfuse the tissue. Animals were monitored during recovery to ensure welfare. Animals 
were allowed to recover for 7 days prior to imaging, this allowed time for myocardial 
remodelling in the presence of the cell sheets. 
Groups included sham surgery with no infarction (n=3) to act as controls, infarcted hearts with 
no cellular monolayers (n=6) and infarcted hearts with cellular monolayers (n=4).  
 
7.1.3.3 MRI methods 
In-vivo imaging was performed with a 9.4T Agilent system (Agilent Technologies Inc., CA, US) 
equipped with a 72mm volume transmit coil and a 4 channel surface receive array. Rats were 
anesthetised under a mixture of isoflurane and oxygen and ECG, respiration and temperature 
monitored for image gating and to maintain depth of anaesthesia.  
Following slice localisation, a stack of cardiac short axis slices were acquired to measure global 
heart function. Cine images were analysed by segmenting the LV borders using Segment 
software.185 Following cine imaging, a Gd-DTPA infusion was delivered via intraperitoneal 
injection at a dose of 46.9mg/g with 20 minutes allowed for circulation and imaged using a LGE 
inversion recovery sequence. 
The cell sheet therapy is a regional treatment and so an in-vivo regional analysis tool is required 
to assess the local influence of the therapeutic cells. Global assessment using cine MRI only 
partially describes the complex contraction of the heart and cannot measure myocardial twist or 
differentiate quantitatively between akinetic scar tissue and actively contracting regions. This 
study was performed prior to my development of SPAMM/HARP or DENSE at our facility 
meaning that these techniques were unavailable. For this reason, the standard tag-cine 
sequence provided with the Agilent imaging system was used. This sequence was a DANTE 
prepared tagged-cine sequence that produced a tagging pattern similar in appearance to 
SPAMM tagging, however the modulation of magnetisation is not sinusoidal with uneven 
spacing between tag places. A tagged cine image for assessing the contractility of the LV was 
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acquired with FOV = 5.2cm2; pixel size = 0.13×0.13×1mm; TE = 2ms; tag spacing= 0.3mm; 
averages=2 with 27 cine frames at a standard rat heart rate. This tagged cine was acquired 
through a slice containing the infarcted/treated myocardium. The uneven tag spacing in these 
images means that the HARP tissue tracking technique cannot be used. Therefore, tagged 
images were analysed using an alternative method implemented through the inTag plugin for 
Osirix. The tag analysis software inTag tracks tag lines using a sine wave modelling approach 
(SinMod).273 In this approach a sine wave model is fitted to each pixel so the moving line of 
hyperintensity is treated a moving wavefront. From this model the displacement can be 
measured to sub pixel resolution based on interpolating the deformations provided by this 
model. SinMod has been shown to give favourable results with respect to HARP and was chosen 
for the availability of a commercial implementation at the time of this study. inTag data was 
used to assess regional circumferential strain over the cardiac cycle. 
 
7.1.3.4 Optical projection tomography 
For ex vivo imaging such as optical projection tomography it is necessary to excise the tissue and 
prevent decay to maintain internal structures. This was achieved through perfusion fixation as 
described by Gage et al. (2012).274 In brief the perfusion fixation protocol consisted of a terminal 
administration of sodium pentobarbital. Once unresponsive and in a surgical plane of 
anaesthesia the chest was opened by incision beneath the sternum and the diaphragm pierced 
to expose the pleural cavity. The left and right side ribs were then cut through up to the 
collarbone and the chest wall pulled back to expose the heart. A 27G needle was then passed 
into the LV through the apex and the right atrium cut to provide an outflow tract for the 
perfusate. Heparinised phosphate buffered saline (PBS) was pumped through the LV at a 
constant flow rate provided by a syringe pump. This removed all blood from the specimen. 
Following sufficient exsanguination, the perfusate was switched to 4% paraformaldehyde (PFA) 
to fix the tissue. The heart was then extracted and immersed in 4% PFA for at least 8 hours to 
finalise fixation. 
Heart tissue was then dehydrated in 3:2 ethanol and dimethyl sulfoxide (DMSO) for 14 days with 
daily changes of solution, then transferred to 1:2 mixture of benzyl alcohol and benzyl benzoate 
(BABB) for 7 days, changing the solution every two days. Imaging was performed using a 
commercial OPT system (Bioptonics, MA, USA) using a Texas Red filter (560nm) to image DiL 
membrane fluorescence and GFP+ filter (470nm) to image long wavelength tissue 
autofluorescence for anatomical reference. Projections were acquired over 360° with 0.45° steps 
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and the tomographic volume reconstructed using a filtered back projection (FBP) algorithm as 
described in 2.4. 
 
7.1.3.5 Statistical tests 
All results are presented as mean value ± standard error. All data were tested for normality using 
the Kolmogorov-Smirnov test and significance values were calculated by one-way analysis of 
variance corrected for multiple comparisons using the Holm-Šídák method. In all cases a p-value 
of less than 0.05 was considered significant.  
 
 
7.1.4 Results 
Results from cardiac MRI are shown in Figure 7.3. Due to low group numbers it would not be 
fully accurate to determine the distribution of data for this reason individual data points are 
plotted on graphs to aid interpretation. End systolic and end diastolic volumes showed no 
significant differences. 
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Figure 7.3 Results of cine MRI. End systolic volume (ESV), end diastolic volume (EDV) and ejection 
fraction were quantified from cine MRI imaging and infarct size was quantified from LGE 
inversion recovery imaging. 
Ejection fraction was significantly (p=0.015) lower in infarcted untreated rats (52±4%) versus 
sham surgery rats (72±4%), this is consistent with the loss of contraction and remodelling effect 
following MI. The treated monolayer group however had an ejection fraction (65±2%) that 
although lower was not significantly different from the sham group. This may indicate 
improvement in global heart function in the treated group suggests that the monolayers may 
provide some therapeutic benefit to global heart function. 
The scar size was quantified from inversion recovery images in the infarcted and treated groups, 
representative LGE images are shown in Figure 7.4. The control group were not assessed as no 
regions of myocardial enhancement were visible. There was a significant (p=0.015) reduction in 
infarct scar size as a percentage of the total LV in the monolayer treated group (3.5±0.9%) versus 
infarction with no treatment (12.9±2.8%).  
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Figure 7.4 Representative LGE images showing the approximate LV scar boundary (yellow) in the 
infarct and treated group. Sham group shows no scar tissue. 
Regional function measurements are shown in Figure 7.5. The plots here show the mean 
circumferential strain as a function of time for a 6 segment model of the LV as was the case with 
the cine structure assessment in Chapter 4. The curves plotted in these figures are a fitted 5th 
order polynomial function to aid in visualisation of the strain-time curves. These segments are 
further characterised by the infarct region in the surgery. The anterolateral region developed the 
infarct, the neighbouring anterior and inferolateral segments were characterised as border zone 
and the inferior, inferoseptal and anteroseptal segments were classified as remote. 
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Figure 7.5 Regional function assessment of monolayer therapy with tagged MRI. Strain curves 
are plotted for each group for comparison in each segment of LV. The segments are 
characterised as infarct regions, border zone or remote tissue. Polynomial curves are fitted to the 
data to aid visualisation. 
In the infarcted region the contraction strain is lower in the monolayer treated group relative to 
the sham and infarct groups, suggesting that the cell therapy was not effective at improving 
function at the site of infarction and reduced contraction in this region. In the anterior infarct 
border zone however, the strain did appear to be improved by the application of the monolayer 
therapy. Remote tissue showed mostly similar results in all groups suggesting that distant 
uninfarcted tissue was not affected. There was increased variability in strain measurement of 
the anteroseptal region for the sham surgery group. This was due to poorly tracked regions of 
tissue in the inTag software. 
Further quantification of the relative contraction in each segment can be provided by the peak 
strain that can be a useful measure to summarise the contraction of a segment of LV. Peak strain 
is compared for infarcted, neighbouring and remote (posterior) segments in Figure 7.6. The 
inferoseptal region was chosen to act as the remote tissue since it receives the smallest relative 
blood supply from the LAD and is therefore least likely to suffer an infarction injury from LAD 
ligation surgery. 
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The infarcted group without treatment showed the smallest peak strain values in the infarct 
zone and border zone segments with similar values across groups in remote myocardium. Strain 
was only significantly different between the infarcted and sham groups (p=0.027) in the 
neighbouring regions (p=0.027). In this region, the peak strain in the infarct group was reduced (-
0.11±0.01) relative to the sham group (-0.21±0.03) but the treated group showed improved 
strain that was not significantly different from the sham group (-0.17±0.05). There was no 
significant difference between peak strains in these segments between the sham and monolayer 
treated group. These results are consistent with the global functional measurements, showing 
the monolayer treated group has similar properties to the sham groups indicating the therapy 
may be effective. The additional information provided by the regional assessment tagged MRI 
techniques has shown that this improved contractility originates from increased contraction in 
the infarct border zone. 
 
Figure 7.6 Comparison of peak strains in infarcted, neighbouring and remote myocardium. The 
infarcted group shows the smallest peak strain in each segment, the monolayer group however 
shows no significant difference compared to the sham surgery. 
To be able to reliably attribute any functional change in the heart to the treatment it is 
necessary to demonstrate the continued presence of the treatment cells. Cell loss is an issue in 
many cardiac regeneration therapies and successful engraftment is essential for the cells to 
stimulate recovery. In this case fluorescent labelled cell membranes allowed tracking of the 
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cardiac fibroblasts using optical projection tomography (OPT).  Representative OPT data is 
shown in Figure 7.7.  
 
Figure 7.7 Representative OPT imaging (L) tomographic reconstruction of a single slice showing 
fluorescence from DiL labelled cells in apical region. (R) 3D surface rendering showing distribution 
of fluorescence on surface of the heart. 
These images show that there in fluorescence at the epicardium 21 days post engraftment, 
suggesting that the treatment cells adhered successfully with the myocardium. OPT is not a 
technique ideally suited to rat hearts due to their relatively large size. The tissue clearing process 
requires good penetration of the dehydration and clearing agents and this can be challenging for 
tissue with a thickness >1mm. The result is that deeper tissues do not clear as well as surface 
tissue and produces and edge enhancement artefact in reconstructions. This is visible as 
hyperenhancement at the tissue surface in reconstruction and a loss of signal in deep tissue in 
Figure 7.7.  
 
7.1.5 Discussion 
This study has established the basic imaging techniques required for quantification of cardiac 
function and viability in myocardial infarction. The imaging techniques were applied to in the 
context of investigating a novel cellular monolayer therapy in rats. The data presented here 
suggests that cell patches composed of neonatal cardiac fibroblasts may help limit the damage 
suffered by the rat heart during infarction. In-vivo analysis of cardiac function shows an 
improvement in ejection fraction when compared to untreated hearts and a regional 
improvement in circumferential contraction in the infarct border zone following engraftment. 
The continued presence of fluorescent membrane stains at 21 days post-engraftment suggests 
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that the cells are adhering to the myocardium. Improved contraction in the infarcted and 
neighbouring regions suggest that the presence of the cell sheet is beneficial to the heart. 
Although fibroblasts do not have the regenerative potential of progenitor cells for cellular 
integration, these results show that a fibroblast patch may stimulate regenerative or damage 
limiting effects through paracrine factors. Over the short timescale of this study regeneration of 
tissue is not expected to occur, making these paracrine effects the most likely factor producing 
therapeutic benefit.  
As this study was powered towards establishing imaging techniques the study has a number of 
limitations that must be discussed in the context of making a conclusion about therapeutic 
effect. The low sample sizes of the infarct with monolayer therapy group (N=4) was due to the 
complexity of producing the cellular monolayers. The cell sheets are inherently delicate and 
were frequently torn and disintegrated during the lifting procedure making engrafting them 
impossible. Despite this some positive outcomes were observed in the animals that did receive 
the therapy. The lack of statistical significance in the ESV and EDV measurements may be in part 
due to the variability in the myocardial infarction surgery. Investigating the distribution of values 
in the infarct group in Figure 7.3 shows that there is a wide range of scar sizes from a minimum 
scar of 1.4% up to 22.1% of the LV. This variability is not only limited to scar size but also scar 
location. The vasculature in the LV is complex with a dense network of collateral venous and 
arterial vessels, meaning that depending on the exact nature of the induced myocardial injury 
will determine the scar properties and this may not be sufficiently reproducible between 
animals. This can be seen by the varying infarct locations in Figure 7.4, the infarct in the 
untreated group example develops in the anterior wall, while in the treated group example it 
develops in the posterolateral wall. An additional consequence of this variability is that 
improvements in cardiac metrics in the treatment group must be treated with caution as there is 
a possibility that in the MI surgery produced only minor infarctions in these animals. Minor 
infarctions in these animals would appear similar to a successful therapy. Monolayers were 
grafted during infarction surgery to negate the need for a complex second thoracotomy to 
enable sheet attachment at a later time point. This meant there was no way to determine 
whether the initial infarction surgery was successful or similar between groups. Ideally LGE and 
cine imaging would be performed post infarction surgery and prior to therapy to establish the 
existence and extent of MI in each animal. A future study developing this therapy would require 
larger sample sizes to minimise the statistical power of this variability. 
Although OPT can produce a high resolution 3D map of cell distribution this technique is non-
quantitative and represents only the presence of cells and cannot provide an accurate 
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quantification of cell population or importantly whether the cells are viable. The signal depends 
only on the presence of the fluorescent molecule DiL and so viable cells and residual fluorescent 
molecules from dead or displaced cells cannot be differentiated. Bioluminescence imaging (BLI) 
was introduced in later studies to allow for imaging of cell viability due to the limitations 
presented here with OPT. The fluorescent cells at the epicardium indicate the cell adhesion has 
occurred between the monolayers and the host tissue but does not confirm full integration. 
Confirming integration would require additional histological staining methods and high 
resolution microscopy such as fluorescence microscopy imaging. However, the OPT chemical 
clearing process makes tissue samples unsuitable to further processing so this could not be 
performed. The OPT quantification of biomaterial location has an additional disadvantage in that 
it is an ex-vivo imaging technique. The OPT tissue clearing process may potentially remove 
therapeutic cells or material that has not fully adhered to the heart. This limitation was 
recognised in this study and led to the development of techniques for the in-vivo detection of 
transplanted biomaterials using gadolinium agents to provide MRI contrast these materials are 
discussed further in 7.3. 
This sheet of a single cell type was able to successfully adhere to the epicardium. However, a 
patch with a more complex structure such as a contractile sheet of cardiomyocytes and 
endothelial cells may offer more scope for regeneration. More advanced patches and constructs 
will come with more complex integration requirements of the construct with the existing tissue. 
For example, orientation and engraftment location will become important if the construct is to 
produce contractile motion. The imaging techniques developed with this study are a valuable 
tool for assessing the position or detrimental effect of engrafted biomaterials. Cell patches as a 
treatment have advantages in terms of regenerative therapy are viable for small animals such as 
rodents but scaling them to be suitable for clinical use has a number of obstacles. The patches 
used in this case were composed of layers approximately 1cm across, scaling layers up to the 
size required for a human heart would require developments to the growth method. Growing 
larger patches makes it more difficult to lift the cell sheet off in one piece due to the likelihood 
of variable cell densities across the monolayer. The thickness of patches is currently limited by 
the diffusion of oxygen to cells. Without integrated vasculature, oxygen can diffuse to a depth of 
approximately 150μm,78 beyond this depth the tissue construct would require its own blood 
supply that is successfully integrated with the host coronary circulation.  
This study proved to be a promising pilot study in establishing cellular monolayers as an effective 
therapy for MI in rats. However, with the departure of Dr Vassilis Georgiadis the technical 
expertise required to grow the monolayers was gone, effectively terminating this avenue of 
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research. Future investigations would have applied the monolayer therapy to larger groups of 
animals to improve statistical power. It would also have been interesting to grow cell sheets 
from cell lines known to have more potential in regenerative medicine such as cardiac stem cells 
or bone marrow mononuclear cells.  
To conclude, this study has established techniques and demonstrated the value of imaging in the 
assessment of regenerative therapy. MRI was able to quantify functional changes in LV 
contraction and structure in MI following the engraftment of a cell sheet composed of neonatal 
rat fibroblasts. Improvements in ejection fraction were observed as well as a reduction in scar 
size. MRI tagging showed that contraction is improved in the cell sheet treated hearts in the 
infarct border zone relative to untreated infarction. OPT found that fluorescence from the 
engrafted cells was detectable at 21-days post engraftment suggesting that adhesion between 
the cellular monolayer and the native epicardium has successfully occurred.   
 
7.1.6 Key results 
 Imaging techniques developed for assessing global and region heart function and 
structure. 
 Rats treated with cell sheets showed reduced scar by LGE size as well as improved 
contraction in the infarct border zone from MRI tagging. 
 Cell adhesion 21-days post engraftment was demonstrated using optical projection 
tomography. 
 In situ imaging of viable cells may offer more information about success of engraftment 
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7.2 MRI visible hydrogel with mechanical matching for 
reduced dysfunction in engraftment region 
 
Some of the work described in this section forms part of the paper Multi-modal hydrogel 
platform to enhance and monitor cardiac progenitor/stem cell engraftment. (under review) by 
Alessondra T. Speidel, Daniel J. Stuckey, Lesley W. Chow, Laurence H. Jackson, Michela Noseda, 
Marta Abreu Paiva, Michael D. Schneider and Molly M. Stevens. 
 
7.2.1 Introduction 
An alternative cell delivery strategy to the surgical engraftment of monolayers method described 
above is suspension of the cells an injectable medium (e.g. saline, alginate, collagen) and 
engrafting the cells by injection. The advantage of this technique is its versatility. The monolayer 
technique described in Part 1 allows for the engraftment of cells with a pre-established cellular 
microstructure but the development of these sheets is technically complex and requires 
specialist materials and skills to manufacture. Injectables are technically simpler to manufacture, 
engraft and are able to be delivered to the transmural myocardium potentially increasing their 
efficacy. The practical advantages of injectable therapies have helped them become widespread 
in clinical and preclinical trials investigating cardiac regeneration.108 The most common method 
for cell delivery in clinical trials has been via intracoronary injection, although a few opt for a 
more direct transendocardial intramyocardial injection delivered through a needle catheter. 
However, injection as a method for delivery of cells can result in a high proportion of the 
injected material being lost immediately following injection due to the contractions of the 
heart.275 The injected material is physically forced from the heart by the contraction of the 
myocardium displacing the material into the pericardial space. The optimal delivery method for 
stem cell therapy remains unknown and remains an area of investigation.276 
As discussed in1.2.5 there are a huge number of variables to consider when designing a 
biomaterial for cardiac regeneration. This study investigated the safety and retention of an 
advanced hydrogel based on poly (ethylene glycol) (PEG) polymers cross linked with dithiol and 
heparin binding peptides functionalised with bound gadolinium contrast and luciferase 
expressing cardiac stem cells (CSCs). This study was performed in collaboration with researchers 
at Imperial College London who provided the stem cells and biomaterial. This study used the MR 
imaging techniques developed in previous chapters to assess the safety of engrafting this 
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functionalised PEG hydrogel by performing ultrasound guided injections of hydrogel into healthy 
hearts in the absence of MI.  
Poly (ethylene glycol) is a hydrophilic polyether molecule (H−(O−CH2−CH2)n−OH) that can be 
crosslinked to form variable 3D polymer networks with a high water content (hydrogel). PEG is a 
synthetic polymer; both synthetic and natural polymers have been utilised in cell therapy 
research and both have their relative advantages. PEG based hydrogels have a wide range of 
biomedical applications such as controlled release platforms for drug or bioactive molecules, cell 
delivery mediums and physical support.277-279 The properties of PEG which make it so widely 
applicable to biomedical fields is its biocompatibility, biodegradability, temperature 
responsiveness, non-ionic properties and versatility in polymerisation. The biocompatibility of 
PEG hydrogels results in a minimal immune reaction following engraftment to the host tissue 
which maximises the survival of transplanted cells. PEG hydrogel microenvironments are highly 
permissible and readily allow diffusion of gases, biomolecules and nutrients. This property 
makes them ideally suited to transplanting cells and aids in the regenerative effect from 
paracrine signalling. However, this same property is seen as a hindrance for controlled release of 
biomolecules since the gel networks are equally permeable to the therapeutic molecules 
controlling their release is a major challenge. PEG hydrogels can be manufactured to gelate at 
physiological temperatures. Jeong et al. (2000) produced a PEG based hydrogel that was 
aqueous at room temperature but solidified at 37°C.280 The authors injected the polymer 
solution in its liquid state subcutaneously into rats. The gel solidified in-situ and maintained 
mechanical integrity up to 1-month post engraftment.  
Controlled degradation of the hydrogel is important for allowing native tissue to regenerate and 
replace the engineered graft. The biodegradation profile of the PEG hydrogel can be changed 
through altering the polymerisation reaction e.g. incorporating a bond breaking reaction at a 
later time point to induce degradation. The most commonly used mechanism is hydrolysis where 
a molecule of water adds to the polymer backbone and breaks a link in the polymer network. 
Alternatively hydrogels can be degraded by enzymatic degradation or photodegradation.281-284 
Gelation of PEG polymers is typically performed through chemical or covalently bonded 
crosslinking that leads to stable and controllable polymerisation. By changing the type, 
concentration or mixture of available crosslinkers allows the manufacture of hydrogels with 
varying permeability, mechanical properties, water content and degradation profiles. As the 
density of cross-linking increases the network mesh size decreases, swelling ratio due to water 
uptake decreases and the stiffness increases. This relationship is roughly described in Figure 7.8. 
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The gelation of PEG hydrogel can be performed at temperatures and pH levels that are 
hospitable to cell culture allowing for live cells to be encapsulated with the hydrogel.  
 
Figure 7.8 Simplified PEG hydrogel where black circle indicate crosslinking points and red lines 
indicated PEG polymers. Changing the density of crosslinking points in the PEG gel allows tuning 
of the hydrogel properties. Properties such as modulus, stiffness and hydrophobicity 
approximately follow trend line A (blue) while permeability, diffusivity, water content, swelling 
ratio follow trend B (red). 
In the field of cardiac regeneration PEG hydrogels have been commonly used as mechanical 
support, injectable cell matrices and bioactive molecule transporters. A study by Jiang et al. 
(2009) showed that the presence of PEG hydrogel even without stem cells or doping with 
bioactive molecules could be beneficial following myocardial infarction.285 The authors induced 
MI in rabbits and injected 200μL of either PEG hydrogel or PBS into the infarcted tissue. Twenty-
eight days later, the hydrogel treated group showed reduced wall thinning and smaller infarcts 
versus the PBS group measured by histology and echocardiography showed higher ejection 
fractions in the hydrogel group. The authors propose the therapeutic mechanism is the presence 
of the hydrogel prevents the infarction induced systolic bulging that leads to adverse 
remodelling. In a study from the same group by Wang et al. (2009) assessed the efficacy of PEG 
based hydrogel in improving bone marrow stem cell (BMSC) survival and retention as well as 
minimising structural damage in the infarcted myocardium of rabbits.286 Echocardiography 
showed that animals that received injections of BMSCs in hydrogel had significantly higher LVEF 
at 4 weeks relative to animals that received BMSCs in PBS and control infarctions. US imaging 
also showed that adverse LV remodelling was reduced with the LV end diastolic diameter 
smallest in the hydrogel group indicating reduced wall thinning. Histology showed reduced scar 
volume in the hydrogel group relative to the BMSC only group with increase vessel density 
around the infarct. The authors suggest that this is a survival enhancing effect due to the 
presence of the stem cells that are retained better in the PEG hydrogel. In a rodent study by 
Rane et al. (2011) injected an inert PEG hydrogel or PBS into the infarcted rat myocardium.287 
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Despite the PEG group showing increased wall thickness at 7-weeks post infarction relative to 
PBS controls, cardiac function assessed by MRI and quantified by LVEF, EDV and ESV showed no 
significant difference to the PBS group. This is in contradiction to the previous study by Jiang et 
al. (2008) who measured improved LVEF by echocardiography. The author propose that the 
biodegradation of the hydrogel is the key parameter effecting the preservative effects of passive 
biomaterial in myocardial infarction. The cell and bioactive molecule penetration into the 
degraded hydrogel is proposed as a mechanism for inert material as a therapy.  
The PEG hydrogel developed for this study was produced and optimised in-vitro by Dr Allie 
Speidel (Imperial College London). The hydrogel was composed of a 4-arm PEG-acrylate 
molecule terminating in thiol chains that was crosslinked with heparin binding peptides (HBP). 
The HBP crosslinkers were chosen due to their demonstrated ability to delivery growth factors 
and promote angiogenesis.288,289  The HBP crosslinkers were further functionalised by binding a 
chelated Gd(III) ion for T1 weighted contrast in MRI. A simplified diagram of the PEG hydrogel 
structure is shown in Figure 7.9. 
 
Figure 7.9 Functionalised PEG hydrogel utilised in this study. PEG- 4-arm poly (ethylene glycol); 
DT- dithiol crosslinker; Gd- chelated gadolinium ion; HBP- heparin binding peptide. 
Macroscopically these hydrogels have a gel like colourless and transparent appearance.  
The development of injectable hydrogels based on natural and synthetic polymers has grown 
into a large body of research with attempts to optimise the properties of the hydrogel for cell 
retention ongoing.290-292 The benefits of making this hydrogel MRI visible has several advantages 
by enabling in situ and non-invasive quantification 1) allowing the degradation profile of the 
hydrogel bioscaffold to be quantified 2) locating the engraftment site to confirm procedure 3) 
associate functional change with presence of material 4) image guided computational modelling 
of outcome. A number of approaches have been taken to make hydrogels MRI visible, this 
involves bestowing a contrast mechanism to the hydrogel through the introduction of contrast 
agents or chemical exchange saturation transfer (CEST) MRI methods. MRI has frequently been 
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used to image the distribution of iron oxide labelled regenerative cells in cell therapy293-296 but 
few have attempted to directly image the hydrogel delivery scaffold. Liu et al. (2015) developed 
a Gd-DTPA doped chitosan based hydrogel for stem cell delivery.297 The authors demonstrated 
the visibility of the hydrogel following subcutaneous engraftment using T1 weighted MRI 
imaging. Visibility of the hydrogel was preserved up to 35 days post engraftment. This study is a 
valuable proof of principle in producing a functionalised hydrogel with contrast agents for 
biomaterial tracking. However, imaging the hydrogel following subcutaneous injection is 
relatively simple compared to intracardiac injection due to the static tissue environment and 
large hydrogel volumes injected. Engrafting hydrogels to the heart and maintaining visibility 
from the smaller volumes will be more challenging. An alternative technique for producing MRI 
contrast from hydrogels is the CEST MRI acquisition scheme. CEST produces MRI contrast 
without exogenous contrast agents and is based on the exchange of saturated protons between 
molecules with different resonant frequencies. CEST hydrogel tracking has been demonstrated 
previously by Liang et al (2015) and Dorsey et al (2015).298,299 These studies have validated CEST 
tracking of biomaterial, with the main advantage relative to contrast agents being the specificity 
in identifying a particular biomaterial non-invasively. CEST is an interesting and powerful 
technique for this purpose but due to the very long acquisition times required for CEST imaging, 
that can be prohibitively long with cardiac gating this method was deemed unsuitable to the 
multiparametric imaging platform that was developed in this work. 
This hydrogel platform underwent several in-vitro experiments prior to the in-vivo 
implementation described here. These in-vitro tests included monitoring gel degradation, 
mechanical properties and cell retention and viability. The Gel presented in this study- consisting 
of 50% dithiol and 50% HBP crosslinkers- was optimised to increase cell retention and have 
similar mechanical properties to myocardium.  
The cell type chosen for these experiments were Sca1+ cardiac stem cells that were isolated and 
derived as described by Noseda et al. (2015).300 These cardiac stem cells represent an attractive 
therapeutic cell for cardiac regeneration since they have been shown to differentiate into 
cardiomyocyte, endothelial and smooth muscle cells.301-303 A study by Liang et al. (2010) 
investigated the fate of these cells following transplantation into the myocardium.304 
Transplanted Sca1+ CSCs were shown to differentiate into cardiomyocytes and endothelial cells 
and were shown to migrate from healthy regions of tissue to damaged myocardium. CSCs have 
been used previously in preclinical studies of regenerating the myocardium following infarction. 
A study by Porrello et al. (2010) showed that when the neonatal mouse heart suffers a severe 
injury by surgical resection of apical tissue it has the ability to regenerate.46 This regeneration of 
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tissue was characterised by cardiomyocyte proliferation and minimal fibrosis making it true 
regeneration as opposed to remodelling processes. The native CSC population is theorised to 
provide this transient regenerative ability. Autologous CSCs have been deployed in clinical 
studies of myocardial regeneration in the CArdiosphere-Derived aUtologous stem CElls to 
reverse ventricUlar dySfunction (CADUCEUS) trial where they were found to reduce scar size and 
increase contractility and wall thickening in the infarct tissue.305  
Due to its optimal balance of durability, mechanical matching and cell retention the 50% HBP 
crosslinked PEG hydrogel was carried forward for use in the in vivo experiment described below. 
The aims of this study were to assess the safety and efficacy of the injectable PEG hydrogel in 
the healthy mouse heart as a preliminary study establishing this PEG hydrogel platform as a 
tailored, in vivo, detectable cell delivery system for enhancing cell and biomaterial retention in 
the mouse heart.  
 
7.2.2 Methods 
7.2.2.1 Cell culture and Hydrogel manufacture 
Cell culture and hydrogel manufacture was performed by Dr Allie Speidel (Imperial College 
London). In brief CSCs were isolated as Sca-1 positive side population cells from adult mouse 
hearts and then deposited as single cells so that clonogenic lines could be harvested and 
expanded to passage 10. The CSC population were cultured at 37°C with 5% CO2 on collagen I 
coated polystyrene dishes. CSCs were passaged at 70% confluence every 7 days by 
trypsinisation. CSCs were transduced with pLenti-III-PGK-Luc2 luciferase lentivirus (Applied 
Biological Materials, Richmond, CAN) so that they would produce the firefly luciferase protein to 
enable bioluminescent imaging for measuring cell retention and viability as described in 2.6. PEG 
hydrogel was then formed by crosslinking the PEG polymer chains with a 50:50 ratio of dithiol 
bonds and heparin binding peptide (HBP). The HBP bonds also included a chelated gadolinium 
ion to provide MRI imaging contrast. 
 
7.2.2.2 Engraftment 
This study was performed in mice due to the availability of murine cardiac stem cells with 
collaborators at Imperial College London. The goals of this study were to examine the safety and 
retention of this material in-vivo and develop the engraftment procedures. For this reason, 
experiments were performed in healthy mice without myocardial infarction to assess damaged 
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caused by the engraftment procedure without the confounding factor of infarction induced 
fibrosis and remodelling.  
CSCs were harvested on the day of engraftment by disassociation and separated by 
centrifugation before being suspended in PBS. Two groups of animals were produced, one 
received intramyocardial injections of PBS with CSCs (n=6) and the other received 
intramyocardial injections of PEG hydrogel with CSCs (n=8). For the PEG hydrogel group, these 
cells were encapsulated in 50% HBP solution containing 2mM Gd (III)-HBP at a concentration of 
1.4 × 106 CSC-Luc2 cells in 160μL of PEG acrylate solution. 
Ultrasound guided injections were performed by Dr Daniel Stuckey (University College London), 
the US guided procedure was performed on a Visualsonics Vevo 2100 system equipped with a 25 
MHz rat imaging transducer in b-mode with an 18mm FOV. A schematic of the setup used is 
shown in Figure 7.10. Wild type mice were anaesthetised under 2.5% isoflurane in oxygen and 
the hair over the chest removed as described in 2.5 to allow unimpeded imaging through the 
parasternal short axis view of the heart for injection. A 27G needle was inserted through the 
intercostal space into the anteroapical region of the heart. Once the position within the 
anteroapical region was confirmed by US b-mode imaging 20μL of PEG was injected. The needle 
was then retracted so that it was outside the myocardium but within the chest wall, the needle 
was then repositioned and another nearby injection site determined for another 20μL injection. 
This process was repeated for a total of 4 localised injection sites.  
 
Figure 7.10 Schematic of the setup used for intramyocardial injections. Each component of the 
setup could be positioned independently on rails (a) syringe containing CSC loaded PEG had 
translational and rotational freedom allowing for accurate needle positioning (b) the animal bed 
could similarly be repositioned and incorporated physiological monitoring and anaesthetic 
delivery. The ultrasound transducer (c) was placed above the animal when prone and was 
positioned to image through the parasternal window producing an image showing both the 
needle and SA view (d). 
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7.2.2.3 Imaging 
Bioluminescence imaging was performed for assessing cell viability and retention. BLI was 
performed as described in 2.6 using the Biospace PhotonImager system.  Animals were imaged 
immediately following the US guided injections to provide a baseline cell engraftment 
population, this provided a way to normalise cell retention across animals regardless of initial 
engraftment variability. Imaging was subsequently performed at 1, 3, 7 and 14-days post 
engraftment.  
Magnetic resonance imaging was performed at 1, 7 and 14-days post engraftment to assess 
changes in cardiac function and assess biomaterial retention. For global cardiac function 
assessment, a standard short axis cine stack was acquired and processed using the standard 
protocol. LGE images were acquired pre-contrast and post-contrast and analysed as described in 
2.3.5 to assess biomaterial retention by utilising the T1 shortening effect in the presence of the 
Gd(III)-HBP. Regional function was assessed using the DANTE tagging sequence with equally 
spaced bright and dark bands resulting in a magnetisation modulation that can be approximated 
as sinusoidal meaning that the HARP processing methods developed as part of this thesis 
described in Chapter 5 can be used. Tagged imaged were acquired in a short axis slice through 
the approximate injection site with imaging parameters; resolution = 0.13×0.13×1mm; TE = 
1.7ms; tag spacing = 0.3mm; and TR = 5ms that in a typical RR interval of 110ms allowed for 20 
cine frames. Tagged imaged were analysed using the HARP toolbox and were reconstructed with 
identical bandpass filtering of the stimulated echoes. Strain tensors were calculated from the 
gradient deformation tensors calculated using a custom Matlab script and translated to 
cylindrical co-ordinates centred at the centre of the LV to produce circumferential and radial 
strains. 
 
7.2.2.4 Statistical tests 
All results are presented as mean value ± standard error. All data were tested for normality using 
the Kolmogorov-Smirnov test and significance values were calculated by one-way analysis of 
variance corrected for multiple comparisons using the Holm-Šídák method. In all cases a p-value 
of less than 0.05 was considered significant.  
 
7.2.3 Results 
Inversion recovery T1 weighted images were acquired pre-contrast and post-contrast (LGE). 
Representative images can be seen in Figure 7.11 for mice injected with PBS and PEG hydrogel. It 
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was theorised that the Gd(III) bound to the HBP cross linkers within the gel would provide T1 
contrast that would allow for biomaterial quantification. The pre contrast images however did 
not consistently show any visible enhancement in biomaterial injected regions in the PEG or PBS 
groups. As pre contrast images were found to provide no capability to detect the gadolinium 
doped hydrogel, this imaging sequence was removed from the protocol after day 1. The post 
contrast groups however consistently show regions of hyperenhancement. These 
hyerpenhanced regions could arise from two mechanisms. The first case is that the injected 
material has created a space within the myocardium and the Gd bolus injected via the IP route is 
occupying this volume. This would suggest that the gadolinium bound to the hydrogel and PEG is 
not providing sufficient T1 contrast for imaging. This could be caused by low concentrations of 
contrast during manufacture, immediate loss of material from the injection site or the volumes 
injected may be too small to effectively alter the T1 of surrounding tissue. The second case 
would be that the Gd contrast bolus is occupying tissue damaged by the engraftment procedure. 
An example of the second case is given by the example given in Figure 7.11B. Here the hydrogel 
injection has damaged the myocardium. This is visually different to the majority of the PEG 
injection images in that it has a clearly defined infarct region and crucially the enhanced region 
develops over time to show characteristics of infarcted myocardium such as wall thinning and 
reduced contraction. This is an isolated case and the remaining PEG gel injections (n=7) do not 
exhibit this clear enhancement or remodelling over time suggesting that they are not 
undergoing the same degree of damage from engraftment. The visibility of enhancement up to 
14 days in the representative PEG animal shown in Figure 7.11A, without adverse myocardial 
remodelling, indicates that the space occupied by the hydrogel is visible and better retained 
than the PBS injection over time. 
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Figure 7.11 Representative LGE images for mice that received the PBS and PEG with CSC 
injections. (A) Shows representative PBS and PEG injected animals. The post contrast images 
show regions of hyperenhancement in both at day 1 and these diminish over time- although 
hyperenhancement in the PEG appears to be better defined. (B) Shows a noteworthy case where 
the injection appeared to induce an inferoseptal infarct that persisted through time and 
produced myocardial remodelling and wall thinning by day 14. The regional function in this 
enhanced tissue is assessed below. 
Global function was assessed using cine MRI and quantified by left ventricular ejection fraction 
(LVEF), these results are shown in Figure 7.12. No significant differences were found over 14 
days for either the PEG hydrogel or the PBS injections. This is a positive result suggesting that 
injections of this biomaterial are mechanically comparable to PBS injections. Despite the single 
instance of major damage shown in Figure 7.11B, the overall trend for the developed 
intramyocardial injection protocol induces no global function change. The PBS injections showed 
little variation with time with a low of 68±3% at day 7 and a high of 70±4% at day 1. The PEG 
group was more variable with a low of 62±2% at 14-days post engraftment but this was that 
significantly different from the day 7 where ejection fraction was measured to be highest at 
71±4%.  
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Quantification of the representative LGE images shown in Figure 7.11 are shown in Figure 7.12. 
These images were quantified by the same semi-automated methods as used for quantification 
of myocardial scarring but with no assumptions about blocked coronary arteries allowing 
quantification of all hyperenhanced regions. Here, increased volumes of gadolinium 
enhancement are given as a measure of retention of the injected material. The PBS injected 
animals showed little variation in enhancement and no significant variation with time with 
enhancement of around 3-4% of the LV volume. The PEG injected animals however had a larger 
volume of enhancement on day 1 of 8.4±3.4% decreasing to 4.0±1.4% on day 7 and dropping to 
3.4±0.7% on day 14. This may indicate better retention of biomaterial at day 1 and day 7 before 
dropping to PBS levels at day 14. Although this trend is promising it did not reach statistical 
significance and observing the plotted data in Figure 7.12 the averages may be partially affected 
by outliers. 
 
Figure 7.12 Results of CMR assessment of PEG hydrogel vs PBS. LVEF is not significantly different 
over 14 days for either PBS of PEG injections. Red markers indicate the animal where the LV was 
damaged during engraftment (Figure 7.11B). Regional enhancement appears higher in the PEG 
group at day 1 indicating better retention of material but does not reach statistical significance 
and may be affected by outliers.  
BLI showing the retention and viability of cells within engrafted hearts are shown in Figure 7.13. 
Representative BLI data is shown in Figure 7.13A showing the BLI signal is largely localised to the 
left-side thorax suggesting that the majority of cells are retained within the region of the heart. 
This could mean that the cells have successfully grafted to the myocardium or the injection has 
leaked into the pericardial space or both. However, having the signal clearly localised to the 
heart is a promising sign for retention of injected material. Figure 7.13B quantifies the 
bioluminescence to assess the cell retention within each group with results presented as mean 
counts ± standard deviation. Relative to the BLI signal at day 0 the PEG gels express higher 
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bioluminescence relative to PBS at day 3 (p = 0.0028) where there is a 6.5x higher BLI signal for 
the PEG injected group relative to PBS. This suggests that a higher proportion of the cells that 
were viable at engraftment are retained over time in the PEG hydrogel relative to the PBS. 
 
Figure 7.13 BLI results comparing PBS and PEG (A) representative images showing the 
bioluminescent signal from CSCs suspended in PEG gel or PBS at 0, 1, 3, 7 and 14 days. Figure 
reproduced with permission from Speidel et al. Unpublished. 
Results from regional function assessment are shown in Figure 7.14. For each segment of 
myocardium, the circumferential strain for both PBS and PEG injections are plotted at 1,7 and 14 
days with the injection site region and neighbouring regions displayed in groups.  
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Figure 7.14 Regional circumferential strain (𝐸𝑐𝑐) assessment using SPAMM cine MRI analysed 
using HARP for PEG and PBS cell suspension at 1, 7 and 14 days post engraftment to healthy 
mice. The injection site, neighbouring regions and remote regions are shown separately to help 
identify the segments of myocardium that should be affected by the presence of the engrafted 
PBS/PEG. 
No significant changes were observed between the two groups in any regions. Despite the lack 
of statistical significance some observations can be made about the mean data trends. The peak 
strain- occurring at the lowest point on the strain curves, appears to be consistently lower at day 
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1 in the PEG group relative to the PBS group suggesting a smaller contraction in this group at 24 
hours. This relative difference appears to diminish at later time points with the two curves taking 
on very similar shapes by 14 days. The PBS (blue) curves appear to be consistent in time, with 
similar shapes and peaks in injected and neighbouring segments suggesting that the PBS 
injection has had minimal effect on contraction as would be expected. The variation in the PEG 
group strain curves over time shows some level of disruption to normal contraction following 
engraftment. The transient nature of this disruption can be seen by the return of the PEG strain 
curves to more closely match the PBS injections by 14 days. This return to normal function could 
be attributed to either the degradation of the PEG gel or the heart adapting to the presence of 
the material.  
Regional function information from tagging can be applied to the problem presented above 
where we are uncertain whether myocardial enhancement in LGE images are due to tissue 
damage or hydrogel accumulation. In Figure 7.15 shows the strain curves in the infarcted 
posterior region of myocardium for the same mouse shown in Figure 7.11B. The magnitude of 
the strain can be seen to be consistently lower in the damaged tissue relative to the mean strain 
curves for the PEG or PBS injections.  
 
Figure 7.15 Tagging results including the infarcted animal shown in Figure 7.11B (green). Strain 
curves are shown for the posterior region where LGE images (Figure 7.11B) indicate a region of 
tissue damage and remodelling. Strain was found to be lower than the mean for that group 
throughout the cardiac cycle suggesting the regional function imaging is sensitive to the 
presence of this tissue damage.  
The abnormal strain values observed in the damaged myocardium (Figure 7.15), suggest that the 
presence of hyperenhancement in the LGE images can be attributed to either the presence of 
hydrogel or regions of tissue damage based on this regional assessment technique. In cases 
where hyperenhancement is present but the tissue shows no dysfunction the enhancement is 
probably hydrogel. When the hyperenhancement coincides with reduced strain it may be due to 
tissue damage. 
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7.2.4 Discussion 
The extensive in-vitro experiments performed to establish and optimise the mechanical 
characteristics and tailor the degradation profile of this PEG hydrogel makes it an exciting 
candidate for cardiac regeneration therapy. This study has shown that the majority of its in-vitro 
characteristics have carried through to the in-vivo case. The key in-vitro experiments aimed to 
optimise mechanical properties, cell retention and MRI visibility. This study has investigated 
each of these optimisations in-vivo. 
Preliminary rheology experiments identified optimal proportions of HBP and DT crosslinking to 
produce a hydrogel with similar mechanical stiffness to the mouse heart. The objective of this 
was to minimise adverse effects following engraftment. The beneficial effect of mechanical 
support provided by an engrafted biomaterial following infarction has been well established as 
discussed in 7.2.1. The benefit provided by this support will be optimal when the stiffness of the 
supporting material is matched to the stiffness of the surrounding tissue and the tissue it is 
intended to replace. The injection of the mechanically matched biomaterial was found to have 
no significant effect on regional contraction at the injection site or neighbouring segments at up 
to 14-days post engraftment to healthy mice. This is evidence that the hydrogel is compatible 
with supporting heart function and is unlikely to be detrimental to contraction when 
transplanted as a therapeutic. This is a vital characteristic for a successful biomaterial for cardiac 
regeneration. 
One of the most common criticisms of cardiac cell therapy studies is the low retention of cells 
following engraftment, this is a major limiting factor to their potential as a therapeutic. The 
retention of viable CSCs was shown to be significantly higher in the PEG hydrogel at 3 days post 
engraftment, relative to the same cells in PBS suspension. This increased retention will give the 
transplanted CSCs a greater chance of providing a therapeutic benefit. The increased retention is 
only significant at 3 days, meaning that this increased retention is relatively short lived. There is 
evidence however that the most beneficial effects of transplanted cells are from paracrine 
factors and not from full integration of transplant cells and replacement of lost tissue. These 
paracrine effects will be most beneficial in the first days following infarction. An important 
caveat to the increased cell viability is that this may not be the case in myocardial infarction. The 
hostile cellular environment following infarction due to factors such as inflammation and fibrosis 
are likely to limit the lifetime of transplanted cells. Additionally, the matched mechanical 
properties of the hydrogel will no longer be true in highly fibrotic scar tissue meaning that the 
time from infarction to engraftment will be an important factor. The PEG gel has been shown to 
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increase retention in the healthy myocardium but a future study would be required to 
investigate its capacity to prolong cell viability in the infarcted myocardium.  
The introduction of chelated Gd(III) to the hydrogel was intended to provide MRI visibility to 
enable tracking of the biomaterial retention. In combination with the BLI for tracking the 
encapsulated cell retention and viability this would provide a comprehensive non-invasive 
technique for tracking the retention of the therapy with high spatial resolution. Unfortunately, 
inversion recovery imaging was not able to delineate the Gd doped biomaterial from the normal 
myocardium. The most likely reason for this that the Gd was unable to effectively alter T1 of 
surrounding tissue. Low concentration of Gd ions in the gel or the tiny volumes injected may be 
the cause of this. A potential solution is to increase the Gd concentration within the gel, the 
alternative of injecting more may be damaging to heart tissue. An external Gd bolus via IP 
injection was able to detect regions of myocardial enhancement. As discussed above this is likely 
to be accumulating in space occupied by the hydrogel providing an alternative means of 
detection. However, when applied as a therapeutic this LGE approach to locating the biomaterial 
will be unable to differentiate between biomaterial and myocardial scarring. Alternative 
techniques are therefore required to locate the biomaterial in-vivo using MRI. T1 mapping in 
combination with ECV mapping may be a possible solution. A T1 map of tissue before and after 
the IP Gd injection will provide information about where Gd accumulates and the fraction of 
space it occupies within each pixel. This technique is discussed in more detail and implemented 
for this purpose in the following section (7.3). 
This study therefore has demonstrated the safety of a PEG hydrogel crosslinked by 50/50 dithiol 
and HBP/Gd(III) as a therapeutic cell-loaded biomaterial for injection into the heart. The 
hydrogel was shown to improve cell retention and viability without have a detrimental effect on 
cardiac function. In this study the role of imaging in establishing the safety of transplanted 
material is demonstrated. The MRI methodologies implemented here are directly translatable to 
investigating clinical cardiac tissue engineering and their use in future clinical studies would be a 
powerful tool for validation of safety. PEG is an FDA approved biomaterial and further 
development of hydrogels based on this synthetic polymer has significant clinical potential.306 
The next step in development of the PEG hydrogel platform discussed here would be to 
investigate therapeutic benefits in a mouse model of myocardial infarction. It is necessary to 
demonstrate that the improved cell retention and minimal functional impact are not limited to 
healthy hearts.  
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7.2.5 Key results 
 PEG gel retains viable CSCs better than PBS following intramyocardial engraftment 
 Established ultrasound guided injection protocol for biomaterial delivery 
 Multiparametric approach using regional function and LGE can attribute enhancement 
to damaged tissue or biomaterial retention  
 Significantly, PEG gel has no effect on regional function relative to PBS indicating well 
matched mechanical properties and a suitable delivery platform for cells 
  
266 
 
7.3 MRI measurements of extracellular, global and 
regional function changes following alginate 
microspheres engrafted to the infarcted myocardium   
 
7.3.1 Introduction 
A major limitation of injectable polymer hydrogels such as the functionalised PEG based 
hydrogel (7.2) is that structurally hydrogels are two component systems. They are composed of 
polymer chains and a cross linking reagent. The result is that for the biomaterial to remain 
injectable the cross-linking process must be only partially complete and the hydrogel remaining 
aqueous until the injection is complete and ideally solidifying in-situ. This means that there is 
significant uncertainty about the mechanical properties of the material immediately following 
injection. If an injection has not solidified sufficiently, it is likely to be immediately displaced by 
the beating heart. This disperses the material and negates the advantage of encapsulating cells 
within the hydrogel. Conversely if the material has solidified too much it will block the syringe 
and prevent engraftment, requiring another engraftment procedure. An alternative to this 
approach is to pre-form the biomaterial in the form of microspheres that are small enough to 
remain injectable while maintaining the beneficial effects of the scaffold. 
Microspheres, are small spheres or beads, typically composed of polymer compounds such as 
alginate or PEG on the order of micrometres. As regenerative structures, microspheres are 
appealing due to their relatively simple fabrication processes, the ability to create multiple 
functional ‘shells’ within them and several advantages associated with their discrete nature.307 
These points will be discussed further in the following section. This study aimed to investigate 
the therapeutic efficacy of macrophages encapsulated in alginate microspheres in myocardial 
infarction. The study aimed to combine all previously developed imaging techniques such as 
HARP and DENSE to establish MRI and BLI imaging protocols for assessing cell and biomaterial 
retention as well as global and regional heart function.  
Microspheres can be manufactured from a single type or combinations of natural and synthetic 
polymers. Various techniques are able to induce the polymer to form spherical forms of various 
sizes. Microspheres have previously been fabricated through electrospraying, phase separation, 
emulsion and cryogenic atomisation techniques.308-311 These methods aim to separate the 
unlinked hydrogel solution into elements that are smaller than the droplets they naturally form 
to the surface tension of the liquid. These smaller droplets form spherical shapes under surface 
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tension and can then be solidified by immersion in cross-linking solution. The size of the 
microsphere is determined by factors such as the concentration of the polymer solution, the 
cross-linker used and the size of the droplets. The concentration of the polymer solution is the 
factor that has the greatest influence on microsphere size.312 Higher concentrations of polymer 
increase the surface tension of the liquid resulting in higher viscosity and larger droplets. 
The discrete nature of microspheres offers several advantages over regular single body 
biomaterials applied to cardiac regeneration. Firstly, the packing of the spheres will always leave 
an interstitial space between adjacent spheres. This space offers room for surrounding 
regenerating tissues to infiltrate the microsphere mass.313 This void also offers highly permissive 
space for the diffusion of bioactive molecules secreted from cells encapsulated with the spheres, 
enabling them to reach and effect surrounding host tissue. Discrete spheres also offer a level of 
control by making it simple to combine multiple microspheres within a treatment with each 
tailored to different functions. This simplifies the process of manufacturing a biomaterial that 
possesses all the desired properties. Producing one biomaterial that is able to support multiple 
cell types and predictably release a range of growth factors and drugs would be a complex task 
whereas, producing a single type of microsphere to possess a certain property is comparatively 
simple. It is then possible to combine different types of microsphere within an injection or 
engraftment that is then a combination of the desired properties.  
Microspheres are most commonly used as a controlled drug release platform. The relatively 
predictable degradation from hydrolytic reactions in vivo make microspheres ideal for this 
purpose. As the microsphere is broken down, the encapsulated drug or active molecules are 
released into the surrounding space where they can produce local effects or disperse 
throughout the body.314 Microspheres have previously been used to deliver vaccines, insulin and 
bioactive glass to regions of the body not typically assessable.315-317 For example, orally 
administered microspheres are able to deliver bioactive molecules to the highly permissive gut 
wall. The advantage of encapsulating these drugs within microspheres is that their release can 
be tailored to the needs of an application. Molecules can be released at a constant rate, or in a 
pulsatile fashion dependent on the degradation profile of the sphere. The encapsulation of these 
molecules within the microspheres also protects them from being absorbed or cleared by the 
immune system.318  
When cells are encapsulated within microspheres the encapsulation protects the cells from 
hostile cellular processes such as the inflammation in tissue following myocardial infarction 
during the remodelling phase. To aid cell retention following myocardial transplant it is possible 
to manufacture a microstructure within the microspheres that is conducive to cell growth by 
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making it similar to the extracellular matrix. Using natural polymers such as alginate or collagen 
produce internal microstructure that is similar to the ECM and promotes cell growth and 
survival. When cell-loaded microspheres are transplanted to the infarcted myocardium, the 
principle mechanism through which they interact with the host tissue will be through paracrine 
signalling. The cells secrete cytokines and other bioactive molecules that are conducive to cell 
survival and have been shown to be beneficial following myocardial infarction. As discussed in 
chapter 1, paracrine signalling is thought to be the most beneficial aspect of transplanting cells 
to the infarcted heart. Encapsulating cells within protective microspheres is thought to aid cell 
retention and viability therefore extending the duration of paracrine factor release.  
Microsphere encapsulated cells have been used previously for therapy in myocardial infarction. 
Yu et al. (2010) produced calcium alginate microspheres encapsulating human mesenchymal 
stem cells (hMSCs) and engrafted them to the rat heart by ultrasound guided injection at 1-week 
post infarction.319 Echocardiography assessment at 10 weeks post injection showed the alginate 
spheres retained LV shape and reduced adverse remodelling effects. Compared to cells 
suspended in PBS the microspheres enhanced survival and retention of encapsulated cells within 
the heart. Cell loaded microspheres have also been demonstrated as a therapy in larger animals 
with MRI for assessment of efficacy and microsphere retention. Gomez-Mauricio et al. (2013) 
encapsulated adipose derived stem cells within alginate microspheres coated with 
superparamagnetic iron oxide nanoparticles (SPIONs).320 The authors injected these 
microspheres into the myocardium of the porcine heart during surgical ligation of the LAD. MRI 
assessment was performed at up to 30 days later to measure global heart function, scar size and 
T2*. The SPION nanoparticles allowed in vivo monitoring of microsphere retention by regions of 
hypointensity and microspheres were shown to be well retained. LVEF showed no significant 
change with the authors suggesting low cell density within the microspheres was the cause.  
The larger hearts of rats and pigs make them more appealing to investigations of myocardial 
regeneration due to the relative simplicity of ligation surgery and engraftment, and their 
similarity to the human heart. However, regeneration studies in mice are valuable for the 
availability of genetically modified mice that can accurately mimic human disease, for example 
the mouse model of β thalassemia discussed in chapter 3. The only previous example of 
intramyocardial injection of alginate microspheres into a mouse model of myocardial infarction 
was performed by Lee et al. (2013).321 The authors created an alginate/hydrogel hybrid for the 
controlled release of heat shock proteins as a therapy for MI. The sustained release of the 
proteins due to the microporous microspheres was shown to improve ejection fraction, reduced 
diastolic dysfunction and increase the pressure produced by the heart during contraction. 
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Alginate microspheres were produced using an electrostatic encapsulator (Nisco, Zurich, SUI). 
This system is illustrated in Figure 7.16. An electrostatic potential is applied between a narrow 
nozzle (<1mm) and the surface the cross linking solution creating an electric field. This E field 
induces a charge at the surface of the liquid proportional to the square of the applied voltage.322 
This charge interferes with intramolecular attraction, reducing surface tension and causes 
droplets to fall under gravity in much smaller particles than they would without the electric field. 
 
Figure 7.16 Electrostatic encapsulator. A syringe pump pumps sodium alginate solution through 
a narrow nozzle suspended above a cross-linking solution bath. The electrostatic potential 
reduces the surface tension of the liquid and causes it to fall under gravity in small droplets. 
These droplets fall into the cross-linking solution and solidify. 
Luciferase transduced resident macrophages were chosen for encapsulation due in part to their 
availability, but also their regenerative potential and relative robustness compared to stem cells 
lines.323 Macrophages are known to control inflammation by secreting a variety of cytokines, 
pro-inflammatory and trophic mediators that beneficially modulate the inflammatory 
response.324 Macrophages have also been shown to clear apoptotic leukocytes to limit the 
extent of inflammatory injury and attenuate progressive collateral tissue damage from extended 
inflammation.325 Since the primary mechanism for macrophage regeneration is through release 
of paracrine factors, they make an ideal candidate for microsphere encapsulation to increase 
retention and survival following engraftment to prolong and localise the release of these factors 
in the heart. 
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7.3.2 Methods 
7.3.2.1 Pilot study 
An initial pilot study was performed in which 4 mice received ultrasound guided injections of 
microspheres without cell loading. These microspheres were fabricated using what became the 
final fabrication protocol described below. The aim of this pilot study group was to confirm that 
the procedure could be performed safely, to practise the fabrication and engraftment procedure 
and to establish the final imaging protocols. Optimised imaging protocols included establishing 
the ECVF mapping technique using segmented k-space acquisitions, determining suitable values 
for the SPAMM and DENSE acquisitions to provide sufficient spatial encoding with sufficient SNR 
and timing the full imaging procedure to ensure all animals could be imaged within the 
experimental timeframe. 
The result of this study was that all mice survived and were engrafted with the microspheres 
described below without macrophage encapsulation. They were imaged using several different 
protocols while seeking optimisation, meaning that the pilot study data cannot be included with 
the main study data due to differences in acquisition technique. This pilot study resulted in an 
optimised protocol developed for engraftment and imaging that is described below in the 
context of the full study. 
 
7.3.2.2 Cell preparation and microsphere encapsulation 
Macrophages were cultured by Dr Stephen Patrick (University College London). Cells were 
harvested no more than 1 hour before encapsulation and no more than 4 hours before 
engraftment. Cells were lifted from the culture flask by scraping and the culture medium and 
cells separated by centrifugation to form a macrophage pellet. The cells were then resuspended 
in 2ml 1% sodium alginate PBS solution using pipette agitation. 
Encapsulation was then performed using an electrostatic encapsulation system (Nisco, Zurich, 
SUI) with an alginate flow rate of 0.5ml/min, potential difference of 9KV and a cross-linking 
solution of 100mM calcium chloride solution. Encapsulation and microsphere size was then 
confirmed by optical microscopy. A sample of the produced microspheres were taken into a 
syringe and passed through a 27G needle to confirm compatibility with injection, shape and cell 
loading of microspheres. Examples of these images are shown in Figure 7.17. The microspheres 
were found to take on approximately spherical shapes and were well seeded with macrophage 
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cells. However, after passing the microspheres through a 27G needle there was reduced sphere 
density within the solution suggesting a fraction of larger spheres were blocking the needle. 
 
Figure 7.17 Visual inspection of encapsulated microspheres. Cells are visible within encapsulated 
microspheres with variable densities. Spheres have roughly spherical shapes and are shown to 
pass through a 27G needle, although with some loss of spheres. Images shown at 20x 
magnification. 
The viability of the encapsulated macrophages in each batch of microspheres was tested after 
fabrication and prior to engraftment. By taking a 100μL sub sample of the microsphere solution 
and adding 20μL luciferase to induce light bioluminescent emission in viable cells. An example 
BLI cell viability test is shown in Figure 7.18. 
 
Figure 7.18 Example BLI acquisition showing that the macrophages remain viable after the 
encapsulation process and are alive immediately prior to  engraftment to the mouse 
myocardium.  
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Identically cultured and harvested macrophage pellets were also resuspended in 0.9% saline. 
The cell loaded PBS and the cell loaded microsphere solutions were manufactured on the day of 
engraftment and stored on ice until ready for injection. 
 
7.3.2.3 Myocardial infarction and engraftment 
In total MI was induced in 32 C57/BL/6 wild type mice using the permanent suture ligation 
technique described in 1.2.3.4. During the open chest phase of the suture ligation 
intramyocardial injections of 20μL were delivered by manually under magnification using a 27G 
needle and low dead space syringe. One group of animals (N=8) received injections of saline 
only, a second group (N=8) received injections of saline + cells, the third group (N=8) received 
injections of microspheres without macrophages and the final group (N=8) received injections of 
macrophage encapsulated microspheres. Very low survival rates were observed following this 
surgery. From the saline group 3/8 mice survived up to the first MRI imaging point at 1-week 
post infarction and engraftment surgery. Survival in other groups was lower, in the cell group 
2/8 mice survived, from the microsphere group 0/8 animals survived and from the cell 
encapsulating microsphere group 2/8 survived. The success of engraftment in the initial pilot 
study (7.3.2.1) suggests that the cause of mortality here was related to the infarction surgery. A 
full discussion of potential causes for this extremely poor outcome are hypothesised in the 
discussion of this section. The consequence of this is that there was a fundamental lack of 
statistical significance when comparing groups. In the results section trends will be observed but 
statistical testing is inappropriate when investigating such small populations.  
 
7.3.2.4 Imaging 
This study utilised two imaging modalities. BLI was performed regularly to assess the survival 
and retention of macrophages following engraftment and MRI was performed to assess 
myocardial structure and global and regional function.  
BLI imaging was performed at 0, 2, 5 and 9 days post engraftment. Mice were anaesthetised 
under 2% isoflurane in oxygen and received 20μL intraperitoneal injections of luciferin. BLI was 
then performed and an identical square region of interest placed over the left thorax of each 
mouse to quantify the bioluminescent radiance from cells retained in the heart.  
MRI was performed at 7 and 14 days post infarction and engraftment. The first scan performed 
was a segmented k-space T1 look locker acquisition this scan was performed to quantify native 
T1 of myocardium to allow calculation of the extracellular volume fraction (7.3.2.5). A Gd-DTPA 
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bolus was then delivered via IP line to the mouse in a standard LGE protocol. While the Gd was 
circulating a cine scan was performed to measure global function in the whole heart. A T1 scout 
image was then acquired, followed by a full resolution LGE acquisition to locate regions of 
hyperenhancement. A second segmented k-space T1 look locker acquisition was then acquired 
to quantify the T1 in tissue with Gd uptake in the interstitial space. Next a SPAMM tagging 
sequence was acquired in the x and y directions with a pixel size of 0.13×0.13×1mm, TE = 1.5ms, 
TR = 3.8ms, 20 cine frames and 10 averages. The tagging frequency for the SPAMM acquisition 
was set to 𝐾𝑒 = 1.49cycles/mm as this was found to be optimal in the development of the 
SPAMM/HARP sequence. This was followed by a second regional function assessment with 
DENSE imaging. DENSE images were acquired with encoding in the x and y directions with a pixel 
size of 0.2×0.2×1mm, TE = 2.2ms, TR = 5ms, 20 cine frames and 15 averages. The artefact echo 
removal technique of choice was through plane dephasing with a strength of 𝐾𝑑 = 1.27 
cycles/mm and an in plane encoding strength of 𝐾𝑒 = 1.7cycles/mm. Cine and LGE image 
analysis was performed in segment, T1 mapping, ECVF, HARP and DENSE reconstruction and 
analysis was performed in Matlab as described previously. 
 
7.3.2.5 ECVF mapping 
Structural changes such as diffuse or focal fibrosis and oedema are known to occur in myocardial 
infarction and can be quantified by changes to the extracellular volume fraction.326 Measuring 
ECVF requires acquisition of quantitative T1 maps of the heart before and after the application 
of a gadolinium contrast agent. The ECVF is measured as the percent of tissue comprised of 
extracellular space. Since the contrast agent is known to only occupy the extracellular space we 
can make measurements of pre and post contrast T1 to assess the fraction of each pixel 
containing gadolinium/ extracellular matrix. ECV was introduced in this study to aid in the 
quantification of myocardial infarction. The regenerative paracrine properties of the 
macrophages were hypothesised to mediate the inflammation and resulting apoptosis following 
myocardial infarction. LGE is used to quantify infarct size thanks to its high resolution and 
positive contrast, but it is not quantitative of the tissue within the infarct due to variability in 
gadolinium bolus dosage, infarct size and signal intensity. ECVF mapping is a reliable quantitative 
method to assess the severity of infarcted tissue that is independent of these parameters.  
The ECV is estimated by acquiring in the dynamic steady state phase following contrast uptake in 
the extracellular matrix. At this point post contrast there is a constant exchange between tissue 
and blood which is faster than the clearance of contrast from the blood. The ECVF is calculated 
from T1 values using Equation 7.1. 
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 𝐸𝐶𝑉𝐹 = (1 − ℎ𝑒𝑚𝑎𝑐𝑟𝑖𝑡)
(
1
𝑇1𝑚𝑦𝑜−𝑝𝑜𝑠𝑡
−
1
𝑇1𝑚𝑦𝑜−𝑝𝑟𝑒
)
(
1
𝑇1𝑏𝑙𝑜𝑜𝑑−𝑝𝑜𝑠𝑡
−
1
𝑇1𝑏𝑙𝑜𝑜𝑑−𝑝𝑟𝑒
)
 Equation 7.1 
 
Where hematocrit is the proportion by volume of the red blood cells within the blood, this value 
is unchanged in MI and is assigned a standard value of 44%.327 The result of this calculation is a 
pixel wise map of ECVF with values in the range of 0 to 1.  Examples from a healthy mouse are 
shown in Figure 7.19. 
 
Figure 7.19 Example ECVF calculation from pre and post contrast T1 maps. In a healthy mouse 
heart, the ECVF is circumferentially uniform and in the region of around 0.2. It is important that 
the mouse does not move between T1 measurements pre and post contrast to prevent partial 
volume effects between maps. 
 
7.3.3 Results 
7.3.3.1 Cell retention 
Bioluminescence imaging was used to track the retention of macrophages and their viability over 
the course of 9 days. The results are shown in Figure 7.20. Note that the scale in this figure is a 
Log10 scale, this was necessary to make the microspheres bioluminescence signal visible since 
the BLI signal was much greater in the saline injections. Initial BLI radiance at day 0 for the saline 
+ cells group was 1164±37.8×102 counts/s/cm2/sr while the microspheres +cells group began at 
1734±941 counts/s/cm2/sr.  
Since the low BLI signal exists at in the microsphere group from day zero this is not a result of 
lower cell viability in the microspheres, the low signal indicates that the intial engraftment of 
cells to the infarct was much lower than the cells in saline. There are two possible reasons for 
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this 1) the cell density was much higher in the saline injections or 2) the microspheres were not 
being deposited in the heart and were become immediately displaced.  
 
Figure 7.20 Bioluminescence from macrophages suspended in saline was higher than the signal 
measured from the macrophages encapsulated in microsphere. This is likely due to a lower cell 
density within the microsphere relative the saline injections. 
 
7.3.3.2 Infarct quantification 
The quantification of myocardial infarction took two approaches. First the LGE images were used 
to quantify the volume of the hyperenhanced scar region as a fraction of LV myocardium as 
performed is previous studies. Secondly the ECVF maps were used to assess the internal severity 
of these regions of hyperenhancement. Representative LGE and ECVF images from each group at 
7 and 14 days can be seen in Figure 7.21. 
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Figure 7.21 Representative LGE image and ECV maps. For each time point and group, it is clear 
that regions of increased signal intensity in LGE imaging correlate with regions of increased 
ECVF. The key advantage of using both of these techniques is that LGE provide high resolution 
quantification of scare size and ECVF reveals details about the underlying tissue structure. 
The LGE and ECV maps show good agreement when identifying regions of myocardial infarction. 
Scar size from LGE images was quantified using the semi-automated EWA method described 
previously (Chapter 2) and these results are presented in Figure 7.22. The volume of LV scar in 
each animal is plotted at 7 and 14 days to show the evolution of the infarction with time. 
Interestingly the saline group without cells showed a decrease in scar size from 7.2±4.5%LV at 7 
days to 1.8±0.4%LV at 14 days. The saline with cells group showed a moderate increase in scar 
volume from 12.0±10.6%LV to 19.8±3.4%. This increase however is visibly skewed by one animal 
who rapidly develops infarction over the measurement period. This is an interesting example 
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and the other measurements in ECV, LVEF and CO all show this same animal rapidly 
deteriorating. It is worth noting however that this animal skews the saline + cells group due to 
the small sample population. The mice treated with the encapsulated macrophages showed no 
overall change with a scar volume of 12.8±7.7%LV at 7 days and 11.5±5.3%LV at 14 days. Also 
shown in Figure 7.22 is the quantification of ECVF in infarcted and remote tissue from 7 to 14 
days. The overall trend observed here shows an increase in ECVF in infarcted tissue from 7 to 14 
days in the macrophage and saline treated group (0.34±0.09 to 0.64±0.08) and the microsphere 
encapsulated macrophage group (0.38±0.10 to 0.68±0.12) with no real change in the saline only 
group (0.26±0.01 to 0.24±0.02). Remote tissue remained largely unchanged overall in all groups. 
The consistent measurement of ECVF in remote tissue at 7 and 14 days in all groups is an 
encouraging sign that the ECVF technique is reproducible. 
 
Figure 7.22 Quantification of LGE scar volume and ECVF in infarcted and remote tissue. Each line 
represents an animal over time and colour indicates the experimental group. Infarct severity 
appeared to increase in macrophage treated groups although overall scar volume was consistent 
for most of these animals. For animal showing rapid increase in LGE from 7-14 days (*) contrast 
did not enter system in this mouse producing an artifactual increase. 
This increase in infarcted tissue ECVF over time suggests that the infarct is still developing and 
that cardiac remodelling along with inflammatory processes, are causing apoptosis in myocardial 
tissue resulting in increased ECVF. The increasing ECVF of the macrophage treated group is the 
opposite of what was hypothesised. In the case of the encapsulated macrophages it was 
observed from the BLI results that very few macrophages were retained within the heart. Low 
retention could be a possible explanation for this group, low cells counts are unlikely to be able 
to produce the beneficial cytokines and cofactors in sufficient quantities to modulate the 
inflammatory response.  
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7.3.3.3 Global heart function 
Global heart function measured by LVEF and cardiac output is shown in Figure 7.23. Overall, 
LVEF appears to be maintained over the imaging period, this is despite increases in ECVF shown 
above for the macrophage treated groups. The saline treated group maintained the highest LVEF 
over the imaging period (61.3±5.5% - 63.0±2.4%). The saline treated group suffered a large drop 
overall (61.1±4.8% - 44.3±7.3%), although this is heavily affected by the rapidly deteriorating 
animal that also showed increased scar volume and ECVF. The encapsulated macrophage group 
had consistently lower LVEF over the imaging period (45.8±16.3% – 44.4±13.3%).  
 
Figure 7.23 LVEF, cardiac output and end diastolic volume measurements. LVEF is most 
maintained between groups. CO recovers over time as the heart adapts to the remodelled 
myocardium. The principle mechanism by which CO is maintained is by expanded end diastolic 
volume. 
Cardiac output (CO) is another measure of global cardiac function. CO is the product of stroke 
volume and heart rate and quantifies the amount of blood pumped per minute. Maintaining 
cardiac output is important to maintain systemic blood flow requirements. There are four major 
factors determining CO and dysfunction in one typically leads to the modulation of the others to 
maintain the same output.328 Heart rate, contractility, preload and afterload are all variables in 
CO. The CO data presented in Figure 7.23 shows initially lowered CO in the cell + saline group 
and the encapsulated cell group (11.8±1.1 and 12.3±0.5 ml/min respectively) relative to the 
saline group where CO is maintained (13.3±0.4ml/min). After 14 days of cardiac remodelling the 
cell treated groups show that CO is adapting the presence of increased ECVF infarct severity and 
scar size with the CO increased to 13.5±0.6 ml/min in the saline + cells group and 
13.8±0.8ml/min in the microsphere group. Measurements of end systolic volume and heart rate 
appear unchanged overall but the end diastolic volume (Figure 7.23) is increased in the 
macrophage groups suggesting that the heart is increasing preload to account for lost function 
and maintain cardiac output.  
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7.3.3.4 Regional heart function 
This was the first study over the course of this project where both SPAMM and DENSE were 
developed to the point they could be compared. Figure 7.24 shows a comparison of the SPAMM 
and DENSE based measurements of regional circumferential strain in each segment of 
myocardium at day 7 and day 14. Along the vertical axis plots are ordered from injection site to 
neighbouring regions to remote regions, the horizontal axis indicated time and imaging 
technique used.  
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Figure 7.24 Comparison of regional circumferential strain measurements (Ecc) by SPAMM and 
DENSE. Each strain time curve shows the circumferential strain through the cardiac cycle in 6 
segments of heart tissue measured either using the SPAMM technique (chapter 5) or DENSE 
(chapter 6). Regions are separated in injections site, neighbouring and remote tissue to aid 
visualisation. 
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Overall the circumferential strain curves were of similar shapes when measured by SPAMM or 
DENSE. The small sample size results in comparatively large error bars compared to the previous 
functionalised hydrogel study (7.3). The denser temporal sampling in DENSE results in smoother 
curves which may provide subtler information about cardiac mechanics for example, the 
comparison between the anteroseptal region at 14 days shows delayed contraction in the 
microspheres group. This is easily visible in the DENSE dataset but appears obscured by lower 
spatial and temporal resolution in the SPAMM data. 
Figure 7.25 shows example regional assessment data from a single animal. This mouse is from 
the saline + cell group and was selected arbitrarily. The LGE image shows hyperenhancement in 
the lateral wall corresponding to a region of infarction, confirmed by ECVF mapping. The 
displacement fields show the 2D displacement of each pixel produced from both the 
SPAMM/HARP processed data and the DENSE dataset in the same slice. The higher density of 
displacement vectors in the SPAMM data is due to the higher resolution of the acquisition. 
However, the lower resolution of the displacement information in SPAMM is visible from the 
high degree of smoothness in the vector field. Conversely the DENSE data has lower acquisition 
resolution due to signal restraints but offers higher displacement resolution. This is visible in the 
circumferential strain data; the DENSE dataset is able to isolate 3 regions of reduced contraction 
within the infarct area. The SPAMM dataset however can resolve only a single broad area of 
dysfunction. Whether the added resolution of DENSE provides better information than the 
smoother SPAMM data is a question that is specific to application. The SPAMM data also 
identifies regions of reduced contraction in the septal wall which do not manifest themselves in 
the LGE of ECVF maps suggesting that this is the result of poorly tracked pixels. Since DENSE 
does not rely on pixel tracking in the post processing but encodes displacement within the 
measured signal DENSE is less susceptible to this kind of error. 
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Figure 7.25 Example images in the same mouse from SPAMM and DENSE. LGE and ECVF maps 
are provided for structural information. Both techniques identify the region of LGE 
hyperenhancement by enhanced strain in the lateral wall. However, SPAMMs information, 
although a better match to the LGE data in the lateral wall is lower resolution more prone to 
tissue tracking errors than DENSE. 
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To further compare the two techniques, the peak strain for each animal was measured and 
segments assigned to either infarct (anterior, anterolateral, inferolateral) or remote (inferior, 
inferoseptal, inferoseptal). These were then compared for each group at day 7 and day 14. The 
results are shown in Figure 7.26. 
In terms of measuring peak strain SPAMM and DENSE provide very similar relationships between 
groups. SPAMM and DENSE both give the same results when investigating which group has 
higher or lower strain. In terms of absolute values DENSE returns higher strain. This is likely due 
to the higher resolution strain information provided by DENSE. The raw displacement 
information is much coarser than the smooth, filtered HARP analysis technique.  The result is 
DENSE displacement maps have a higher displacement gradient at boundaries between 
neighbouring pixels that causes increased strain measurements. 
 
Figure 7.26 Comparison of peak strains in infarct tissue and remote tissue. HARP and DENSE 
provided similar results in terms of the relationships between groups but gave much higher strain 
magnitude relative to HARP.  
284 
 
Finally, to compare the two a correlation plot of peak circumferential strain measured by 
SPAMM and by DENSE is shown in Figure 7.27 along with a Bland-Altman analysis of peak strain. 
There was a no real correlation (R2 = 0.07) between HARP and DENSE measures of peak 
circumferential strain in this case. The Bland-Altman analysis shows an increasing difference with 
increasing average. This suggests that the similarities between the two techniques is poorest at 
high strain values. All of the points in the Bland Altman plot show positive differences which 
corresponds to the positive bias where strain values measured by DENSE are higher relative to 
SPAMM. 
 
Figure 7.27 Comparison of HARP and DENSE measurements of peak circumferential strain. The 
solid black line indicates the line fitted by least squares regression and the light grey represents 
the 1-1 line. Bland-Altman analysis showed increased differences at high strain peaks suggesting 
there is a magnitude dependence on the correlation. 
The lack of correlation between the two measures may be partly explained by the different 
resolutions of the strain information. The strain maps produced by SPAMM are convolved by the 
bandpass filter used in k-space to isolate the displacement encoded peak. This means that the 
relative displacement between neighbouring elements of tissue is smoothed, with the true pixel 
wise displacement masked by the poor resolution. The use of DENSE where full resolution pixel 
wise displacement is available produces maps where each pixel is measured independently from 
the surrounding tissue. The result of this is more variation in the displacements measured since 
each corner of the quadrilateral strain element can move independently.  
To validate the sensitivity of DENSE or HARP to regional dysfunction the circumferential strain in 
the infarct segments and the remote segments were compared to the ECVF in the infarct and 
remote segments. The results of this comparison are shown in Figure 7.28. The circumferential 
strain measurements made by HARP show no dependence on ECVF in the infarct or remote 
tissue. The DENSE measurements of strain show a relationship in the infarct zone, and no 
relationship in the remote tissue. The suggests that the ECVF changes present in the infarct 
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myocardium are creating regional variations in circumferential strain that DENSE regional 
imaging is sensitive to.  
 
Figure 7.28 Correlation of DENSE and HARP measurements of circumferential strain against ECVF 
measurements in the infarct and remote tissue. DENSE shows a higher sensitivity to the ECVF 
induced changes in circumferential strain in the infarcted myocardium. 
 
7.3.4 Discussion 
This study has investigated the engraftment of macrophages encapsulated within calcium 
alginate microspheres for regenerative therapy in the heart. Overall, the results showed no 
benefit to engrafting microspheres or macrophages in terms of cardiac function, myocardial scar 
size or scar evolution. The results from the surviving animals seems to suggest that injecting 
saline into the infarcted myocardium is more beneficial than delivering cells microspheres. The 
evidence for this conclusion is weak due to low sample populations. However, it may be best to 
consider the infarct and infarct + microsphere encapsulated macrophages as the same group 
since the retention of cells is very low in this group. The saline injection group consistently 
showed the smallest infarcts at 7 and 14 days- this may indicate mild infarctions rather than an 
effective therapy. The main problem with this study is the small sample sizes and the poor 
survival of animals following engraftment. The pilot study described in (7.3.2.1) showed survival 
in all animals following engraftment of identical microspheres. This pilot study used ultrasound 
guided injection to deliver the microspheres to the non-infarcted heart. For the full study the 
microspheres were engrafted using two modifications to the engraftment procedure 1) 
microspheres were delivered to the infarcted heart and 2) injections were performed by hand 
during surgery. The decision to inject by hand rather than using the ultrasound guidance was 
taken due to the difficulty in performing cardiac injection in the infarcted heart. The complex 
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infarct environment produces multiple reflective boundaries that can make resolving the 
myocardium difficult, especially during the early remodelling phase of MI. The decision to inject 
during the surgery was justified by providing the optimal conditions for the macrophages to 
provide a therapeutic effect, before the inflammatory response was triggered. These two 
decisions are likely to be the cause of the poor engraftment process. The engraftment of the 
microspheres to the myocardium at the same time as the induction of MI appears to place too 
much pressure on the heart at once and results in acute heart failure. Previous studies that have 
engrafted microspheres to the infarcted heart have allowed 7 days for the infarct to develop and 
cardiac remodelling to begin before performing the injection.319 Injections by hand were 
performed during surgery since this reduced the number of invasive procedures the mice would 
need to undergo. The problem with manual injections is that it relies heavily on the skill of the 
surgeon and the small dimensions of the mouse heart make the procedure extremely difficult. If 
this study were repeated, the engraftment procedure would more closely mimic the pilot study 
and previous published work by engrafting via ultrasound guidance and performing the 
engraftment after allowing the myocardium time to adapt to infarction. 
The discrete nature of microsphere although beneficial in many ways, has several consequences. 
Mechanically the behaviour of microspheres is less predictable than a single interconnected 
bolus of biomaterial. Additionally, the smaller that the microspheres are manufactured the more 
likely they are to become displaced following engraftment. A study by Teng et al. (2006) showed 
that injected microspheres are liable to become immediately displaced following intracardiac 
injection. This mechanical leakage could account for the lack of microsphere retention following 
injection shown by the BLI data. Key to the success of the microsphere approach is finding ways 
to increase this microsphere retention. Microsphere size and location of engraftment are likely 
to be important factors in optimising retention. Larger microsphere will be less likely to be 
displaced but will be harder to engraft. Some studies have taken the approach of engrafting a 
cluster of microspheres to the epicardium where they are unlikely to be affected by myocardial 
contraction but are also limited in their ability to regenerate transmural myocardium.  
Regional function was assessed by measuring the peak strain for each animal, this is the 
conventional way to summarise the strain-time curve with a single value and quantifies the 
maximum deformation. Whether this is the best value for this purpose is debatable, the area of 
the strain-time curve may offer a more complete value of contraction over the whole cardiac 
cycle. The lack or correlation in circumferential strain measurements in HARP and DENSE is 
interesting. Since they are measuring the same mechanical property of tissue it would be 
expected that a strong correlation would exist between them. Indeed, this has been 
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demonstrated in previous DENSE development papers, where they have compared the relatively 
new DENSE technique to the gold standard SPAMM and HARP methods.329 The most likely 
reasons for this variation are the spatial and displacement resolution of the acquisitions. The 
DENSE acquisition had a lower acquisition resolution compared to the SPAMM sequence since 
the additional SNR provided by larger pixels was required however it provided a higher 
displacement resolution since it does not require filtering in k-space that removes a large 
fraction of the spatial information. Observing the displacement field examples given in Figure 
7.25, the DENSE displacement field appears more physiological and a closer match to the 
expected motion paths compared to the SPAMM data. The smoothness of the SPAMM data 
leads to low resolution strain maps that are unable to reveal the finer details of the strain field 
that may be important in a repeated biomaterial experiment with higher samples sizes. Another 
important factor that may be affecting strain calculations is the masking applied to isolate 
displacement of the LV form the large artifactual displacements in the pulmonary cavity and 
blood pool. A binary mask is applied to separate these values, in the current processing pipeline 
these are drawn manually based on SPAMM and DENSE images. SPAMM and DENSE images are 
both poorly suited to isolating myocardial boundaries due to the presence of tag lines and low 
SNR respectively. It was not possible to apply the same mask due to differences in the sizes of 
the acquisitions. A solution to this that would be an important modification to future work 
comparing the sequences would be to acquire a standard cine image in the same slice 
orientation with the same dimensions as the SPAMM and DENSE acquisitions. This could be 
segmented to provide an independent mask for both acquisitions and remove this variability. 
To date, this experiment has utilised the largest fraction of the complete preclinical cardiac MRI 
assessment toolset developed over the course of this thesis. Global heart function was assessed 
with cine MRI, quantified by LVEF, CO and EDV. Regional heart structure was assessed using both 
LGE and ECVF mapping, the use of ECVF requires two T1 maps of the heart but these are not 
shown due to the more standardised nature of ECVF. Regional heart function was then assessed 
using both the advanced SPAMM and DENSE sequences I developed during this work. This study 
was intended to be a final exhibition of the imaging techniques developed.  
Despite the setbacks in this experiment microspheres are an exciting prospect for cardiac 
regeneration therapy. The versatility and theoretical reproducibility of this therapy is a key 
advantage compared to in-situ formed hydrogels. If this experiment were repeated the 
engraftment procedure would be refined as described above to enable a higher graft acceptance 
and DENSE would be chosen as the regional function measure of choice due to the higher 
resolution strain information it provides. Additional refinements to the microspheres could also 
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include the inclusion of additional bioactive molecules such as VEGF or HGF. Mechanical 
validation of the microspheres by rheology could also improve the therapy. The PEG hydrogel 
discussed in 7.3 was tuned to myocardial tissue and showed little mechanical impact on the 
contraction in these hearts. Forming this functionalised PEG hydrogel into microspheres may be 
the most promising regenerative biomaterial to take forward for further investigation. 
 
7.3.5 Key results 
 Poor surgical outcome from microsphere engraftment in myocardial infarction 
 DENSE shows a relationship to the degree of extracellular volume fraction in infarcted 
tissue and is more sensitive to this dysfunction than SPAMM 
 SPAMM and DENSE provide different information where SPAMM is susceptible to 
mistracked myocardium and DENSE data suffers from image noise 
 
 
7.4 Summary 
This chapter has described 3 of the experiments I performed over the course of this thesis to 
validate the developing MRI imaging toolset. Part 1 described the imaging of scaffoldless 
fibroblast cell sheets in myocardial infarction. Results showed improved LVEF and reduced scar 
size in treated hearts. Basic regional assessment tools were used to show contractile 
improvements in the border zone of infarcts.  
In part 2 I discuss a collaborative project in which I assessed the safety of a highly optimised 
synthetic hydrogel for CSC transplant. This study also introduced the field of injectable 
biomaterials and the developed protocol for ultrasound guided intramyocardial injection. 
Despite covalently bound contrast agents the hydrogel could not be visualised. However, the 
hydrogel was shown to increase in-vivo cell retention and the engraftment was shown to have 
no significant effect in any segment of myocardium demonstrating that the in-vitro optimisation 
for mechanical properties was successful and that the gel is ready for further studies in cardiac 
regeneration.  
Finally, in part 3 I discuss a study that aimed to bring the separate imaging components of this 
thesis together to assess the regenerative potential of cell encapsulating alginate microspheres. 
Due to poor engraftment and infarction outcome this experiment was limited in assessing 
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regenerative potential. However, the imaging tools that will enhance studies such as this in the 
future were exhibited and the value of such techniques demonstrated.  
The central role of imaging in these studies shows its value as in imaging of regeneration 
therapy. The non-invasive and in vivo nature of MRI allows it to be used to monitor myocardial 
structure and function serially as in part 1 and 2. Restoration of contractile function is a target of 
all cardiac regenerative therapies and MRI offers the gold standard in global and regional 
function assessment. It is hoped that the demonstration of these techniques will help in the 
uptake of these imaging tools in future clinical and preclinical studies of cardiac regeneration.  
  
290 
 
  
291 
 
Chapter 8 Final discussion  
 
This thesis has described my work in developing preclinical MRI acquisition techniques for the 
assessment of myocardial structure and function for applications in regenerative medicine. 
Cardiovascular disease remains the number one cause of death worldwide, the WHO attributed 
30% of all deaths to cardiovascular disease in 2005.330 Over the past 20 years therapies for 
cardiac disease have come of age. Treating coronary heart disease in particular has seen a 
revolution in new treatments such as statins, stents and beta blockers. These therapies have 
slowed death rates and are able to minimise ischemic heart damage following myocardial 
infarction. Crucially however, they are unable to recover the lost heart function due to 
cardiomyocyte death resulting in poor prognosis for patients.331 Myocardial regeneration 
therapy is a new strategy towards treating cardiac disease that engrafts regenerative cells and 
biomaterials to the myocardium to stimulate repair of tissue and restoration of contractile 
function.332 Cardiac regeneration therapy has made a rapid translation from preclinical research 
to clinical trials as early as 2001.333 Clinical results in the years since however have been 
underwhelming108 and there is a general consensus that further preclinical optimisation utilising 
powerful non-invasive imaging data will be key to the future success of regenerative medicine in 
humans.  
Medical and biomedical imaging techniques will play a central role in the optimisation into the 
safety and efficacy of future regenerative therapies. Imaging across scales will provide crucial 
information for the development of regenerative therapies over the next decade. Modern 
microscopy techniques such as two-photon fluorescence microscopy offer unparalleled views of 
the cellular architecture at sub-cellular resolutions with high sensitivity and specificity for 
characterising dynamic changes at micron scales. This information is valuable for in-vitro 
optimisation studies but it will be the imaging of whole organ systems using in-vivo techniques 
such as ultrasound, SPECT/PET, X-ray CT and MRI that will give the best insight into regenerative 
efficacy. In vivo imaging provides powerful information on the internal physiological changes 
induced by disease and in response to therapeutic intervention that cannot be provided by in 
vitro experiments. The practicality and availability of ultrasound imaging systems make them 
widely used in clinical and preclinical research. They offer high temporal and spatial resolution as 
well as allowing high throughput and cost effective imaging studies to be performed and are well 
suited to imaging the heart. The sensitivity and specificity of SPECT and PET imaging make them 
the gold standard for quantitative cell tracking and these modalities will provide valuable data 
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for enhancing cell retention following engraftment. Magnetic resonance imaging is unparalleled 
in providing non-invasive multiparametric imaging of both global and regional cardiac structure 
and function. MRI provides high spatiotemporal resolution and multiple contrast mechanisms 
revealing information about molecular changes in the myocardium. These imaging abilities make 
MRI a versatile and powerful tool in the preclinical optimisation of cardiac regeneration 
therapies. Over the chapters presented in this thesis I have established a set of MR imaging 
protocols that enable valuable in vivo characterisation of cardiac function and structure in 
mouse models of regenerative therapy.  
In chapter 3, a set of multiparametric MRI imaging sequences were used to characterise a mouse 
model of cardiac disease and quantify how it affected cardiac function. Also investigated was 
how the accumulation of pathological iron within the heart and other organs could be quantified 
using appropriate MRI relaxometry. The disease model that was imaged was a mouse model of 
beta thalassemia expressing cardiac iron overload. I have established imaging tools to quantify 
the disease characteristics for applications in novel gene and chelation therapies. This is similar 
to the overall research goals in this thesis, where we aim to develop imaging tools for the 
assessment of novel cardiac regeneration therapies. The imaging data found that iron 
sequestration in the heart, liver and spleen could be quantified using a combination of T1, T2 
and T2* relaxometry techniques. Global cardiac function quantified by cine MRI was found to be 
unchanged, despite the pathological iron overload in these organs. It is known that iron 
accumulation in iron metabolising organs such as the liver and spleen predisposes a patient to 
heart failure. This study has produced early imaging biomarkers for identifying iron overload 
prior to cardiac dysfunction using multiparametric MRI techniques. The experience gained from 
this study in terms of NMR relaxation model fitting, quantification of global cardiac function and 
experimental process were carried through to the biomaterial regeneration studies outlined in 
chapter 7. The next step for continuation of this work is the application of these MRI techniques 
for the assessment novel therapies. The characterisation of this mouse model in disease and iron 
overload pathology enables development of new therapies such as correcting the defective beta 
globin gene in utero or producing novel iron chelation agents. 
Chapter 4 introduced the vital importance of quantification of regional function in myocardial 
regeneration. MI is characterised by the formation of non-contractile scar region as well as a 
border zone of damaged but salvageable tissue. Using global functional measurements such as 
ejection fraction limit the scope of an investigation. Global function is a commonly used clinical 
diagnostic measure but in clinical and preclinical research the function of individual segments of 
heart tissue provides more powerful information of the efficacy of a therapy or the extent of 
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damage. This chapter discusses the limitations of global cardiac function and presents key 
studies that make use of regional function measurements in cardiac pathology and cardiac 
regeneration. Regional techniques developed over the course of this thesis were used in Chapter 
7 to demonstrate improved function in border zone tissue that could not be identified from 
global cine MRI. Chapter 4 also introduces the assessment of regional function from standard 
cine MRI. Assessment of a mouse model of myocardial infarction without therapy showed that 
the cine MRI analysis was able to quantify regional loss of wall thickening in the infarcted region 
and a whole LV reduced fractional shortening. This information is limited in that it describes only 
the radial 1 dimensional dysfunction of the LV segments. There is therefore a requirement for 
more powerful 2D and 3D displacement measuring tools that are able to fully characterise the 
complex motion of the contracting heart which led to my development of the SPAMM and 
DENSE sequences in subsequent chapters. The greatest potential of the wall thickening and 
fractional shortening measurements I produced in this chapter is in retrospective analysis. It is 
standard practice to acquire a cine MRI scan to visually assess the contraction of the heart 
during a cardiac MRI procedure. The ability to go back to data and reanalyse it for regional 
dysfunction will enable new interpretation of data. A future study is planned to use the methods 
developed here to retrospectively improve upon a study of diastolic dysfunction in myocardial 
infarction.  
Chapter 5 described the development of a spatial modulation of magnetisation (SPAMM) MRI 
acquisition technique and the associated harmonic phase (HARP) tissue tracking method. 
SPAMM is an MRI tagging based technique that saturates the heart in a 1D sinusoidal pattern 
allowing tracking of regions of tissue by the deformation of the sinusoid. SPAMM has been 
successfully used in clinical research since the development of the HARP technique that greatly 
facilitates the post processing of data.237 SPAMM and HARP were developed and optimised over 
the course of this chapter and were validated against a programmable motion phantom. This 
motion phantom could be programmed to simulate a range of periodic displacements that were 
imaged using an evolving SPAMM acquisition protocols and processed with HARP to 
demonstrate accurate displacement mapping. A limitation of this sequence is the relatively low 
spatial resolution of displacement information. A high fraction of the MRI acquisition is 
discarded during the HARP technique when the displacement encoded information is isolated. 
This loss of information may be important in cardiac regeneration therapy at the boundaries of 
regenerative biomaterials where mechanical matching will play a crucial role in engraftment 
safety. The SPAMM technique is recognised as the clinical standard for regional function 
measurements and so it is an essential imaging tool to have available in the MR imaging toolbox 
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I was developing for tracking regenerative therapy. However, the low spatial resolution led me 
to the development of the displacement encoding using stimulated echoes (DENSE) imaging 
protocol that provides higher resolution spatial information at a cost of image SNR.  
Chapter 6 followed the development, validation and optimisation of the high resolution DENSE 
protocol for assessing regional cardiac mechanics. DENSE is presented as a natural evolution of 
the HARP processing method, it uses similar mathematical principles to encode spatial 
information within a single displacement echo. However, rather than use a frequency filter to 
remove spatial information it uses a decoding magnetic gradient during acquisition. This shifts 
this echo to the centre of k-space where it can be isolated while keeping the high frequency 
information intact. A novel application of the projection onto dipole field phase correction 
technique was applied to DENSE acquisitions to correct for background phase due to poor 
magnetic homogeneity in the heart and reducing the acquisition time by a third. A number of 
different techniques for isolating the displacement echo were presented including two different 
complementary acquisition methods and through plane dephasing. These echo removal 
techniques were compared and the through plane dephasing method chosen as the optimal 
balance of artefact suppression and acquisition time. Due to malfunction the motion phantom 
used to validate the SPAMM and HARP sequences was not available for validation of DENSE. 
Future development of DENSE would involve redevelopment of the phantom and using it to 
optimise and validate the DENSE sequence. With a fully optimised DENSE acquisition sequence 
the next step would be to use it in a full study of cardiac regeneration. Unfortunately, it was not 
available until the final study presented in chapter 7 where the study population was severely 
limited.  
With the development of DENSE and SPAMM as well as the functional, relaxometry and viability 
imaging techniques described in chapters 3 and 4 a complete set of imaging tools were 
established for assessment of myocardial mechanics, structure and composition using non-
invasive imaging with in vivo methods. These imaging techniques were then applied in mouse 
models of cardiac regeneration therapy in chapter 7. The three experiments described in this 
chapter were performed over the 4 years taken to develop the work in this thesis. Consequently, 
not all of the imaging techniques I developed over this time were available at the time of the 
study. However, following each experiment, experience was gained and guided my decision as to 
what imaging tool would require development next to improve upon the study. In this way this 
final chapter presents the evolving regenerative imaging platform I have been developing over 
the course of this work and provides examples of experiments in which they are applicable.  
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Future applications of the work presented in this thesis would be the incorporation of these 
imaging techniques into large preclinical studies of cardiac regeneration therapy. The imaging 
techniques presented here are applicable to any cardiac regeneration study that requires 
knowledge of changes in heart structure and function. The non-invasive nature of MRI makes it a 
powerful tool for serial assessment of potential therapies. The ability to serially monitor cardiac 
structure (e.g. ECV mapping, relaxometry) and function at a global (cine) and regional level (e.g. 
DENSE, HARP) is of huge benefit to optimisation of regenerative medicine. Future work resulting 
from this thesis would be to repeat one of the pilot studies presented in Chapter 7 with the 
developments produced from the pilot data. This repeated study would serially monitor a 
statistically robust study population with wild type, infarct, treated with cells + biomaterial and 
treated with biomaterial only groups. Imaging tools could include the full range of 
structural/relaxometry sequences and high resolution DENSE for regional function. A study with 
this structure would be able to determine the therapeutic effect of a cell loaded biomaterial 
relative to the benefits provided by the biomaterial alone. Of the biomaterials investigated in 
Chapter 7 the most likely candidate for further study are the alginate microspheres. The highly 
versatile microsphere platform allows widely customisable therapy that can be highly optimised 
by variation in microsphere size and structure. Crucially any type of microspheres can easily be 
combined with another in a single injection. An example of this may be the combination of cell 
laoded microspheres combined with tailored microspheres for releasing bioactive molecules 
(e.g. VEGF) to support the transplanted cells. 
There is scope for further developments of the techniques developed here. Of particular interest 
would be development of the PDF technique for removal of background phase contributions in 
DENSE. Alternative methods for phase removal may provide a more efficient method for 
removing this contribution e.g. incorporating a solution to the Laplacian boundary value 
problem (LBV). Establishing the benefit of these alternative techniques would be a subject for 
future work. As discussed in chapter 5 the use of the tag fading present in tagged images for 
cardiac T1 mapping is also of particular interest. A sequence that is able to simultaneously 
quantify regional function and T1 is a useful tool and provides a highly efficient use of scan time. 
Cardiac regeneration therapy is an exciting field of rapid development. Clinicians can be 
cautiously optimistic regarding the modest response to therapy seen in clinical trials. Successful 
translation represents a long term goal and extensive preclinical validation work will be required 
with many challenges remaining open. These challenges include optimisations in cell type, 
delivery method, timing of delivery and biomaterial properties. The role of preclinical imaging in 
this optimisation process will provide the valuable validation of methods and will be essential to 
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successful translation to clinical practice. It is hoped that the methods developed over the 
course of this thesis aid in the uptake of imaging applications in studies of regenerative medicine 
and that the wide range of imaging tools deployed help to bring regenerative medicine closer to 
practical clinical therapy.  
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Appendix 
A1. ‘Muscle Fibres of the Heart’ Image 
 
‘Muscle Fibres of the Heart’ an image I developed using DTI imaging in the ex vivo mouse heart. 
This image was acquired in an ex-vivo naïve mouse heart using a 3D fast spin echo diffusion 
weighted sequence. The tractography image visualises the spiralling myofibre architecture of the 
heart with a smooth transition from left handed helical fibres at the epicardium to right hand 
helical fibres at the endocardium. Images such as this help convey the complex microstructure of 
the heart and describe the magnitude of the task facing regenerative medicine.  
 
